Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
33100.0 | 2019-01-24 00:00:00 UTC | Abbott (ABT) Q4 Earnings Meet Estimates, Organic Growth Solid | ABT | https://www.nasdaq.com/articles/abbott-abt-q4-earnings-meet-estimates-organic-growth-solid-2019-01-24 | nan | nan | Abbott LaboratoriesABT reported fourth-quarter 2018 adjusted earnings from continuing operations of 81 cents per share, in line with the Zacks Consensus Estimate. The bottom line improved 9.5% year over year and fell within the company's guided range of 80-82 cents. Reported earnings from continuing operation in the quarter came in at 37 cents against the year-ago loss of 48 cents per share.
Full-year adjusted EPS was $2.88, a 15.2% improvement from the year-ago period. However, it missed the Zacks Consensus Estimate by a penny.
Fourth-quarter worldwide sales came in at $7.77 billion, up 2.3% year over year on a reported basis. The top line remained slightly below the Zacks Consensus Estimate of $7.79 billion.
On an organic basis (adjusting for the impact of foreign exchange as well as certain acquisitions and divestments), sales increased 6.4% year over year in the reported quarter.
For 2018, sales were $30.6 billion, up 11.6% on a reported basis and up 7.3% on an organic basis from 2017. The top line remained in line with the Zacks Consensus Estimate.
Quarter in Detail
Abbott operates through four segments, namely Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics.
Abbott Laboratories Price, Consensus and EPS Surprise
Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote
In the fourth quarter, EPD sales dropped 4.8% on a reported basis (improved 3.6% on an organic basis) to $1.09 billion. This included an 8.4% adverse impact from currency fluctuations. Sales in the key emerging markets declined 6.2% year over year on a 10.5% adverse impact of foreign exchange. Organically, sales improved 4.3% in this market.
The Medical Devices business sales increased 6.7% on a reported basis to $2.92 billion. On an organic basis, sales grew 9%.
Cardiovascular and Neuromodulation sales reportedly (up 4.8% on an organic basis) rose 6.7% on double-digit growth in Electrophysiology and Structural Heart.In Electrophysiology, growth was led by strong performance in cardiac mapping and ablation catheters. Within Structural Heart, growth was driven by several product areas across Abbott's broad portfolio, including AMPLATZERPFO Occluder and MitraClip.
Diabetes Care sales improved 28.3% (up 32.4% organically), buoyed consistent consumer uptake of FreeStyle Libre, the revolutionary continuous glucose monitoring system of Abbott.
Nutrition sales were down 0.4% year over year on a reported basis (up 3.6% on an organic basis) to $1.78 billion. Pediatric Nutrition sales increased 3.7% on an organic basis. Adult Nutrition sales were up 3.5% organically.
Diagnostics sales were up 2.9% year over year on a reported basis (up 7.4% on a comparable operational basis) to $1.96 billion. Core Laboratory Diagnostics sales grew 9.4% while Point of Care Diagnostics slipped 5.1%, on an organic basis. Molecular Diagnostics sales were up 3.8% banking on strong growth in the infectious disease testing business. Rapid Diagnostics recorded sales of $548 million, driven by solid contributions from cardiometabolic testing.
2019 Guidance
Abbott has initiated its 2019 guidance.
Adjusting for certain net specified items for the full year, adjusted earnings from continuing operations are expected in the band of $3.15-$3.25. The Zacks Consensus Estimate of $3.19 remains within this projected range. Organic sales growth is expected in the range of 6.5% -7.5%. The Zacks Consensensus Estimate for the top line is pegged at $32.03 billion.
The company has also provided first-quarter 2019 adjusted earnings per share outlook. It expects to report adjusted earnings from continuing operations in the range of 60-62 cents. The consensus mark of 66 cents falls outside the predicted range.
Our Take
Abbott exited the fourth quarter on a mixed note with earnings in line with the Zacks Consensus Estimate and revenues missing the mark on a close margin. Increasing currency headwinds to some extent dented the company's international performance.
Overall, we are optimistic about Abbott's strong and consistent EPD and Medical Devices performance organically. Particularly, Abbott has been riding high on a healthy growth within its Diabetes Care business. The company has been hogging the limelight for developments in the flagship, sensor-based continuous glucose monitoring (CGM) system - FreeStyle Libre System. Also, solid contributions from the company's other two businesses encourage us.
Meanwhile, the company's emerging market performance has been extremely promising on several strategic developments.
Zacks Rank & Key Picks
Abbott currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space are BioTelemetry, Inc. BEAT , ABIOMED, Inc. ABMD and DexCom, Inc. DXCM .
BioTelemetry is expected to release fourth-quarter 2018 results on Feb 28. The Zacks Consensus Estimate for the period's adjusted EPS is 42 cents and for revenues, $103.02 million. The stock sports a Zacks Rank #1 (Strong Buy).
ABIOMED is expected to release fourth-quarter fiscal 2018 results on Jan 31. The Zacks Consensus Estimate for the quarter's adjusted EPS is pegged at 94 cents and for revenues stands at $214 million. The stock has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
DexCom is slated to release fourth-quarter 2018 results on Jan 26. The Zacks Consensus Estimate for adjusted EPS for the to-be-reported quarter is 14 cents and for the top line, $330.5 million. The stock carries a Zacks Rank of 2.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
ABIOMED, Inc. (ABMD): Free Stock Analysis Report
DexCom, Inc. (DXCM): Free Stock Analysis Report
BioTelemetry, Inc. (BEAT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT reported fourth-quarter 2018 adjusted earnings from continuing operations of 81 cents per share, in line with the Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report BioTelemetry, Inc. (BEAT): Free Stock Analysis Report To read this article on Zacks.com click here. Diabetes Care sales improved 28.3% (up 32.4% organically), buoyed consistent consumer uptake of FreeStyle Libre, the revolutionary continuous glucose monitoring system of Abbott. | Abbott LaboratoriesABT reported fourth-quarter 2018 adjusted earnings from continuing operations of 81 cents per share, in line with the Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report BioTelemetry, Inc. (BEAT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote In the fourth quarter, EPD sales dropped 4.8% on a reported basis (improved 3.6% on an organic basis) to $1.09 billion. | Abbott LaboratoriesABT reported fourth-quarter 2018 adjusted earnings from continuing operations of 81 cents per share, in line with the Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report BioTelemetry, Inc. (BEAT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote In the fourth quarter, EPD sales dropped 4.8% on a reported basis (improved 3.6% on an organic basis) to $1.09 billion. | Abbott LaboratoriesABT reported fourth-quarter 2018 adjusted earnings from continuing operations of 81 cents per share, in line with the Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report BioTelemetry, Inc. (BEAT): Free Stock Analysis Report To read this article on Zacks.com click here. Organic sales growth is expected in the range of 6.5% -7.5%. |
33101.0 | 2019-01-23 00:00:00 UTC | U.S. STOCKS ON THE MOVE-IBM, Synchrony Financial, Twitter | ABT | https://www.nasdaq.com/articles/us-stocks-move-ibm-synchrony-financial-twitter-2019-01-23 | nan | nan | The Day Ahead newsletter:
The Morning News Call newsletter:
U.S. stocks rose on Wednesday, as strong earnings from IBM, United Technologies and Procter & Gamble led a rebound for Wall Street from its second biggest decline in 2019.
At 10:17 ET, the Dow Jones Industrial Average was up 0.96 percent at 24,638.62. The S&P 500 was up 0.56 percent at 2,647.77 and the Nasdaq Composite was up 0.69 percent at 7,068.989.
The top three S&P 500 percentage gainers:
** Waters Corp, up 11.3 pct
** Synchrony Financial, up 11.1 pct
** IBM Corp, up 8 pct
The top three S&P 500 percentage losers:
** Rollins Inc, down 6.4 pct
** Capital One Financial Corp, down 5.6 pct
** Twitter Inc, down 3.5 pct
The top three NYSE percentage gainers:
** Waters Corp, up 11.3 pct
** Synchrony Financial, up 11.1 pct
** Vipshop Hold Ltd, up 10.7 pct
The top three NYSE percentage losers:
** Quotient Technology, down 17.8 pct
** Fb Financial Corp, down 9.4 pct
** Trinseo Sa, down 8.9 pct
The top three Nasdaq percentage gainers:
** Boxlight Corp, up 65 pct
** Microbot Medical, up 20.6 pct
** Reto Eco Solutions, up 18.1 pct
The top three Nasdaq percentage losers:
** Avalon Globocare, down 34.5 pct
** Bridgford Food, down 17.9 pct
** Datasea Inc, down 16 pct
** United Technologies Corp: up 6.1 pct
United Technologies Corp: Shares rise on Q4 profit beat
United Tech profit beats on higher aero parts sales
** Procter & Gamble Co: up 5.9 pct
Procter & Gamble: Up as Q2 results beat
P&G raises forecast on strength of skin care, detergent brands
** Comcast Corp: up 6.1 pct
Comcast Corp: Set to jump as Q4 revenue beats analyst expectations
Comcast results beat on lower-than-expected video losses
** Rollins Inc: down 6.4 pct
Rollins Inc: Drops after Q4 EPS and revenue miss
** Waters Corp: up 11.7 pct
Waters Corp: Eyes one-year high on sparkling FY profit forecast
** Accuray Inc: up 9.9 pct
Accuray Inc: Jumps as strong China orders spur profitability target
** PTC Therapeutics: down 9.0 pct
PTC Therapeutics: Slides on $200 mln stock offering plan
** Restaurant Brands: up 7.4 pct
Restaurant Brands: Rises after naming Burger King chief Jose Cil as CEO
Restaurant Brands names Burger King boss Jose Cil as CEO
** Bellerophon Therapeutics Inc: down 23.4 pct
Small drugmakers Bellerophon and Rexahn slide on stock deal plans
** IBM Corp: up 8.6 pct
IBM: Gains on strong 2019 profit forecast
** Merck & Co: down 0.5 pct
Merck's Keytruda seems ahead of Bristol-Myers' Opdivo in Q4
** Tesla Inc: down 2.6 pct
Tesla: 'Dream deferred,' sell the 'Elon premium' - RBC
** Walmart Inc: up 1.5 pct
MS cautious of hard goods retailers, ups Walmart to 'outperform'
** Teva Pharmaceuticals Industries Ltd: up 4.7 pct
Teva: Rises after UBS says stock "too cheap to ignore", upgrades
** Synchrony Financial: up 10.8 pct
Synchrony Financial: Rises after Walmart drops lawsuit, strong Q4 results
** Kimberly-Clark Corp: down 1.9 pct
Kimberly-Clark: Drops on weak 2019 profit forecast
Kimberly-Clark misses profit estimates, shares fall
** Abbott Laboratories: down 0.4 pct
Abbott Labs: Falls on Q4 revenue miss; weak Q1 profit forecast
** Athersys Inc: up 13.7 pct
Athersys: Surges on positive lung disease treatment results
The 11 major S&P 500 sectors:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks rose on Wednesday, as strong earnings from IBM, United Technologies and Procter & Gamble led a rebound for Wall Street from its second biggest decline in 2019. At 10:17 ET, the Dow Jones Industrial Average was up 0.96 percent at 24,638.62. The top three S&P 500 percentage gainers: ** Waters Corp, up 11.3 pct ** Synchrony Financial, up 11.1 pct ** IBM Corp, up 8 pct The top three S&P 500 percentage losers: ** Rollins Inc, down 6.4 pct ** Capital One Financial Corp, down 5.6 pct ** Twitter Inc, down 3.5 pct The top three NYSE percentage gainers: ** Waters Corp, up 11.3 pct ** Synchrony Financial, up 11.1 pct ** Vipshop Hold Ltd, up 10.7 pct The top three NYSE percentage losers: ** Quotient Technology, down 17.8 pct ** Fb Financial Corp, down 9.4 pct ** Trinseo Sa, down 8.9 pct The top three Nasdaq percentage gainers: ** Boxlight Corp, up 65 pct ** Microbot Medical, up 20.6 pct ** Reto Eco Solutions, up 18.1 pct The top three Nasdaq percentage losers: ** Avalon Globocare, down 34.5 pct ** Bridgford Food, down 17.9 pct ** Datasea Inc, down 16 pct ** United Technologies Corp: up 6.1 pct United Technologies Corp: Shares rise on Q4 profit beat United Tech profit beats on higher aero parts sales ** Procter & Gamble Co: up 5.9 pct Procter & Gamble: Up as Q2 results beat P&G raises forecast on strength of skin care, detergent brands ** Comcast Corp: up 6.1 pct Comcast Corp: Set to jump as Q4 revenue beats analyst expectations Comcast results beat on lower-than-expected video losses ** Rollins Inc: down 6.4 pct Rollins Inc: Drops after Q4 EPS and revenue miss ** Waters Corp: up 11.7 pct Waters Corp: Eyes one-year high on sparkling FY profit forecast ** Accuray Inc: up 9.9 pct Accuray Inc: Jumps as strong China orders spur profitability target ** PTC Therapeutics: down 9.0 pct PTC Therapeutics: Slides on $200 mln stock offering plan ** Restaurant Brands: up 7.4 pct Restaurant Brands: Rises after naming Burger King chief Jose Cil as CEO Restaurant Brands names Burger King boss Jose Cil as CEO ** Bellerophon Therapeutics Inc: down 23.4 pct Small drugmakers Bellerophon and Rexahn slide on stock deal plans ** IBM Corp: up 8.6 pct IBM: Gains on strong 2019 profit forecast ** Merck & Co: down 0.5 pct Merck's Keytruda seems ahead of Bristol-Myers' Opdivo in Q4 ** Tesla Inc: down 2.6 pct Tesla: 'Dream deferred,' sell the 'Elon premium' - RBC ** Walmart Inc: up 1.5 pct MS cautious of hard goods retailers, ups Walmart to 'outperform' ** Teva Pharmaceuticals Industries Ltd: up 4.7 pct Teva: Rises after UBS says stock "too cheap to ignore", upgrades ** Synchrony Financial: up 10.8 pct Synchrony Financial: Rises after Walmart drops lawsuit, strong Q4 results ** Kimberly-Clark Corp: down 1.9 pct Kimberly-Clark: Drops on weak 2019 profit forecast Kimberly-Clark misses profit estimates, shares fall ** Abbott Laboratories: down 0.4 pct Abbott Labs: Falls on Q4 revenue miss; weak Q1 profit forecast ** Athersys Inc: up 13.7 pct Athersys: Surges on positive lung disease treatment results The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks rose on Wednesday, as strong earnings from IBM, United Technologies and Procter & Gamble led a rebound for Wall Street from its second biggest decline in 2019. The S&P 500 was up 0.56 percent at 2,647.77 and the Nasdaq Composite was up 0.69 percent at 7,068.989. The top three S&P 500 percentage gainers: ** Waters Corp, up 11.3 pct ** Synchrony Financial, up 11.1 pct ** IBM Corp, up 8 pct The top three S&P 500 percentage losers: ** Rollins Inc, down 6.4 pct ** Capital One Financial Corp, down 5.6 pct ** Twitter Inc, down 3.5 pct The top three NYSE percentage gainers: ** Waters Corp, up 11.3 pct ** Synchrony Financial, up 11.1 pct ** Vipshop Hold Ltd, up 10.7 pct The top three NYSE percentage losers: ** Quotient Technology, down 17.8 pct ** Fb Financial Corp, down 9.4 pct ** Trinseo Sa, down 8.9 pct The top three Nasdaq percentage gainers: ** Boxlight Corp, up 65 pct ** Microbot Medical, up 20.6 pct ** Reto Eco Solutions, up 18.1 pct The top three Nasdaq percentage losers: ** Avalon Globocare, down 34.5 pct ** Bridgford Food, down 17.9 pct ** Datasea Inc, down 16 pct ** United Technologies Corp: up 6.1 pct United Technologies Corp: Shares rise on Q4 profit beat United Tech profit beats on higher aero parts sales ** Procter & Gamble Co: up 5.9 pct Procter & Gamble: Up as Q2 results beat P&G raises forecast on strength of skin care, detergent brands ** Comcast Corp: up 6.1 pct Comcast Corp: Set to jump as Q4 revenue beats analyst expectations Comcast results beat on lower-than-expected video losses ** Rollins Inc: down 6.4 pct Rollins Inc: Drops after Q4 EPS and revenue miss ** Waters Corp: up 11.7 pct Waters Corp: Eyes one-year high on sparkling FY profit forecast ** Accuray Inc: up 9.9 pct Accuray Inc: Jumps as strong China orders spur profitability target ** PTC Therapeutics: down 9.0 pct PTC Therapeutics: Slides on $200 mln stock offering plan ** Restaurant Brands: up 7.4 pct Restaurant Brands: Rises after naming Burger King chief Jose Cil as CEO Restaurant Brands names Burger King boss Jose Cil as CEO ** Bellerophon Therapeutics Inc: down 23.4 pct Small drugmakers Bellerophon and Rexahn slide on stock deal plans ** IBM Corp: up 8.6 pct IBM: Gains on strong 2019 profit forecast ** Merck & Co: down 0.5 pct Merck's Keytruda seems ahead of Bristol-Myers' Opdivo in Q4 ** Tesla Inc: down 2.6 pct Tesla: 'Dream deferred,' sell the 'Elon premium' - RBC ** Walmart Inc: up 1.5 pct MS cautious of hard goods retailers, ups Walmart to 'outperform' ** Teva Pharmaceuticals Industries Ltd: up 4.7 pct Teva: Rises after UBS says stock "too cheap to ignore", upgrades ** Synchrony Financial: up 10.8 pct Synchrony Financial: Rises after Walmart drops lawsuit, strong Q4 results ** Kimberly-Clark Corp: down 1.9 pct Kimberly-Clark: Drops on weak 2019 profit forecast Kimberly-Clark misses profit estimates, shares fall ** Abbott Laboratories: down 0.4 pct Abbott Labs: Falls on Q4 revenue miss; weak Q1 profit forecast ** Athersys Inc: up 13.7 pct Athersys: Surges on positive lung disease treatment results The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | At 10:17 ET, the Dow Jones Industrial Average was up 0.96 percent at 24,638.62. The S&P 500 was up 0.56 percent at 2,647.77 and the Nasdaq Composite was up 0.69 percent at 7,068.989. The top three S&P 500 percentage gainers: ** Waters Corp, up 11.3 pct ** Synchrony Financial, up 11.1 pct ** IBM Corp, up 8 pct The top three S&P 500 percentage losers: ** Rollins Inc, down 6.4 pct ** Capital One Financial Corp, down 5.6 pct ** Twitter Inc, down 3.5 pct The top three NYSE percentage gainers: ** Waters Corp, up 11.3 pct ** Synchrony Financial, up 11.1 pct ** Vipshop Hold Ltd, up 10.7 pct The top three NYSE percentage losers: ** Quotient Technology, down 17.8 pct ** Fb Financial Corp, down 9.4 pct ** Trinseo Sa, down 8.9 pct The top three Nasdaq percentage gainers: ** Boxlight Corp, up 65 pct ** Microbot Medical, up 20.6 pct ** Reto Eco Solutions, up 18.1 pct The top three Nasdaq percentage losers: ** Avalon Globocare, down 34.5 pct ** Bridgford Food, down 17.9 pct ** Datasea Inc, down 16 pct ** United Technologies Corp: up 6.1 pct United Technologies Corp: Shares rise on Q4 profit beat United Tech profit beats on higher aero parts sales ** Procter & Gamble Co: up 5.9 pct Procter & Gamble: Up as Q2 results beat P&G raises forecast on strength of skin care, detergent brands ** Comcast Corp: up 6.1 pct Comcast Corp: Set to jump as Q4 revenue beats analyst expectations Comcast results beat on lower-than-expected video losses ** Rollins Inc: down 6.4 pct Rollins Inc: Drops after Q4 EPS and revenue miss ** Waters Corp: up 11.7 pct Waters Corp: Eyes one-year high on sparkling FY profit forecast ** Accuray Inc: up 9.9 pct Accuray Inc: Jumps as strong China orders spur profitability target ** PTC Therapeutics: down 9.0 pct PTC Therapeutics: Slides on $200 mln stock offering plan ** Restaurant Brands: up 7.4 pct Restaurant Brands: Rises after naming Burger King chief Jose Cil as CEO Restaurant Brands names Burger King boss Jose Cil as CEO ** Bellerophon Therapeutics Inc: down 23.4 pct Small drugmakers Bellerophon and Rexahn slide on stock deal plans ** IBM Corp: up 8.6 pct IBM: Gains on strong 2019 profit forecast ** Merck & Co: down 0.5 pct Merck's Keytruda seems ahead of Bristol-Myers' Opdivo in Q4 ** Tesla Inc: down 2.6 pct Tesla: 'Dream deferred,' sell the 'Elon premium' - RBC ** Walmart Inc: up 1.5 pct MS cautious of hard goods retailers, ups Walmart to 'outperform' ** Teva Pharmaceuticals Industries Ltd: up 4.7 pct Teva: Rises after UBS says stock "too cheap to ignore", upgrades ** Synchrony Financial: up 10.8 pct Synchrony Financial: Rises after Walmart drops lawsuit, strong Q4 results ** Kimberly-Clark Corp: down 1.9 pct Kimberly-Clark: Drops on weak 2019 profit forecast Kimberly-Clark misses profit estimates, shares fall ** Abbott Laboratories: down 0.4 pct Abbott Labs: Falls on Q4 revenue miss; weak Q1 profit forecast ** Athersys Inc: up 13.7 pct Athersys: Surges on positive lung disease treatment results The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks rose on Wednesday, as strong earnings from IBM, United Technologies and Procter & Gamble led a rebound for Wall Street from its second biggest decline in 2019. At 10:17 ET, the Dow Jones Industrial Average was up 0.96 percent at 24,638.62. The S&P 500 was up 0.56 percent at 2,647.77 and the Nasdaq Composite was up 0.69 percent at 7,068.989. |
33102.0 | 2019-01-23 00:00:00 UTC | Health Care Sector Update for 01/23/2019: BLPH, ATHX, JNJ, PFE, MRK, ABT, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-01232019-blph-athx-jnj-pfe-mrk-abt-amgn-2019-01-23 | nan | nan | Top Health Care Stocks:
JNJ: -0.21%
PFE: -0.64%
ABT: -2.08%
MRK: -0.84%
AMGN: Flat
Wednesday pre-bell saw mostly lower heath care stocks.
Early movers include:
(-) Bellerophon Therapeutics ( BLPH ), which was sinking by over 25% after it priced a public offering of 10 million common shares at $0.70 apiece, for gross proceeds of $7 million.
(+) Athersys ( ATHX ) was up by more than 20% after saying summary results from its study of the intravenous administration of MultiStem cell therapy to treat patients suffering from acute respiratory distress syndrome ( ARDS ) showed lower mortality and a greater number of ventilator-free and intensive care unit (ICU) free days in the first month following diagnosis relative to patients receiving placebo.
(-) Abbott Laboratories ( ABT ) was declining by over 2% as i t report ed Q4 adjusted earnings of $0.81 per diluted share, up from $0.74 per share a year ago in line with the $0.81 average estimate from analysts polled by Capital IQ.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (-) Abbott Laboratories ( ABT ) was declining by over 2% as i t report ed Q4 adjusted earnings of $0.81 per diluted share, up from $0.74 per share a year ago in line with the $0.81 average estimate from analysts polled by Capital IQ. AMGN: Flat Wednesday pre-bell saw mostly lower heath care stocks. (+) Athersys ( ATHX ) was up by more than 20% after saying summary results from its study of the intravenous administration of MultiStem cell therapy to treat patients suffering from acute respiratory distress syndrome ( ARDS ) showed lower mortality and a greater number of ventilator-free and intensive care unit (ICU) free days in the first month following diagnosis relative to patients receiving placebo. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (-) Abbott Laboratories ( ABT ) was declining by over 2% as i t report ed Q4 adjusted earnings of $0.81 per diluted share, up from $0.74 per share a year ago in line with the $0.81 average estimate from analysts polled by Capital IQ. AMGN: Flat Wednesday pre-bell saw mostly lower heath care stocks. | (-) Abbott Laboratories ( ABT ) was declining by over 2% as i t report ed Q4 adjusted earnings of $0.81 per diluted share, up from $0.74 per share a year ago in line with the $0.81 average estimate from analysts polled by Capital IQ. (+) Athersys ( ATHX ) was up by more than 20% after saying summary results from its study of the intravenous administration of MultiStem cell therapy to treat patients suffering from acute respiratory distress syndrome ( ARDS ) showed lower mortality and a greater number of ventilator-free and intensive care unit (ICU) free days in the first month following diagnosis relative to patients receiving placebo. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (-) Abbott Laboratories ( ABT ) was declining by over 2% as i t report ed Q4 adjusted earnings of $0.81 per diluted share, up from $0.74 per share a year ago in line with the $0.81 average estimate from analysts polled by Capital IQ. Top Health Care Stocks: AMGN: Flat Wednesday pre-bell saw mostly lower heath care stocks. |
33103.0 | 2019-01-23 00:00:00 UTC | U.S. STOCKS ON THE MOVE-United Technologies, P&G, IBM, Synchrony | ABT | https://www.nasdaq.com/articles/us-stocks-move-united-technologies-pg-ibm-synchrony-2019-01-23 | nan | nan | The Day Ahead newsletter:
The Morning News Call newsletter:
U.S. stocks were set to open higher on Wednesday, with strong earnings from Dow components IBM, United Technologies and Procter & Gamble looking to propel a rebound after Wall Street suffered its second biggest decline in 2019.
At 9:14 ET, Dow e-minis were up 0.78 percent at 24,580. S&P 500 e-minis were up 0.50 percent at 2,645.25, while Nasdaq 100 e-minis were up 0.54 percent at 6,689.25.
The top three NYSE percentage gainers premarket:
** Synchrony Financial, up 12.3 pct
** Portland General Electric Co, up 10.1 pct
** Restaurant Brands International Inc, up 8.8 pct
The top three NYSE percentage losers premarket:
** Trinseo Sa, down 12.3 pct
** Bellatrix Exploration Ltd, down 8.8 pct
** Quotient Technology Inc, down 9.4 pct
The top three Nasdaq percentage gainers premarket:
** Auris Medical Holding, up 31.9 pct
** Soligenix Inc, up 30.1 pct
** Athersys Inc, up 20.1 pct
The top three Nasdaq percentage losers premarket:
** Bellerophon Therapeutics Inc, down 25.9 pct
** Selecta Biosciences Inc, down 23.7 pct
** Avalon Globocare Corp, down 23.5 pct
** United Technologies Corp: up 4.9 pct premarket
United Technologies Corp: Shares rise on Q4 profit beat
United Tech profit beats on higher aero parts sales
** Procter & Gamble Co: up 4.4 pct premarket
Procter & Gamble: Up as Q2 results beat
P&G raises forecast on strength of skin care, detergent brands
** Comcast Corp: up 2.9 pct premarket
Comcast Corp: Set to jump as Q4 revenue beats analyst expectations
Comcast results beat on lower-than-expected video losses
** Rollins Inc: down 4.9 pct premarket
Rollins Inc: Drops after Q4 EPS and revenue miss
** PTC Therapeutics: down 8.9 pct premarket
PTC Therapeutics: Slides on $200 mln stock offering plan
** Restaurant Brands: up 8.8 pct premarket
Restaurant Brands: Rises after naming Burger King chief Jose Cil as CEO
Restaurant Brands names Burger King boss Jose Cil as CEO
** Bellerophon Therapeutics Inc: down 25.9 pct premarket
Small drugmakers Bellerophon and Rexahn slide on stock deal plans
** IBM Corp: up 7.2 pct premarket
IBM: Gains on strong 2019 profit forecast
** Merck & Co: down 0.3 pct premarket
Merck needs more aggressive business development - BMO Capital Markets
** Tesla Inc: down 2.2 pct premarket
Tesla: 'Dream deferred,' sell the 'Elon premium' - RBC
** Walmart Inc: up 1.4 pct premarket
MS cautious of hard goods retailers, ups Walmart to 'outperform'
** Teva Pharmaceuticals Industries Ltd: up 2.9 pct premarket
Teva: Rises after UBS says stock "too cheap to ignore", upgrades
** Synchrony Financial: up 12.3 pct premarket
Synchrony Financial: Rises after Walmart drops lawsuit, strong Q4 results
** Kimberly-Clark Corp: down 3.7 pct premarket
Kimberly-Clark: Drops on weak 2019 profit forecast
Kimberly-Clark misses profit estimates, shares fall
** Abbott Laboratories: down 2.4 pct premarket
Abbott Labs: Falls on Q4 revenue miss; weak Q1 profit forecast
** Athersys Inc: up 20.1 pct premarket
Athersys: Surges on positive lung disease treatment results
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks were set to open higher on Wednesday, with strong earnings from Dow components IBM, United Technologies and Procter & Gamble looking to propel a rebound after Wall Street suffered its second biggest decline in 2019. At 9:14 ET, Dow e-minis were up 0.78 percent at 24,580. The top three NYSE percentage gainers premarket: ** Synchrony Financial, up 12.3 pct ** Portland General Electric Co, up 10.1 pct ** Restaurant Brands International Inc, up 8.8 pct The top three NYSE percentage losers premarket: ** Trinseo Sa, down 12.3 pct ** Bellatrix Exploration Ltd, down 8.8 pct ** Quotient Technology Inc, down 9.4 pct The top three Nasdaq percentage gainers premarket: ** Auris Medical Holding, up 31.9 pct ** Soligenix Inc, up 30.1 pct ** Athersys Inc, up 20.1 pct The top three Nasdaq percentage losers premarket: ** Bellerophon Therapeutics Inc, down 25.9 pct ** Selecta Biosciences Inc, down 23.7 pct ** Avalon Globocare Corp, down 23.5 pct ** United Technologies Corp: up 4.9 pct premarket United Technologies Corp: Shares rise on Q4 profit beat United Tech profit beats on higher aero parts sales ** Procter & Gamble Co: up 4.4 pct premarket Procter & Gamble: Up as Q2 results beat P&G raises forecast on strength of skin care, detergent brands ** Comcast Corp: up 2.9 pct premarket Comcast Corp: Set to jump as Q4 revenue beats analyst expectations Comcast results beat on lower-than-expected video losses ** Rollins Inc: down 4.9 pct premarket Rollins Inc: Drops after Q4 EPS and revenue miss ** PTC Therapeutics: down 8.9 pct premarket PTC Therapeutics: Slides on $200 mln stock offering plan ** Restaurant Brands: up 8.8 pct premarket Restaurant Brands: Rises after naming Burger King chief Jose Cil as CEO Restaurant Brands names Burger King boss Jose Cil as CEO ** Bellerophon Therapeutics Inc: down 25.9 pct premarket Small drugmakers Bellerophon and Rexahn slide on stock deal plans ** IBM Corp: up 7.2 pct premarket IBM: Gains on strong 2019 profit forecast ** Merck & Co: down 0.3 pct premarket Merck needs more aggressive business development - BMO Capital Markets ** Tesla Inc: down 2.2 pct premarket Tesla: 'Dream deferred,' sell the 'Elon premium' - RBC ** Walmart Inc: up 1.4 pct premarket MS cautious of hard goods retailers, ups Walmart to 'outperform' ** Teva Pharmaceuticals Industries Ltd: up 2.9 pct premarket Teva: Rises after UBS says stock "too cheap to ignore", upgrades ** Synchrony Financial: up 12.3 pct premarket Synchrony Financial: Rises after Walmart drops lawsuit, strong Q4 results ** Kimberly-Clark Corp: down 3.7 pct premarket Kimberly-Clark: Drops on weak 2019 profit forecast Kimberly-Clark misses profit estimates, shares fall ** Abbott Laboratories: down 2.4 pct premarket Abbott Labs: Falls on Q4 revenue miss; weak Q1 profit forecast ** Athersys Inc: up 20.1 pct premarket Athersys: Surges on positive lung disease treatment results The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks were set to open higher on Wednesday, with strong earnings from Dow components IBM, United Technologies and Procter & Gamble looking to propel a rebound after Wall Street suffered its second biggest decline in 2019. S&P 500 e-minis were up 0.50 percent at 2,645.25, while Nasdaq 100 e-minis were up 0.54 percent at 6,689.25. The top three NYSE percentage gainers premarket: ** Synchrony Financial, up 12.3 pct ** Portland General Electric Co, up 10.1 pct ** Restaurant Brands International Inc, up 8.8 pct The top three NYSE percentage losers premarket: ** Trinseo Sa, down 12.3 pct ** Bellatrix Exploration Ltd, down 8.8 pct ** Quotient Technology Inc, down 9.4 pct The top three Nasdaq percentage gainers premarket: ** Auris Medical Holding, up 31.9 pct ** Soligenix Inc, up 30.1 pct ** Athersys Inc, up 20.1 pct The top three Nasdaq percentage losers premarket: ** Bellerophon Therapeutics Inc, down 25.9 pct ** Selecta Biosciences Inc, down 23.7 pct ** Avalon Globocare Corp, down 23.5 pct ** United Technologies Corp: up 4.9 pct premarket United Technologies Corp: Shares rise on Q4 profit beat United Tech profit beats on higher aero parts sales ** Procter & Gamble Co: up 4.4 pct premarket Procter & Gamble: Up as Q2 results beat P&G raises forecast on strength of skin care, detergent brands ** Comcast Corp: up 2.9 pct premarket Comcast Corp: Set to jump as Q4 revenue beats analyst expectations Comcast results beat on lower-than-expected video losses ** Rollins Inc: down 4.9 pct premarket Rollins Inc: Drops after Q4 EPS and revenue miss ** PTC Therapeutics: down 8.9 pct premarket PTC Therapeutics: Slides on $200 mln stock offering plan ** Restaurant Brands: up 8.8 pct premarket Restaurant Brands: Rises after naming Burger King chief Jose Cil as CEO Restaurant Brands names Burger King boss Jose Cil as CEO ** Bellerophon Therapeutics Inc: down 25.9 pct premarket Small drugmakers Bellerophon and Rexahn slide on stock deal plans ** IBM Corp: up 7.2 pct premarket IBM: Gains on strong 2019 profit forecast ** Merck & Co: down 0.3 pct premarket Merck needs more aggressive business development - BMO Capital Markets ** Tesla Inc: down 2.2 pct premarket Tesla: 'Dream deferred,' sell the 'Elon premium' - RBC ** Walmart Inc: up 1.4 pct premarket MS cautious of hard goods retailers, ups Walmart to 'outperform' ** Teva Pharmaceuticals Industries Ltd: up 2.9 pct premarket Teva: Rises after UBS says stock "too cheap to ignore", upgrades ** Synchrony Financial: up 12.3 pct premarket Synchrony Financial: Rises after Walmart drops lawsuit, strong Q4 results ** Kimberly-Clark Corp: down 3.7 pct premarket Kimberly-Clark: Drops on weak 2019 profit forecast Kimberly-Clark misses profit estimates, shares fall ** Abbott Laboratories: down 2.4 pct premarket Abbott Labs: Falls on Q4 revenue miss; weak Q1 profit forecast ** Athersys Inc: up 20.1 pct premarket Athersys: Surges on positive lung disease treatment results The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | At 9:14 ET, Dow e-minis were up 0.78 percent at 24,580. S&P 500 e-minis were up 0.50 percent at 2,645.25, while Nasdaq 100 e-minis were up 0.54 percent at 6,689.25. The top three NYSE percentage gainers premarket: ** Synchrony Financial, up 12.3 pct ** Portland General Electric Co, up 10.1 pct ** Restaurant Brands International Inc, up 8.8 pct The top three NYSE percentage losers premarket: ** Trinseo Sa, down 12.3 pct ** Bellatrix Exploration Ltd, down 8.8 pct ** Quotient Technology Inc, down 9.4 pct The top three Nasdaq percentage gainers premarket: ** Auris Medical Holding, up 31.9 pct ** Soligenix Inc, up 30.1 pct ** Athersys Inc, up 20.1 pct The top three Nasdaq percentage losers premarket: ** Bellerophon Therapeutics Inc, down 25.9 pct ** Selecta Biosciences Inc, down 23.7 pct ** Avalon Globocare Corp, down 23.5 pct ** United Technologies Corp: up 4.9 pct premarket United Technologies Corp: Shares rise on Q4 profit beat United Tech profit beats on higher aero parts sales ** Procter & Gamble Co: up 4.4 pct premarket Procter & Gamble: Up as Q2 results beat P&G raises forecast on strength of skin care, detergent brands ** Comcast Corp: up 2.9 pct premarket Comcast Corp: Set to jump as Q4 revenue beats analyst expectations Comcast results beat on lower-than-expected video losses ** Rollins Inc: down 4.9 pct premarket Rollins Inc: Drops after Q4 EPS and revenue miss ** PTC Therapeutics: down 8.9 pct premarket PTC Therapeutics: Slides on $200 mln stock offering plan ** Restaurant Brands: up 8.8 pct premarket Restaurant Brands: Rises after naming Burger King chief Jose Cil as CEO Restaurant Brands names Burger King boss Jose Cil as CEO ** Bellerophon Therapeutics Inc: down 25.9 pct premarket Small drugmakers Bellerophon and Rexahn slide on stock deal plans ** IBM Corp: up 7.2 pct premarket IBM: Gains on strong 2019 profit forecast ** Merck & Co: down 0.3 pct premarket Merck needs more aggressive business development - BMO Capital Markets ** Tesla Inc: down 2.2 pct premarket Tesla: 'Dream deferred,' sell the 'Elon premium' - RBC ** Walmart Inc: up 1.4 pct premarket MS cautious of hard goods retailers, ups Walmart to 'outperform' ** Teva Pharmaceuticals Industries Ltd: up 2.9 pct premarket Teva: Rises after UBS says stock "too cheap to ignore", upgrades ** Synchrony Financial: up 12.3 pct premarket Synchrony Financial: Rises after Walmart drops lawsuit, strong Q4 results ** Kimberly-Clark Corp: down 3.7 pct premarket Kimberly-Clark: Drops on weak 2019 profit forecast Kimberly-Clark misses profit estimates, shares fall ** Abbott Laboratories: down 2.4 pct premarket Abbott Labs: Falls on Q4 revenue miss; weak Q1 profit forecast ** Athersys Inc: up 20.1 pct premarket Athersys: Surges on positive lung disease treatment results The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks were set to open higher on Wednesday, with strong earnings from Dow components IBM, United Technologies and Procter & Gamble looking to propel a rebound after Wall Street suffered its second biggest decline in 2019. At 9:14 ET, Dow e-minis were up 0.78 percent at 24,580. S&P 500 e-minis were up 0.50 percent at 2,645.25, while Nasdaq 100 e-minis were up 0.54 percent at 6,689.25. |
33104.0 | 2019-01-23 00:00:00 UTC | US STOCKS-Wall Street bounces back on strong corporate earnings | ABT | https://www.nasdaq.com/articles/us-stocks-wall-street-bounces-back-strong-corporate-earnings-2019-01-23 | nan | nan | (For a live blog on the U.S. stock market, click LIVE/ ortype LIVE/ in a news window.)
* P&G, UTX, Comcast rise after results beat
* IBM biggest gainer among Dow components
* Abbott, Kimberly-Clark fall on disappointing results
* Indexes up: Dow 1.16 pct, S&P 0.71 pct, Nasdaq 0.84 pct (Updates to open)
By Shreyashi Sanyal
Jan 23 (Reuters) - U.S. stocks rose on Wednesday, as strongearnings from IBM, United Technologies and Procter & Gamble leda rebound for Wall Street from its second biggest decline in2019.
International Business Machines CorpIBM.N jumped 8.78percent and led the gains on the Dow Jones Industrial Average .DJI after the technology services company projected 2019profit above expectations. urn:newsml:reuters.com:*:nL3N1ZM56C
Gains in shares of IBM also lifted the S&P technology sector .SPLRCT , which rose 1.19 percent.
A 6.65 percent rise in United Technologies CorpUTX.N ,which reported a better-than-expected quarterly profit, helpedpush the S&P industrials sector .SPLRCI 1.05 percent higher. urn:newsml:reuters.com:*:nL3N1ZN3YA
Fellow industrial companies Boeing CoBA.N , CaterpillarInc CAT.N and 3M CoMMM.N rose between 0.5 percent and 1.2percent.
Wall Street's gain follows a more than 1 percent loss onTuesday on worries about global growth due to a gloomy economicoutlook from the International Monetary Fund, signs of furthercooling in China's economy and mixed reports on U.S.-China tradetalks.
"Given a day like yesterday, a bounce driven by earnings isnot unusual," said Michael Antonelli, managing director,institutional sales trading at Robert W. Baird in Milwaukee.
"UTX, being an industrial company, is definitely somethinginvestors are looking at for hints on the impact of a globaleconomic slowdown. The fact that it provided a strong forecastjust shows the U.S. economy is actually solid."
Easing some concerns about trade talks, White House economicadviser Kevin Hassett said he believed the United States andChina could reach a trade deal by a March 1 deadline. urn:newsml:reuters.com:*:nW1N1WR025
At 9:56 a.m. ET the Dow Jones Industrial Average .DJI wasup 283.95 points, or 1.16 percent, at 24,688.43, the S&P 500 .SPX was up 18.80 points, or 0.71 percent, at 2,651.70 and theNasdaq Composite .IXIC was up 58.66 points, or 0.84 percent,at 7,079.02.
Despite the pullback on Tuesday, the benchmark S&P 500 index .SPX is less than 10 percent away from its record closing highon Sept.20 and has climbed about 6 percent this year.
Procter & Gamble CoPG.N rose 5.98 percent, helping theconsumer staples sector .SPLRCS rise 1.41 percent, after itsquarterly revenue beat Wall Street expectation. urn:newsml:reuters.com:*:nL3N1ZN3T0
The biggest decliner in the sector was Kimberly-Clark CorpKMB.N , which fell 1.96 percent after its quarterly profitmissed analysts' estimates due to rising raw materials costs anda strong U.S. dollar. urn:newsml:reuters.com:*:nL3N1ZN43P
The communication services sector .SPLRCL rose 0.93percent on a 6.35 percent gain in cable services providerComcast Corp CMCSA.O , which beat analysts' estimates forrevenue on lower-than-expected video subscriber losses. urn:newsml:reuters.com:*:nL1N1ZM1SD
Abbott LaboratoriesABT.N dropped 1.36 percent after thehealthcare company missed quarterly revenue estimate due tolower sales of generic drugs in emerging markets and gave adownbeat forecast for the current quarter. urn:newsml:reuters.com:*:nL3N1ZN44X
Of the 61 S&P 500 companies that reported until Tuesday,78.7 percent have beat Wall Street's profit estimates and thatis above the historical average of 64 percent, according toRefinitiv data.
However, earnings growth estimates have dropped to 14.1percent from 20.1 percent at the start of October.
Advancing issues outnumbered decliners by a 2.83-to-1 ratioon the NYSE and by a 2.83-to-1 ratio on the Nasdaq.
The S&P index recorded three new 52-week highs and no newlows, while the Nasdaq recorded 11 new highs and 14 new lows. (Reporting by Shreyashi Sanyal and additional reporting bySruthi Shankar in Bengaluru; Editing by Arun Koyyur) ((Shreyashi.Sanyal@thomsonreuters.com; +1 646 223 8780 ;Reuters Messaging:Shreyashi.Sanyal.thomsonreuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | urn:newsml:reuters.com:*:nL1N1ZM1SD Abbott LaboratoriesABT.N dropped 1.36 percent after thehealthcare company missed quarterly revenue estimate due tolower sales of generic drugs in emerging markets and gave adownbeat forecast for the current quarter. Wall Street's gain follows a more than 1 percent loss onTuesday on worries about global growth due to a gloomy economicoutlook from the International Monetary Fund, signs of furthercooling in China's economy and mixed reports on U.S.-China tradetalks. "Given a day like yesterday, a bounce driven by earnings isnot unusual," said Michael Antonelli, managing director,institutional sales trading at Robert W. Baird in Milwaukee. | urn:newsml:reuters.com:*:nL1N1ZM1SD Abbott LaboratoriesABT.N dropped 1.36 percent after thehealthcare company missed quarterly revenue estimate due tolower sales of generic drugs in emerging markets and gave adownbeat forecast for the current quarter. * P&G, UTX, Comcast rise after results beat * IBM biggest gainer among Dow components * Abbott, Kimberly-Clark fall on disappointing results * Indexes up: Dow 1.16 pct, S&P 0.71 pct, Nasdaq 0.84 pct (Updates to open) By Shreyashi Sanyal Jan 23 (Reuters) - U.S. stocks rose on Wednesday, as strongearnings from IBM, United Technologies and Procter & Gamble leda rebound for Wall Street from its second biggest decline in2019. Procter & Gamble CoPG.N rose 5.98 percent, helping theconsumer staples sector .SPLRCS rise 1.41 percent, after itsquarterly revenue beat Wall Street expectation. | urn:newsml:reuters.com:*:nL1N1ZM1SD Abbott LaboratoriesABT.N dropped 1.36 percent after thehealthcare company missed quarterly revenue estimate due tolower sales of generic drugs in emerging markets and gave adownbeat forecast for the current quarter. * P&G, UTX, Comcast rise after results beat * IBM biggest gainer among Dow components * Abbott, Kimberly-Clark fall on disappointing results * Indexes up: Dow 1.16 pct, S&P 0.71 pct, Nasdaq 0.84 pct (Updates to open) By Shreyashi Sanyal Jan 23 (Reuters) - U.S. stocks rose on Wednesday, as strongearnings from IBM, United Technologies and Procter & Gamble leda rebound for Wall Street from its second biggest decline in2019. ET the Dow Jones Industrial Average .DJI wasup 283.95 points, or 1.16 percent, at 24,688.43, the S&P 500 .SPX was up 18.80 points, or 0.71 percent, at 2,651.70 and theNasdaq Composite .IXIC was up 58.66 points, or 0.84 percent,at 7,079.02. | urn:newsml:reuters.com:*:nL1N1ZM1SD Abbott LaboratoriesABT.N dropped 1.36 percent after thehealthcare company missed quarterly revenue estimate due tolower sales of generic drugs in emerging markets and gave adownbeat forecast for the current quarter. urn:newsml:reuters.com:*:nL3N1ZM56C Gains in shares of IBM also lifted the S&P technology sector .SPLRCT , which rose 1.19 percent. urn:newsml:reuters.com:*:nL3N1ZN44X Of the 61 S&P 500 companies that reported until Tuesday,78.7 percent have beat Wall Street's profit estimates and thatis above the historical average of 64 percent, according toRefinitiv data. |
33105.0 | 2019-01-23 00:00:00 UTC | US STOCKS-Wall St set to open higher on strong earnings from Dow members | ABT | https://www.nasdaq.com/articles/us-stocks-wall-st-set-open-higher-strong-earnings-dow-members-2019-01-23 | nan | nan | (For a live blog on the U.S. stock market, click LIVE/ ortype LIVE/ in a news window.)
* P&G, UTX rise premarket after results beat
* IBM biggest premarket gainer on Dow
* Futures up: Dow 0.65 pct, S&P 0.38 pct, Nasdaq 0.39 pct (Updates prices, adds comments, background)
By Shreyashi Sanyal
Jan 23 (Reuters) - U.S. stocks were set to open higher onWednesday, with strong earnings from Dow components IBM, UnitedTechnologies and Procter & Gamble looking to propel a reboundafter Wall Street suffered its second biggest decline in 2019.
Futures pointed to a 0.7 percent gain on the Dow JonesIndustrial Average at the open, with shares of InternationalBusiness Machines CorpIBM.N jumping 6.9 percent afterprojecting 2019 profit above expectations. urn:newsml:reuters.com:*:nL3N1ZM56C
United Technologies CorpUTX.N rose 4.3 percent after theindustrial conglomerate reported a better-than-expected profitand forecast 2019 earnings above estimates, boosted byacquisition of aero parts maker Rockwell Collins. urn:newsml:reuters.com:*:nL3N1ZN3YA
Fellow industrial companies in the Dow, Boeing CoBA.N ,Caterpillar IncCAT.N and 3M CoMMM.N rose between 0.2percent and 0.9 percent.
The gains follow Wall Street's more than 1 percent loss onTuesday as worries about slowing global growth came to the foreafter a gloomy economic outlook from the International MonetaryFund, signs of further cooling in China's economy and mixedreports on U.S.-China trade talks.
"Given a day like yesterday, a bounce driven by earnings isnot unusual," said Michael Antonelli, managing director,institutional sales trading at Robert W. Baird in Milwaukee.
"UTX being an industrial company, is definitely somethinginvestors are looking at for hints on the impact of a globaleconomic slowdown. The fact that it provided a strong forecastjust shows the U.S. economy is actually solid," Antonelli said.
At 8:46 a.m. ET, Dow e-minis 1YMc1 were up 159 points, or0.65 percent. S&P 500 e-minis ESc1 were up 10 points, or 0.38percent and Nasdaq 100 e-minis NQc1 were up 25.75 points, or0.39 percent.
Despite the pullback on Tuesday, the benchmark S&P 500 index .SPX is about 10 percent away from its record closing high onSept. 20 and has climbed about 5 percent this year.
Procter & Gamble CoPG.N rose 4.3 percent after itsquarterly revenue beat Wall Street's expectation, driven bystrong demand for beauty and fabric care products. urn:newsml:reuters.com:*:nL3N1ZN3T0
U.S. cable services provider Comcast CorpCMCSA.O rose 2.6 percent after its quarterly revenue beat analysts'estimates, helped by lower-than-expected video subscriberlosses. urn:newsml:reuters.com:*:nL1N1ZM1SD
Among the decliners were shares of Kimberly-Clark CorpKMB.N , which fell 4.2 percent after the Kleenex-tissuesmaker's profit missed analysts' estimates due to rising rawmaterials costs and a strong U.S. dollar. urn:newsml:reuters.com:*:nL3N1ZN43P
Abbott LaboratoriesABT.N dropped 2.4 percent after thehealthcare company missed quarterly revenue estimate due tolower sales of generic drugs in emerging markets and gave adownbeat forecast for the current quarter. urn:newsml:reuters.com:*:nL3N1ZN44X
Of the 61 S&P 500 companies that reported until Tuesday,78.7 percent have beat Wall Street's profit estimates and thatis above the historical average of 64 percent, according toRefinitiv data.
However, earnings growth estimates have dropped to 14.1percent from 20.1 percent at the start of October. (Reporting by Shreyashi Sanyal and additional reporting bySruthi Shankar in Bengaluru; Editing by Arun Koyyur) ((Shreyashi.Sanyal@thomsonreuters.com; +1 646 223 8780 ;Reuters Messaging:Shreyashi.Sanyal.thomsonreuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | urn:newsml:reuters.com:*:nL3N1ZN43P Abbott LaboratoriesABT.N dropped 2.4 percent after thehealthcare company missed quarterly revenue estimate due tolower sales of generic drugs in emerging markets and gave adownbeat forecast for the current quarter. urn:newsml:reuters.com:*:nL3N1ZM56C United Technologies CorpUTX.N rose 4.3 percent after theindustrial conglomerate reported a better-than-expected profitand forecast 2019 earnings above estimates, boosted byacquisition of aero parts maker Rockwell Collins. The gains follow Wall Street's more than 1 percent loss onTuesday as worries about slowing global growth came to the foreafter a gloomy economic outlook from the International MonetaryFund, signs of further cooling in China's economy and mixedreports on U.S.-China trade talks. | urn:newsml:reuters.com:*:nL3N1ZN43P Abbott LaboratoriesABT.N dropped 2.4 percent after thehealthcare company missed quarterly revenue estimate due tolower sales of generic drugs in emerging markets and gave adownbeat forecast for the current quarter. * P&G, UTX rise premarket after results beat * IBM biggest premarket gainer on Dow * Futures up: Dow 0.65 pct, S&P 0.38 pct, Nasdaq 0.39 pct (Updates prices, adds comments, background) By Shreyashi Sanyal Jan 23 (Reuters) - U.S. stocks were set to open higher onWednesday, with strong earnings from Dow components IBM, UnitedTechnologies and Procter & Gamble looking to propel a reboundafter Wall Street suffered its second biggest decline in 2019. Procter & Gamble CoPG.N rose 4.3 percent after itsquarterly revenue beat Wall Street's expectation, driven bystrong demand for beauty and fabric care products. | urn:newsml:reuters.com:*:nL3N1ZN43P Abbott LaboratoriesABT.N dropped 2.4 percent after thehealthcare company missed quarterly revenue estimate due tolower sales of generic drugs in emerging markets and gave adownbeat forecast for the current quarter. * P&G, UTX rise premarket after results beat * IBM biggest premarket gainer on Dow * Futures up: Dow 0.65 pct, S&P 0.38 pct, Nasdaq 0.39 pct (Updates prices, adds comments, background) By Shreyashi Sanyal Jan 23 (Reuters) - U.S. stocks were set to open higher onWednesday, with strong earnings from Dow components IBM, UnitedTechnologies and Procter & Gamble looking to propel a reboundafter Wall Street suffered its second biggest decline in 2019. urn:newsml:reuters.com:*:nL3N1ZN44X Of the 61 S&P 500 companies that reported until Tuesday,78.7 percent have beat Wall Street's profit estimates and thatis above the historical average of 64 percent, according toRefinitiv data. | urn:newsml:reuters.com:*:nL3N1ZN43P Abbott LaboratoriesABT.N dropped 2.4 percent after thehealthcare company missed quarterly revenue estimate due tolower sales of generic drugs in emerging markets and gave adownbeat forecast for the current quarter. Futures pointed to a 0.7 percent gain on the Dow JonesIndustrial Average at the open, with shares of InternationalBusiness Machines CorpIBM.N jumping 6.9 percent afterprojecting 2019 profit above expectations. urn:newsml:reuters.com:*:nL3N1ZN3YA Fellow industrial companies in the Dow, Boeing CoBA.N ,Caterpillar IncCAT.N and 3M CoMMM.N rose between 0.2percent and 0.9 percent. |
33106.0 | 2019-01-23 00:00:00 UTC | Noteworthy ETF Outflows: XLV, ABT, LLY, TMO | ABT | https://www.nasdaq.com/articles/noteworthy-etf-outflows-xlv-abt-lly-tmo-2019-01-23 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $120.8 million dollar outflow -- that's a 0.6% decrease week over week (from 211,220,000 to 209,870,000). Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 1.2%, Lilly (Eli) & Co (Symbol: LLY) is up about 0.8%, and Thermo Fisher Scientific Inc (Symbol: TMO) is higher by about 0.5%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $89.60. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 1.2%, Lilly (Eli) & Co (Symbol: LLY) is up about 0.8%, and Thermo Fisher Scientific Inc (Symbol: TMO) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $120.8 million dollar outflow -- that's a 0.6% decrease week over week (from 211,220,000 to 209,870,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 1.2%, Lilly (Eli) & Co (Symbol: LLY) is up about 0.8%, and Thermo Fisher Scientific Inc (Symbol: TMO) is higher by about 0.5%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $89.60. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 1.2%, Lilly (Eli) & Co (Symbol: LLY) is up about 0.8%, and Thermo Fisher Scientific Inc (Symbol: TMO) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $120.8 million dollar outflow -- that's a 0.6% decrease week over week (from 211,220,000 to 209,870,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $89.60. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 1.2%, Lilly (Eli) & Co (Symbol: LLY) is up about 0.8%, and Thermo Fisher Scientific Inc (Symbol: TMO) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $120.8 million dollar outflow -- that's a 0.6% decrease week over week (from 211,220,000 to 209,870,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $89.60. |
33107.0 | 2019-01-23 00:00:00 UTC | S&P, Nasdaq dip as healthcare, financials weigh; IBM keeps Dow higher | ABT | https://www.nasdaq.com/articles/sp-nasdaq-dip-healthcare-financials-weigh-ibm-keeps-dow-higher-2019-01-23 | nan | nan | By Shreyashi Sanyal
Jan 23 () - The S&P 500 and the Nasdaq reversed course to dip slightly on Wednesday due to losses in healthcare and financial sectors, while the Dow stayed afloat on positive earnings reports from IBM, United Technologies and Procter & Gamble.
Eight of the 11 major S&P sectors were lower. The healthcare sector dropped 0.5 percent, with Abbott Laboratories falling 2.4 percent after projecting current-quarter earnings below analysts' estimates.
Wall Street's attempt to rebound from a more than 1 percent loss on Tuesday, which was spurred by worries about slowing global growth, was bolstered by a string of strong corporate earnings.
The blue-chip index was buoyed by International Business Machines Corp, which jumped 7.46 percent after projecting 2019 profit above expectations.
Gains in shares of IBM also lifted the S&P technology sector, which rose 0.10 percent.
"It's a relatively quiet day and some of this is just snap back from yesterday," said Paul Springmeyer, head of investments at U.S. Bank Private Wealth Management in Minneapolis.
"As the information continues to come out, everybody is realizing that we're in a slowing earnings environment, yet have to remind ourselves that is a positive one."
Of the 76 S&P 500 companies that have reported so far, 77.6 percent have beat Wall Street's profit estimates and that is above the historical average of 64 percent, according to Refinitiv data.
However, earnings growth estimates have dropped to 14.2 percent from 20.1 percent at the start of October.
At 11:22 a.m. ET the Dow Jones Industrial Average was up 50.43 points, or 0.21 percent, at 24,454.91, the S&P 500 was down 3.01 points, or 0.11 percent, at 2,629.89 and the Nasdaq Composite was down 12.09 points, or 0.17 percent, at 7,008.26.
A 3.48 percent rise in United Technologies Corp, which reported a better-than-expected quarterly profit, helped the industrials sector eke out a 0.12 percent gain.
The consumer staples sector gained 0.62 percent, the most among the 11 major S&P sector, after Procter & Gamble Co's quarterly revenue beat Wall Street expectation. Its shares rose 4.20 percent.
The biggest decliner in the sector was Kimberly-Clark Corp, which fell 2.62 percent after its quarterly profit missed analysts' estimates due to rising raw materials costs and a strong U.S. dollar.
The energy index slipped 0.56 percent after oil prices fell.
Advancing issues outnumbered decliners by a 1.10-to-1 ratio on the NYSE and by a 1.21-to-1 ratio on the Nasdaq.
The S&P index recorded four new 52-week highs and one new low, while the Nasdaq recorded 16 new highs and 18 new lows.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Shreyashi Sanyal Jan 23 () - The S&P 500 and the Nasdaq reversed course to dip slightly on Wednesday due to losses in healthcare and financial sectors, while the Dow stayed afloat on positive earnings reports from IBM, United Technologies and Procter & Gamble. Wall Street's attempt to rebound from a more than 1 percent loss on Tuesday, which was spurred by worries about slowing global growth, was bolstered by a string of strong corporate earnings. The biggest decliner in the sector was Kimberly-Clark Corp, which fell 2.62 percent after its quarterly profit missed analysts' estimates due to rising raw materials costs and a strong U.S. dollar. | By Shreyashi Sanyal Jan 23 () - The S&P 500 and the Nasdaq reversed course to dip slightly on Wednesday due to losses in healthcare and financial sectors, while the Dow stayed afloat on positive earnings reports from IBM, United Technologies and Procter & Gamble. A 3.48 percent rise in United Technologies Corp, which reported a better-than-expected quarterly profit, helped the industrials sector eke out a 0.12 percent gain. The biggest decliner in the sector was Kimberly-Clark Corp, which fell 2.62 percent after its quarterly profit missed analysts' estimates due to rising raw materials costs and a strong U.S. dollar. | The healthcare sector dropped 0.5 percent, with Abbott Laboratories falling 2.4 percent after projecting current-quarter earnings below analysts' estimates. ET the Dow Jones Industrial Average was up 50.43 points, or 0.21 percent, at 24,454.91, the S&P 500 was down 3.01 points, or 0.11 percent, at 2,629.89 and the Nasdaq Composite was down 12.09 points, or 0.17 percent, at 7,008.26. A 3.48 percent rise in United Technologies Corp, which reported a better-than-expected quarterly profit, helped the industrials sector eke out a 0.12 percent gain. | Wall Street's attempt to rebound from a more than 1 percent loss on Tuesday, which was spurred by worries about slowing global growth, was bolstered by a string of strong corporate earnings. A 3.48 percent rise in United Technologies Corp, which reported a better-than-expected quarterly profit, helped the industrials sector eke out a 0.12 percent gain. The consumer staples sector gained 0.62 percent, the most among the 11 major S&P sector, after Procter & Gamble Co's quarterly revenue beat Wall Street expectation. |
33108.0 | 2019-01-23 00:00:00 UTC | US STOCKS-S&P, Nasdaq dip as healthcare, financials weigh; IBM keeps Dow higher | ABT | https://www.nasdaq.com/articles/us-stocks-sp-nasdaq-dip-healthcare-financials-weigh-ibm-keeps-dow-higher-2019-01-23 | nan | nan | (For a live blog on the U.S. stock market, click LIVE/ or typeLIVE/ in a news window.)
* Three of the 11 major S&P sectors higher
* P&G, UTX, IBM rise after results beat
* Indexes: Dow up 0.21 pct; S&P down 0.11 pct, Nasdaq off0.17 pct (Updates prices, adds comments, background)
By Shreyashi Sanyal
Jan 23 (Reuters) - The S&P 500 and the Nasdaq reversedcourse to dip slightly on Wednesday due to losses in healthcareand financial sectors, while the Dow stayed afloat on positiveearnings reports from IBM, United Technologies and Procter &Gamble.
Eight of the 11 major S&P sectors were lower. The healthcaresector .SPXHC dropped 0.5 percent, with Abbott LaboratoriesABT.N falling 2.4 percent after projecting current-quarterearnings below analysts' estimates.
The financials sector .SPSY was weighed by a 6.38 percentfall in Capital One FinancialCOF.N , after the regional bank'squarterly revenue missed estimates.
Wall Street's attempt to rebound from a more than 1 percentloss on Tuesday, which was spurred by worries about slowingglobal growth, was bolstered by a string of strong corporateearnings.
The blue-chip index .DJI was buoyed by InternationalBusiness Machines CorpIBM.N , which jumped 7.46 percent afterprojecting 2019 profit above expectations.
Gains in shares of IBM also lifted the S&P technology sector .SPLRCT , which rose 0.10 percent.
"It's a relatively quiet day and some of this is just snapback from yesterday," said Paul Springmeyer, head of investmentsat U.S. Bank Private Wealth Management in Minneapolis.
"As the information continues to come out, everybody isrealizing that we're in a slowing earnings environment, yet haveto remind ourselves that is a positive one."
Of the 76 S&P 500 companies that have reported so far, 77.6percent have beat Wall Street's profit estimates and that isabove the historical average of 64 percent, according toRefinitiv data.
However, earnings growth estimates have dropped to 14.2percent from 20.1 percent at the start of October.
At 11:22 a.m. ET the Dow Jones Industrial Average .DJI wasup 50.43 points, or 0.21 percent, at 24,454.91, the S&P 500 .SPX was down 3.01 points, or 0.11 percent, at 2,629.89 andthe Nasdaq Composite .IXIC was down 12.09 points, or 0.17percent, at 7,008.26.
A 3.48 percent rise in United Technologies CorpUTX.N ,which reported a better-than-expected quarterly profit, helpedthe industrials sector .SPLRCI eke out a 0.12 percent gain.
The biggest decliner in the sector was Kimberly-Clark CorpKMB.N , which fell 2.62 percent after its quarterly profitmissed analysts' estimates due to rising raw materials costs anda strong U.S. dollar.
The energy index .SPNY slipped 0.56 percent after oilprices fell. O/R
Advancing issues outnumbered decliners by a 1.10-to-1 ratioon the NYSE and by a 1.21-to-1 ratio on the Nasdaq.
The S&P index recorded four new 52-week highs and one newlow, while the Nasdaq recorded 16 new highs and 18 new lows. (Reporting by Shreyashi Sanyal and additional reporting bySruthi Shankar in Bengaluru; Editing by Arun Koyyur) ((Shreyashi.Sanyal@thomsonreuters.com; +1 646 223 8780 ;Reuters Messaging:Shreyashi.Sanyal.thomsonreuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The healthcaresector .SPXHC dropped 0.5 percent, with Abbott LaboratoriesABT.N falling 2.4 percent after projecting current-quarterearnings below analysts' estimates. Wall Street's attempt to rebound from a more than 1 percentloss on Tuesday, which was spurred by worries about slowingglobal growth, was bolstered by a string of strong corporateearnings. "It's a relatively quiet day and some of this is just snapback from yesterday," said Paul Springmeyer, head of investmentsat U.S. Bank Private Wealth Management in Minneapolis. | The healthcaresector .SPXHC dropped 0.5 percent, with Abbott LaboratoriesABT.N falling 2.4 percent after projecting current-quarterearnings below analysts' estimates. * Three of the 11 major S&P sectors higher * P&G, UTX, IBM rise after results beat * Indexes: Dow up 0.21 pct; S&P down 0.11 pct, Nasdaq off0.17 pct (Updates prices, adds comments, background) By Shreyashi Sanyal Jan 23 (Reuters) - The S&P 500 and the Nasdaq reversedcourse to dip slightly on Wednesday due to losses in healthcareand financial sectors, while the Dow stayed afloat on positiveearnings reports from IBM, United Technologies and Procter &Gamble. A 3.48 percent rise in United Technologies CorpUTX.N ,which reported a better-than-expected quarterly profit, helpedthe industrials sector .SPLRCI eke out a 0.12 percent gain. | The healthcaresector .SPXHC dropped 0.5 percent, with Abbott LaboratoriesABT.N falling 2.4 percent after projecting current-quarterearnings below analysts' estimates. * Three of the 11 major S&P sectors higher * P&G, UTX, IBM rise after results beat * Indexes: Dow up 0.21 pct; S&P down 0.11 pct, Nasdaq off0.17 pct (Updates prices, adds comments, background) By Shreyashi Sanyal Jan 23 (Reuters) - The S&P 500 and the Nasdaq reversedcourse to dip slightly on Wednesday due to losses in healthcareand financial sectors, while the Dow stayed afloat on positiveearnings reports from IBM, United Technologies and Procter &Gamble. ET the Dow Jones Industrial Average .DJI wasup 50.43 points, or 0.21 percent, at 24,454.91, the S&P 500 .SPX was down 3.01 points, or 0.11 percent, at 2,629.89 andthe Nasdaq Composite .IXIC was down 12.09 points, or 0.17percent, at 7,008.26. | The healthcaresector .SPXHC dropped 0.5 percent, with Abbott LaboratoriesABT.N falling 2.4 percent after projecting current-quarterearnings below analysts' estimates. * Three of the 11 major S&P sectors higher * P&G, UTX, IBM rise after results beat * Indexes: Dow up 0.21 pct; S&P down 0.11 pct, Nasdaq off0.17 pct (Updates prices, adds comments, background) By Shreyashi Sanyal Jan 23 (Reuters) - The S&P 500 and the Nasdaq reversedcourse to dip slightly on Wednesday due to losses in healthcareand financial sectors, while the Dow stayed afloat on positiveearnings reports from IBM, United Technologies and Procter &Gamble. A 3.48 percent rise in United Technologies CorpUTX.N ,which reported a better-than-expected quarterly profit, helpedthe industrials sector .SPLRCI eke out a 0.12 percent gain. |
33109.0 | 2019-01-23 00:00:00 UTC | Wall St set to open higher on strong earnings from Dow members | ABT | https://www.nasdaq.com/articles/wall-st-set-open-higher-strong-earnings-dow-members-2019-01-23 | nan | nan | By Shreyashi Sanyal
Jan 23 () - U.S. stocks were set to open higher on Wednesday, with strong earnings from Dow components IBM, United Technologies and Procter & Gamble looking to propel a rebound after Wall Street suffered its second biggest decline in 2019.
Futures pointed to a 0.7 percent gain on the Dow Jones Industrial Average at the open, with shares of International Business Machines Corp jumping 6.9 percent after projecting 2019 profit above expectations.
Fellow industrial companies in the Dow, Boeing Co, Caterpillar Inc and 3M Co rose between 0.2 percent and 0.9 percent.
The gains follow Wall Street's more than 1 percent loss on Tuesday as worries about slowing global growth came to the fore after a gloomy economic outlook from the International Monetary Fund, signs of further cooling in China's economy and mixed reports on U.S.-China trade talks.
"Given a day like yesterday, a bounce driven by earnings is not unusual," said Michael Antonelli, managing director, institutional sales trading at Robert W. Baird in Milwaukee.
"UTX being an industrial company, is definitely something investors are looking at for hints on the impact of a global economic slowdown. The fact that it provided a strong forecast just shows the U.S. economy is actually solid," Antonelli said.
At 8:46 a.m. ET, Dow e-minis were up 159 points, or 0.65 percent. S&P 500 e-minis were up 10 points, or 0.38 percent and Nasdaq 100 e-minis were up 25.75 points, or 0.39 percent.
Despite the pullback on Tuesday, the benchmark S&P 500 index is about 10 percent away from its record closing high on Sept. 20 and has climbed about 5 percent this year.
Procter & Gamble Co rose 4.3 percent after its quarterly revenue beat Wall Street's expectation, driven by strong demand for beauty and fabric care products.
U.S. cable services provider Comcast Corp rose 2.6 percent after its quarterly revenue beat analysts' estimates, helped by lower-than-expected video subscriber losses.
Among the decliners were shares of Kimberly-Clark Corp, which fell 4.2 percent after the Kleenex-tissues maker's profit missed analysts' estimates due to rising raw materials costs and a strong U.S. dollar.
Abbott Laboratories dropped 2.4 percent after the healthcare company missed quarterly revenue estimate due to lower sales of generic drugs in emerging markets and gave a downbeat forecast for the current quarter.
Of the 61 S&P 500 companies that reported until Tuesday, 78.7 percent have beat Wall Street's profit estimates and that is above the historical average of 64 percent, according to Refinitiv data.
However, earnings growth estimates have dropped to 14.1 percent from 20.1 percent at the start of October.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Shreyashi Sanyal Jan 23 () - U.S. stocks were set to open higher on Wednesday, with strong earnings from Dow components IBM, United Technologies and Procter & Gamble looking to propel a rebound after Wall Street suffered its second biggest decline in 2019. The gains follow Wall Street's more than 1 percent loss on Tuesday as worries about slowing global growth came to the fore after a gloomy economic outlook from the International Monetary Fund, signs of further cooling in China's economy and mixed reports on U.S.-China trade talks. Among the decliners were shares of Kimberly-Clark Corp, which fell 4.2 percent after the Kleenex-tissues maker's profit missed analysts' estimates due to rising raw materials costs and a strong U.S. dollar. | Procter & Gamble Co rose 4.3 percent after its quarterly revenue beat Wall Street's expectation, driven by strong demand for beauty and fabric care products. U.S. cable services provider Comcast Corp rose 2.6 percent after its quarterly revenue beat analysts' estimates, helped by lower-than-expected video subscriber losses. Of the 61 S&P 500 companies that reported until Tuesday, 78.7 percent have beat Wall Street's profit estimates and that is above the historical average of 64 percent, according to Refinitiv data. | Futures pointed to a 0.7 percent gain on the Dow Jones Industrial Average at the open, with shares of International Business Machines Corp jumping 6.9 percent after projecting 2019 profit above expectations. S&P 500 e-minis were up 10 points, or 0.38 percent and Nasdaq 100 e-minis were up 25.75 points, or 0.39 percent. Of the 61 S&P 500 companies that reported until Tuesday, 78.7 percent have beat Wall Street's profit estimates and that is above the historical average of 64 percent, according to Refinitiv data. | Futures pointed to a 0.7 percent gain on the Dow Jones Industrial Average at the open, with shares of International Business Machines Corp jumping 6.9 percent after projecting 2019 profit above expectations. Procter & Gamble Co rose 4.3 percent after its quarterly revenue beat Wall Street's expectation, driven by strong demand for beauty and fabric care products. Abbott Laboratories dropped 2.4 percent after the healthcare company missed quarterly revenue estimate due to lower sales of generic drugs in emerging markets and gave a downbeat forecast for the current quarter. |
33110.0 | 2019-01-23 00:00:00 UTC | U.S. STOCKS ON THE MOVE-IBM, Synchrony Financial, Waters, Boxlight | ABT | https://www.nasdaq.com/articles/us-stocks-move-ibm-synchrony-financial-waters-boxlight-2019-01-23 | nan | nan | The Day Ahead newsletter:
The Morning News Call newsletter:
The S&P 500 and the Nasdaq reversed course to dip slightly on Wednesday due to losses in healthcare and financial sectors, while the Dow stayed afloat on positive earnings reports from IBM, United Technologies and Procter & Gamble.
The top three S&P 500 percentage gainers:
** Waters Corp, up 10.1 pct
** Synchrony Financial, up 8.7 pct
** IBM Corp, up 7.6 pct
The top three S&P 500 percentage losers:
** Capital One Financial, down 6.5 pct
** Whirlpool Corp, down 5.3 pct
** Take Two, down 5.1 pct
The top three NYSE percentage gainers:
** Daxor Corp, up 13.2 pct
** Vipshop Hold Ltd, up 10.7 pct
** Waters Corp, up 10.1 pct
The top three NYSE percentage losers:
** Quotient Technlogy, down 14.5 pct
** Ion Geophysical, down 11.5 pct
** Trinseo Sa, down 11.1 pct
The top three Nasdaq percentage gainers:
** Spi Energy Co, up 199.5 pct
** Boxlight Corp, up 40.8 pct
** Blink Charging Co, up 25 pct
The top three Nasdaq percentage losers:
** Avalon Globocare, down 48.2 pct
** Borqs Technl Ord, down 15.6 pct
** Cocrystal Pharma Inc, down 15.4 pct
** United Technologies Corp: up 3.5 pct
United Technologies Corp: Shares rise on Q4 profit beat
United Tech profit beats on higher aero parts sales
** Procter & Gamble Co: up 3.8 pct
Procter & Gamble: Up as Q2 results beat
P&G raises forecast on strength of skin care, detergent brands
** Comcast Corp: up 4.1 pct
Comcast Corp: Set to jump as Q4 revenue beats analyst expectations
Comcast results beat on lower-than-expected video losses
** Rollins Inc: down 4.7 pct
Rollins Inc: Drops after Q4 EPS and revenue miss
** Amdocs Ltd: down 12.4 pct
Amdocs: Short-seller Spruce Point sets 'strong sell' rating
** Waters Corp: up 9.9 pct
Waters Corp: Eyes one-year high on sparkling FY profit forecast
** Quotient Technology: down 15.0 pct
Quotient Technology: Hits near 3-year low after slashing revenue forecast
** Dell: up 1.5 pct
Dell: 'Buy' rating at Citi snaps lackluster Wall St run
** TE Connectivity Ltd: down 2.2 pct
TE Connectivity Ltd: Cuts fiscal 2019 forecast on China weakness
** Accuray Inc: up 11.1 pct
Accuray Inc: Jumps as strong China orders spur profitability target
** Bellerophon Therapeutics: down 23.8 pct
Selecta Biosciences: down 20.0 pct
PTC Therapeutics: down 10.4 pct
Four healthcare companies slide on pricing of stock deals
** Restaurant Brands: up 7.3 pct
Restaurant Brands: Rises after M&A chatter, CEO appointment
Restaurant Brands names Burger King boss Jose Cil as CEO
** IBM Corp: up 7.8 pct
IBM: Gains on strong 2019 profit forecast
** Merck & Co: down 1.1 pct
Merck's Keytruda seems ahead of Bristol-Myers' Opdivo in Q4
** Tesla Inc: down 2.6 pct
Tesla: 'Dream deferred,' sell the 'Elon premium' - RBC
** Walmart Inc: up 0.6 pct
MS cautious of hard goods retailers, ups Walmart to 'outperform'
** Teva Pharmaceuticals Industries Ltd: up 2.9 pct
Teva: Rises after UBS says stock "too cheap to ignore", upgrades
** Synchrony Financial: up 9.6 pct
Synchrony Financial: Rises after Walmart drops lawsuit, strong Q4 results
** Kimberly-Clark Corp: down 3.0 pct
Kimberly-Clark: Drops on weak 2019 profit forecast
Kimberly-Clark misses profit estimates, shares fall
** Abbott Laboratories: down 2.1 pct
Abbott Labs: Falls on Q4 revenue miss; weak Q1 profit forecast
** Athersys Inc: up 12.9 pct
Athersys: Surges on positive lung disease treatment results
The 11 major S&P 500 sectors:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: The S&P 500 and the Nasdaq reversed course to dip slightly on Wednesday due to losses in healthcare and financial sectors, while the Dow stayed afloat on positive earnings reports from IBM, United Technologies and Procter & Gamble. The top three S&P 500 percentage gainers: ** Waters Corp, up 10.1 pct ** Synchrony Financial, up 8.7 pct ** IBM Corp, up 7.6 pct The top three S&P 500 percentage losers: ** Capital One Financial, down 6.5 pct ** Whirlpool Corp, down 5.3 pct ** Take Two, down 5.1 pct The top three NYSE percentage gainers: ** Daxor Corp, up 13.2 pct ** Vipshop Hold Ltd, up 10.7 pct ** Waters Corp, up 10.1 pct The top three NYSE percentage losers: ** Quotient Technlogy, down 14.5 pct ** Ion Geophysical, down 11.5 pct ** Trinseo Sa, down 11.1 pct The top three Nasdaq percentage gainers: ** Spi Energy Co, up 199.5 pct ** Boxlight Corp, up 40.8 pct ** Blink Charging Co, up 25 pct The top three Nasdaq percentage losers: ** Avalon Globocare, down 48.2 pct ** Borqs Technl Ord, down 15.6 pct ** Cocrystal Pharma Inc, down 15.4 pct ** United Technologies Corp: up 3.5 pct United Technologies Corp: Shares rise on Q4 profit beat United Tech profit beats on higher aero parts sales ** Procter & Gamble Co: up 3.8 pct Procter & Gamble: Up as Q2 results beat P&G raises forecast on strength of skin care, detergent brands ** Comcast Corp: up 4.1 pct Comcast Corp: Set to jump as Q4 revenue beats analyst expectations Comcast results beat on lower-than-expected video losses ** Rollins Inc: down 4.7 pct Rollins Inc: Drops after Q4 EPS and revenue miss ** Amdocs Ltd: down 12.4 pct Amdocs: Short-seller Spruce Point sets 'strong sell' rating ** Waters Corp: up 9.9 pct Waters Corp: Eyes one-year high on sparkling FY profit forecast ** Quotient Technology: down 15.0 pct Quotient Technology: Hits near 3-year low after slashing revenue forecast ** Dell: up 1.5 pct Dell: 'Buy' rating at Citi snaps lackluster Wall St run ** TE Connectivity Ltd: down 2.2 pct TE Connectivity Ltd: Cuts fiscal 2019 forecast on China weakness ** Accuray Inc: up 11.1 pct Accuray Inc: Jumps as strong China orders spur profitability target ** Bellerophon Therapeutics: down 23.8 pct Selecta Biosciences: down 20.0 pct PTC Therapeutics: down 10.4 pct Four healthcare companies slide on pricing of stock deals ** Restaurant Brands: up 7.3 pct Restaurant Brands: Rises after M&A chatter, CEO appointment Restaurant Brands names Burger King boss Jose Cil as CEO ** IBM Corp: up 7.8 pct IBM: Gains on strong 2019 profit forecast ** Merck & Co: down 1.1 pct Merck's Keytruda seems ahead of Bristol-Myers' Opdivo in Q4 ** Tesla Inc: down 2.6 pct Tesla: 'Dream deferred,' sell the 'Elon premium' - RBC ** Walmart Inc: up 0.6 pct MS cautious of hard goods retailers, ups Walmart to 'outperform' ** Teva Pharmaceuticals Industries Ltd: up 2.9 pct Teva: Rises after UBS says stock "too cheap to ignore", upgrades ** Synchrony Financial: up 9.6 pct Synchrony Financial: Rises after Walmart drops lawsuit, strong Q4 results ** Kimberly-Clark Corp: down 3.0 pct Kimberly-Clark: Drops on weak 2019 profit forecast Kimberly-Clark misses profit estimates, shares fall ** Abbott Laboratories: down 2.1 pct Abbott Labs: Falls on Q4 revenue miss; weak Q1 profit forecast ** Athersys Inc: up 12.9 pct Athersys: Surges on positive lung disease treatment results The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: The S&P 500 and the Nasdaq reversed course to dip slightly on Wednesday due to losses in healthcare and financial sectors, while the Dow stayed afloat on positive earnings reports from IBM, United Technologies and Procter & Gamble. The top three S&P 500 percentage gainers: ** Waters Corp, up 10.1 pct ** Synchrony Financial, up 8.7 pct ** IBM Corp, up 7.6 pct The top three S&P 500 percentage losers: ** Capital One Financial, down 6.5 pct ** Whirlpool Corp, down 5.3 pct ** Take Two, down 5.1 pct The top three NYSE percentage gainers: ** Daxor Corp, up 13.2 pct ** Vipshop Hold Ltd, up 10.7 pct ** Waters Corp, up 10.1 pct The top three NYSE percentage losers: ** Quotient Technlogy, down 14.5 pct ** Ion Geophysical, down 11.5 pct ** Trinseo Sa, down 11.1 pct The top three Nasdaq percentage gainers: ** Spi Energy Co, up 199.5 pct ** Boxlight Corp, up 40.8 pct ** Blink Charging Co, up 25 pct The top three Nasdaq percentage losers: ** Avalon Globocare, down 48.2 pct ** Borqs Technl Ord, down 15.6 pct ** Cocrystal Pharma Inc, down 15.4 pct ** United Technologies Corp: up 3.5 pct United Technologies Corp: Shares rise on Q4 profit beat United Tech profit beats on higher aero parts sales ** Procter & Gamble Co: up 3.8 pct Procter & Gamble: Up as Q2 results beat P&G raises forecast on strength of skin care, detergent brands ** Comcast Corp: up 4.1 pct Comcast Corp: Set to jump as Q4 revenue beats analyst expectations Comcast results beat on lower-than-expected video losses ** Rollins Inc: down 4.7 pct Rollins Inc: Drops after Q4 EPS and revenue miss ** Amdocs Ltd: down 12.4 pct Amdocs: Short-seller Spruce Point sets 'strong sell' rating ** Waters Corp: up 9.9 pct Waters Corp: Eyes one-year high on sparkling FY profit forecast ** Quotient Technology: down 15.0 pct Quotient Technology: Hits near 3-year low after slashing revenue forecast ** Dell: up 1.5 pct Dell: 'Buy' rating at Citi snaps lackluster Wall St run ** TE Connectivity Ltd: down 2.2 pct TE Connectivity Ltd: Cuts fiscal 2019 forecast on China weakness ** Accuray Inc: up 11.1 pct Accuray Inc: Jumps as strong China orders spur profitability target ** Bellerophon Therapeutics: down 23.8 pct Selecta Biosciences: down 20.0 pct PTC Therapeutics: down 10.4 pct Four healthcare companies slide on pricing of stock deals ** Restaurant Brands: up 7.3 pct Restaurant Brands: Rises after M&A chatter, CEO appointment Restaurant Brands names Burger King boss Jose Cil as CEO ** IBM Corp: up 7.8 pct IBM: Gains on strong 2019 profit forecast ** Merck & Co: down 1.1 pct Merck's Keytruda seems ahead of Bristol-Myers' Opdivo in Q4 ** Tesla Inc: down 2.6 pct Tesla: 'Dream deferred,' sell the 'Elon premium' - RBC ** Walmart Inc: up 0.6 pct MS cautious of hard goods retailers, ups Walmart to 'outperform' ** Teva Pharmaceuticals Industries Ltd: up 2.9 pct Teva: Rises after UBS says stock "too cheap to ignore", upgrades ** Synchrony Financial: up 9.6 pct Synchrony Financial: Rises after Walmart drops lawsuit, strong Q4 results ** Kimberly-Clark Corp: down 3.0 pct Kimberly-Clark: Drops on weak 2019 profit forecast Kimberly-Clark misses profit estimates, shares fall ** Abbott Laboratories: down 2.1 pct Abbott Labs: Falls on Q4 revenue miss; weak Q1 profit forecast ** Athersys Inc: up 12.9 pct Athersys: Surges on positive lung disease treatment results The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: The S&P 500 and the Nasdaq reversed course to dip slightly on Wednesday due to losses in healthcare and financial sectors, while the Dow stayed afloat on positive earnings reports from IBM, United Technologies and Procter & Gamble. The top three S&P 500 percentage gainers: ** Waters Corp, up 10.1 pct ** Synchrony Financial, up 8.7 pct ** IBM Corp, up 7.6 pct The top three S&P 500 percentage losers: ** Capital One Financial, down 6.5 pct ** Whirlpool Corp, down 5.3 pct ** Take Two, down 5.1 pct The top three NYSE percentage gainers: ** Daxor Corp, up 13.2 pct ** Vipshop Hold Ltd, up 10.7 pct ** Waters Corp, up 10.1 pct The top three NYSE percentage losers: ** Quotient Technlogy, down 14.5 pct ** Ion Geophysical, down 11.5 pct ** Trinseo Sa, down 11.1 pct The top three Nasdaq percentage gainers: ** Spi Energy Co, up 199.5 pct ** Boxlight Corp, up 40.8 pct ** Blink Charging Co, up 25 pct The top three Nasdaq percentage losers: ** Avalon Globocare, down 48.2 pct ** Borqs Technl Ord, down 15.6 pct ** Cocrystal Pharma Inc, down 15.4 pct ** United Technologies Corp: up 3.5 pct United Technologies Corp: Shares rise on Q4 profit beat United Tech profit beats on higher aero parts sales ** Procter & Gamble Co: up 3.8 pct Procter & Gamble: Up as Q2 results beat P&G raises forecast on strength of skin care, detergent brands ** Comcast Corp: up 4.1 pct Comcast Corp: Set to jump as Q4 revenue beats analyst expectations Comcast results beat on lower-than-expected video losses ** Rollins Inc: down 4.7 pct Rollins Inc: Drops after Q4 EPS and revenue miss ** Amdocs Ltd: down 12.4 pct Amdocs: Short-seller Spruce Point sets 'strong sell' rating ** Waters Corp: up 9.9 pct Waters Corp: Eyes one-year high on sparkling FY profit forecast ** Quotient Technology: down 15.0 pct Quotient Technology: Hits near 3-year low after slashing revenue forecast ** Dell: up 1.5 pct Dell: 'Buy' rating at Citi snaps lackluster Wall St run ** TE Connectivity Ltd: down 2.2 pct TE Connectivity Ltd: Cuts fiscal 2019 forecast on China weakness ** Accuray Inc: up 11.1 pct Accuray Inc: Jumps as strong China orders spur profitability target ** Bellerophon Therapeutics: down 23.8 pct Selecta Biosciences: down 20.0 pct PTC Therapeutics: down 10.4 pct Four healthcare companies slide on pricing of stock deals ** Restaurant Brands: up 7.3 pct Restaurant Brands: Rises after M&A chatter, CEO appointment Restaurant Brands names Burger King boss Jose Cil as CEO ** IBM Corp: up 7.8 pct IBM: Gains on strong 2019 profit forecast ** Merck & Co: down 1.1 pct Merck's Keytruda seems ahead of Bristol-Myers' Opdivo in Q4 ** Tesla Inc: down 2.6 pct Tesla: 'Dream deferred,' sell the 'Elon premium' - RBC ** Walmart Inc: up 0.6 pct MS cautious of hard goods retailers, ups Walmart to 'outperform' ** Teva Pharmaceuticals Industries Ltd: up 2.9 pct Teva: Rises after UBS says stock "too cheap to ignore", upgrades ** Synchrony Financial: up 9.6 pct Synchrony Financial: Rises after Walmart drops lawsuit, strong Q4 results ** Kimberly-Clark Corp: down 3.0 pct Kimberly-Clark: Drops on weak 2019 profit forecast Kimberly-Clark misses profit estimates, shares fall ** Abbott Laboratories: down 2.1 pct Abbott Labs: Falls on Q4 revenue miss; weak Q1 profit forecast ** Athersys Inc: up 12.9 pct Athersys: Surges on positive lung disease treatment results The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: The S&P 500 and the Nasdaq reversed course to dip slightly on Wednesday due to losses in healthcare and financial sectors, while the Dow stayed afloat on positive earnings reports from IBM, United Technologies and Procter & Gamble. The top three S&P 500 percentage gainers: ** Waters Corp, up 10.1 pct ** Synchrony Financial, up 8.7 pct ** IBM Corp, up 7.6 pct The top three S&P 500 percentage losers: ** Capital One Financial, down 6.5 pct ** Whirlpool Corp, down 5.3 pct ** Take Two, down 5.1 pct The top three NYSE percentage gainers: ** Daxor Corp, up 13.2 pct ** Vipshop Hold Ltd, up 10.7 pct ** Waters Corp, up 10.1 pct The top three NYSE percentage losers: ** Quotient Technlogy, down 14.5 pct ** Ion Geophysical, down 11.5 pct ** Trinseo Sa, down 11.1 pct The top three Nasdaq percentage gainers: ** Spi Energy Co, up 199.5 pct ** Boxlight Corp, up 40.8 pct ** Blink Charging Co, up 25 pct The top three Nasdaq percentage losers: ** Avalon Globocare, down 48.2 pct ** Borqs Technl Ord, down 15.6 pct ** Cocrystal Pharma Inc, down 15.4 pct ** United Technologies Corp: up 3.5 pct United Technologies Corp: Shares rise on Q4 profit beat United Tech profit beats on higher aero parts sales ** Procter & Gamble Co: up 3.8 pct Procter & Gamble: Up as Q2 results beat P&G raises forecast on strength of skin care, detergent brands ** Comcast Corp: up 4.1 pct Comcast Corp: Set to jump as Q4 revenue beats analyst expectations Comcast results beat on lower-than-expected video losses ** Rollins Inc: down 4.7 pct Rollins Inc: Drops after Q4 EPS and revenue miss ** Amdocs Ltd: down 12.4 pct Amdocs: Short-seller Spruce Point sets 'strong sell' rating ** Waters Corp: up 9.9 pct Waters Corp: Eyes one-year high on sparkling FY profit forecast ** Quotient Technology: down 15.0 pct Quotient Technology: Hits near 3-year low after slashing revenue forecast ** Dell: up 1.5 pct Dell: 'Buy' rating at Citi snaps lackluster Wall St run ** TE Connectivity Ltd: down 2.2 pct TE Connectivity Ltd: Cuts fiscal 2019 forecast on China weakness ** Accuray Inc: up 11.1 pct Accuray Inc: Jumps as strong China orders spur profitability target ** Bellerophon Therapeutics: down 23.8 pct Selecta Biosciences: down 20.0 pct PTC Therapeutics: down 10.4 pct Four healthcare companies slide on pricing of stock deals ** Restaurant Brands: up 7.3 pct Restaurant Brands: Rises after M&A chatter, CEO appointment Restaurant Brands names Burger King boss Jose Cil as CEO ** IBM Corp: up 7.8 pct IBM: Gains on strong 2019 profit forecast ** Merck & Co: down 1.1 pct Merck's Keytruda seems ahead of Bristol-Myers' Opdivo in Q4 ** Tesla Inc: down 2.6 pct Tesla: 'Dream deferred,' sell the 'Elon premium' - RBC ** Walmart Inc: up 0.6 pct MS cautious of hard goods retailers, ups Walmart to 'outperform' ** Teva Pharmaceuticals Industries Ltd: up 2.9 pct Teva: Rises after UBS says stock "too cheap to ignore", upgrades ** Synchrony Financial: up 9.6 pct Synchrony Financial: Rises after Walmart drops lawsuit, strong Q4 results ** Kimberly-Clark Corp: down 3.0 pct Kimberly-Clark: Drops on weak 2019 profit forecast Kimberly-Clark misses profit estimates, shares fall ** Abbott Laboratories: down 2.1 pct Abbott Labs: Falls on Q4 revenue miss; weak Q1 profit forecast ** Athersys Inc: up 12.9 pct Athersys: Surges on positive lung disease treatment results The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33111.0 | 2019-01-23 00:00:00 UTC | Abbott Sees Q1 Profit Below View | ABT | https://www.nasdaq.com/articles/abbott-sees-q1-profit-below-view-2019-01-23 | nan | nan | (RTTNews.com) - Abbott Laboratories ( ABT ) said it expects first-quarter 2019 earnings per share from continuing operations under GAAP of $0.25 to $0.27. Abbott forecasts specified items for the first quarter 2019 of $0.35 per share primarily related to intangible amortization, acquisition-related expenses, cost reduction initiatives and other expenses. Excluding specified items, projected adjusted earnings per share from continuing operations would be $0.60 to $0.62 for the first quarter. Analysts polled by Thomson Reuters expect the company to report earnings of $0.64 per share. Analysts' estimates typically exclude special items.
Looking ahead for full-year 2019, the company projects full-year 2019 organic sales growth of 6.5 to 7.5 percent, which excludes the impact of foreign exchange, and earnings per share from continuing operations of $1.80 to $1.90. Abbott forecasts net specified items for the full year 2019 of $1.35 per share. Specified items include intangible amortization expense, acquisition-related expenses, charges associated with cost reduction initiatives and other expenses. Excluding specified items, projected adjusted earnings per share from continuing operations would be $3.15 to $3.25 for the full year 2019. Analysts expect annual earnings of $3.20 per share.
Read the original article on RTTNews (http://www.rttnews.com/2971821/abbott-sees-q1-profit-below-view.aspx)
For comments and feedback: contact editorial@rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews.com) - Abbott Laboratories ( ABT ) said it expects first-quarter 2019 earnings per share from continuing operations under GAAP of $0.25 to $0.27. Excluding specified items, projected adjusted earnings per share from continuing operations would be $0.60 to $0.62 for the first quarter. Excluding specified items, projected adjusted earnings per share from continuing operations would be $3.15 to $3.25 for the full year 2019. | (RTTNews.com) - Abbott Laboratories ( ABT ) said it expects first-quarter 2019 earnings per share from continuing operations under GAAP of $0.25 to $0.27. Abbott forecasts specified items for the first quarter 2019 of $0.35 per share primarily related to intangible amortization, acquisition-related expenses, cost reduction initiatives and other expenses. Excluding specified items, projected adjusted earnings per share from continuing operations would be $0.60 to $0.62 for the first quarter. | (RTTNews.com) - Abbott Laboratories ( ABT ) said it expects first-quarter 2019 earnings per share from continuing operations under GAAP of $0.25 to $0.27. Abbott forecasts specified items for the first quarter 2019 of $0.35 per share primarily related to intangible amortization, acquisition-related expenses, cost reduction initiatives and other expenses. Excluding specified items, projected adjusted earnings per share from continuing operations would be $0.60 to $0.62 for the first quarter. | (RTTNews.com) - Abbott Laboratories ( ABT ) said it expects first-quarter 2019 earnings per share from continuing operations under GAAP of $0.25 to $0.27. Abbott forecasts specified items for the first quarter 2019 of $0.35 per share primarily related to intangible amortization, acquisition-related expenses, cost reduction initiatives and other expenses. Excluding specified items, projected adjusted earnings per share from continuing operations would be $3.15 to $3.25 for the full year 2019. |
33112.0 | 2019-01-23 00:00:00 UTC | Abbott misses revenue estimates, sees lackluster first-qtr profit | ABT | https://www.nasdaq.com/articles/abbott-misses-revenue-estimates-sees-lackluster-first-qtr-profit-2019-01-23 | nan | nan | By Manas Mishra
Jan 23 () - Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.
Shares of the Chicago-based company were down 2.1 percent at $70.02 in afternoon trading.
He added he thought the underlying growth rates in emerging markets were solid, and that the company could power through the "windiness of the currency markets."
A strengthening dollar is expected to hurt profits at large medical device makers that derive a large chunk of their revenue from outside the United States.
Abbott said it expects adjusted earnings of 60 cents to 62 cents per share in the first quarter, below estimates of 64 cents, according to IBES data from Refinitiv.
"Some may look at these results and guidance as nothing too special, especially since Abbott had a lower tax rate than what we were anticipating, which helped this quarter's results," Edward Jones analyst John Boylan said.
Abbott forecast full-year organic sales growth in the range of 6.5 percent to 7.5 percent, after posting a 7.3 percent organic sales growth in 2018.
Cowen and Co analyst Joshua Jennings said he is optimistic that Abbott can continue to generate above consensus results in 2019, given the consistency and strength of its top-line growth.
Fourth-quarter sales in the company's pharmaceuticals unit, which sells generic drugs in countries such as India and China, fell 4.8 percent to $1.09 billion, while analysts on average had expected $1.16 billion.
A better-than-expected 6.7 percent rise in sales at the medical device segment, its largest, partly lifted the overall sales by 2.3 percent to $7.77 billion, but missed expectation of $7.82 billion.
The company posted net earnings of $654 million in the fourth quarter ended Dec. 31, compared with a loss of $828 million a year earlier, when it had taken a $1.4 billion charge related to the U.S. tax overhaul.
Excluding items, the company earned 81 cents per share, in line with estimates.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Manas Mishra Jan 23 () - Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations. Cowen and Co analyst Joshua Jennings said he is optimistic that Abbott can continue to generate above consensus results in 2019, given the consistency and strength of its top-line growth. Excluding items, the company earned 81 cents per share, in line with estimates. | By Manas Mishra Jan 23 () - Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations. Abbott said it expects adjusted earnings of 60 cents to 62 cents per share in the first quarter, below estimates of 64 cents, according to IBES data from Refinitiv. Abbott forecast full-year organic sales growth in the range of 6.5 percent to 7.5 percent, after posting a 7.3 percent organic sales growth in 2018. | Abbott forecast full-year organic sales growth in the range of 6.5 percent to 7.5 percent, after posting a 7.3 percent organic sales growth in 2018. Fourth-quarter sales in the company's pharmaceuticals unit, which sells generic drugs in countries such as India and China, fell 4.8 percent to $1.09 billion, while analysts on average had expected $1.16 billion. A better-than-expected 6.7 percent rise in sales at the medical device segment, its largest, partly lifted the overall sales by 2.3 percent to $7.77 billion, but missed expectation of $7.82 billion. | By Manas Mishra Jan 23 () - Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations. Abbott forecast full-year organic sales growth in the range of 6.5 percent to 7.5 percent, after posting a 7.3 percent organic sales growth in 2018. Excluding items, the company earned 81 cents per share, in line with estimates. |
33113.0 | 2019-01-23 00:00:00 UTC | Abbott Laboratories (ABT) Q4 2018 Earnings Conference Call Transcript | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-q4-2018-earnings-conference-call-transcript-2019-01-23 | nan | nan | Abbott Laboratories (NYSE: ABT)
Q4 2018 Earnings Conference Call
Jan. 23, 2019, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning and thank you for standing by. Welcome to Abbott's Fourth Quarter 2018 Earnings Conference Call. All participants will be able to listen only until the question and answer portion of this call. During the question and answer session, you will be able to ask your questions by pressing *1 on your touchtone phone. Should you become disconnected throughout this conference call, please redial the number provided to you and reference the Abbott earnings call .
This call is being recorded by Abbott. With the exception of any participants' questions asked during the question and answer session, the entire call, including the question and answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's express written permission. I would now like to introduce Mr. Scott Leinenweber, Vice President, Investor Relations, Licensing, and Acquisitions.
Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions
Good morning and thank you for joining us. With me today are Miles White, Chairman of the Board and Chief Executive Officer, and Brian Yoor, Executive Vice President, Finance and Chief Financial Officer. Miles will provide opening remarks and Brian will discuss our performance and outlook in more detail. Following their comments, Miles, Brian, and I will take your questions.
Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2019. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological, and other factors that may affect Abbott's operations are discussed in Items 1A, Risk Factors, to our annual report on Securities and Exchange Commission Form 10-K for the year ended December 31st, 2017. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments except as required by law. Please note that fourth-quarter financial results and guidance provided on the call today for sales, EPS, and line items of the P&L will be for continuing operations only.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
On today's conference call, as in the past, non-GAAP financial measures will be used to help investors understand Abbott's ongoing business performance. These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at Abbott.com. Unless otherwise noted, our commentary on sales growth refers to organic sales growth, which is defined in our earnings news release issued earlier today. With that, I will now turn the call over to Miles.
Miles D. White -- Chairman and Chief Executive Officer
Thanks, Scott, and good morning. Today, I'll discuss our 2018 results as well as our outlook for 2019. For the full year 2018, we achieved ongoing earnings per share of $2.88, representing 15% growth versus the prior year. Strong performance across our businesses along with underlying margin expansion and our synergy capture from recent acquisitions enabled us to achieve EPS at the upper end of the initial guidance range we issued at the beginning of last year despite unfavorable currency shifts as we progressed through the year.
With our recent strategic shaping completed, our focus in 2018 was on running the company we've built, and the result was an excellent year by every measure. All four of our major businesses performed well, contributing to overall organic sales growth of more than 7%, which is above the initial guidance range we set at the beginning of last year. At the same time, we generated operating cash flow of more than $6 billion, returning $2 billion to shareholders in the form o f dividends , and announced a 14% increase in our dividend beginning this year.
We also increased our investments in capabilities for the future, including expanding manufacturing capacity in two important areas that will drive significant long-term growth: Freestyle Libre, our revolutionary continuous glucose monitoring system, and Alinity, our family of highly differentiated diagnostic systems. And lastly, following two major acquisitions in 2017, we repaid more than $8 billion of debt, which significantly enhances our strategic flexibility going forward.
Our performance this past year demonstrates the strength of our strategy and execution, and for 2019, we're forecasting another year of strong financial performance. As we announced this morning, we forecast organic sales growth of 6.5-7.5% and adjusted earnings per share of $3.15-3.25, reflecting double-digit growth.
I'll now provide a brief overview of our 2018 results and 2019 outlook for each business. I'll start with Nutrition, where sales increased mid-single digits in 2018, reflecting a notable improvement in our growth rate versus the prior year. Sales growth this past year was well balanced across our pediatric and adult nutrition businesses. Internationally, our focus on enhancing competitiveness with our well-known and trusted brands led to strong growth in both Asia and Latin America. In China, we saw improvement in both the market and our performance after the government transitioned to new food safety regulations in that country at the beginning of last year.
And, in the U.S., growth was driven by our pediatric nutrition business, led by above-market growth of Similac, our market-leading infant formula brand, and Pedialite, our market-leading rehydration brand. Overall, the fundamental demographic and socioeconomic trends in the global nutrition market remain favorable and our position in the market remains very competitive.
In Established Pharmaceuticals or EPD, sales grew 7% in 2018, led by double-digit growth in both India and China. Our strategy in EPD is unique and quite simple: To build significant presence, scale, and leadership positions in the most attractive emerging markets, where long-term growth in medicines will be driven by aging populations and the related rise in chronic diseases, increasing incomes, and expanding access to care.
We've built our business over time through a series of strategic steps to be powered globally but driven locally. Our global scale sets us apart and provides a unique competitive advantage versus local players, particularly when it comes to manufacturing and innovation, and our local decision-making allows us to be nimble and navigate the complexities of each country. Healthcare spending in most emerging markets is less than half that of developed markets, which means there's lots of room for future growth, and our focus continues to be on strong execution across all elements of our business model to capitalize on the growth opportunities ahead.
Moving to Diagnostics, where we've consistently achieved above-market growth with our leading platforms, 2018 was no different, with global organic sales growth of 7%. This past year was particularly important as we accelerated the launch of Alinity, our family of highly differentiated instruments, in Europe and other international markets. Customer feedback has been outstanding, which quite frankly isn't a surprise to us given that Alinity was designed based on countless hours of listening to and observing the needs of our customers. These systems are designed to be more efficient, running more tests in less space, generating results faster, minimizing human errors while continuing to provide quality results.
In 2019, while the international launch continues to gain momentum, we anticipate obtaining U.S. regulatory approvals for a critical mass of our test menu over the coming months, which will allow us to accelerate the launch of Alinity in the U.S. later this year.
2018 was also an important year for our newly formed Rapid Diagnostics business. We achieved our sales and synergy targets for the year and are very pleased with the pace and progress of the integration of this business. We also made important advancements in our pipeline, with new product launches in the areas of diabetes and cardiac care, as well as molecular rapid tests for infectious diseases. These new products, along with continued focus on strong execution across our portfolio, will drive accelerated growth for this business going forward.
Lastly, I'll cover Medical Devices, where sales grew 9% in 2018, exceeding the initial guidance range we set at the beginning of the year. Strong growth this past year was led by several areas, including electrophysiology, structural heart, and diabetes care, as well as stabilization in our rhythm management and vascular businesses. In electrophysiology, growth of 20% was led by our heart-mapping and ablation portfolio. During the year, we advanced our product portfolio in this area with the launch of our Advisor HD catheter, which creates highly detailed maps of the heart, and earlier this week, we announced U.S. FDA approval of our innovative TactiCath sensor-enabled catheter, which will further strengthen our competitiveness in this highly underpenetrated market.
In structural heart, 2018 was a landmark year for our business. We achieved double-digit growth, and perhaps more importantly, announced clinical trial results from MitraClip, our market-leading device for the minimally invasive repair of the mitral valve, which demonstrated improved survival and clinical outcomes in patients with the most prevalent form of this heart disease. We submitted the study data to the U.S. FDA during the fourth quarter to support consideration of an expanded indication for MitraClip. If approved, this advancement would further enhance our leadership position in this large and highly underpenetrated disease area and offer the potential to create a new multi-billion-dollar cardiac device market over time.
And lastly, in diabetes care, we achieved growth of 35% in 2018. Growth was led by Freestyle Libre, which achieved global sales of more than $1 billion, an increase of 100% versus the prior year. During the fourth quarter, we added 300,000 new users. As of the end of 2018, there are now approximately 1.3 million active users worldwide, of which approximately two thirds are Type 1 diabetics and one third are Type 2. In the U.S., we saw an accelerating trend of new users as we ramped up our awareness efforts during the second half of the year, and pharmacy insurance coverage continued to increase, including an emerging trend of seeing Libre granted preferred copay status versus competitive systems due to its compelling overall value proposition.
In Europe, during the fourth quarter, we initiated the launch of Libre 2.0, which includes optional alarms to warn patients if glucose levels fall out of range. Due to our unique product design and highly automated manufacturing process, we're able to offer this feature to Libre users without increasing the cash-paid price. This affordable and simple-to-use device is fundamentally changing the way people with diabetes manage their disease, and given the fact that more than 400 million people are living with diabetes around the world, Libre promises to be a significant growth driver for years to come.
So, in summary, 2018 was another outstanding year for us. We achieved our strategic and financial objectives despite challenging currency shifts during the year. Our top-tier performance demonstrates the strength of our strategy, our portfolio, and our execution, and for 2019, we're forecasting continued strong organic sales growth and double-digit EPS growth. I'll now turn the call over to Brian to discuss our 2018 results and our 2019 outlook in a bit more detail. Brian?
Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer
Thanks, Miles. As Scott mentioned earlier, please note that all references to sales growth rates -- unless otherwise noted -- are on an organic basis, which is consistent with our previous guidance. Turning to our results, sales for the fourth quarter increased 6.4% on an organic basis, in line with our guidance of mid- to high-single-digit growth. Rapid Diagnostics, which was acquired in late 2017, and is therefore not included in our 2018 organic sales growth results, achieved sales of $548 million. Exchange had an unfavorable year-over-year impact of 3.7% on fourth-quarter sales.
During the quarter, we saw the U.S. dollar continue to strengthen modestly, resulting in a somewhat larger unfavorable impact on our results in the fourth quarter compared to expectations had exchange rates held steady since the time of our earnings call in October. Regarding other aspects of the P&L, the adjusted gross margin ratio was 59.3% of sales, adjusted R&D investment was 7.2% of sales, and adjusted SG&A expense was 29.2% of sales. Overall, as we look back at 2018, we delivered strong organic sales growth of more than 7%, adjusted earnings-per-share growth of 15%, and exceeded our cash flow and debt repayment objectives.
Turning to our outlook for the full year 2019, today we issued guidance for adjusted earnings per share of $3.15-3.25. For the full year, we forecast organic sales growth of 6.5-7.5%. Based on current rates, we would expect exchange to have an unfavorable impact of approximately 3% on our full-year reported sales, with the vast majority of the impact expected to occur in the first half of the year. We forecast an adjusted gross margin ratio of somewhat above 59.5% of sales for the full year, which reflects underlying gross margin improvement across our businesses, partially offset by the impact of currency. We forecast adjusted R&D investment of around 7.5% of sales and adjusted SG&A expense of approximately 29.5% of sales. We forecast net interest expense of around $600 million and non-operating income of around $200 million. Lastly, we forecast an adjusted tax rate of around 15% for the full year 2019, which contemplates the anticipated impact from U.S. tax reform.
Turning to our outlook for the first quarter, we forecast adjusted EPS of $0.60-0.62, which reflects strong double-digit underlying growth, partially offset by the impact of foreign exchange on our results. We forecast organic sales growth of a little less than 7%, which contemplates a difficult comparison versus the first quarter of last year, when we saw abnormally strong sales in our Rapid Diagnostics business due to a record flu season. At current rates, we would expect exchange to have a negative impact of around 5.5% on our first-quarter reported sales. We forecast an adjusted gross margin ratio of around 58.5% of sales, adjusted R&D investment of around 7.5% of sales, and adjusted SG&A expense of somewhat above 32% of sales.
Before we open the call for questions, I'll now provide a quick overview of our first-quarter and full-year organic sales growth outlook by business. For Established Pharmaceuticals, we forecast mid-single-digit growth in the first quarter, which is comprised of mid- to high-single-digit growth in our priority key emerging markets along with a modest decline in other EPD sales, which reflects the recent discontinuation of a non-core, low-margin, third-party supply agreement. For the full year, we forecast Established Pharmaceuticals growth of mid- to high-single digits.
In Nutrition, we forecast low- to mid-single digit growth for both the first quarter and the full year. In Diagnostics, we forecast Abbott's legacy Diagnostics businesses, which is comprised of core laboratory, molecular, and point-of-care, to grow mid- to high-single digits for both the first quarter and full year, driven by continued strong sales momentum across our portfolio of instruments.
Rapid Diagnostics, which will now be included in our organic sales growth results in 2019, is expected to be relatively flat in the first quarter, reflecting the difficult flu season comparison I mentioned earlier. For the full year, we forecast Rapid Diagnostics growth of low- to mid-single digits. And, in Medical Devices, we forecast high-single-digit sales growth for both the first quarter and the full year, which reflects continued double-digit growth in several areas of the business. With that, we will now open the call for questions.
Questions and Answers:
Operator
Ladies and gentlemen, if you have a question at this time, please press *1 on your touchtone telephone. If your question has been answered or you wish to remove yourself from the queue, please press #. We kindly ask that if you are using a speakerphone, please pick up the handset before asking your question. And again, that's *1 to ask a question. And, our first question will come from Matt Taylor from UBS. Your line is open.
Matt Taylor -- UBS -- Executive Director
Hi. Thank you for taking the question. I wanted to ask about Freestyle Libre to start off. You had another good quarter of patient add, and it seems like you're expanding more into Type 2 with the new disclosure. Could you talk about the trends there, what the 2.0 adds, and some of your longer-term vision for Libre?
Miles D. White -- Chairman and Chief Executive Officer
Sure, Matt. Well, two things about Libre -- actually, several things about Libre. First of all, it's going extremely well. We did add 300,000 patients last quarter. That's almost equivalent to the entire user base of the No. 2 competitor in the space, so I'd say that's going very well. We've got over 1.3 million patients now. Two thirds of those are Type 1. Our intent with this device has been to serve the entire diabetic community and not niche it because we think it has mass-market potential worldwide. So, we target both segments -- both Type 1 and Type 2 -- and we're doing very well in the Type 1 segment, actually, and as our capacity expands, we'll put even more effort behind the expansion with Type 2 patients.
There's a constant...I'll say "cadence" of enhancements, et cetera, to the product. We recently launched 2.0 in Europe. That should come to the U.S. shortly. We've obviously invested a fair bit in capacity expansion, and at the rate we're adding patients, obviously, that's something we started paying attention to a couple years ago, and I'd say a significant quantum of capacity will come online in the second half of this year. From my perspective, that allows us to open the floodgate much wider. At this point, we're having a tremendous amount of success with Libre without putting much push behind it, and at that point, we're going to have an ability to turn on a lot of push. And then, we've got a steady cadence of capacity additions after that.
Because of the magnitude of the size of the diabetic market, both for Type 1 diabetics and Type 2 diabetics, our view was this had to have a value proposition for patients and for the healthcare system that was accessible and affordable by everybody, and not just driven by a rebate system and so forth. So, we've got a very low-cost position, we've got a good value-access price point, and I think all of that is playing through our markets, patient groups, influence groups, and so forth very well. The product, obviously, is getting all the emphasis in development, et cetera that anybody would like to see. I think this is a very big long-term sustainable growth product for the company. I don't have any other way to say it. This is a happy topic.
Matt Taylor -- UBS -- Executive Director
Yeah, it's been phenomenal growth. I was just curious -- as you look forward in segmenting the markets, you now have the Libre 2 with alarm, you have partnership with a pump company. Can you talk about how you might bifurcate your strategy to go after different segments, whether you need low-cost offering and a higher-feature offering as you expand through the Libre portfolio?
Miles D. White -- Chairman and Chief Executive Officer
Well, I'm going to be careful how much I say publicly on the phone. I think you can assume that we're obviously developing every aspect of this product that you can imagine, and that's all going very well. I wouldn't communicate what I would forecast as timelines. I think that the current growth rate speaks for itself. The current submissions and features of the product that we're adding speak for themselves. We're pretty highly focused on bringing that capacity online, not because we're constrained yet, but right now, we're adding -- as I said -- 300,000 patients a quarter and growing, so you have to pay attention to keeping that momentum increasing.
At this point, with that many patients and the magnitude of the opportunity, our intent is to make this very much a mass-market product, but with 40 million Type 1 diabetics out there, "mass market" means every one of those Type 1 diabetics ought to be able to access this product economically, and that's worldwide. And then, of course, there's an enormous Type 2 market beyond that. So, this is not a product that's targeted solely at Type 1 or solely at Type 2. Its accuracy and performance obviously has meaning and efficacy in all segments.
Our cost position is as low as anything in the industry. We have probably the No. 1 cost position, No. 1 volume-of-patients position; I think we can pretty easily declare ourselves the leader in continuous glucose monitoring and growing faster than everybody else. So, I'd just say that all the things that you would expect us to be doing, including working with other third-party partners who would benefit from this technology, are all under way and have been for some time.
Matt Taylor -- UBS -- Executive Director
Great. Thanks for the detailed answer. I'll let some others jump in.
Operator
Thank you. And, our next question comes from Robbie Marcus from J.P. Morgan. Your line is open.
Robert Marcus -- J.P. Morgan Chase -- Analyst
Great. Thanks for taking the question. Miles, maybe I can ask a guidance question. So, Abbott's guidance for 2019 is 6.5-7.5%, basically in line with 2018 and a bit better than the Street was expecting to start the year. Maybe you could give us a little background what your confidence is at the starting point, and maybe specifically touch on some of the key growth drivers for 2019 that people are focused on -- MitraClip, you talked about Libre, and maybe hit on Alinity?
Miles D. White -- Chairman and Chief Executive Officer
I think you've touched base there on several of them already. What you should read into the guidance is we had an outstanding '18 and we just gave you guidance that's even better than '18. The underlying growth rates are strong, the pipelines are strong, it's all organic growth, it's not dependent on lapping an acquisition, it's not driven by lapping an acquisition, it's not dependent on acquiring something. All the things that are driving our growth are coming right out of our own pipeline and launching globally. So, if I take that a piece at a time, Libre as a story just gets better and better, so obviously, that's a pretty big and high-growth driver. That's a good thing.
The Alinity program has had an outstanding year rolling out in the core lab, which is primarily driven by Europe, and we haven't really unleashed it yet fully in the U.S. or even fully in Asian markets, and as that menu reaches what I'll call critical mass, that will tip up as well, and so far, everything we've seen with the rollout in Europe has been exceptional. Our share capture, our retention of rolling over a lot of our own customers and our own install base, our price point and value point were...I'd say "extremely competitive," but it's better than that. So, that's going well, and that momentum only gets better as we expand geographies.
Frankly, there's a couple aspects of that program that haven't really gone to market yet fully -- our hematology piece, et cetera. So, I think those are strong drivers. When we acquired Alere in the diagnostics space, it was a declining to slightly -- at best, flat business, and that's been a nice story for us in terms of integrating it. We're going to be looking for now improving the growth and the new product pipeline and momentum going forward in that business, which is incrementally positive for the business.
As I already mentioned, Nutrition compared to the prior four or five years has a nice, steady, sustainable forward-looking growth in the 3-5% range, somewhere in there, and that's a plus. That's an upside. The pipeline in Devices is strong. It's good. We spoke earlier in the year about the COAPT trial driving MitraClip in structural heart, and there's a nice pipeline of products and enhancements coming behind that. We just launched -- got approval for HeartMate 3 for destination therapy, some additional catheters in our electrophysiology business that help us be even more competitive than the 20% growth rate we've got now. Everything across the board gets better.
Where do we see problems? Well, we've got a couple of places that we're not too happy about our own performance in. We know neuromod is a super-good-growth business. We expect to see sequentially improving growth out of that business over the course of the year. I've talked about that on previous calls. We believe we're in control of our destiny there, and if anything, I've probably estimated the speed at which we can correct our direction there wrong. It's taken a little longer than I would have guessed, but that's going to get sequentially better, and I think that's a plus.
The point-of-care business that's part of our Diagnostic business -- not Alere, but our own point-of-care business -- we have some corrections to make in our strategy, and we've done that, so I'm quite optimistic that our management team there has a good path, a good management team, et cetera. That'll improve. So, if I had a concern at all, it's the things I can't control. I think our fundamental, underlying strategy in the Pharmaceutical business is solid. I think the underlying growth rates in emerging markets are solid. I know the world worries about the volatility of those markets, and the reliability of those markets, and, in particular, currency, and we're all going to live with currency if we're a multinational company, and I don't think we're any different. To be honest, we're not that differently indexed now with the addition of Medical Devices, Diagnostics, and so forth in the company.
So, while we may have...let's call it individual spotty circumstances in any given emerging market in any given year, which we kind of expect, I think the underlying growth of that business driven by development of those economies and healthcare systems is solid. So, I look at all aspects of the company. Whenever we're not performing where we think we should in a given business, we do take corrective steps, and as I look across the portfolio, every single business which had such a great year last year ought to actually have a little better one this year or a lot better one this year, and on a sustainable basis going forward.
So, as I look forward into '19, I note that there's a lot of caution in the world about economies and any number of other things. We base our growth rates and our growth projections on our products, on the market dynamics we see in each of our product areas and the segments we compete in, and we've got a rich portfolio of products right now, and a rich portfolio of products coming out of our organic R&D, and a lot of longevity on the driving of those products in the market for years to come. So, whatever the windiness of the currency market s or other things may be, we've demonstrated through '18 and we'll demonstrate into '19 that we can power through that and continue to deliver the kind of growth that our shareholders reliably expect.
Robert Marcus -- J.P. Morgan Chase -- Analyst
Great, that's really helpful. And, maybe one for Brian. On the bottom line, EPS guidance implies growth of 9-13% on a reported basis, closer to mid-teens on a constant currency basis. This is higher than what we've seen in the past from Abbott, but also off the higher starting top line. So, as we go through the year, if there's incremental upside, how should investors think about the willingness to allow that to fall to the bottom line versus reinvesting in the business at these growth rates.
Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer
I'll defer to Miles on that question because I know he makes the choices, ultimately, between the balanced growth and sustainable growth versus what we give back to shareholders, but I think we've shown a good propensity to be balanced in that. We showed that demonstration even last year as we gave some pennies back to the Street when we had a favorable tax rate, but invested heavily in the growth opportunities that Miles talked about that create the kind of sustainable growth that we're looking for.
Your math is right. I said back on the October call that exchange would be around 4% for the bottom-line impact. It's just a little touch above 4%. You could imply that that would mean about mid-teens EPS growth, and even as you look at our quarters, I mentioned in my script that FX would be more front-end loaded. It's first-half phenomena, but underlying growth that we're portraying here for the first quarter and the full year is pretty range-bound in that underlying double-digi t earnings -per-share growth of mid-teens plus or minus a couple points, and there's a lot of underlying gross margin improvement still going on across our businesses, there's a lot of synergy still being captured in gross margins, as well as SG&A as it pertains to our continued integration with St. Jude and also with Rapid Diagnostics, so you're seeing the margin expansion come through in our off-margin line in our guidance.
Miles D. White -- Chairman and Chief Executive Officer
Yeah, I'd reiterate a couple of things -- this is Miles. First of all, Brian mentioned exchanges. We know right now it's factored into our guidance, and it's factored into our EPS growth. The exchange that we're seeing in our guidance is a factor of last year, meaning '18, that we've got to lap. And so, it's that roll-through that is currently taking us from what otherwise would have been 15% to what, at the midpoint, would be 11%. So, we're still healthy double digits, and in effect, it's caused by lapping last year's guidance. None of us are currency traders, so there's no way to predict what's going to happen with the year, and I hesitate to do so for fear that fate strike us down.
But, with regard to profits, performance, and so forth, I'd say the company has always been fortunate that it's had strong profits and strong cash flow, and with regard to forecasting and so forth, we start every year with a double-digit target and a high bar, and that's our aspiration every single year, and gosh, more often than not, that's where we start with our guidance. Now, having said that, out of the last 11 years -- and, why do I not go back further than 11 years? I don't have the data, but I could get it. But, out of the last 44 quarters that we've reported, we have beat 39 of them, exceeded the investors' expectations, beat 39 of them, and met on five.
And so, I think the company has demonstrated that if it exceeds its expectations, if it exceeds Wall Street's expectations, if it exceeds in performance, we do share that back to our investors in increased profitability or increased return to the investor, and there's no reason to see a change to that. We've got strong cash flow, we're able to cover all of our cash and investment needs from a capital standpoint, from a dividend standpoint, we have the capacity to buy back shares to offset dilution -- frankly, buy back shares if it's the best investment that we can make.
We have the capacity to do M&A. We've obviously been able to pay down a lot of debt, and very rapidly, so that we would have the balance sheet flexibility that we want. So, we have very strong performance, strong profitability, strong cash flow. And so, if we...exceed our expectations and our performance, then obviously, we have the decision -- and, that's a nice place to be -- we have the decision to share that with our investors, which is exactly what our investors would expect, and you can tell that 90% of the quarters for the last 11 years, investors have benefited.
Robert Marcus -- J.P. Morgan Chase -- Analyst
Thanks a lot.
Operator
Thank you. Our next question comes from David Lewis from Morgan Stanley. Your line is open.
David Lewis -- Morgan Stanley -- Managing Director
Good morning. Thanks for taking the question. Miles, just a couple for you. In thinking about or listening to your commentary on 2019, the one comment that comes to mind was balance -- your commentary that most businesses get better or a lot better. That being said, a lot of investors are still very focused on Libre and MitraClip, so as you think about the guidance and how it was formulated, how dependent is 2019 guidance on a significant inflection for MitraClip or Libre 2 product launch?
Miles D. White -- Chairman and Chief Executive Officer
Zero.
David Lewis -- Morgan Stanley -- Managing Director
Okay. That's pretty clear. I guess we can leave it at that. Well, the second question --
Miles D. White -- Chairman and Chief Executive Officer
Well, it is. To be honest -- I'm not trying to be coy with you -- it's very hard to predict. What regulatory timing will be, for example, on MitraClip -- and, there's no reason for us to play with the number and play with something that we're not sure we can predict. So, what we do know is when it comes -- which is very compelling -- there's a number of things that has to happen. FDA has to approve it, we obviously would want CMS to reimburse it, and so on, and I think it'll have that kind of compelling story with the regulatory bodies. Obviously, the COAPT study was very powerful, and I think the regulatory bodies will give that all the right consideration.
But, trying to pin that down and trying to pin down timing and so forth is not something that's easy to do, and I'm not sure we'd be doing our investors any good service by trying to predict that. What I do know is it's compelling, when it comes, it'll come, and it'll have impact, and rather than put it in our estimates, we haven't.
David Lewis -- Morgan Stanley -- Managing Director
Okay, very clear. And then, just following up on another point you made this morning, thinking about the balance sheet, you went from, two years ago, an over-levered to now, frankly, relative to peers, an under-levered company, and I think debt paydown and free cash generation were sort of the unsung heroes of last year. So, many other companies have picked up the relative pace of M&A. You're still growing at a pretty robust 7% rate without significant M&A in the last couple of years. So, where do you stand now as you think about reinvestment for growth? How active are you likely to be in '19 relative to '18 on the M&A front?
Miles D. White -- Chairman and Chief Executive Officer
Well, I'd say a couple things. First of all, you earn your highest return on organic growth and not your highest return on M&A. As you know, a lot of M&A deals struggle to return a good return to shareholders. We've had an excellent track record going back deep in our history with Knoll
The growth we're getting from all our businesses and even St. Jude is coming out of pipeline, and it's coming out of our own organic development, et cetera, and right now, those are the highest returns, those are the biggest opportunities, and we certainly don't see gaps right now that we have to fill with M&As, so we're able to return a pretty good sales and profit growth rate across the business. We've also been careful over time -- there's times to be in the M&A markets and there's times not to be. When multiples are really high, it's a bad time to buy.
But, to be honest, I don't see anything right now that is so appealing that we feel like that's necessarily a good direction for us, and the kinds of things we might look at -- well, I would never tell you anyway, and you know that -- but right now, our opportunities are so good with our own organic products and execution that we don't need it, and there's not something that's so attractive...
All of the various investment banking houses that you can imagine have put many things in front of us as opportunities, as they do every company, et cetera, so it's not like we're not aware of what opportunities may be out there. It's just -- they wouldn't meet our criteria, I don't see something compelling, I don't see something that we need, and right now, we're in a fortunate position where we've got very strong products, pipelines, and strategies across all of our businesses. I would say we could execute better in some places, but you can't buy that, so we fix our own execution with our talent and strategies and so forth, but it's not necessary for us to put our money into M&A right now because I don't think we'd turn a better return for our shareholders now or in the foreseeable future doing that.
We're going to make a lot more money for our shareholders investing in our growth, investing in the products we have, investing in our expansion, investing in our own capital, and as you know, we have plenty of cash flow to do that, and we have plenty of cash flow that we can still return increasing dividends, and at some point here, we'll have a choice. We're going to keep paying down debt because I think it's a good idea. Our net debt to EBITDA ratio now is below 2x, and as you know, it was more like 4-4.3x when we completed the Alere and St. Jude deals.
That wasn't that long ago, so to have brought our net debt to EBITDA ratio down that far that fast -- and particularly, as we look forward at a rising interest rate environment, or potentially so, depending on what you believe, I think we're doing the right things in the management of our balance sheet. I've wanted to get that debt down fast -- we have. I've wanted to have strategic flexibility -- we have it. What I really want is capital allocation flexibility to earn optimal returns for our shareholders, and I think we're in that position, so I don't see M&A right now as a high priority.
David Lewis -- Morgan Stanley -- Managing Director
Okay, very clear. I'll jump back in queue. Thanks, Miles.
Operator
Thank you. Our next question comes from Joanne Wuensch from BMO Capital Markets. Your line is open.
Joanne Wuensch -- BMO Capital Markets -- Managing Director
Good morning, everybody, and thank you for taking the questions. I'm going to take the flip side of David's question. Instead of thinking about M&A and adding things, how do you feel about having all four legs of the stool remain in the Abbott house? I think there was some lay press discussion regarding possible sale of the Nutritionals business.
Miles D. White -- Chairman and Chief Executive Officer
Well, I get that speculation -- jeez. If I don't get it every quarter, it's almost every quarter, so thanks for asking the question, Joanne. We like our mix right now. There's a role to everything in our portfolio. The one I'm asked more frequently about than anything is Nutrition. You can transact, you can try to make money for your shareholders with transactions, but I would say this: As you know, Joanne, I've been in this job a long time, and earlier in my tenure, there was a role for Nutrition in our portfolio, and I got the same question then. One of the roles was it's got a global presence, global infrastructure, it's highly profitable, generates a lot of cash, and a lot of the M&A activities and other things that we did back in my earlier years benefited from the cash flows and position of Nutrition. And, even today, there are great benefits to our Nutrition business to the company. Now, that's not to say that any given part of the company has to be part of it. It's clearly a different business, as is our Pharmaceutical business, et cetera.
But today, I'd say it makes sense as part of our company. I don't think we need to be considering a transaction just to do it. We're well valued, we're performing well, I don't honestly think I would create more value for our investors by separating it... If everybody asks you about it often enough, you go look at it. Okay, I've looked at it. I don't think we can create differential improved value for our shareholders than what is already being executed by us. I think that's a plus. I think that in general, while a lot of people might ask me about it, it's also performing well. I'm happy that it's performing a lot better than it did for a couple of years there.
So, it's just not on my radar screen. I don't think we're going to improve Abbott, I don't think we're going to create value by considering it, and I think we'll distract ourselves with that at a time we don't even need to be distracted. So, it's just not on my radar screen as a way to create value for shareholders because I don't think it will, and I think it's being well valued as part of Abbott, as is the rest of Abbott. So, it's just not on my radar screen, nor do I think it's necessarily beneficial to us. I guess that's the simplest thing to say.
Joanne Wuensch -- BMO Capital Markets -- Managing Director
Okay, I appreciate that. As a follow-up, two businesses I just want to talk about the pipeline. Neuromod -- what does it take to reaccelerate that growth rate? And then, you talked about an Alere pipeline, which I don't think the Street is really focused on. Could you just give us some highlights there? Thank you?
Miles D. White -- Chairman and Chief Executive Officer
First of all, the single biggest thing that will immediately change how we're doing in neuromod is actually our sales force expansion in the U.S. and our training and execution there, and that's what we're focused on. Then, longer-term, we've put a lot of emphasis in our R&D pipeline. We have a number of new people, new management, broader pipeline, underdevelopment -- I'm not going to give you any insights to it and so forth because I don't really want to get the world focused on it, but it's an area where we think there's a lot of opportunity in the types of products we have. We don't think we've fully gotten the benefit of the two main products we have now, so I'd say it's got our attention, we've doubled our investment in R&D there, and I think in the coming years, we'll see that roll out. What was the second part after neuromod?
Joanne Wuensch -- BMO Capital Markets -- Managing Director
Pipeline in Alere.
Miles D. White -- Chairman and Chief Executive Officer
We've reorganized the Rapid Diagnostics business into four segments. Each of them has their emphasis, their target. Each has an R&D plan, each has a new product plan. We are increasing our investment in R&D also there. I can give you a couple of high points and examples: Infectious disease product ID NOW, which we think has got a lot of potential, that we're rolling out. The Afinion 2 cardiometabolic platform -- another opportunity that we're putting emphasis behind. But, generally speaking, there's a lot more possibility for us in incrementally updating and renewing a number of these platforms, and then there's newer stuff than that.
And so, when we took over the company, which we've now had in our possession a little over a year, one of our targets was to get our hands around the R&D of each of these segments and make sure we had an R&D plan in place so there was a steady cadence of improvements in new products in each of these businesses that does take a little time. In our first year, a lot of our focus was stabilizing the organization and structure, the management, people, execution of what we've got, synergies, et cetera, which we've talked about. Now, our attention turns to this, and it has been. We've been increasing our spending and increasing our focus on this, and that's what the management team is focused on now, is that new product cadence. So, beyond that, I don't want to be more specific. Otherwise, we'll be tracking it all here.
Joanne Wuensch -- BMO Capital Markets -- Managing Director
Thank you very much.
Operator
Thank you. Our next question comes from Bob Hopkins from Bank of America. Your line is open.
Bob Hopkins -- Bank of America Merrill Lynch -- Managing Director
Thanks, and good morning. I just wanted to follow up, if I might, on the commentary earlier on MitraClip given its visibility. Can you give us a sense as to what the growth rate of MitraClip was in the fourth quarter? And then, to be clear relative to your earlier comments, do you really not assume U.S. approval and reimbursement for MitraClip and FMR at all in 2019? Is that not assumed at all?
Miles D. White -- Chairman and Chief Executive Officer
No, that's not what I said, and that's not what the question was. I'm not assuming that. But, the question was whether or not that was pivotal to making our earnings guidance for the year or sales guidance, and the answer was it has no bearing on our sales and earnings guidance for the year. But, you're asking me a different question now -- do I expect approval? I'd say, "Well, we'll see." We're certainly hopeful that we'll get that kind of consideration. Is it possible? I suppose it's possible, but we don't know. We just don't know. Scott?
Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions
With respect to the MitraClip growth rate, MitraClip grew about 30% in the fourth quarter.
Bob Hopkins -- Bank of America Merrill Lynch -- Managing Director
Okay. So, accelerated a little bit. Okay, I hear you on MitraClip. And then, the other product-oriented question I wanted to ask is that you mentioned in your remarks that Libre is getting some preferred copay status, and I was just -- I found that intriguing. I was just wondering if you could expand on what that means specifically and how broad the program is. Is that just because Libre's a little lower-cost, or a payer's trying to incentivize patients to use Libre? So, maybe just a little color on the copay status.
Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions
Yeah, as you think about copay status and the way payers use it, that is essentially what they're trying to do, is they're trying to incent a preferred offering with respect to the value proposition that that offering brings. So, as we progressed through the second half of the year in our payer dialogue, we saw that certain payers were starting to put Libre in a higher tier -- Tier 2 -- which would result for the end patient in a lower copay, quite frankly, and again, I think as they look at the overall value proposition, the outcomes data, and whatnot, they see a compelling argument to do it, and we're starting to see that trend.
Bob Hopkins -- Bank of America Merrill Lynch -- Managing Director
Great. Thanks very much.
Operator
Thank you. Our next question comes from Glenn Novarro from RBC Capital Markets. Your line is open.
Glenn Novarro -- RBC Capital Markets -- Managing Director
Hi, good morning, guys. Two device questions. First, on rhythm management in the quarter, down 2-3%. Is that market softness, or are you guys just losing share to Boston Scientific because of their Heart Logic feature or losing share to Medtronic because they've got Micra, the leadless pacer? That's the first question. And then, the vascular business -- down 5% in the U.S. That's surprising to me given you're launching XIENCE Sierra. So, similar question -- is this just that the market is weaker in drug-eluting stents for the U.S., is there more pricing pressure, or is the product simply not gaining traction? Thanks.
Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions
Hi, Glenn. I'll start with rhythm management. As you know, when we acquired that business, it was declining at a fairly heavy clip. We've been able to stabilize it. The overall market, to your point, is down modestly, and our performance is generally in line with that. When it comes to vascular, same thing. Again, the market is down modestly. XIENCE Sierra is doing well. It's capturing share. In fact, we gained about five share points since the launch of XIENCE Sierra. Pricing in the space remains a challenge for all the market, but XIENCE Sierra is definitely performing there. Quite frankly, our performance overall is a little bit above the market.
Miles D. White -- Chairman and Chief Executive Officer
Glenn, what you're also seeing there is a reduction in third-party royalty revenue, not share. The stent and the system -- XIENCE Sierra -- are capturing share, but what you're seeing is the roll-through of loss of third-party revenue.
Glenn Novarro -- RBC Capital Markets -- Managing Director
Okay, and one follow-up. Can you give us an update on both your TAVR and mitral program? TAVR -- specifically Portico -- when do we see a U.S. filing and approval? And then, mitral -- an update on Tendyne enrollment and maybe comment on the latest acquisition. Thanks.
Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions
On TAVR, we would expect to file that here in the second half of this year. We're wrapping up that trial as we speak. With respect to Tendyne and Cephea, obviously, we're expanding. We've had a long-term vision here in the mitral space to really build a toolbox. Tendyne -- we filed, actually, for CE mark before the end of last year, so we could possibly see approval here this year. The U.S. is still several years away. The Cephea program looks like a really great program, but again, still several years away.
Glenn Novarro -- RBC Capital Markets -- Managing Director
Okay, great. Thanks, Scott.
Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions
Thanks. Operator, we'll take one more question.
Operator
Thank you. And, our final question comes from Rick Wise from Stifel. Your line is open.
Rick Wise -- Stifel Financial Corporation -- Analyst
Good morning, Miles. Maybe just one big-picture and one product question. Brian and the team have done a fabulous job paying down debt. You highlighted some thoughts about your comfort in not doing M&A in today's portfolio. Obviously, that suggests share buyback and dividend. You've touched on it a little bit, but just wondering -- are you feeling strongly about taking your excess cash and dividing it equally depending on stock price? Do you have a priority? Is this some -- how are you thinking about it?
Miles D. White -- Chairman and Chief Executive Officer
I don't think of it as dividing it equally. For any particular capital use, there's a timing or there's a need. If we've got to invest in capacity internally, manufacturing, and so forth, obviously, that's a good thing. As I've said, we can afford all of that and more. We're keeping our dividend healthy. We target our dividend generally in a range...40% or higher of our EPS as a payout ratio, a nice healthy range, and a number of our peers don't do that at all. So, I think we've got a good, healthy dividend, and that matters to us because we've got a large segment of investors that care about that.
With regard to M&A, M&A is necessarily opportunistic. It depends on the product, the company, the business, the timing, market values, multiples -- all sorts of things. And right now, I don't see any of that lining up to say, "Wow, there's something we're dying to go look at." And then, with regard to share buybacks, Rick, it sort of depends on valuations in the market. There's time when share buybacks aren't that economical and other times when they're high-return, and in our case, right now, we've got the flexibility... If we want to do any kind of share buyback to offset dilution and so forth, we can do that, but I think you've got to look at it and say, "Is that my best use of cash?"
I still want to pay down debt. I don't want to assume we're just going to carry this forward. We've paid down a lot of debt fast. It would actually be in our interest to keep doing that, to keep paying it down. I think we're well into a reasonable range now of debt, but we still want to keep paying that debt down. And, our cash flow is strong enough that we do have a choice. We do -- we have the ability to pay the dividend. We have the ability to do all these things. We can satisfy our capital needs internally.
So, I guess the best think about it is we don't think about it in any mechanistic or formula way -- dividing it in half or whatever. We look at where the need is and where the best return is, and I think it behooves us to leave ourselves also in a very strong position at a lower debt level. So, we've got places to use it and places to use it economically. Before tax reform, when so much cash was trapped overseas, we were fortunate that we had M&A opportunities to invest that cash for good return.
We're not stuck like that now. We can manage cash, manage the cash flows of the company, and so forth far more efficiently in terms of the best returns or the best needs, and that's kind of how we look at it. If we find that our best use of the cash or a strong use of the cash is share buybacks, we'd certainly consider that, but right now, I wouldn't say that's our highest priority either. It's still a high priority to keep paying down the debt. A couple of years down the road here, depending on what happens with interest rates and so forth, we'll probably be glad we did, and we'll have tremendous strategic flexibility and still have very strong cash flow. So, I think it depends on circumstances at a given point in time.
Rick Wise -- Stifel Financial Corporation -- Analyst
Yeah, that's a good answer. Lastly -- quickly -- I know you love to talk about what could push you to the upper end of your 6.5-7.5% guidance for '19, but there were some wild cards that helped out. You exceeded your initial 2018 organic growth guidance in '18. Maybe just touch on -- quickly, if you would -- what could push you to the upper end or above for your '19 rates? Thank you.
Miles D. White -- Chairman and Chief Executive Officer
Rick, I think there's a number of product things that could do that. We've already mentioned MitraClip's possibility. It wouldn't take a whole lot -- a couple of ticks in any of these businesses -- of improvement. Last year, our Nutrition business actually did better than we expected. We thought it would do better than prior years, but it did better than that and better than we expected. Some of those tick-ups make a big difference. So, I think if we turn the corner as we expect to and plan to, things like neuromod and other places where we know the fundamental underlying business is strong, it doesn't take a whole lot to correct the underperformance of some businesses, whether it's our point-of-care business, or neuromod, or individual countries in the Pharmaceutical business, and the upside here is fairly strong.
Rick Wise -- Stifel Financial Corporation -- Analyst
Much appreciated. Thank you.
Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions
Very good. Well, thank you, operator, and thank you for all of your questions. This now concludes Abbott's conference call. A webcast replay of this call will be available after 11:00 a.m. Central time today on Abbott's Investor Relations website at Abbottinvestor.com. Thank you for joining us today.
Operator
Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Everyone have a wonderful day.
Duration: 59 minutes
Call participants:
Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions
Miles D. White -- Chairman and Chief Executive Officer
Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer
Matt Taylor -- UBS -- Executive Director
Robert Marcus -- J.P. Morgan Chase -- Analyst
David Lewis -- Morgan Stanley -- Managing Director
Joanne Wuensch -- BMO Capital Markets -- Managing Director
Bob Hopkins -- Bank of America Merrill Lynch -- Managing Director
Glenn Novarro -- RBC Capital Markets -- Managing Director
Rick Wise -- Stifel Financial Corporation -- Analyst
More ABT analysis
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Motley Fool Transcription has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (NYSE: ABT) Q4 2018 Earnings Conference Call Jan. 23, 2019, 9:00 a.m. Duration: 59 minutes Call participants: Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer Matt Taylor -- UBS -- Executive Director Robert Marcus -- J.P. Morgan Chase -- Analyst David Lewis -- Morgan Stanley -- Managing Director Joanne Wuensch -- BMO Capital Markets -- Managing Director Bob Hopkins -- Bank of America Merrill Lynch -- Managing Director Glenn Novarro -- RBC Capital Markets -- Managing Director Rick Wise -- Stifel Financial Corporation -- Analyst More ABT analysis This article is a transcript of this conference call produced for The Motley Fool. Our strategy in EPD is unique and quite simple: To build significant presence, scale, and leadership positions in the most attractive emerging markets, where long-term growth in medicines will be driven by aging populations and the related rise in chronic diseases, increasing incomes, and expanding access to care. | Duration: 59 minutes Call participants: Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer Matt Taylor -- UBS -- Executive Director Robert Marcus -- J.P. Morgan Chase -- Analyst David Lewis -- Morgan Stanley -- Managing Director Joanne Wuensch -- BMO Capital Markets -- Managing Director Bob Hopkins -- Bank of America Merrill Lynch -- Managing Director Glenn Novarro -- RBC Capital Markets -- Managing Director Rick Wise -- Stifel Financial Corporation -- Analyst More ABT analysis This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q4 2018 Earnings Conference Call Jan. 23, 2019, 9:00 a.m. Strong performance across our businesses along with underlying margin expansion and our synergy capture from recent acquisitions enabled us to achieve EPS at the upper end of the initial guidance range we issued at the beginning of last year despite unfavorable currency shifts as we progressed through the year. | Duration: 59 minutes Call participants: Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer Matt Taylor -- UBS -- Executive Director Robert Marcus -- J.P. Morgan Chase -- Analyst David Lewis -- Morgan Stanley -- Managing Director Joanne Wuensch -- BMO Capital Markets -- Managing Director Bob Hopkins -- Bank of America Merrill Lynch -- Managing Director Glenn Novarro -- RBC Capital Markets -- Managing Director Rick Wise -- Stifel Financial Corporation -- Analyst More ABT analysis This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q4 2018 Earnings Conference Call Jan. 23, 2019, 9:00 a.m. We base our growth rates and our growth projections on our products, on the market dynamics we see in each of our product areas and the segments we compete in, and we've got a rich portfolio of products right now, and a rich portfolio of products coming out of our organic R&D, and a lot of longevity on the driving of those products in the market for years to come. | Duration: 59 minutes Call participants: Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer Matt Taylor -- UBS -- Executive Director Robert Marcus -- J.P. Morgan Chase -- Analyst David Lewis -- Morgan Stanley -- Managing Director Joanne Wuensch -- BMO Capital Markets -- Managing Director Bob Hopkins -- Bank of America Merrill Lynch -- Managing Director Glenn Novarro -- RBC Capital Markets -- Managing Director Rick Wise -- Stifel Financial Corporation -- Analyst More ABT analysis This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q4 2018 Earnings Conference Call Jan. 23, 2019, 9:00 a.m. The U.S. is still several years away. |
33114.0 | 2019-01-23 00:00:00 UTC | Abbott Laboratories Q4 18 Earnings Conference Call At 9:00 AM ET | ABT | https://www.nasdaq.com/articles/abbott-laboratories-q4-18-earnings-conference-call-900-am-et-2019-01-23 | nan | nan | (RTTNews.com) - Abbott Laboratories ( ABT ) will host a conference call at 9:00 AM ET on Jan. 23, 2019, to discuss Q4 18 earnings results.
To access the live webcast, log on to www.abbottinvestor.com
Read the original article on RTTNews (http://www.rttnews.com/2971476/abbott-laboratories-q4-18-earnings-conference-call-at-9-00-am-et.aspx)
For comments and feedback: contact editorial@rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews.com) - Abbott Laboratories ( ABT ) will host a conference call at 9:00 AM ET on Jan. 23, 2019, to discuss Q4 18 earnings results. To access the live webcast, log on to www.abbottinvestor.com Read the original article on RTTNews (http://www.rttnews.com/2971476/abbott-laboratories-q4-18-earnings-conference-call-at-9-00-am-et.aspx) For comments and feedback: contact editorial@rttnews.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews.com) - Abbott Laboratories ( ABT ) will host a conference call at 9:00 AM ET on Jan. 23, 2019, to discuss Q4 18 earnings results. To access the live webcast, log on to www.abbottinvestor.com Read the original article on RTTNews (http://www.rttnews.com/2971476/abbott-laboratories-q4-18-earnings-conference-call-at-9-00-am-et.aspx) For comments and feedback: contact editorial@rttnews.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews.com) - Abbott Laboratories ( ABT ) will host a conference call at 9:00 AM ET on Jan. 23, 2019, to discuss Q4 18 earnings results. To access the live webcast, log on to www.abbottinvestor.com Read the original article on RTTNews (http://www.rttnews.com/2971476/abbott-laboratories-q4-18-earnings-conference-call-at-9-00-am-et.aspx) For comments and feedback: contact editorial@rttnews.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews.com) - Abbott Laboratories ( ABT ) will host a conference call at 9:00 AM ET on Jan. 23, 2019, to discuss Q4 18 earnings results. To access the live webcast, log on to www.abbottinvestor.com Read the original article on RTTNews (http://www.rttnews.com/2971476/abbott-laboratories-q4-18-earnings-conference-call-at-9-00-am-et.aspx) For comments and feedback: contact editorial@rttnews.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33115.0 | 2019-01-23 00:00:00 UTC | 5 Must-See Stock Charts for Thursday: ABT, IBM, SBUX, PZZA | ABT | https://www.nasdaq.com/articles/5-must-see-stock-charts-thursday-abt-ibm-sbux-pzza-2019-01-23 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Stocks started off higher on Wednesday, but have lost most of those gains as major U.S. indices hover near breakeven. With earnings in full swing and no shortage of announcements, we've got plenty of must-see stock charts as we head into the last two days of the trading week.
Must-See Stock Charts #1: IBM
Shares of IBM (NYSE: IBM ) are roaring higher after beating estimates and providing better-than-expected guidance . The stock is up 8.5% on the day and hitting multi-month highs as a result.
The question is, can IBM continue the momentum?
5 Terrific Tech Stocks That Will Make You Forget About FANG
When we're talking about a low-growth name like IBM, it's hard to get too excited about chasing it up over 8%. Not to mention that IBM is up four weeks in a row before this week's move.
Near $110, IBM had an attractive risk/reward. Up near $133 though and it's a different story. Right now it's kind of in no man's land. If it can power through the 50-week and 200-week moving averages then it could challenge downtrend resistance near $145 to $150.
On the downside, I want to see the 10-week moving average near $120 hold as support. If it does, bulls might consider getting long near this level.
Must-See Stock Charts #2: Abbott Labs
Abbott Labs (NYSE: ABT ) shares are down 2% after the company reported in-line earnings results and missed on revenue expectations. Overall, the trend has been higher but it's been a choppy ride the last few months.
As long as shares stay above its 50-day and 21-day moving averages and/or uptrend support (blue line) then the bulls are likely okay . Below these marks and ABT will likely pay a visit to the 200-day. If it can push over this $71 to $72 level, ABT could challenge its highs just over $74.
Must-See Stock Charts #3: Papa John's
Shares are up over 7% on the day as Papa John's Pizza (NYSE: PZZA ) is reportedly receiving some takeover interest. While the news is resulting in a nice pop, PZZA stock is similar to IBM in that it's somewhat in no man's land here.
Technically, it could continue to push up to its 50-day moving average and perhaps beyond, up to its 200-day moving average. Who wants to short a name that's a possible takeover target? Not me. And maybe that will help fuel some of the squeeze higher.
That said, buyers are a little late to the game if they weren't in today. Look to see if PZZA pulls back and consolidates below its prior range or if it rallies into moving average resistance. On the longer term charts, I would expect some resistance near $47.50 to $50 as well.
Must-See Stock Charts #4: Starbucks
Despite the recent pullback, Starbucks (NASDAQ: SBUX ) has been trading well lately. So have these other four . SBUX tried but failed to breakout on Tuesday but is making its move again on Wednesday.
It's encouraging to see Starbucks showing relative strength at a time where the markets have been struggling. It makes me think that if we get some bullish action in the indices, Starbucks can run.
Seeing which stocks are doing well when the market is doing bad is always worth taking note of. It doesn't mean they are guaranteed to breakout, but it improves the odds. If it does, look for a possible run to $70.
Keep in mind SBUX has earnings Thursday evening.
Must-See Stock Charts #5: Disney
It admittedly lacks some conviction here on the charts, but it's encouraging to see Disney (NYSE: DIS ) stock back up above prior downtrend resistance. This level kept Disney in check for years - so to see it hovering just above it now is encouraging.
7 Stupidly Cheap Stocks to Buy Now
Long-term investors could justify adding or initiating a position in this name, with the option to add more on a decline near $102.
Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell . As of this writing, Bret Kenwell is long SBUX.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
10 Consumer Stocks to Buy for Income
7 Dark Horse Stocks You Really Need to Look at for 2019
7 Retail Stocks to Buy for the Rise of Menswear
Compare Brokers
The post 5 Must-See Stock Charts for Thursday: ABT, IBM, SBUX, PZZA appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Must-See Stock Charts #2: Abbott Labs Abbott Labs (NYSE: ABT ) shares are down 2% after the company reported in-line earnings results and missed on revenue expectations. Below these marks and ABT will likely pay a visit to the 200-day. If it can push over this $71 to $72 level, ABT could challenge its highs just over $74. | Must-See Stock Charts #2: Abbott Labs Abbott Labs (NYSE: ABT ) shares are down 2% after the company reported in-line earnings results and missed on revenue expectations. More From InvestorPlace 2 Toxic Pot Stocks You Should Avoid 10 Consumer Stocks to Buy for Income 7 Dark Horse Stocks You Really Need to Look at for 2019 7 Retail Stocks to Buy for the Rise of Menswear Compare Brokers The post 5 Must-See Stock Charts for Thursday: ABT, IBM, SBUX, PZZA appeared first on InvestorPlace . Below these marks and ABT will likely pay a visit to the 200-day. | More From InvestorPlace 2 Toxic Pot Stocks You Should Avoid 10 Consumer Stocks to Buy for Income 7 Dark Horse Stocks You Really Need to Look at for 2019 7 Retail Stocks to Buy for the Rise of Menswear Compare Brokers The post 5 Must-See Stock Charts for Thursday: ABT, IBM, SBUX, PZZA appeared first on InvestorPlace . Must-See Stock Charts #2: Abbott Labs Abbott Labs (NYSE: ABT ) shares are down 2% after the company reported in-line earnings results and missed on revenue expectations. Below these marks and ABT will likely pay a visit to the 200-day. | More From InvestorPlace 2 Toxic Pot Stocks You Should Avoid 10 Consumer Stocks to Buy for Income 7 Dark Horse Stocks You Really Need to Look at for 2019 7 Retail Stocks to Buy for the Rise of Menswear Compare Brokers The post 5 Must-See Stock Charts for Thursday: ABT, IBM, SBUX, PZZA appeared first on InvestorPlace . Must-See Stock Charts #2: Abbott Labs Abbott Labs (NYSE: ABT ) shares are down 2% after the company reported in-line earnings results and missed on revenue expectations. Below these marks and ABT will likely pay a visit to the 200-day. |
33116.0 | 2019-01-23 00:00:00 UTC | Abbott Labs (ABT) Stock Slips Despite Solid Q4 Earnings | ABT | https://www.nasdaq.com/articles/abbott-labs-abt-stock-slips-despite-solid-q4-earnings-2019-01-23 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Abbott Labs (NYSE: ABT ) reported its latest quarterly earnings results early in the day Wednesday, which came were in line with Wall Street's expectations, but the company's stock declined during regular trading hours and after the bell.
The Chicago-based health care company said that for its fourth quarter of its fiscal 2018 , it brought in net income of $654 million, topping the company's loss during the same period a year ago. This amounted to roughly 37 cents per share, or 81 cents per share when adjusting for nonrecurring costs and discontinued operations.
The results were in line with the Wall Street consensus estimate, which called for adjusted earnings of 81 cents per share, according to data compiled by 10 analysts who were surveyed by Zacks Investment Research . Abbott Labs added that the company's revenue for the period tallied up to $7.77 billion, which was below Wall Street's guidance.
Seven analysts who were surveyed by Zacks were calling for sales of $7.79 billion. For its fiscal 2018, the company's profit was $2.37 billion, or $1.33 per share, while Abbott Labs' revenue came in at $30.58 billion.
For its first quarter of its fiscal 2019, the company projects earnings of 60 cents to 62 cents per share. Plus, the company sees its fiscal 2019 earnings as being somewhere in the range of $3.15 to $3.25 per share.
ABT stock is down more than 2.2% on Wednesday following the company's results. Shares were down an additional 1% after the bell.
More From InvestorPlace
7 Stupidly Cheap Stocks to Buy Now
7 Dark Horse Stocks You Really Need to Look at for 2019
7 Retail Stocks to Buy for the Rise of Menswear
Compare Brokers
The post Abbott Labs (ABT) Stock Slips Despite Solid Q4 Earnings appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Labs (NYSE: ABT ) reported its latest quarterly earnings results early in the day Wednesday, which came were in line with Wall Street's expectations, but the company's stock declined during regular trading hours and after the bell. ABT stock is down more than 2.2% on Wednesday following the company's results. More From InvestorPlace 7 Stupidly Cheap Stocks to Buy Now 7 Dark Horse Stocks You Really Need to Look at for 2019 7 Retail Stocks to Buy for the Rise of Menswear Compare Brokers The post Abbott Labs (ABT) Stock Slips Despite Solid Q4 Earnings appeared first on InvestorPlace . | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Labs (NYSE: ABT ) reported its latest quarterly earnings results early in the day Wednesday, which came were in line with Wall Street's expectations, but the company's stock declined during regular trading hours and after the bell. ABT stock is down more than 2.2% on Wednesday following the company's results. More From InvestorPlace 7 Stupidly Cheap Stocks to Buy Now 7 Dark Horse Stocks You Really Need to Look at for 2019 7 Retail Stocks to Buy for the Rise of Menswear Compare Brokers The post Abbott Labs (ABT) Stock Slips Despite Solid Q4 Earnings appeared first on InvestorPlace . | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Labs (NYSE: ABT ) reported its latest quarterly earnings results early in the day Wednesday, which came were in line with Wall Street's expectations, but the company's stock declined during regular trading hours and after the bell. More From InvestorPlace 7 Stupidly Cheap Stocks to Buy Now 7 Dark Horse Stocks You Really Need to Look at for 2019 7 Retail Stocks to Buy for the Rise of Menswear Compare Brokers The post Abbott Labs (ABT) Stock Slips Despite Solid Q4 Earnings appeared first on InvestorPlace . ABT stock is down more than 2.2% on Wednesday following the company's results. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Labs (NYSE: ABT ) reported its latest quarterly earnings results early in the day Wednesday, which came were in line with Wall Street's expectations, but the company's stock declined during regular trading hours and after the bell. ABT stock is down more than 2.2% on Wednesday following the company's results. More From InvestorPlace 7 Stupidly Cheap Stocks to Buy Now 7 Dark Horse Stocks You Really Need to Look at for 2019 7 Retail Stocks to Buy for the Rise of Menswear Compare Brokers The post Abbott Labs (ABT) Stock Slips Despite Solid Q4 Earnings appeared first on InvestorPlace . |
33117.0 | 2019-01-23 00:00:00 UTC | Abbott (ABT) Meets Q4 Earnings Estimates | ABT | https://www.nasdaq.com/articles/abbott-abt-meets-q4-earnings-estimates-2019-01-23 | nan | nan | Abbott (ABT) came out with quarterly earnings of $0.81 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.74 per share a year ago. These figures are adjusted for non-recurring items.
A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would pos t earnings of $0.74 per share when it actually produced earnings of $0.75, delivering a surprise of 1.35%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $7.77 billion for the quarter ended December 2018, missing the Zacks Consensus Estimate by 0.29%. This compares to year-ago revenues of $7.59 billion. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call .
Abbott shares have lost about 1.2% since the beginning of the year versus the S&P 500's gain of 5%.
What's Next for Abbott?
While Abbott has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power o f earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Abbott was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.65 on $7.61 billion in revenues for the coming quarter and $3.19 on $31.99 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) came out with quarterly earnings of $0.81 per share, in line with the Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. | Abbott (ABT) came out with quarterly earnings of $0.81 per share, in line with the Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. | Abbott (ABT) came out with quarterly earnings of $0.81 per share, in line with the Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $7.77 billion for the quarter ended December 2018, missing the Zacks Consensus Estimate by 0.29%. | Abbott (ABT) came out with quarterly earnings of $0.81 per share, in line with the Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. The company has topped consensus revenue estimates two times over the last four quarters. |
33118.0 | 2019-01-23 00:00:00 UTC | Earnings Reaction History: Abbott Laboratories, 50.0% Follow-Through Indicator, 2.3% Sensitive | ABT | https://www.nasdaq.com/articles/earnings-reaction-history-abbott-laboratories-500-follow-through-indicator-23-sensitive | nan | nan | Expected Earnings Release: 01/23/2019, Premarket
Avg. Extended-Hours Dollar Volume: $3,591,905
Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in ABT indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close.
Last 12 Qtrs Positive Only Price Reactions
Percent of time added to extended-hours gains: 57.1%
Average next regular session additional gain: 1.2%
Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.2%.
Last 12 Qtrs Negative Only Price Reactions
Percent of time added to extended-hours losses: 40%
Average next regular session additional loss: 2.7%
Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close.
Data provided by the MT Pro service at MTNewswires.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 57.1% Average next regular session additional gain: 1.2% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.2%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 40% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $3,591,905 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 57.1% Average next regular session additional gain: 1.2% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.2%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 40% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $3,591,905 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 57.1% Average next regular session additional gain: 1.2% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.2%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 40% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $3,591,905 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Extended-Hours Dollar Volume: $3,591,905 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 57.1% Average next regular session additional gain: 1.2% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.2%. Historical earnings event related premarket and after-hours trading activity in ABT indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close. |
33119.0 | 2019-01-23 00:00:00 UTC | Abbott Lab's fourth-quarter revenue rises 2.3 pct | ABT | https://www.nasdaq.com/articles/abbott-labs-fourth-quarter-revenue-rises-23-pct-2019-01-23 | nan | nan | Jan 23 () - Abbott Laboratories posted a 2.3 percent rise in fourth-quarter revenue on Wednesday, helped by growing demand for its heart valves and glucose monitoring devices.
The company posted net earnings of $654 million, or 37 cents per share, in the fourth quarter ended Dec. 31, from a loss of $828 million, or 48 cents per share, a year earlier, when it had taken a $1.4 billion charge related to changes to the U.S. tax law.
Net sales of the diversified healthcare company rose to $7.77 billion from $7.59 billion.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Jan 23 () - Abbott Laboratories posted a 2.3 percent rise in fourth-quarter revenue on Wednesday, helped by growing demand for its heart valves and glucose monitoring devices. The company posted net earnings of $654 million, or 37 cents per share, in the fourth quarter ended Dec. 31, from a loss of $828 million, or 48 cents per share, a year earlier, when it had taken a $1.4 billion charge related to changes to the U.S. tax law. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company posted net earnings of $654 million, or 37 cents per share, in the fourth quarter ended Dec. 31, from a loss of $828 million, or 48 cents per share, a year earlier, when it had taken a $1.4 billion charge related to changes to the U.S. tax law. Net sales of the diversified healthcare company rose to $7.77 billion from $7.59 billion. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Jan 23 () - Abbott Laboratories posted a 2.3 percent rise in fourth-quarter revenue on Wednesday, helped by growing demand for its heart valves and glucose monitoring devices. The company posted net earnings of $654 million, or 37 cents per share, in the fourth quarter ended Dec. 31, from a loss of $828 million, or 48 cents per share, a year earlier, when it had taken a $1.4 billion charge related to changes to the U.S. tax law. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Jan 23 () - Abbott Laboratories posted a 2.3 percent rise in fourth-quarter revenue on Wednesday, helped by growing demand for its heart valves and glucose monitoring devices. The company posted net earnings of $654 million, or 37 cents per share, in the fourth quarter ended Dec. 31, from a loss of $828 million, or 48 cents per share, a year earlier, when it had taken a $1.4 billion charge related to changes to the U.S. tax law. Net sales of the diversified healthcare company rose to $7.77 billion from $7.59 billion. |
33120.0 | 2019-01-23 00:00:00 UTC | U.S. STOCKS ON THE MOVE-IBM, P&G, Synchrony Financial | ABT | https://www.nasdaq.com/articles/us-stocks-move-ibm-pg-synchrony-financial-2019-01-23 | nan | nan | The Day Ahead newsletter:
The Morning News Call newsletter:
Strong earnings from Dow members IBM, United Technologies and Procter & Gamble lifted U.S. stock index futures on Wednesday, putting Wall Street on track to recover from its second biggest decline in 2019.
At 8:08 ET, Dow e-minis were up 0.82 percent at 24,589. S&P 500 e-minis were up 0.55 percent at 2,646.5, while Nasdaq 100 e-minis were up 0.60 percent at 6,693.25.
The top three NYSE percentage gainers premarket:
** Amtrust Financal, up 21.8 pct
** Synchrony Financial, up 10.5 pct
** IBM Corp, up 7.2 pct
The top three NYSE percentage losers premarket:
** Trinseo Sa.N, down 10.2 pct
** K12 Inc, down 9.1 pct
** Capital One Financial Corp, down 5.9 pct
The top three Nasdaq percentage gainers premarket:
** Recon Technology Ltd, up 33.7 pct
** Soligenix Inc, up 28.2 pct
** Athersys | The Day Ahead newsletter: The Morning News Call newsletter: Strong earnings from Dow members IBM, United Technologies and Procter & Gamble lifted U.S. stock index futures on Wednesday, putting Wall Street on track to recover from its second biggest decline in 2019. At 8:08 ET, Dow e-minis were up 0.82 percent at 24,589. The top three NYSE percentage gainers premarket: ** Amtrust Financal, up 21.8 pct ** Synchrony Financial, up 10.5 pct ** IBM Corp, up 7.2 pct The top three NYSE percentage losers premarket: ** Trinseo Sa.N, down 10.2 pct ** K12 Inc, down 9.1 pct ** Capital One Financial Corp, down 5.9 pct The top three Nasdaq percentage gainers premarket: ** Recon Technology Ltd, up 33.7 pct ** Soligenix Inc, up 28.2 pct ** Athersys | At 8:08 ET, Dow e-minis were up 0.82 percent at 24,589. S&P 500 e-minis were up 0.55 percent at 2,646.5, while Nasdaq 100 e-minis were up 0.60 percent at 6,693.25. The top three NYSE percentage gainers premarket: ** Amtrust Financal, up 21.8 pct ** Synchrony Financial, up 10.5 pct ** IBM Corp, up 7.2 pct The top three NYSE percentage losers premarket: ** Trinseo Sa.N, down 10.2 pct ** K12 Inc, down 9.1 pct ** Capital One Financial Corp, down 5.9 pct The top three Nasdaq percentage gainers premarket: ** Recon Technology Ltd, up 33.7 pct ** Soligenix Inc, up 28.2 pct ** Athersys | The Day Ahead newsletter: The Morning News Call newsletter: Strong earnings from Dow members IBM, United Technologies and Procter & Gamble lifted U.S. stock index futures on Wednesday, putting Wall Street on track to recover from its second biggest decline in 2019. S&P 500 e-minis were up 0.55 percent at 2,646.5, while Nasdaq 100 e-minis were up 0.60 percent at 6,693.25. The top three NYSE percentage gainers premarket: ** Amtrust Financal, up 21.8 pct ** Synchrony Financial, up 10.5 pct ** IBM Corp, up 7.2 pct The top three NYSE percentage losers premarket: ** Trinseo Sa.N, down 10.2 pct ** K12 Inc, down 9.1 pct ** Capital One Financial Corp, down 5.9 pct The top three Nasdaq percentage gainers premarket: ** Recon Technology Ltd, up 33.7 pct ** Soligenix Inc, up 28.2 pct ** Athersys | The Day Ahead newsletter: The Morning News Call newsletter: Strong earnings from Dow members IBM, United Technologies and Procter & Gamble lifted U.S. stock index futures on Wednesday, putting Wall Street on track to recover from its second biggest decline in 2019. At 8:08 ET, Dow e-minis were up 0.82 percent at 24,589. S&P 500 e-minis were up 0.55 percent at 2,646.5, while Nasdaq 100 e-minis were up 0.60 percent at 6,693.25. |
33121.0 | 2019-01-22 00:00:00 UTC | All Signals Are Positive for Buying Abbott Laboratories | ABT | https://www.nasdaq.com/articles/all-signals-are-positive-buying-abbott-laboratories-2019-01-22 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Abbott Laboratories (NYSE: ABT ) stock rose steadily in the last year and is up around 20% in that time. Though shares hover near yearly highs, thanks to a quick bounce from $66 to $71.42 recently, biotech investors should still consider investing in this company. Last quarter's strong results, plus a recent dividend hike, signal a healthy 2019 year for this medical appliance and equipment firm.
Abbott Laboratories will report Q4 results on Jan. 23 that will likely repeat Q3 2018 results, which were posted last October. The firm reported sales of $7.7 billion, up 7.8% on an organic basis. Since divesting its Abbott Medical Optics ("AMO") and integrating St. Jude Medical vascular business, it is more focused on heart and diabetic machines. Diagnostics, medical devices, nutrition, and established pharmaceuticals all grew in the healthy single digits.
Full-Year 2018 Forecast for ABT Stock
Abbott forecast earnings of $2.87 to $2.89 (adjusted), reflecting growth of 15%. It owes its growth to developments in its medical devices. For example, the U.S. approved the FreeStyle Libre 14-day system, so sales should start adding to results. FreeStyle Libre 2 system and High Sensitive Troponin, available in Europe, will bring healthy geographic diversification to its revenue.
7 Retail Stocks to Buy for the Rise of Menswear
On Dec. 16, 2018, Abbott declared a 32-cent a share quarterly dividend. This increase from 28-cents a share, or up 14.3%, gives investors a forward yield of 1.8%. This is below that of Bristol-Myers Squibb (NYSE: BMY ), at 3.27%, Merck & Co. (NYSE: MRK ), at 2.9%, or Pfizer (NYSE: PFE ), at 3.39%. Medtronic (NYSE: MDT ) has a comparable dividend yield of 2.29%. Despite dividend yields below that of comparable medical firms, this is still a bullish signal.
Management is demonstrating its confidence in future cash flow growth and rewarding shareholders with income. Plus, the firm pays a higher dividend yield than the bottom 25% of dividend payers in the U.S. (according to simplywall.st ).
Abbott Balance Sheet Analysis
Abbott's net worth increased in 2017 to $31.5 billion, but debt also rose, too, to $23.8 billion. This is due to the St. Jude Medical acquisition.
Markets do not seem to care about the higher debt because its long term, the debt/equity ratio is only 0.62X, according to MacroTrends. In the drug space, Bausch Health Companies (NYSE: BHC ) has a debt/equity of nearly 8x while Mylan N.V. (NASDAQ: MYL ) is at 1.2X.
The point here is that Abbot can handle the debt due to its healthy debt coverage. Its Operating cash flow of 26% exceeds its over 20% of total debt. Interest payment on the debt is covered by 4.8 times its EBIT.
Abbott Laboratories debt levels increased from merger and acquisition activities. (Source: https://simplywall.st)
Outlook for ABT Stock
Synergies from the integration of Abbott's St Jude unit will save on costs. Because management puts an emphasis on improving its underlying gross margin, look for the unit to keep performing better and adding more to profits.
The Alere unit, which will bring in $2 billion in revenue for fiscal 2018, will add positively to profits. Last year, Abbott stabilized and integrated the business. With that activity complete, it may concentrate on growing the business. As it happened that the strong flu season will benefit results, sustaining growth will depend on new product introductions from the unit.
Based on the six analysts covering ABT stock, the average price target is $79.33, representing upside of 11%. Investors may build a bearish to neutral 10-year DCF Revenue Exit model that assumes revenue slowing in the single digits. Even in that scenario, the model from finbox.io would still suggest a fair value of $73, not far from the recent stock price of ABT.
Abbott put a priority on its dividends over debt repayment. Its businesses are growing steadily and the product list is getting bigger. Cash flow growth will let the company meet its dividend payment obligations while paring debt levels over the long-term.
ABT stock is suitable for income investors who want to own a growing medical appliances firm at a reasonable price.
As of this writing, Chris Lau did not hold a position in any of the aforementioned securities.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
10 High-Growth Stocks for the Return of the Bull
The 10 Best Index Funds to Buy and Hold
10 Lithium Stocks to Buy Despite the Market's Irrationality
Compare Brokers
The post All Signals Are Positive for Buying Abbott Laboratories appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (Source: https://simplywall.st) Outlook for ABT Stock Synergies from the integration of Abbott's St Jude unit will save on costs. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Laboratories (NYSE: ABT ) stock rose steadily in the last year and is up around 20% in that time. Full-Year 2018 Forecast for ABT Stock Abbott forecast earnings of $2.87 to $2.89 (adjusted), reflecting growth of 15%. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Laboratories (NYSE: ABT ) stock rose steadily in the last year and is up around 20% in that time. Full-Year 2018 Forecast for ABT Stock Abbott forecast earnings of $2.87 to $2.89 (adjusted), reflecting growth of 15%. (Source: https://simplywall.st) Outlook for ABT Stock Synergies from the integration of Abbott's St Jude unit will save on costs. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Laboratories (NYSE: ABT ) stock rose steadily in the last year and is up around 20% in that time. Full-Year 2018 Forecast for ABT Stock Abbott forecast earnings of $2.87 to $2.89 (adjusted), reflecting growth of 15%. (Source: https://simplywall.st) Outlook for ABT Stock Synergies from the integration of Abbott's St Jude unit will save on costs. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Laboratories (NYSE: ABT ) stock rose steadily in the last year and is up around 20% in that time. ABT stock is suitable for income investors who want to own a growing medical appliances firm at a reasonable price. Full-Year 2018 Forecast for ABT Stock Abbott forecast earnings of $2.87 to $2.89 (adjusted), reflecting growth of 15%. |
33122.0 | 2019-01-22 00:00:00 UTC | Health Care Sector Update for 01/22/2019: TGTX, SRNE, JNJ, ABT, MRK, AMGN, PFE | ABT | https://www.nasdaq.com/articles/health-care-sector-update-01222019-tgtx-srne-jnj-abt-mrk-amgn-pfe-2019-01-22 | nan | nan | Top Health Care Stocks:
JNJ: -2.06%
PFE: -0.12%
ABT: -0.15%
MRK: Flat
AMGN: -1.06%
Health care stocks were declining in pre-market trading Tuesday.
Early movers include:
(+) TG Therapeutics ( TGTX ), which was advancing by more than 9% after the biopharmaceutical company said the US Food and Drug Administration (FDA) has granted breakthrough therapy designation for umbralisib (TGR-1202) to treat adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20 regimen.
(+) Sorrento Therapeutics ( SRNE ) was over 6% higher as i t report ed "positive activity" in a phase 1b study of its non-opioid, afferent nerve-ablating drug candidate resiniferatoxin, for the treatment of pain from osteoarthritis in the knee.
(-) Johnson & Johnson ( JNJ ) was down more than 2% after reporting Q4 earnings and revenue that both topped expectations and issuing 2019 guidance that was mixed. The company booked earnings of $1.97 a share, excluding special items, up from $1.74 last year and ahead of consensus from Capital IQ for $1.95 a share. Revenue came in at $20.4 billion, up 1% from $20.2 billion in the same quarter last year. The Street view was for revenue of $20.27 billion.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care stocks were declining in pre-market trading Tuesday. Early movers include: (+) TG Therapeutics ( TGTX ), which was advancing by more than 9% after the biopharmaceutical company said the US Food and Drug Administration (FDA) has granted breakthrough therapy designation for umbralisib (TGR-1202) to treat adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20 regimen. (+) Sorrento Therapeutics ( SRNE ) was over 6% higher as i t report ed "positive activity" in a phase 1b study of its non-opioid, afferent nerve-ablating drug candidate resiniferatoxin, for the treatment of pain from osteoarthritis in the knee. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Top Health Care Stocks: | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Early movers include: (+) TG Therapeutics ( TGTX ), which was advancing by more than 9% after the biopharmaceutical company said the US Food and Drug Administration (FDA) has granted breakthrough therapy designation for umbralisib (TGR-1202) to treat adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20 regimen. | Top Health Care Stocks: MRK: Flat The Street view was for revenue of $20.27 billion. |
33123.0 | 2019-01-22 00:00:00 UTC | Medical Product Stocks' Earnings on Jan 23: ABT, NXGN & VAR | ABT | https://www.nasdaq.com/articles/medical-product-stocks-earnings-on-jan-23%3A-abt-nxgn-var-2019-01-22 | nan | nan | The fourth-quarter earnings season has seen releases from 55 members in the S&P 500 cohort as of Jan 18. Per the latest Earnings Preview , performances of these index participants indicate a 16.9% increase in total earnings on 9% higher revenues.
By the end of the season, earnings of the S&P 500 companies, as a whole, are expected to grow 10.7% from the year-ago quarter on a 5.3% rise in revenues.
Earnings Expectations From Medical Sector
Medical - one of the 16 Zacks sectors - is expected to record earnings growth this season. For the quarter under review, the projected earnings growth rate for the sector is 7.2% on 6.1% revenue growth.
What's in Store for the Medical Products Space?
Going by a CISION report, United States is the largest Medical Products market in the world, raking in more than $180 billion in revenues a year. It has clearly been a very profitable investment space of late.
The sector benefits from favorable consumer behavior, growing prevalence of minimally-invasive surgeries, demand for liquid biopsy tests, use of IT for quick and improved patient care along with the shift of the payment system to a value-based model.
The latest Tax Cuts and Jobs Act, which among many other changes, slashed corporate tax rates to 21% from the earlier 35%, has provided impetus to the market.
This apart, U.S. medical device companies are currently riding on R&D innovation, courtesy of the 2.3% Medical Device tax abolition earlier this year. According to an article published in Xtalks, the Medical Device tax was responsible for a $34-million reduction in R&D spending by companies. The bill also delays the Cadillac tax, a 40% tax on employer insurance, until 2022.
However, the Medical Products space is confronted with short-term hurdles associated with the U.S.-China trade war. According to a survey conducted by the Medical Imaging & Technology Alliance (MITA), the tariffs will cost Medical Products companies nearly $138 million every year.
Companies will thus be compelled to reduce workforce and investments in R&D to meet this 'new and unnecessary expense.' This also increases the chances of costs being passed on to end users, making healthcare more expensive.
Against this backdrop, let's take a look at a few leading Medical Product stocks scheduled to release earnings numbers on Jan 23:
Per the quantitative Zacks model, stocks with the perfect combination of a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) and a positive Earnings ESP have substantially higher chances of beating estimates. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Abbott LaboratoriesABT is anticipated to gain from a strong fourth-quarter performance by the Established Pharmaceuticals Division business. The division has been recording impressive operational sales growth over the last few quarters. The consistent strength in the Diagnostics business, courtesy of contributions from all sub-segments, namely, Core Laboratories Diagnostics, Molecular Diagnostics and Point of Care is also encouraging (read more: What Lies Ahead for Abbott Stock This Earnings Season? ).
For the quarter to be reported, the Zacks Consensus Estimate for revenues is pegged at $7.79 billion, reflecting a year-over-year rise of 2.6%. The consensus estimate for adjusted earnings per share stands at 81 cents, indicating an increase of 9.5%. Abbott delivered positive surprises in the trailing four reported quarters, the average being 1.82%.
However, our quantitative Zacks model does not conclusively show an earnings beat for the company, given the combination of a Zacks Rank of 3 and an Earnings ESP of 0.00%.
NextGen Healthcare, Inc.NXGN is expected to gain from consistent momentum in quarterly bookings on the company's growing pipeline and coveted RCM (Revenue Cycle Management) services platform in its upcoming third-quarter fiscal 2019 results. Strength in the company's flagship NextGen Mobile and NextGen Office solutions can also be a major growth driver.
For the quarter to be reported, the Zacks Consensus Estimate for revenues is pegged at $130.79 million, reflecting a year-over-year decline of 0.7%. The Zacks Consensus Estimate for adjusted earnings per share stands at 15 cents, flat on a year-over-year basis. On average, Quality Systems delivered a positive earnings surprise of 13.7% for three of the trailing four quarters.
However, our quantitative Zacks model does not conclusively predict an earnings beat for the company, given the combination of a Zacks Rank of 3 and an Earnings ESP of 0.00%.
Varian Medical Systems, Inc . VAR is likely to gain from a strong overseas presence and product launches in the upcoming first-quarter fiscal 2019 results. (read more: Varian Medical to Report Q1 Earnings: What's in Store? )
For the quarter to be reported, the Zacks Consensus Estimate for revenues is pegged at $717.88 million, reflecting a year-over-year rise of 5.8%. The Zacks Consensus Estimate for adjusted earnings per share stands at $1.06, flat year over year. On average, Varian Medical delivered a positive earnings surprise of 4.3% over three of the trailing four quarters.
However, our quantitative Zacks model does not conclusively predict an earnings beat for the company, given the combination of a Zacks Rank of 3 and an Earnings ESP of 0.00%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Get Free Report
Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report
Quality Systems, Inc. (NXGN): Get Free Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT is anticipated to gain from a strong fourth-quarter performance by the Established Pharmaceuticals Division business. Click to get this free report Abbott Laboratories (ABT): Get Free Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Quality Systems, Inc. (NXGN): Get Free Report To read this article on Zacks.com click here. The sector benefits from favorable consumer behavior, growing prevalence of minimally-invasive surgeries, demand for liquid biopsy tests, use of IT for quick and improved patient care along with the shift of the payment system to a value-based model. | Click to get this free report Abbott Laboratories (ABT): Get Free Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Quality Systems, Inc. (NXGN): Get Free Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is anticipated to gain from a strong fourth-quarter performance by the Established Pharmaceuticals Division business. Earnings Expectations From Medical Sector Medical - one of the 16 Zacks sectors - is expected to record earnings growth this season. | Abbott LaboratoriesABT is anticipated to gain from a strong fourth-quarter performance by the Established Pharmaceuticals Division business. Click to get this free report Abbott Laboratories (ABT): Get Free Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Quality Systems, Inc. (NXGN): Get Free Report To read this article on Zacks.com click here. Earnings Expectations From Medical Sector Medical - one of the 16 Zacks sectors - is expected to record earnings growth this season. | Abbott LaboratoriesABT is anticipated to gain from a strong fourth-quarter performance by the Established Pharmaceuticals Division business. Click to get this free report Abbott Laboratories (ABT): Get Free Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Quality Systems, Inc. (NXGN): Get Free Report To read this article on Zacks.com click here. Earnings Expectations From Medical Sector Medical - one of the 16 Zacks sectors - is expected to record earnings growth this season. |
33124.0 | 2019-01-22 00:00:00 UTC | Pre-Market Earnings Report for January 23, 2019 : PG, CMCSA, ABT, UTX, ASML, KMB, PGR, TEL, APH, NTRS, SYF, WAT | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-january-23-2019-pg-cmcsa-abt-utx-asml-kmb-pgr-tel-aph-ntrs-syf | nan | nan | The following companies are expected to repor t earnings prior to market open on 01/23/2019. Visit our Earnings Calendar for a full list of expected earnings releases.
Procter & Gamble Company ( PG ) is reporting for the quarter ending December 31, 2018. The cleaning company's consensus earnings per share forecast from the 10 analysts that follow the stock is $1.21. This value represents a 1.68% increase compared to the same quarter last year. In the past year PG has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 2.75%. Zacks Investment Research reports that the 2019 Price to Earnings ratio for PG is 20.68 vs. an industry ratio of 21.40.
Comcast Corporation ( CMCSA ) is reporting for the quarter ending December 31, 2018. The cable tv company's consensus earnings per share forecast from the 12 analysts that follow the stock is $0.62. This value represents a 26.53% increase compared to the same quarter last year. In the past year CMCSA has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 6.56%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for CMCSA is 14.26 vs. an industry ratio of 26.70.
Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2018. The medical products company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.81. This value represents a 9.46% increase compared to the same quarter last year. In the past year ABT has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 1.35%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABT is 24.71 vs. an industry ratio of -40.30, implying that they will have a higher earnings growth than their competitors in the same industry.
United Technologies Corporation ( UTX ) is reporting for the quarter ending December 31, 2018. The diversified operations company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.51. This value represents a 5.63% decrease compared to the same quarter last year. In the past year UTX has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 6.63%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for UTX is 15.86 vs. an industry ratio of 13.60, implying that they will have a higher earnings growth than their competitors in the same industry.
ASML Holding N.V. ( ASML ) is reporting for the quarter ending December 31, 2018. The capital goods company's consensus earnings per share forecast from the 1 analyst that follows the stock is $2.04. This value represents a 15.25% increase compared to the same quarter last year. ASML missed the consensus earnings per share in the 3rd calendar quarter of 2018 by -2.11%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ASML is 23.58 vs. an industry ratio of 13.40, implying that they will have a higher earnings growth than their competitors in the same industry.
Kimberly-Clark Corporation ( KMB ) is reporting for the quarter ending December 31, 2018. The consumer company's consensus earnings per share forecast from the 6 analysts that follow the stock is $1.68. This value represents a 7.01% increase compared to the same quarter last year. In the past year KMB has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2018 Price to Earnings ratio for KMB is 17.47 vs. an industry ratio of 18.40.
Progressive Corporation ( PGR ) is reporting for the quarter ending December 31, 2018. The insurance (property & casualty) company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.01. This value represents a 27.85% increase compared to the same quarter last year. In the past year PGR has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 37.72%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for PGR is 13.51 vs. an industry ratio of 15.70.
TE Connectivity Ltd. ( TEL ) is reporting for the quarter ending December 31, 2018. The electrical instrument company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.28. This value represents a 8.57% decrease compared to the same quarter last year. In the past year TEL has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 1.5%. Zacks Investment Research reports that the 2019 Price to Earnings ratio for TEL is 14.25 vs. an industry ratio of 17.20.
Amphenol Corporation ( APH ) is reporting for the quarter ending December 31, 2018. The electrical connectors company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.98. This value represents a 13.95% increase compared to the same quarter last year. In the past year APH has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 5.21%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for APH is 22.29 vs. an industry ratio of 10.20, implying that they will have a higher earnings growth than their competitors in the same industry.
Northern Trust Corporation ( NTRS ) is reporting for the quarter ending December 31, 2018. The bank company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.63. This value represents a 20.74% increase compared to the same quarter last year. NTRS missed the consensus earnings per share in the 3rd calendar quarter of 2018 by -1.25%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for NTRS is 13.96 vs. an industry ratio of 10.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Synchrony Financial ( SYF ) is reporting for the quarter ending December 31, 2018. The financial services company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.93. This value represents a 32.86% increase compared to the same quarter last year. In the past year SYF has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 13.75%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for SYF is 7.34 vs. an industry ratio of 8.00.
Waters Corporation ( WAT ) is reporting for the quarter ending December 31, 2018. The scientific instrument company's consensus earnings per share forecast from the 9 analysts that follow the stock is $2.65. This value represents a 5.58% increase compared to the same quarter last year. In the past year WAT has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 1.05%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for WAT is 25.67 vs. an industry ratio of 25.00, implying that they will have a higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2018. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABT is 24.71 vs. an industry ratio of -40.30, implying that they will have a higher earnings growth than their competitors in the same industry. | Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABT is 24.71 vs. an industry ratio of -40.30, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2018. In the past year ABT has beat the expectations every quarter. | Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABT is 24.71 vs. an industry ratio of -40.30, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2018. In the past year ABT has beat the expectations every quarter. | Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2018. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABT is 24.71 vs. an industry ratio of -40.30, implying that they will have a higher earnings growth than their competitors in the same industry. |
33125.0 | 2019-01-18 00:00:00 UTC | Can Medical Devices Strength Drive Abbott (ABT) Q4 Earnings? | ABT | https://www.nasdaq.com/articles/can-medical-devices-strength-drive-abbott-abt-q4-earnings-2019-01-18 | nan | nan | Abbott 's ABT Medical Devices business has been going strong of late on solid sub-segmental performance.
We expect this strength to get reflected in fourth-quarter 2018 results, which are scheduled for release on Jan 23, before the market opens.
Click here to know how the company's overall Q4 performance is expected to be.
Medical Devices in Focus
Abbott's Medical Devices segment presently comprises the new Cardiovascular and Neuromodulation, Heart Failure, Electrophysiology, Structural Heart, Rhythm Management, Vascular businesses along with the Diabetes Care business.
Management expects high single-digit growth in Medical Devices' fourth-quarter 2018 sales along with continued double-digit growth in certain sub-segments.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
The Zacks Consensus Estimate for Medical Devices revenues in the United States of $1.29 billion indicates a rise of 6.6% from the year-ago quarter. Internationally, the consensus estimate of $1.63 billion shows growth of 6.5%.
In the last quarter, sales improvement at the segment was driven by double-digit growth in Electrophysiology, Structural Heart and Diabetes Care. Moreover, the company received approvals for a few products alongside achieving clinical trial milestones.
Let's see how things are shaping up within these sub-segments before the fourth-quarter results.
Electrophysiology , which accounted for 14.4% of Medical Devices revenues in third-quarter 2018, has been gaining strongly from strength in cardiac mapping and ablation catheters. The trend is expected to continue in the fourth quarter.
The company is expected to gain from continued solid demand for its Confirm Rx Insertable Cardiac Monitor this quarter.
The Zacks Consensus Estimate for Electrophysiology revenues of $430 million indicates an increase of 12.9% from a year ago. The company is expected to keep gaining from this business.
The Structural Heart business has maintained an impressive top-line performance. In the las t report ed quarter, this business accounted for 10.8% of total revenues under the broader Medical Devices segment. The upside was led by strong performances from MitraClip and AMPLATZER PFO Occluder.
Last September, Abbott presented positive clinical results from its COAPT study supporting the efficacy of MitraClip for select patients with functional mitral regurgitation.
This positive development is expected to boost the uptake of the product and top-line contributions from this sub-segment in the to-be-reported quarter. Our estimate for Structural Heart revenues of $345 million indicates a rise of 19% from the year-ago quarter.
In Diabetes Care , international sales growth of 42% on a reported basis in the prior quarter was driven by Abbott's FreeStyle Libre. The company has initiated the launch of FreeStyleLibre in the United States as well.
Proceeding with initiatives to boost this arm, the company received FDA approval for its FreeStyle Libre 14 day sensor in August 2018. In October, Abbott was granted CE Mark for its next-generation product with optional real-time alarms - FreeStyle Libre 2 system.
Following the developments, Abbott is expected to keep gaining from the continued uptake of the FreeStyle Libre in the to-be-reported quarter. The Zacks Consensus Estimate for Diabetes Care revenues of $544 million indicates a surge of 31.7% from the year-ago quarter.
Zacks Rank & Stocks to Consider
Abbott carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space include Veeva Systems VEEV , Amedisys, Inc. AMED and Illumina, Inc. ILMN .
Veeva Systems' long-term earnings growth rate is estimated at 19.5%. The stock flaunts a Zacks Rank of 1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Amedisys' long-term earnings growth rate is projected at 18.8%. The stock carries a Zacks Rank #2 (Buy).
Illumina's long-term earnings growth rate is expected at 23.4%. The stock carries a Zacks Rank of 2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Veeva Systems Inc. (VEEV): Free Stock Analysis Report
Abbott Laboratories (ABT): Get Free Report
Illumina, Inc. (ILMN): Free Stock Analysis Report
Amedisys, Inc. (AMED): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott 's ABT Medical Devices business has been going strong of late on solid sub-segmental performance. Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Abbott Laboratories (ABT): Get Free Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Electrophysiology , which accounted for 14.4% of Medical Devices revenues in third-quarter 2018, has been gaining strongly from strength in cardiac mapping and ablation catheters. | Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Abbott Laboratories (ABT): Get Free Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott 's ABT Medical Devices business has been going strong of late on solid sub-segmental performance. Management expects high single-digit growth in Medical Devices' fourth-quarter 2018 sales along with continued double-digit growth in certain sub-segments. | Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Abbott Laboratories (ABT): Get Free Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott 's ABT Medical Devices business has been going strong of late on solid sub-segmental performance. Medical Devices in Focus Abbott's Medical Devices segment presently comprises the new Cardiovascular and Neuromodulation, Heart Failure, Electrophysiology, Structural Heart, Rhythm Management, Vascular businesses along with the Diabetes Care business. | Abbott 's ABT Medical Devices business has been going strong of late on solid sub-segmental performance. Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Abbott Laboratories (ABT): Get Free Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Management expects high single-digit growth in Medical Devices' fourth-quarter 2018 sales along with continued double-digit growth in certain sub-segments. |
33126.0 | 2019-01-18 00:00:00 UTC | Is a Surprise Coming for Abbott (ABT) This Earnings Season? | ABT | https://www.nasdaq.com/articles/is-a-surprise-coming-for-abbott-abt-this-earnings-season-2019-01-18 | nan | nan | Investors are always looking for stocks that are poised to beat a t earnings season and Abbott LaboratoriesABT may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Abbott is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings - with the most up-to-date information possible - is a pretty good indicator of some favorable trends underneath the surface for ABT in this report.
In fact, the Most Accurate Estimate for the current quarter is currently higher than the broader Zacks Consensus Estimate of 81 cents per share. This suggests that analysts have very recently bumped up their estimates for ABT, giving the stock a Zacks Earnings ESP of +0.25% heading into earnings season.
Abbott Laboratories Price and EPS Surprise | Investors are always looking for stocks that are poised to beat a t earnings season and Abbott LaboratoriesABT may be one such company. After all, analysts raising estimates right before earnings - with the most up-to-date information possible - is a pretty good indicator of some favorable trends underneath the surface for ABT in this report. This suggests that analysts have very recently bumped up their estimates for ABT, giving the stock a Zacks Earnings ESP of +0.25% heading into earnings season. | Investors are always looking for stocks that are poised to beat a t earnings season and Abbott LaboratoriesABT may be one such company. This suggests that analysts have very recently bumped up their estimates for ABT, giving the stock a Zacks Earnings ESP of +0.25% heading into earnings season. After all, analysts raising estimates right before earnings - with the most up-to-date information possible - is a pretty good indicator of some favorable trends underneath the surface for ABT in this report. | After all, analysts raising estimates right before earnings - with the most up-to-date information possible - is a pretty good indicator of some favorable trends underneath the surface for ABT in this report. This suggests that analysts have very recently bumped up their estimates for ABT, giving the stock a Zacks Earnings ESP of +0.25% heading into earnings season. Investors are always looking for stocks that are poised to beat a t earnings season and Abbott LaboratoriesABT may be one such company. | Investors are always looking for stocks that are poised to beat a t earnings season and Abbott LaboratoriesABT may be one such company. After all, analysts raising estimates right before earnings - with the most up-to-date information possible - is a pretty good indicator of some favorable trends underneath the surface for ABT in this report. This suggests that analysts have very recently bumped up their estimates for ABT, giving the stock a Zacks Earnings ESP of +0.25% heading into earnings season. |
33127.0 | 2019-01-16 00:00:00 UTC | Abbott (ABT) Earnings Expected to Grow: Should You Buy? | ABT | https://www.nasdaq.com/articles/abbott-abt-earnings-expected-to-grow%3A-should-you-buy-2019-01-16 | nan | nan | Wall Street expects a year-over-year increase in earnings on higher revenues when Abbott (ABT) reports results for the quarter ended December 2018. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on January 23, 2019, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call , it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus Estimate
This maker of infant formula, medical devices and drugs is expected to pos t quarterly earnings of $0.81 per share in its upcoming report, which represents a year-over-year change of +9.5%.
Revenues are expected to be $7.79 billion, up 2.6% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0.61% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time , and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Abbott?
For Abbott, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +0.25%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination indicates that Abbott will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the las t report ed quarter, it was expected that Abbott would pos t earnings of $0.74 per share when it actually produced earnings of $0.75, delivering a surprise of +1.35%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Abbott appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Wall Street expects a year-over-year increase in earnings on higher revenues when Abbott (ABT) reports results for the quarter ended December 2018. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. Zacks Consensus Estimate This maker of infant formula, medical devices and drugs is expected to pos t quarterly earnings of $0.81 per share in its upcoming report, which represents a year-over-year change of +9.5%. | Wall Street expects a year-over-year increase in earnings on higher revenues when Abbott (ABT) reports results for the quarter ended December 2018. Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). | Wall Street expects a year-over-year increase in earnings on higher revenues when Abbott (ABT) reports results for the quarter ended December 2018. Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change. | Wall Street expects a year-over-year increase in earnings on higher revenues when Abbott (ABT) reports results for the quarter ended December 2018. Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time , and a solid Zacks Rank actually increases the predictive power of Earnings ESP. |
33128.0 | 2019-01-16 00:00:00 UTC | 3 Healthcare Stocks That Will Keep Your Portfolio Healthy | ABT | https://www.nasdaq.com/articles/3-healthcare-stocks-will-keep-your-portfolio-healthy-2019-01-16 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Healthcare stocks cover a wide range of equities. Pharmaceuticals, equipment providers, insurers, pharmacies, technology, and even healthcare-related real estate investment trusts (REIT) can all fall under this category.
However, these companies all benefit from the same trends. The share of healthcare in the overall U.S. economy continues to grow. The Centers for Medicare and Medicaid Services (CMS) estimates that healthcare encompasses about 17.9% of the U.S. economy . Moreover, with an estimated 10,000 baby boomers aging into Medicare a day, the pressure on limited healthcare resources continues to mount.
7 Oversold Small-Cap Stocks With Massive Profit Growth
While this can mean pain for the healthcare consumer, it can also bring benefit to those who invest in healthcare. With more of the baby boom generation on Medicare, a larger percentage of the population benefits from a healthcare subsidy. This gives a noticeable boost to healthcare stocks. Here are three that could help you benefit from this trend.
AbbVie (ABBV)
Source: Shutterstock
Few healthcare stocks find themselves in a better position for both income and growth potential than AbbVie (NYSE: ABBV ). Abbott Laboratories (NYSE: ABT ) created AbbVie when it spun off its pharmaceutical division in 2013. After a growth spurt in 2017, ABBV fell as concerns about patent expirations on its blockbuster drug Humira weighed on the stock. Today it trades at about 30% below its 52-week high.
However, ABBV stock also looks well-positioned to make a comeback. The Humira-driven swoon in ABBV has taken the forward P/E ratio to around 9.8. This comes in well below the average P/E of 18.2 over the last five years. Moreover, Evaluate Pharma ranks AbbVie's drug pipeline as second-best in the industry for value creation. Also, the company has time to transition to its next high-revenue drug. It will hold a patent on Humira in the U.S. until at least 2022. Analysts also do not seem worried as they predict profit growth of almost 10% per year through at least 2021.
Furthermore, Wall Street considers AbbVie a dividend aristocrat due to its previous ties to Abbott. As a result, the company faces tremendous pressure to increase its dividend annually. AbbVie increased its payout from $3.59 per share to $4.28 per share this year. Hence, despite a generous yield of almost 4.9%, investors can probably expect annual increases in future years.
Also, I see this massive dividend increase as a vote of confidence in itself. Couple that with the low P/E and the high ratings that AbbVie's drug pipeline has received, and ABBV should be one of the few healthcare stocks which will outperform in both the growth and income categories.
Teladoc Health (TDOC)
Source: MayApps207 via WikiMedia
Buying Teladoc Health (NYSE: TDOC ) amounts to buying into the future of healthcare. Without a doubt, the 17.9% of the economy that healthcare now consumes weighs heavily on family budgets. Teladoc allows patients to see a licensed doctor at any time via a PC or mobile device, reducing the need to take time off from work. It also saves money as visits can run as low as $40.
Telehealth has only begun to realize its potential. Analysts estimate telehealth can handle about one-third of the 1.25 billion office visits that take place each year in the U.S. With Teladoc handling an estimated two million visits in 2018, the company still covers less than 1% of its potential market.
Teladoc also shows that it can acquire the right partners to improve its quality and reach more patients. It widened its competitive moat by investing in diagnostic capabilities with a takeover of Best Doctors. It also partnered with CVS Health (NYSE: CVS ) to provide care to its customers. Additionally, it boosted its offshore footprint by buying Advance Medical. Advance Medical was the leading telehealth provider outside the U.S. before TDOC purchased the company.
Investors should note that TDOC remains expensive. Its price in the $55 per share range places it at around 9.3 times sales. Still, it has fallen almost 40% from its October high. Also, revenue grew by 78% in 2018. Although that growth will fall over time, analysts estimate that the company will turn profitable in 2021.
10 Growth Stocks With the Future Written All Over Them
Teladoc remains one of the more speculative healthcare stocks. However, with a $3.8 billion market cap, and a majority market share in a business that has reached less than one percent of its full potential, Teladoc could become one of the best stocks in healthcare.
Dentsply Sirona (XRAY)
Source: Shutterstock
An aging population creates an increasing need for dental care and the equipment provided by Dentsply Sirona (NASDAQ: XRAY ). As the ticker implies, Dentsply manufactures dental imaging equipment as well as consumable supplies and specialty dental products.
Medicare rarely covers dental needs. However, many consumers place a high value on having a beautiful smile and the ability to chew food. Hence, most customers will spend money on services requiring XRAY's supplies and equipment. This also holds true outside of the U.S. Dentsply Sirona conducts business in over 120 countries. These other countries account for about 65% of the company's revenue.
XRAY stock rose steadily between 2009 and 2018. However, in 2018, the stock lost almost half of its value. By late October, it traded as low as $33.93 per share, a level first seen in 2011. The stock sold off for most of the year on lower-than-expected sales. An impairment charge on goodwill and intangible assets in the second quarter hurt earnings. The stock fell by nearly 20% on August 7 following this announcement.
However, management responded with a restructuring plan. While that breeds uncertainty, the forecasts indicate an opportunity for buyers. The forward P/E ratio stands at around 18, well below the five-year average of 28.1. Furthermore, analysts predict 11.2% consensus profit growth this year. They also foresee double-digit profit increases through at least 2021.
XRAY faced a great deal of pain in 2018. Still, the need for dental supplies and equipment will only rise in the coming years. For this reason, the lower multiple and the predicted profit growth should bring about a recovery in Dentsply Sirona.
As of this writing, Will Healy is long TDOC stock. You canfollow Will on Twitterat @HealyWriting.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
Top 10 Global Stock Ideas for 2019 From RBC Capital
10 A-Rated Stocks the Smart Money Is Piling Into
5 Best Bank ETFs for This Week's Earnings Avalanche
Compare Brokers
The post 3 Healthcare Stocks That Will Keep Your Portfolio Healthy appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (NYSE: ABT ) created AbbVie when it spun off its pharmaceutical division in 2013. Pharmaceuticals, equipment providers, insurers, pharmacies, technology, and even healthcare-related real estate investment trusts (REIT) can all fall under this category. Moreover, with an estimated 10,000 baby boomers aging into Medicare a day, the pressure on limited healthcare resources continues to mount. | Abbott Laboratories (NYSE: ABT ) created AbbVie when it spun off its pharmaceutical division in 2013. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Healthcare stocks cover a wide range of equities. Teladoc Health (TDOC) Source: MayApps207 via WikiMedia Buying Teladoc Health (NYSE: TDOC ) amounts to buying into the future of healthcare. | Abbott Laboratories (NYSE: ABT ) created AbbVie when it spun off its pharmaceutical division in 2013. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Healthcare stocks cover a wide range of equities. 7 Oversold Small-Cap Stocks With Massive Profit Growth While this can mean pain for the healthcare consumer, it can also bring benefit to those who invest in healthcare. | Abbott Laboratories (NYSE: ABT ) created AbbVie when it spun off its pharmaceutical division in 2013. 7 Oversold Small-Cap Stocks With Massive Profit Growth While this can mean pain for the healthcare consumer, it can also bring benefit to those who invest in healthcare. Although that growth will fall over time, analysts estimate that the company will turn profitable in 2021. |
33129.0 | 2019-01-15 00:00:00 UTC | SPDR Portfolio S&P 500 Growth ETF Experiences Big Inflow | ABT | https://www.nasdaq.com/articles/spdr-portfolio-sp-500-growth-etf-experiences-big-inflow-2019-01-15 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $190.2 million dollar inflow -- that's a 5.9% increase week over week in outstanding units (from 96,700,000 to 102,400,000). Among the largest underlying components of SPYG, in trading today Mastercard Inc (Symbol: MA) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is up about 2%, and PepsiCo Inc (Symbol: PEP) is up by about 0.8%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average:
Looking at the chart above, SPYG's low point in its 52 week range is $30.31 per share, with $38.55 as the 52 week high point - that compares with a last trade of $33.73. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SPYG, in trading today Mastercard Inc (Symbol: MA) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is up about 2%, and PepsiCo Inc (Symbol: PEP) is up by about 0.8%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $30.31 per share, with $38.55 as the 52 week high point - that compares with a last trade of $33.73. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of SPYG, in trading today Mastercard Inc (Symbol: MA) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is up about 2%, and PepsiCo Inc (Symbol: PEP) is up by about 0.8%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $30.31 per share, with $38.55 as the 52 week high point - that compares with a last trade of $33.73. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SPYG, in trading today Mastercard Inc (Symbol: MA) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is up about 2%, and PepsiCo Inc (Symbol: PEP) is up by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $190.2 million dollar inflow -- that's a 5.9% increase week over week in outstanding units (from 96,700,000 to 102,400,000). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $30.31 per share, with $38.55 as the 52 week high point - that compares with a last trade of $33.73. | Among the largest underlying components of SPYG, in trading today Mastercard Inc (Symbol: MA) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is up about 2%, and PepsiCo Inc (Symbol: PEP) is up by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $190.2 million dollar inflow -- that's a 5.9% increase week over week in outstanding units (from 96,700,000 to 102,400,000). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $30.31 per share, with $38.55 as the 52 week high point - that compares with a last trade of $33.73. |
33130.0 | 2019-01-15 00:00:00 UTC | 3 Top Diabetes Stocks to Watch in January | ABT | https://www.nasdaq.com/articles/3-top-diabetes-stocks-watch-january-2019-01-15 | nan | nan | Diabetes affects tens of millions of Americans, and even more are at risk of developing diabetes, as they suffer from prediabetes. With such a large population suffering from the condition, it's clearly a disease that gets much attention and investment. We asked three of our contributors to pick a company worth watching that is addressing some aspect of the illness, and they selected Abbott Laboratories (NYSE: ABT) , DexCom (NASDAQ: DXCM) , and Novo Nordisk (NYSE: NVO) .
Diabetes and a lot more
Keith Speights (Abbott Laboratories): While the broader market floundered in 2018, Abbott Labs turned in a great performance. Shares of the medical device company soared nearly 27%. The diabetes market was key to Abbott's success.
In Abbott's Q3 earnings call in October, CEO Miles White highlighted the great launch for the company's Freestyle Libre continuous glucose monitoring (CGM) system that doesn't require finger sticks. White said that more than 1 million customers now use the product, an impressive number to achieve in a relatively short time. Sales for Freestyle Libre more than doubled year over year to over $300 million.
Expect Freestyle Libre to continue to drive growth for Abbott in the future. The company also hopes to win U.S. approval to launch version two of the product, which includes an alarm feature that lets users know when their glucose levels are too low or too high.
But Abbott Labs has a lot more going for it. The company is the global leader in minimally invasive surgical solutions for leaky heart valves. And Abbott continues to generate growth from its established pharmaceuticals, nutrition, and electrophysiology businesses.
Abbott has two products to watch in addition to Freestyle Libre. The first is its MitraClip device for mitral valve repair. There's a lot of growth potential for MitraClip, especially if Abbott wins an expanded indication for the device (approval from the FDA for use in more situations). The company also has a pivotal study underway for a new product, Tendyne, that could enable the replacement of damaged mitral heart valves without open-heart surgery.
Innovations like Freestyle Libre in diabetes and Tendyne in structural heart devices make Abbott Labs a stock to keep your eyes on -- in January and beyond.
$40 million to $1 billion in 8 years
Todd Campbell(DexCom): What does disruption look like to an investor? How about going from $40 million in annual sales to over $1 billion in annual sales in eight years? That's impressive, but it may only hint at the revenue opportunity ahead for DexCom, the leading maker of continuous glucose monitors (CGMs) for diabetes patients.
In the past, patients with insulin-intensive diabetes had to rely on many finger sticks to provide point-in-time insight into blood sugar. Historically, the haphazard insight offered by finger sticks meant the average patient spent 70% of their time outside their desired blood sugar range, which put them at risk of new symptoms including cardiovascular disease, nerve damage, and blindness -- or even death.
That's not the case anymore. Today, DexCom's CGMs provide real-time insight into blood sugar without the need for finger sticks, giving patients, caregivers, and doctors an unprecedented ability to manage disease.
DexCom estimates its current addressable market of insulin-intensive type and type 2 diabetes patients is 3.2 million; however, advances that will make CGMs smarter, smaller, and cheaper could increase that market significantly. Addressing the gestational diabetes market could increase its target market by about 800,000 patients; monitoring patients in hospitals would add about 10 million patients; and serving the entire type 2 diabetes population expands the addressable population to roughly 27 million in the U.S alone.
DexCom's $1.03 billion in sales grew 42% year over year, in part because its newest CGM, the G6, is a part of the automated insulin delivery device from Tandem Diabetes Care (NASDAQ: TNDM) . In 2019 sales are expected to grow up to 20% as the G6 launch spreads. Sales could accelerate even faster when DexCom's next CGM -- the G7 -- is launched in 2020. With double-digit growth on tap and a massive and growing market, I think DexCom's a great stock to consider adding to portfolios now.
The biggest player in the insulin market
Chuck Saletta(Novo Nordisk): Diabetes happens either because your own body can't produce insulin (type 1) or because your body has become resistant to the insulin it does produce (type 2). For patients suffering from type 1 diabetes and many who suffer from type 2, treatment with insulin is a critical part of managing the disease. With over 100 million Americans suffering from either diabetes or prediabetes, it's clearly a huge disease -- and insulin is a huge part of fighting it.
That's what makes Novo Nordisk an incredibly important company to watch. Novo Nordisk produces about half the insulin sold commercially around the world. That makes it something of a barometer when it comes to the overall state of the diabetes industry, and certainly makes it worth watching for investors interested in treating the condition.
Its large market position in the fight against a huge disease gives Novo Nordisk a certain amount of pricing power. It recently increased prices on its insulin products by around 5%, showcasing its belief that it will be able to maintain its strong market position despite those higher prices.
While there's talk of a potential cure for Type 1 diabetes on the horizon, the unfortunate likelihood is that diabetes will be with us for a long time to come. And should a cure actually come about, chances are decent that Novo Nordisk will play a role there too. That makes Novo Nordisk a contender for consideration not just for this month, but for the long haul as well.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Chuck Saletta has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. Todd Campbell owns shares of DexCom. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We asked three of our contributors to pick a company worth watching that is addressing some aspect of the illness, and they selected Abbott Laboratories (NYSE: ABT) , DexCom (NASDAQ: DXCM) , and Novo Nordisk (NYSE: NVO) . In Abbott's Q3 earnings call in October, CEO Miles White highlighted the great launch for the company's Freestyle Libre continuous glucose monitoring (CGM) system that doesn't require finger sticks. Historically, the haphazard insight offered by finger sticks meant the average patient spent 70% of their time outside their desired blood sugar range, which put them at risk of new symptoms including cardiovascular disease, nerve damage, and blindness -- or even death. | We asked three of our contributors to pick a company worth watching that is addressing some aspect of the illness, and they selected Abbott Laboratories (NYSE: ABT) , DexCom (NASDAQ: DXCM) , and Novo Nordisk (NYSE: NVO) . In Abbott's Q3 earnings call in October, CEO Miles White highlighted the great launch for the company's Freestyle Libre continuous glucose monitoring (CGM) system that doesn't require finger sticks. Innovations like Freestyle Libre in diabetes and Tendyne in structural heart devices make Abbott Labs a stock to keep your eyes on -- in January and beyond. | We asked three of our contributors to pick a company worth watching that is addressing some aspect of the illness, and they selected Abbott Laboratories (NYSE: ABT) , DexCom (NASDAQ: DXCM) , and Novo Nordisk (NYSE: NVO) . DexCom estimates its current addressable market of insulin-intensive type and type 2 diabetes patients is 3.2 million; however, advances that will make CGMs smarter, smaller, and cheaper could increase that market significantly. Addressing the gestational diabetes market could increase its target market by about 800,000 patients; monitoring patients in hospitals would add about 10 million patients; and serving the entire type 2 diabetes population expands the addressable population to roughly 27 million in the U.S alone. | We asked three of our contributors to pick a company worth watching that is addressing some aspect of the illness, and they selected Abbott Laboratories (NYSE: ABT) , DexCom (NASDAQ: DXCM) , and Novo Nordisk (NYSE: NVO) . Diabetes and a lot more Keith Speights (Abbott Laboratories): While the broader market floundered in 2018, Abbott Labs turned in a great performance. Expect Freestyle Libre to continue to drive growth for Abbott in the future. |
33131.0 | 2019-01-14 00:00:00 UTC | Abbott: FDA Approves Amplatzer Piccolo Occluder Medical Device - Quick Facts | ABT | https://www.nasdaq.com/articles/abbott-fda-approves-amplatzer-piccolo-occluder-medical-device-quick-facts-2019-01-14 | nan | nan | (RTTNews.com) - Abbott Laboratories ( ABT ) said Monday that the U.S. Food and Drug Administration or FDA approved the Amplatzer Piccolo Occluder, the world's first medical device that can be implanted in the tiniest babies - weighing as little as two pounds - using a minimally invasive procedure to treat patent ductus arteriosus, or PDA.
Abbott noted that the Amplatzer Piccolo, a device even smaller than a small pea, now offers hope to premature infants and newborns who need corrective treatment, and who may be non-responsive to medical management and high risk to undergo corrective surgery.
One of the most common congenital heart defects occurring in premature babies, PDA is a potentially life-threatening opening between two blood vessels leading from the heart. This channel, which is present in normally developing fetuses, is important prior to birth to allow oxygen-rich blood from the mother to circulate throughout the fetus' body.
For most infants, the pathway, or duct, seals itself shortly after birth. In some cases, primarily in babies born prematurely, the PDA fails to spontaneously close, which can make it difficult for babies to breathe normally due to increased blood flow to the lungs. PDA accounts for up to 10 percent of all congenital heart disease.
About 60,000 premature babies in the U.S. are born each year with a very low birth weight, and nearly 12,000, or one out of five, of these have a hemodynamically significant PDA - a PDA that is large and causes symptoms - which will require urgent treatment for the baby to survive.
According to Abbott, the Amplatzer Piccolo Occluder is a self-expanding, wire mesh device that is inserted through a small incision in the leg and guided through vessels to the heart, where it is placed to seal the opening in the heart.
It is designed to allow the physician to insert it through the aortic or pulmonary artery, as well as to retrieve and redeploy the device for optimal placement. Because the device is deployed in a minimally invasive procedure, many of the premature babies who are critically ill in the neonatal intensive care unit are able to be weaned from artificial respirator support soon after the procedure.
Read the original article on RTTNews (http://www.rttnews.com/2969295/abbott-fda-approves-amplatzer-piccolo-occluder-medical-device-quick-facts.aspx)
For comments and feedback: contact editorial@rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews.com) - Abbott Laboratories ( ABT ) said Monday that the U.S. Food and Drug Administration or FDA approved the Amplatzer Piccolo Occluder, the world's first medical device that can be implanted in the tiniest babies - weighing as little as two pounds - using a minimally invasive procedure to treat patent ductus arteriosus, or PDA. Abbott noted that the Amplatzer Piccolo, a device even smaller than a small pea, now offers hope to premature infants and newborns who need corrective treatment, and who may be non-responsive to medical management and high risk to undergo corrective surgery. It is designed to allow the physician to insert it through the aortic or pulmonary artery, as well as to retrieve and redeploy the device for optimal placement. | (RTTNews.com) - Abbott Laboratories ( ABT ) said Monday that the U.S. Food and Drug Administration or FDA approved the Amplatzer Piccolo Occluder, the world's first medical device that can be implanted in the tiniest babies - weighing as little as two pounds - using a minimally invasive procedure to treat patent ductus arteriosus, or PDA. In some cases, primarily in babies born prematurely, the PDA fails to spontaneously close, which can make it difficult for babies to breathe normally due to increased blood flow to the lungs. According to Abbott, the Amplatzer Piccolo Occluder is a self-expanding, wire mesh device that is inserted through a small incision in the leg and guided through vessels to the heart, where it is placed to seal the opening in the heart. | (RTTNews.com) - Abbott Laboratories ( ABT ) said Monday that the U.S. Food and Drug Administration or FDA approved the Amplatzer Piccolo Occluder, the world's first medical device that can be implanted in the tiniest babies - weighing as little as two pounds - using a minimally invasive procedure to treat patent ductus arteriosus, or PDA. One of the most common congenital heart defects occurring in premature babies, PDA is a potentially life-threatening opening between two blood vessels leading from the heart. About 60,000 premature babies in the U.S. are born each year with a very low birth weight, and nearly 12,000, or one out of five, of these have a hemodynamically significant PDA - a PDA that is large and causes symptoms - which will require urgent treatment for the baby to survive. | (RTTNews.com) - Abbott Laboratories ( ABT ) said Monday that the U.S. Food and Drug Administration or FDA approved the Amplatzer Piccolo Occluder, the world's first medical device that can be implanted in the tiniest babies - weighing as little as two pounds - using a minimally invasive procedure to treat patent ductus arteriosus, or PDA. This channel, which is present in normally developing fetuses, is important prior to birth to allow oxygen-rich blood from the mother to circulate throughout the fetus' body. According to Abbott, the Amplatzer Piccolo Occluder is a self-expanding, wire mesh device that is inserted through a small incision in the leg and guided through vessels to the heart, where it is placed to seal the opening in the heart. |
33132.0 | 2019-01-14 00:00:00 UTC | Abbott (ABT) Dips More Than Broader Markets: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-dips-more-than-broader-markets%3A-what-you-should-know-2019-01-14 | nan | nan | Abbott (ABT) closed at $68.27 in the latest trading session, marking a -1.53% move from the prior day. This change lagged the S&P 500's daily loss of 0.53%. Elsewhere, the Dow lost 0.36%, while the tech-heavy Nasdaq lost 0.94%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 3.95% over the past month. This has was narrower than the Medical sector's loss of 3.96% and lagged the S&P 500's loss of 1.47% in that time.
Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. This is expected to be January 23, 2019. In tha t report , analysts expect ABT to post earnings of $0.81 per share. This would mark year-over-year growth of 9.46%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.79 billion, up 2.62% from the year-ago period.
Investors might also notice recent changes to analyst estimates for ABT. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.08% lower. ABT currently has a Zacks Rank of #3 (Hold).
Investors should also note ABT's current valuation metrics, including its Forward P/E ratio of 21.76. Its industry sports an average Forward P/E of 21.43, so we one might conclude that ABT is trading at a premium comparatively.
We can also see that ABT currently has a PEG ratio of 1.86. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products industry currently had an average PEG ratio of 2.01 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 106, putting it in the top 42% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed at $68.27 in the latest trading session, marking a -1.53% move from the prior day. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. In tha t report , analysts expect ABT to post earnings of $0.81 per share. | Abbott (ABT) closed at $68.27 in the latest trading session, marking a -1.53% move from the prior day. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. In tha t report , analysts expect ABT to post earnings of $0.81 per share. | Abbott (ABT) closed at $68.27 in the latest trading session, marking a -1.53% move from the prior day. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. In tha t report , analysts expect ABT to post earnings of $0.81 per share. | Abbott (ABT) closed at $68.27 in the latest trading session, marking a -1.53% move from the prior day. Investors should also note ABT's current valuation metrics, including its Forward P/E ratio of 21.76. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. |
33133.0 | 2019-01-11 00:00:00 UTC | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for January 14, 2019 | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-ex-dividend-date-scheduled-january-14-2019-2019-01-11 | nan | nan | Abbott Laboratories ( ABT ) will begin trading ex-dividend on January 14, 2019. A cash dividend payment of $0.32 per share is scheduled to be paid on February 15, 2019. Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 14.29% increase over prior dividend payment.
The previous trading day's last sale of ABT was $69.08, representing a -7.79% decrease from the 52 week high of $74.92 and a 24.29% increase over the 52 week low of $55.58.
ABT is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Pfizer, Inc. ( PFE ). ABT's current earnings per share, an indicator of a company's profitability, is $.48. Zacks Investment Research reports ABT's forecasted earnings growth in 2018 as 15.45%, compared to an industry average of 3.9%.
For more information on the declaration, record and payment dates, visit the ABT Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ABT through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABT as a top-10 holding:
iShares U.S. Medical Devices ETF ( IHI )
First Trust Nasdaq Pharmaceuticals ETF ( FTXH )
Invesco Dynamic Pharmaceuticals ETF ( PJP )
AdvisorShares Vice ETF ( ACT )
SPDR Select Sector Fund - Health Care ( XLV ).
The top-performing ETF of this group is IHI with an decrease of -2.52% over the last 100 days. It also has the highest percent weighting of ABT at 8.76%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABT's forecasted earnings growth in 2018 as 15.45%, compared to an industry average of 3.9%. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. | The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) First Trust Nasdaq Pharmaceuticals ETF ( FTXH ) Invesco Dynamic Pharmaceuticals ETF ( PJP ) AdvisorShares Vice ETF ( ACT ) SPDR Select Sector Fund - Health Care ( XLV ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories ( ABT ) will begin trading ex-dividend on January 14, 2019. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) First Trust Nasdaq Pharmaceuticals ETF ( FTXH ) Invesco Dynamic Pharmaceuticals ETF ( PJP ) AdvisorShares Vice ETF ( ACT ) SPDR Select Sector Fund - Health Care ( XLV ). | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) First Trust Nasdaq Pharmaceuticals ETF ( FTXH ) Invesco Dynamic Pharmaceuticals ETF ( PJP ) AdvisorShares Vice ETF ( ACT ) SPDR Select Sector Fund - Health Care ( XLV ). Abbott Laboratories ( ABT ) will begin trading ex-dividend on January 14, 2019. |
33134.0 | 2019-01-10 00:00:00 UTC | Ex-Dividend Reminder: Becton, Dickinson, Abbott Laboratories and American Financial Group | ABT | https://www.nasdaq.com/articles/ex-dividend-reminder-becton-dickinson-abbott-laboratories-and-american-financial-group | nan | nan | Looking at the universe of stocks we cover at Dividend Channel , on 1/14/19, Becton, Dickinson & Co (Symbol: BDXA), Abbott Laboratories (Symbol: ABT), and American Financial Group Inc (Symbol: AFG) will all trade ex-dividend for their respective upcoming dividends. Becton, Dickinson & Co will pay its quarterly dividend of $0.7656 on 2/1/19, Abbott Laboratories will pay its quarterly dividend of $0.32 on 2/15/19, and American Financial Group Inc will pay its quarterly dividend of $0.40 on 1/25/19. As a percentage of BDXA's recent stock price of $58.37, this dividend works out to approximately 1.31%, so look for shares of Becton, Dickinson & Co to trade 1.31% lower - all else being equal - when BDXA shares open for trading on 1/14/19. Similarly, investors should look for ABT to open 0.46% lower in price and for AFG to open 0.43% lower, all else being equal.
Below are dividend history charts for BDXA, ABT, and AFG, showing historical dividends prior to the most recent ones declared.
Becton, Dickinson & Co (Symbol: BDXA) :
Abbott Laboratories (Symbol: ABT) :
American Financial Group Inc (Symbol: AFG) :
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recen t dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 5.25% for Becton, Dickinson & Co, 1.86% for Abbott Laboratories, and 1.74% for American Financial Group Inc.
In Thursday trading, Becton, Dickinson & Co shares are currently up about 1.6%, Abbott Laboratories shares are off about 0.8%, and American Financial Group Inc shares are up about 0.1% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the universe of stocks we cover at Dividend Channel , on 1/14/19, Becton, Dickinson & Co (Symbol: BDXA), Abbott Laboratories (Symbol: ABT), and American Financial Group Inc (Symbol: AFG) will all trade ex-dividend for their respective upcoming dividends. Similarly, investors should look for ABT to open 0.46% lower in price and for AFG to open 0.43% lower, all else being equal. Below are dividend history charts for BDXA, ABT, and AFG, showing historical dividends prior to the most recent ones declared. | Looking at the universe of stocks we cover at Dividend Channel , on 1/14/19, Becton, Dickinson & Co (Symbol: BDXA), Abbott Laboratories (Symbol: ABT), and American Financial Group Inc (Symbol: AFG) will all trade ex-dividend for their respective upcoming dividends. Becton, Dickinson & Co (Symbol: BDXA) : Abbott Laboratories (Symbol: ABT) : American Financial Group Inc (Symbol: AFG) : In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for ABT to open 0.46% lower in price and for AFG to open 0.43% lower, all else being equal. | Looking at the universe of stocks we cover at Dividend Channel , on 1/14/19, Becton, Dickinson & Co (Symbol: BDXA), Abbott Laboratories (Symbol: ABT), and American Financial Group Inc (Symbol: AFG) will all trade ex-dividend for their respective upcoming dividends. Becton, Dickinson & Co (Symbol: BDXA) : Abbott Laboratories (Symbol: ABT) : American Financial Group Inc (Symbol: AFG) : In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for ABT to open 0.46% lower in price and for AFG to open 0.43% lower, all else being equal. | Looking at the universe of stocks we cover at Dividend Channel , on 1/14/19, Becton, Dickinson & Co (Symbol: BDXA), Abbott Laboratories (Symbol: ABT), and American Financial Group Inc (Symbol: AFG) will all trade ex-dividend for their respective upcoming dividends. Similarly, investors should look for ABT to open 0.46% lower in price and for AFG to open 0.43% lower, all else being equal. Below are dividend history charts for BDXA, ABT, and AFG, showing historical dividends prior to the most recent ones declared. |
33135.0 | 2019-01-10 00:00:00 UTC | Zacks Value Trader Highlights: PayPal, Abbott Labs, UnitedHealth, Lam Research and Visa | ABT | https://www.nasdaq.com/articles/zacks-value-trader-highlights%3A-paypal-abbott-labs-unitedhealth-lam-research-and-visa-2019 | nan | nan | For Immediate Release
Chicago, IL - January 10, 2019 - Zacks Value Trader is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here:
https://www.zacks.com/stock/news/346585/these-5-companies-are-earnings-perfection
These 5 Companies Are Earnings Perfection
The "official" start to the fourth quarter 2018 earnings season is just a week away when JP Morgan and Bank of America will kick it off.
But traders need to get their earnings strategy in place now before all the action begins.
That means looking for the companies with the bes t earnings surprise track records on the Street.
What it Takes to Beat Every Quarter
Despite what you may think, it's not easy to beat the earnings estimate quarter after quarter, year after year. Only a couple of dozen companies can say they have this record. It's an elite group.
And it's certainly not easy to beat for years under changing economic conditions. It takes skilled management, great communication with Wall Street analysts and maybe a little bit of luck along the way.
These 5 companies have done it. They are truly earnings all-stars. The best of the best.
Of course, past performance is no guarantee of future success. All companies end up missing at some point.
But, for now, these 5 companies have amazing earnings streaks on the line this earnings season.
Will they keep them?
5 Companies with Perfect Earnings Records
1. PayPalPYPL is a bit of a cheater pick here but it still qualifies as being perfect so I'm including it. It hasn't missed since its 2015 IPO. Sure, that's not the full 5-year period. But it still has an impressive chart even though shares treaded water in 2018. Will they regain their momentum in 2019?
2. Abbott LabsABT has the best chart of the big drug stocks. Not only has it beat every quarter over the last 5 years but it's last miss was all the way back in 2007. Think about what has occurred since that time (hint: the Great Recession). Yet Abbott kept beating. Shares are up 70% over the last 2 years.
3. UnitedHealth GroupUNH has one of the best charts on the Street. Not only has it beat every quarter the last 5 years but it's track record extends back to 2008. That's 10 years of beating. Impressive. Over the last two years, shares are up 50% versus the S&P 500 return of just 13%. Can the managed care companies keep out performing?
4. Lam ResearchLRCX has seen its shares pull back off the early 2018 highs as the semiconductor stocks have entered the downward slope of their cycle. But that hasn't stopped Lam from continuing to beat on earnings. Not only does it have a perfect 5-year track record but it's last miss was back in 2012. Even with the recent decline in the shares, they're still up 30% over the last 2 years compared with just 13% for the S&P 500.
5. VisaV has the best chart on the Street. Period. Since it went IPO in 2008 it has NEVER missed. That's beyond impressive. Investors have been rewarded during that time. Over the last 5 years, shares are up 140% versus the S&P 500 which is up 40% in that same period.
Zacks' Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/performance
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report
Lam Research Corporation (LRCX): Free Stock Analysis Report
Visa Inc. (V): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LabsABT has the best chart of the big drug stocks. Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report To read this article on Zacks.com click here. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. | Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LabsABT has the best chart of the big drug stocks. To listen to the podcast, click here: https://www.zacks.com/stock/news/346585/these-5-companies-are-earnings-perfection These 5 Companies Are Earnings Perfection The "official" start to the fourth quarter 2018 earnings season is just a week away when JP Morgan and Bank of America will kick it off. | Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LabsABT has the best chart of the big drug stocks. To listen to the podcast, click here: https://www.zacks.com/stock/news/346585/these-5-companies-are-earnings-perfection These 5 Companies Are Earnings Perfection The "official" start to the fourth quarter 2018 earnings season is just a week away when JP Morgan and Bank of America will kick it off. | Abbott LabsABT has the best chart of the big drug stocks. Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report To read this article on Zacks.com click here. 5 Companies with Perfect Earnings Records 1. |
33136.0 | 2019-01-09 00:00:00 UTC | These 5 Companies are Earnings Perfection | ABT | https://www.nasdaq.com/articles/these-5-companies-are-earnings-perfection-2019-01-09 | nan | nan | The "official" start to the fourth quarter 2018 earnings season is just a week away when JP Morgan and Bank of America will kick it off.
But traders need to get their earnings strategy in place now before all the action begins.
That means looking for the companies with the bes t earnings surprise track records on the Street.
What it Takes to Beat Every Quarter
Despite what you may think, it's not easy to beat the earnings estimate quarter after quarter, year after year. Only a couple of dozen companies can say they have this record. It's an elite group.
And it's certainly not easy to beat for years under changing economic conditions. It takes skilled management, great communication with Wall Street analysts and maybe a little bit of luck along the way.
These 5 companies have done it. They are truly earnings all-stars. The best of the best.
Of course, past performance is no guarantee of future success. All companies end up missing at some point.
But, for now, these 5 companies have amazing earnings streaks on the line this earnings season.
Will they keep them?
5 Companies with Perfect Earnings Records
1. PayPal PYPL is a bit of a cheater pick here but it still qualifies as being perfect so I'm including it. It hasn't missed since its 2015 IPO. Sure, that's not the full 5-year period. But it still has an impressive chart even though shares treaded water in 2018. Will they regain their momentum in 2019?
2. Abbott Labs ABT has the best chart of the big drug stocks. Not only has it beat every quarter over the last 5 years but it's last miss was all the way back in 2007. Think about what has occurred since that time (hint: the Great Recession). Yet Abbott kept beating. Shares are up 70% over the last 2 years.
3. UnitedHealth Group UNH has one of the best charts on the Street. Not only has it beat every quarter the last 5 years but it's track record extends back to 2008. That's 10 years of beating. Impressive. Over the last two years, shares are up 50% versus the S&P 500 return of just 13%. Can the managed care companies keep out performing?
4. Lam Research LRCX has seen its shares pull back off the early 2018 highs as the semiconductor stocks have entered the downward slope of their cycle. But that hasn't stopped Lam from continuing to beat on earnings. Not only does it have a perfect 5-year track record but it's last miss was back in 2012. Even with the recent decline in the shares, they're still up 30% over the last 2 years compared with just 13% for the S&P 500.
5. Visa V has the best chart on the Street. Period. Since it went IPO in 2008 it has NEVER missed. That's beyond impressive. Investors have been rewarded during that time. Over the last 5 years, shares are up 140% versus the S&P 500 which is up 40% in that same period.
Zacks' Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report
Lam Research Corporation (LRCX): Free Stock Analysis Report
Visa Inc. (V): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ABT has the best chart of the big drug stocks. Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report To read this article on Zacks.com click here. The "official" start to the fourth quarter 2018 earnings season is just a week away when JP Morgan and Bank of America will kick it off. | Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT has the best chart of the big drug stocks. What it Takes to Beat Every Quarter Despite what you may think, it's not easy to beat the earnings estimate quarter after quarter, year after year. | Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT has the best chart of the big drug stocks. What it Takes to Beat Every Quarter Despite what you may think, it's not easy to beat the earnings estimate quarter after quarter, year after year. | Abbott Labs ABT has the best chart of the big drug stocks. Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report To read this article on Zacks.com click here. 5 Companies with Perfect Earnings Records 1. |
33137.0 | 2019-01-08 00:00:00 UTC | Abbott To Present At J.P. Morgan Conference; Webcast At 12:00 PM ET | ABT | https://www.nasdaq.com/articles/abbott-present-jp-morgan-conference-webcast-1200-pm-et-2019-01-08 | nan | nan | (RTTNews.com) - Abbott Laboratories ( ABT ) will present at the 37th Annual J.P. Morgan Healthcare Conference.
The event is scheduled to begin at 12:00 PM ET on Jan. 8, 2019.
To access the live webcast, log on to www.abbottinvestor.com
Read the original article on RTTNews (http://www.rttnews.com/2967777/abbott-to-present-at-j-p-morgan-conference-webcast-at-12-00-pm-et.aspx)
For comments and feedback: contact editorial@rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews.com) - Abbott Laboratories ( ABT ) will present at the 37th Annual J.P. Morgan Healthcare Conference. The event is scheduled to begin at 12:00 PM ET on Jan. 8, 2019. To access the live webcast, log on to www.abbottinvestor.com Read the original article on RTTNews (http://www.rttnews.com/2967777/abbott-to-present-at-j-p-morgan-conference-webcast-at-12-00-pm-et.aspx) For comments and feedback: contact editorial@rttnews.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews.com) - Abbott Laboratories ( ABT ) will present at the 37th Annual J.P. Morgan Healthcare Conference. The event is scheduled to begin at 12:00 PM ET on Jan. 8, 2019. To access the live webcast, log on to www.abbottinvestor.com Read the original article on RTTNews (http://www.rttnews.com/2967777/abbott-to-present-at-j-p-morgan-conference-webcast-at-12-00-pm-et.aspx) For comments and feedback: contact editorial@rttnews.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews.com) - Abbott Laboratories ( ABT ) will present at the 37th Annual J.P. Morgan Healthcare Conference. The event is scheduled to begin at 12:00 PM ET on Jan. 8, 2019. To access the live webcast, log on to www.abbottinvestor.com Read the original article on RTTNews (http://www.rttnews.com/2967777/abbott-to-present-at-j-p-morgan-conference-webcast-at-12-00-pm-et.aspx) For comments and feedback: contact editorial@rttnews.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews.com) - Abbott Laboratories ( ABT ) will present at the 37th Annual J.P. Morgan Healthcare Conference. The event is scheduled to begin at 12:00 PM ET on Jan. 8, 2019. To access the live webcast, log on to www.abbottinvestor.com Read the original article on RTTNews (http://www.rttnews.com/2967777/abbott-to-present-at-j-p-morgan-conference-webcast-at-12-00-pm-et.aspx) For comments and feedback: contact editorial@rttnews.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33138.0 | 2019-01-07 00:00:00 UTC | Noteworthy ETF Outflows: XLV, MRK, ABT, AMGN | ABT | https://www.nasdaq.com/articles/noteworthy-etf-outflows-xlv-mrk-abt-amgn-2019-01-07 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $459.9 million dollar outflow -- that's a 2.5% decrease week over week (from 213,470,000 to 208,120,000). Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is down about 0.9%, Abbott Laboratories (Symbol: ABT) is up about 1.5%, and Amgen Inc (Symbol: AMGN) is up by about 0.3%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $86.12. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is down about 0.9%, Abbott Laboratories (Symbol: ABT) is up about 1.5%, and Amgen Inc (Symbol: AMGN) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $459.9 million dollar outflow -- that's a 2.5% decrease week over week (from 213,470,000 to 208,120,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is down about 0.9%, Abbott Laboratories (Symbol: ABT) is up about 1.5%, and Amgen Inc (Symbol: AMGN) is up by about 0.3%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $86.12. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is down about 0.9%, Abbott Laboratories (Symbol: ABT) is up about 1.5%, and Amgen Inc (Symbol: AMGN) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $459.9 million dollar outflow -- that's a 2.5% decrease week over week (from 213,470,000 to 208,120,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $86.12. | Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is down about 0.9%, Abbott Laboratories (Symbol: ABT) is up about 1.5%, and Amgen Inc (Symbol: AMGN) is up by about 0.3%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $86.12. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
33139.0 | 2019-01-07 00:00:00 UTC | Abbott (ABT) Outpaces Stock Market Gains: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-outpaces-stock-market-gains%3A-what-you-should-know-2019-01-07 | nan | nan | Abbott (ABT) closed the most recent trading day at $69.13, moving +1.5% from the previous trading session. This change outpaced the S&P 500's 0.7% gain on the day. Elsewhere, the Dow gained 0.42%, while the tech-heavy Nasdaq added 1.26%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 4.79% over the past month. This has was narrower than the Medical sector's loss of 6.76% and the S&P 500's loss of 6.13% in that time.
Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. This is expected to be January 23, 2019. The company is expected to report EPS of $0.81, up 9.46% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $7.79 billion, up 2.62% from the year-ago period.
Any recent changes to analyst estimates for ABT should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.03% higher. ABT is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, ABT currently has a Forward P/E ratio of 21.35. Its industry sports an average Forward P/E of 20.92, so we one might conclude that ABT is trading at a premium comparatively.
We can also see that ABT currently has a PEG ratio of 1.82. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Products stocks are, on average, holding a PEG ratio of 1.98 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 155, which puts it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed the most recent trading day at $69.13, moving +1.5% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. Any recent changes to analyst estimates for ABT should also be noted by investors. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) closed the most recent trading day at $69.13, moving +1.5% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. | Abbott (ABT) closed the most recent trading day at $69.13, moving +1.5% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. Any recent changes to analyst estimates for ABT should also be noted by investors. | Abbott (ABT) closed the most recent trading day at $69.13, moving +1.5% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. Any recent changes to analyst estimates for ABT should also be noted by investors. |
33140.0 | 2019-01-04 00:00:00 UTC | 3 Big Stock Charts for Friday: Incyte, Schlumberger and Abbott Laboratories | ABT | https://www.nasdaq.com/articles/3-big-stock-charts-for-friday%3A-incyte-schlumberger-and-abbott-laboratories-2019-01-04 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
After teasing investors with a taste of a recovery, stocks slumped on the second trading day of the year. Led lower by Apple (NASDAQ: AAPL ), which fell 10% on Thursday after issuing a rare revenue warning for its recently-completed quarter, the S&P 500 logged a 2.48% loss yesterday. The volume behind the selloff wasn't exactly light either.
Apple had help, to be clear. Advanced Micro Devices (NASDAQ: AMD ) tumbled to the tune of 9.5%, and rival/peer Nvidia (NASDAQ: NVDA ) wasn't far behind with a 6% setback mostly in response to an impending class action lawsuit being prepared to levy against the latter company. Some investors feel Nvidia didn't fully disclose the full potential of a collapse of the cryptocurrency mining market .
It's a weak legal argument, but an alarming headline all the same.
There were winners, though few and far between. Celgene (NASDAQ: CELG ) popped nearly 21% after Bristol-Myers Squibb (NYSE: BMY ) made a $74 billion bid for the biopharma name. Buyout offers can't inspire long-lasting bullishness for other names though, particularly in the midst of a strong selloff that leaves the market within sight of bear market territory.
The market environment makes trading tricky for the foreseeable future, but the stock charts of Schlumberger Limited (NYSE: SLB ), Abbott Laboratories (NYSE: ABT ) and Incyte Corporation (NASDAQ: INCY ) look positioned to do their own thing regardless of what the broad market does from here.
Abbott Laboratories (ABT)
With nothing more than a quick glance at Abbott Laboratories, the last few days just look like the same volatility other stocks have faced of last. That's not the case, however. Zooming out to a weekly chart of ABT, the recent wild swings are different, and telling.
10 Top Stock Picks From the Street's Best Analysts
Perhaps worse, Abbott is back to a critical make-or-break line in the sand. One more bad day could push it over the edge.
Click to Enlarge • The big line in the sand is the 200-day moving average, plotted in white on both stock charts. It looked like a pushoff point a couple of weeks ago, but we're back to the brink.
• At the same time, notice that the bearish days have been on higher volume than the recent bullish days. The weekly chart's Chaikin line moved back below zero three weeks ago.
• Notice the height of the weekly bars since November. Consistently taller bars suggests more wrangling between the bulls and the bears, which is a new development for Abbott shares.
Incyte (INCY)
Three weeks ago, after spending several months in a consolidation range, it looked like Incyte was finally about to fall out of that range … to the downside. At the last possible point before sliding into a freefall, though, the buyers started to push back.
It's a good thing they did. Yesterday's upgrade from Guggenheim Partners has pushed INCY back up to the upper side of that sideways trading range. Better yet, a little more progress will push INCY shares above a huge technical ceiling that could prove catalytic with just a little more traction above it.
Click to Enlarge • The technical ceiling is around $69.85, plotted in yellow. That's where the stock's peaked a few times since September, including Thursday.
• Moving back into play is the 200-day moving average line, plotted in white on both stock charts. Incyte temporarily moved above that level yesterday, though wasn't able to close above it.
• The more technical ceilings INCY clears, the better-developed the breakout effort will become. Moving above the final one around $75, plotted in red, could prove explosive after months of consolidation.
Schlumberger (SLB)
Last but not least, though it's got more to do with an impending recovery of the entire energy market than with the company itself, Schlumberger is still one of the best-positioned stocks within the sector to drive a sizeable rebound move.
The first of its make-or-break lines was defined yesterday.
Click to Enlarge • That pivotal line is the 20-day moving average line, plotted in blue. SLB kissed that line Thursday, but wasn't able to push its way above it.
• Though not yet decisively so, we've seen a little more bullish volume than bearish volume since Christmas, after a high-volume meltdown leading to December's multiyear low.
• While Schlumberger is oversold and ripe for a rebound, it's still tethered fairly strongly to the price of oil. This budding effort will need help from crude prices if it's to last.
As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter , at @jbrumley.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
10 Stocks to Pull From the Bear Market Bargain Bin
7 Reasons Tesla Stock Will Win in 2019
7 Bargain-Bin ETFs For Frugal Investors
Compare Brokers
The post 3 Big Stock Charts for Friday: Incyte, Schlumberger and Abbott Laboratories appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The market environment makes trading tricky for the foreseeable future, but the stock charts of Schlumberger Limited (NYSE: SLB ), Abbott Laboratories (NYSE: ABT ) and Incyte Corporation (NASDAQ: INCY ) look positioned to do their own thing regardless of what the broad market does from here. Abbott Laboratories (ABT) With nothing more than a quick glance at Abbott Laboratories, the last few days just look like the same volatility other stocks have faced of last. Zooming out to a weekly chart of ABT, the recent wild swings are different, and telling. | The market environment makes trading tricky for the foreseeable future, but the stock charts of Schlumberger Limited (NYSE: SLB ), Abbott Laboratories (NYSE: ABT ) and Incyte Corporation (NASDAQ: INCY ) look positioned to do their own thing regardless of what the broad market does from here. Abbott Laboratories (ABT) With nothing more than a quick glance at Abbott Laboratories, the last few days just look like the same volatility other stocks have faced of last. Zooming out to a weekly chart of ABT, the recent wild swings are different, and telling. | The market environment makes trading tricky for the foreseeable future, but the stock charts of Schlumberger Limited (NYSE: SLB ), Abbott Laboratories (NYSE: ABT ) and Incyte Corporation (NASDAQ: INCY ) look positioned to do their own thing regardless of what the broad market does from here. Abbott Laboratories (ABT) With nothing more than a quick glance at Abbott Laboratories, the last few days just look like the same volatility other stocks have faced of last. Zooming out to a weekly chart of ABT, the recent wild swings are different, and telling. | The market environment makes trading tricky for the foreseeable future, but the stock charts of Schlumberger Limited (NYSE: SLB ), Abbott Laboratories (NYSE: ABT ) and Incyte Corporation (NASDAQ: INCY ) look positioned to do their own thing regardless of what the broad market does from here. Abbott Laboratories (ABT) With nothing more than a quick glance at Abbott Laboratories, the last few days just look like the same volatility other stocks have faced of last. Zooming out to a weekly chart of ABT, the recent wild swings are different, and telling. |
33141.0 | 2019-01-02 00:00:00 UTC | U.S. STOCKS ON THE MOVE-General Electric, Netflix, Tesla, MyoKardia | ABT | https://www.nasdaq.com/articles/us-stocks-move-general-electric-netflix-tesla-myokardia-2019-01-02 | nan | nan | The Day Ahead newsletter:
The Morning News Call newsletter:
U.S. stocks were flat on Wednesday morning, clawing back from losses of more than 1 percent earlier, helped by energy stocks as oil prices reversed earlier losses and bank stocks as 10-year U.S. treasury yields moved off a near year-low.
The top three S&P 500 percentage gainers:
** General Electric Co, up 5.5 pct [
** Wynn Resorts Ltd, up 5.4 pct
** Perrigo Company PLC, up 4.7 pct
The top three S&P 500 percentage losers:
** Hologic Inc, down 6 pct
** Abbott Labs, down 4 pct
** Akamai Technologies Inc, down 4 pct
The top three NYSE percentage gainers:
** MedEquities Realty Trust Inc, up 44.4 pct
** PermRock Royalty Trust, up 22.3 pct
** Bright Scholar Education Holdings Ltd, up 21.2 pct
The top NYSE percentage loser:
** Bitauto Holdings Ltd, down 18.1 pct
The top three Nasdaq percentage gainers:
** Estre Ambiental Inc, up 43 pct
** Novus Therapeutics Inc, up 25.6 pct
** Windstream Holdings Inc, up 25.4 pct
The top two Nasdaq percentage losers:
** Uxin Ltd, down 17.9 pct
** Pingtan Marine Enterprise Ltd, down 14.5 pct
** General Electric Co: up 6.1 pct
Hits more than 1-month high
** The Estee Lauder Companies Inc: up 1.2 pct
Citi upgrades rating to "buy", sees upside to 2019 EPS forecast
** JPMorgan Chase & Co.: up 1.2 pct
** The Goldman Sachs Group Inc.: up 2.3 pct
Barclays positive on U.S. large-cap banks
** Wells Fargo & Co: up 1.5 pct
Not "out of the woods" yet regarding regulatory issues, says RBC
** CVS Health Corp: down 0.7 pct
Stock an execution story in 2019
** Walgreens Boots Alliance Inc: down 0.5 pct
Jefferies sees choppy year ahead
** Hologic Inc: down 6.0 pct
MS downgrades to underweight, sees limited room for end-market growth
** Moderna Inc: down 3.7 pct
Brokerages start with bullish ratings on Moderna's shares
** Netflix Inc: down 1.2 pct
Suntrust Robinson cuts PT, says Q4 new subscribers could be less than co's guidance
** Tesla Inc: down 6.9 pct
Set to erase 2018's gains on slide as Q4 deliveries miss estimates
** Akamai Technologies Inc: down 4.0 pct
Cowen moves to sidelines expecting slowing revenue trends
** MyoKardia Inc: down 14.2 pct
Drops on conclusion of collaboration with Sanofi
** Bausch Health Companies Inc: up 7.0 pct
Climbs after Piper upgrade to "overweight"
** Schlumberger NV: up 3.4 pct
Susquehanna cuts PT on lower crude prices
** Sirius XM Holdings Inc: up 2.8 pct
JPM's double upgrade to 'outperform' lifts shares
** Wynn Resorts Ltd: up 5.4 pct
** Melco Resorts & Entertainment Ltd: up 3.9 pct
** Las Vegas Sands Corp: up 3.3 pct
** MGM Resorts International: up 2.9 pct
** Caesars Entertainment Corp: up 1.2 pct
U.S. casinos: Higher after Macau Dec gambling revenue beats estimates
The 11 major S&P 500 sectors:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks were flat on Wednesday morning, clawing back from losses of more than 1 percent earlier, helped by energy stocks as oil prices reversed earlier losses and bank stocks as 10-year U.S. treasury yields moved off a near year-low. The top three S&P 500 percentage gainers: ** General Electric Co, up 5.5 pct [ ** Wynn Resorts Ltd, up 5.4 pct ** Perrigo Company PLC, up 4.7 pct The top three S&P 500 percentage losers: ** Hologic Inc, down 6 pct ** Abbott Labs, down 4 pct ** Akamai Technologies Inc, down 4 pct The top three NYSE percentage gainers: ** MedEquities Realty Trust Inc, up 44.4 pct ** PermRock Royalty Trust, up 22.3 pct ** Bright Scholar Education Holdings Ltd, up 21.2 pct The top NYSE percentage loser: ** Bitauto Holdings Ltd, down 18.1 pct The top three Nasdaq percentage gainers: ** Estre Ambiental Inc, up 43 pct ** Novus Therapeutics Inc, up 25.6 pct ** Windstream Holdings Inc, up 25.4 pct The top two Nasdaq percentage losers: ** Uxin Ltd, down 17.9 pct ** Pingtan Marine Enterprise Ltd, down 14.5 pct ** General Electric Co: up 6.1 pct Hits more than 1-month high ** The Estee Lauder Companies Inc: up 1.2 pct Citi upgrades rating to "buy", sees upside to 2019 EPS forecast ** JPMorgan Chase & Co.: up 1.2 pct ** The Goldman Sachs Group Inc.: up 2.3 pct Barclays positive on U.S. large-cap banks ** Wells Fargo & Co: up 1.5 pct Not "out of the woods" yet regarding regulatory issues, says RBC ** CVS Health Corp: down 0.7 pct Stock an execution story in 2019 ** Walgreens Boots Alliance Inc: down 0.5 pct Jefferies sees choppy year ahead ** Hologic Inc: down 6.0 pct MS downgrades to underweight, sees limited room for end-market growth ** Moderna Inc: down 3.7 pct Brokerages start with bullish ratings on Moderna's shares ** Netflix Inc: down 1.2 pct Suntrust Robinson cuts PT, says Q4 new subscribers could be less than co's guidance ** Tesla Inc: down 6.9 pct Set to erase 2018's gains on slide as Q4 deliveries miss estimates ** Akamai Technologies Inc: down 4.0 pct Cowen moves to sidelines expecting slowing revenue trends ** MyoKardia Inc: down 14.2 pct Drops on conclusion of collaboration with Sanofi ** Bausch Health Companies Inc: up 7.0 pct Climbs after Piper upgrade to "overweight" ** Schlumberger NV: up 3.4 pct Susquehanna cuts PT on lower crude prices ** Sirius XM Holdings Inc: up 2.8 pct JPM's double upgrade to 'outperform' lifts shares ** Wynn Resorts Ltd: up 5.4 pct ** Melco Resorts & Entertainment Ltd: up 3.9 pct ** Las Vegas Sands Corp: up 3.3 pct ** MGM Resorts International: up 2.9 pct ** Caesars Entertainment Corp: up 1.2 pct U.S. casinos: Higher after Macau Dec gambling revenue beats estimates The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks were flat on Wednesday morning, clawing back from losses of more than 1 percent earlier, helped by energy stocks as oil prices reversed earlier losses and bank stocks as 10-year U.S. treasury yields moved off a near year-low. The top three S&P 500 percentage gainers: ** General Electric Co, up 5.5 pct [ ** Wynn Resorts Ltd, up 5.4 pct ** Perrigo Company PLC, up 4.7 pct The top three S&P 500 percentage losers: ** Hologic Inc, down 6 pct ** Abbott Labs, down 4 pct ** Akamai Technologies Inc, down 4 pct The top three NYSE percentage gainers: ** MedEquities Realty Trust Inc, up 44.4 pct ** PermRock Royalty Trust, up 22.3 pct ** Bright Scholar Education Holdings Ltd, up 21.2 pct The top NYSE percentage loser: ** Bitauto Holdings Ltd, down 18.1 pct The top three Nasdaq percentage gainers: ** Estre Ambiental Inc, up 43 pct ** Novus Therapeutics Inc, up 25.6 pct ** Windstream Holdings Inc, up 25.4 pct The top two Nasdaq percentage losers: ** Uxin Ltd, down 17.9 pct ** Pingtan Marine Enterprise Ltd, down 14.5 pct ** General Electric Co: up 6.1 pct Hits more than 1-month high ** The Estee Lauder Companies Inc: up 1.2 pct Citi upgrades rating to "buy", sees upside to 2019 EPS forecast ** JPMorgan Chase & Co.: up 1.2 pct ** The Goldman Sachs Group Inc.: up 2.3 pct Barclays positive on U.S. large-cap banks ** Wells Fargo & Co: up 1.5 pct Not "out of the woods" yet regarding regulatory issues, says RBC ** CVS Health Corp: down 0.7 pct Stock an execution story in 2019 ** Walgreens Boots Alliance Inc: down 0.5 pct Jefferies sees choppy year ahead ** Hologic Inc: down 6.0 pct MS downgrades to underweight, sees limited room for end-market growth ** Moderna Inc: down 3.7 pct Brokerages start with bullish ratings on Moderna's shares ** Netflix Inc: down 1.2 pct Suntrust Robinson cuts PT, says Q4 new subscribers could be less than co's guidance ** Tesla Inc: down 6.9 pct Set to erase 2018's gains on slide as Q4 deliveries miss estimates ** Akamai Technologies Inc: down 4.0 pct Cowen moves to sidelines expecting slowing revenue trends ** MyoKardia Inc: down 14.2 pct Drops on conclusion of collaboration with Sanofi ** Bausch Health Companies Inc: up 7.0 pct Climbs after Piper upgrade to "overweight" ** Schlumberger NV: up 3.4 pct Susquehanna cuts PT on lower crude prices ** Sirius XM Holdings Inc: up 2.8 pct JPM's double upgrade to 'outperform' lifts shares ** Wynn Resorts Ltd: up 5.4 pct ** Melco Resorts & Entertainment Ltd: up 3.9 pct ** Las Vegas Sands Corp: up 3.3 pct ** MGM Resorts International: up 2.9 pct ** Caesars Entertainment Corp: up 1.2 pct U.S. casinos: Higher after Macau Dec gambling revenue beats estimates The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks were flat on Wednesday morning, clawing back from losses of more than 1 percent earlier, helped by energy stocks as oil prices reversed earlier losses and bank stocks as 10-year U.S. treasury yields moved off a near year-low. The top three S&P 500 percentage gainers: ** General Electric Co, up 5.5 pct [ ** Wynn Resorts Ltd, up 5.4 pct ** Perrigo Company PLC, up 4.7 pct The top three S&P 500 percentage losers: ** Hologic Inc, down 6 pct ** Abbott Labs, down 4 pct ** Akamai Technologies Inc, down 4 pct The top three NYSE percentage gainers: ** MedEquities Realty Trust Inc, up 44.4 pct ** PermRock Royalty Trust, up 22.3 pct ** Bright Scholar Education Holdings Ltd, up 21.2 pct The top NYSE percentage loser: ** Bitauto Holdings Ltd, down 18.1 pct The top three Nasdaq percentage gainers: ** Estre Ambiental Inc, up 43 pct ** Novus Therapeutics Inc, up 25.6 pct ** Windstream Holdings Inc, up 25.4 pct The top two Nasdaq percentage losers: ** Uxin Ltd, down 17.9 pct ** Pingtan Marine Enterprise Ltd, down 14.5 pct ** General Electric Co: up 6.1 pct Hits more than 1-month high ** The Estee Lauder Companies Inc: up 1.2 pct Citi upgrades rating to "buy", sees upside to 2019 EPS forecast ** JPMorgan Chase & Co.: up 1.2 pct ** The Goldman Sachs Group Inc.: up 2.3 pct Barclays positive on U.S. large-cap banks ** Wells Fargo & Co: up 1.5 pct Not "out of the woods" yet regarding regulatory issues, says RBC ** CVS Health Corp: down 0.7 pct Stock an execution story in 2019 ** Walgreens Boots Alliance Inc: down 0.5 pct Jefferies sees choppy year ahead ** Hologic Inc: down 6.0 pct MS downgrades to underweight, sees limited room for end-market growth ** Moderna Inc: down 3.7 pct Brokerages start with bullish ratings on Moderna's shares ** Netflix Inc: down 1.2 pct Suntrust Robinson cuts PT, says Q4 new subscribers could be less than co's guidance ** Tesla Inc: down 6.9 pct Set to erase 2018's gains on slide as Q4 deliveries miss estimates ** Akamai Technologies Inc: down 4.0 pct Cowen moves to sidelines expecting slowing revenue trends ** MyoKardia Inc: down 14.2 pct Drops on conclusion of collaboration with Sanofi ** Bausch Health Companies Inc: up 7.0 pct Climbs after Piper upgrade to "overweight" ** Schlumberger NV: up 3.4 pct Susquehanna cuts PT on lower crude prices ** Sirius XM Holdings Inc: up 2.8 pct JPM's double upgrade to 'outperform' lifts shares ** Wynn Resorts Ltd: up 5.4 pct ** Melco Resorts & Entertainment Ltd: up 3.9 pct ** Las Vegas Sands Corp: up 3.3 pct ** MGM Resorts International: up 2.9 pct ** Caesars Entertainment Corp: up 1.2 pct U.S. casinos: Higher after Macau Dec gambling revenue beats estimates The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks were flat on Wednesday morning, clawing back from losses of more than 1 percent earlier, helped by energy stocks as oil prices reversed earlier losses and bank stocks as 10-year U.S. treasury yields moved off a near year-low. The top three S&P 500 percentage gainers: ** General Electric Co, up 5.5 pct [ ** Wynn Resorts Ltd, up 5.4 pct ** Perrigo Company PLC, up 4.7 pct The top three S&P 500 percentage losers: ** Hologic Inc, down 6 pct ** Abbott Labs, down 4 pct ** Akamai Technologies Inc, down 4 pct The top three NYSE percentage gainers: ** MedEquities Realty Trust Inc, up 44.4 pct ** PermRock Royalty Trust, up 22.3 pct ** Bright Scholar Education Holdings Ltd, up 21.2 pct The top NYSE percentage loser: ** Bitauto Holdings Ltd, down 18.1 pct The top three Nasdaq percentage gainers: ** Estre Ambiental Inc, up 43 pct ** Novus Therapeutics Inc, up 25.6 pct ** Windstream Holdings Inc, up 25.4 pct The top two Nasdaq percentage losers: ** Uxin Ltd, down 17.9 pct ** Pingtan Marine Enterprise Ltd, down 14.5 pct ** General Electric Co: up 6.1 pct Hits more than 1-month high ** The Estee Lauder Companies Inc: up 1.2 pct Citi upgrades rating to "buy", sees upside to 2019 EPS forecast ** JPMorgan Chase & Co.: up 1.2 pct ** The Goldman Sachs Group Inc.: up 2.3 pct Barclays positive on U.S. large-cap banks ** Wells Fargo & Co: up 1.5 pct Not "out of the woods" yet regarding regulatory issues, says RBC ** CVS Health Corp: down 0.7 pct Stock an execution story in 2019 ** Walgreens Boots Alliance Inc: down 0.5 pct Jefferies sees choppy year ahead ** Hologic Inc: down 6.0 pct MS downgrades to underweight, sees limited room for end-market growth ** Moderna Inc: down 3.7 pct Brokerages start with bullish ratings on Moderna's shares ** Netflix Inc: down 1.2 pct Suntrust Robinson cuts PT, says Q4 new subscribers could be less than co's guidance ** Tesla Inc: down 6.9 pct Set to erase 2018's gains on slide as Q4 deliveries miss estimates ** Akamai Technologies Inc: down 4.0 pct Cowen moves to sidelines expecting slowing revenue trends ** MyoKardia Inc: down 14.2 pct Drops on conclusion of collaboration with Sanofi ** Bausch Health Companies Inc: up 7.0 pct Climbs after Piper upgrade to "overweight" ** Schlumberger NV: up 3.4 pct Susquehanna cuts PT on lower crude prices ** Sirius XM Holdings Inc: up 2.8 pct JPM's double upgrade to 'outperform' lifts shares ** Wynn Resorts Ltd: up 5.4 pct ** Melco Resorts & Entertainment Ltd: up 3.9 pct ** Las Vegas Sands Corp: up 3.3 pct ** MGM Resorts International: up 2.9 pct ** Caesars Entertainment Corp: up 1.2 pct U.S. casinos: Higher after Macau Dec gambling revenue beats estimates The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33142.0 | 2019-01-02 00:00:00 UTC | U.S. STOCKS ON THE MOVE-Netflix, Tesla, Walgreens, Hologic | ABT | https://www.nasdaq.com/articles/us-stocks-move-netflix-tesla-walgreens-hologic-2019-01-02 | nan | nan | The Day Ahead newsletter:
The Morning News Call newsletter:
U.S. stocks started the new year with a more than 1 percent decline on Wednesday, as weak data in Asia and Europe confirmed fears of a global economic slowdown while the U.S. government shutdown dragged on.
The top three S&P 500 percentage gainers:
** General Electric Co, up 4.2 pct
** Wynn Resorts Ltd, up 3.8 pct
** Nektar Therapeutics, up 3.3 pct
The top three S&P 500 percentage losers:
** Hologic Inc, down 6 pct
** Akamai Technologies Inc, down 4.4 pct
** Abbott Labs, down 3.4 pct
The top two NYSE percentage gainers:
** MedEquities Realty Trust Inc, up 43.9 pct
** Bright Scholar Education Holdings Ltd, up 16 pct
The top two NYSE percentage losers:
** Bitauto Holdings Ltd, down 16.6 pct
** James Hardie Industries Plc, down 10.4 pct
The top three Nasdaq percentage gainers:
** China Ceramics Co. Ltd, up 44.4 pct
** Apyx Medical | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks started the new year with a more than 1 percent decline on Wednesday, as weak data in Asia and Europe confirmed fears of a global economic slowdown while the U.S. government shutdown dragged on. The top three S&P 500 percentage gainers: ** General Electric Co, up 4.2 pct ** Wynn Resorts Ltd, up 3.8 pct ** Nektar Therapeutics, up 3.3 pct The top three S&P 500 percentage losers: ** Hologic Inc, down 6 pct ** Akamai Technologies Inc, down 4.4 pct ** Abbott Labs, down 3.4 pct The top two NYSE percentage gainers: ** MedEquities Realty Trust Inc, up 43.9 pct ** Bright Scholar Education Holdings Ltd, up 16 pct The top two NYSE percentage losers: ** Bitauto Holdings Ltd, down 16.6 pct ** James Hardie Industries Plc, down 10.4 pct The top three Nasdaq percentage gainers: ** China Ceramics Co. Ltd, up 44.4 pct ** Apyx Medical | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks started the new year with a more than 1 percent decline on Wednesday, as weak data in Asia and Europe confirmed fears of a global economic slowdown while the U.S. government shutdown dragged on. The top three S&P 500 percentage gainers: ** General Electric Co, up 4.2 pct ** Wynn Resorts Ltd, up 3.8 pct ** Nektar Therapeutics, up 3.3 pct The top three S&P 500 percentage losers: ** Hologic Inc, down 6 pct ** Akamai Technologies Inc, down 4.4 pct ** Abbott Labs, down 3.4 pct The top two NYSE percentage gainers: ** MedEquities Realty Trust Inc, up 43.9 pct ** Bright Scholar Education Holdings Ltd, up 16 pct The top two NYSE percentage losers: ** Bitauto Holdings Ltd, down 16.6 pct ** James Hardie Industries Plc, down 10.4 pct The top three Nasdaq percentage gainers: ** China Ceramics Co. Ltd, up 44.4 pct ** Apyx Medical | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks started the new year with a more than 1 percent decline on Wednesday, as weak data in Asia and Europe confirmed fears of a global economic slowdown while the U.S. government shutdown dragged on. The top three S&P 500 percentage gainers: ** General Electric Co, up 4.2 pct ** Wynn Resorts Ltd, up 3.8 pct ** Nektar Therapeutics, up 3.3 pct The top three S&P 500 percentage losers: ** Hologic Inc, down 6 pct ** Akamai Technologies Inc, down 4.4 pct ** Abbott Labs, down 3.4 pct The top two NYSE percentage gainers: ** MedEquities Realty Trust Inc, up 43.9 pct ** Bright Scholar Education Holdings Ltd, up 16 pct The top two NYSE percentage losers: ** Bitauto Holdings Ltd, down 16.6 pct ** James Hardie Industries Plc, down 10.4 pct The top three Nasdaq percentage gainers: ** China Ceramics Co. Ltd, up 44.4 pct ** Apyx Medical | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks started the new year with a more than 1 percent decline on Wednesday, as weak data in Asia and Europe confirmed fears of a global economic slowdown while the U.S. government shutdown dragged on. The top three S&P 500 percentage gainers: ** General Electric Co, up 4.2 pct ** Wynn Resorts Ltd, up 3.8 pct ** Nektar Therapeutics, up 3.3 pct The top three S&P 500 percentage losers: ** Hologic Inc, down 6 pct ** Akamai Technologies Inc, down 4.4 pct ** Abbott Labs, down 3.4 pct The top two NYSE percentage gainers: ** MedEquities Realty Trust Inc, up 43.9 pct ** Bright Scholar Education Holdings Ltd, up 16 pct The top two NYSE percentage losers: ** Bitauto Holdings Ltd, down 16.6 pct ** James Hardie Industries Plc, down 10.4 pct The top three Nasdaq percentage gainers: ** China Ceramics Co. Ltd, up 44.4 pct ** Apyx Medical |
33143.0 | 2018-12-31 00:00:00 UTC | The Zacks Analyst Blog Highlights: Merck, Abbott, Lockheed Martin, United Parcel Service and Bank of New York Mellon | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-merck-abbott-lockheed-martin-united-parcel-service-and | nan | nan | For Immediate Release
Chicago, IL - December 31, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck MRK , Abbott ABT , Lockheed Martin LMT , United Parcel Service UPS and Bank of New York Mellon BK .
Here are highlights from Friday's Analyst Blog:
Top Analyst Reports for Merck, Abbott and Lockheed Martin
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Merck, Abbot) and Lockheed Martin. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Buy-ranked Merck 's shares have gained +33.9% year to date, significantly outperforming the Zacks Large Cap Pharmaceuticals industry, which has gained +2.8% over the same period. The Zacks analyst emphasizes that Merck's new products like Keytruda, Lynparza and Bridion are contributing meaningfully to the top line.
Keytruda sales are gaining momentum with approval for additional indications, especially in the first-line lung cancer setting as it is the only anti-PD-1 approved in this setting. Animal health and vaccine products are also performing strongly and remain core growth drivers for Merck. Meanwhile, Merck will continue to focus on cost-cutting initiatives to drive the bottom line.
However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line. Rising competitive pressure on the diabetes franchise and on products like Isentress (HIV), Zepatier (HCV) and Zostavax (vaccine) remains.
Shares of Abbott have lost -4.7% over the past three months, outperforming the Zacks Medical Products industry, which has declined -14.2% over the same period. Increasing currency headwinds to some extent dented the company's strong international performance in the last reported quarter. Meanwhile, emerging market performance has been promising.
The Zacks analyst is optimistic about the strong and consistent performance by the company's EPD and Medical Devices segments. The company has been hogging the limelight within Diabetic Care on growth with FreeStyle Libre. Within Structural Heart, worldwide strong uptake of MitraClip improves further following the FDA approval of its upgraded version.
This apart, synergies from Alere consolidation in the form of revenues from Rapid Diagnostics have been driving growth. On the flip side, sluggish Vascular arm continues to dent growth.
Buy-ranked Lockheed Martin 's shares have lost -19.1% over the past one year, underperforming the Zacks Aerospace Defense sector, which has declined -9.1% over the same period. The Zacks analyst emphasizes that Lockheed Martin, being the largest defense contractor in the world, enjoys a strong demand for its high-end military equipment in domestic as well as international markets.
Consequently, strong order growth has been a primary growth driver for this company. Lately, the company has been witnessing strong demand for its equipment, ranging from C-130J aircraft in France and Germany to helicopters in Poland to missile defense systems in the Asia-Pacific, Europe, and Middle East regions.
Its backlog climbed to a record $109 billion, in the third quarter. However, it faces intense competition for its broad portfolio of products and services in both domestic and international markets.
Other noteworthy reports we are featuring today include United Parcel Service and Bank of New York Mellon.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss . This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Bank of New York Mellon Corporation (BK): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Lockheed Martin Corporation (LMT): Free Stock Analysis Report
United Parcel Service, Inc. (UPS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include: Merck MRK , Abbott ABT , Lockheed Martin LMT , United Parcel Service UPS and Bank of New York Mellon BK . Click to get this free report The Bank of New York Mellon Corporation (BK): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Lockheed Martin Corporation (LMT): Free Stock Analysis Report United Parcel Service, Inc. (UPS): Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks analyst emphasizes that Lockheed Martin, being the largest defense contractor in the world, enjoys a strong demand for its high-end military equipment in domestic as well as international markets. | Stocks recently featured in the blog include: Merck MRK , Abbott ABT , Lockheed Martin LMT , United Parcel Service UPS and Bank of New York Mellon BK . Click to get this free report The Bank of New York Mellon Corporation (BK): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Lockheed Martin Corporation (LMT): Free Stock Analysis Report United Parcel Service, Inc. (UPS): Free Stock Analysis Report To read this article on Zacks.com click here. Here are highlights from Friday's Analyst Blog: Top Analyst Reports for Merck, Abbott and Lockheed Martin The Zacks Research Daily presents the best research output of our analyst team. | Click to get this free report The Bank of New York Mellon Corporation (BK): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Lockheed Martin Corporation (LMT): Free Stock Analysis Report United Parcel Service, Inc. (UPS): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: Merck MRK , Abbott ABT , Lockheed Martin LMT , United Parcel Service UPS and Bank of New York Mellon BK . Here are highlights from Friday's Analyst Blog: Top Analyst Reports for Merck, Abbott and Lockheed Martin The Zacks Research Daily presents the best research output of our analyst team. | Stocks recently featured in the blog include: Merck MRK , Abbott ABT , Lockheed Martin LMT , United Parcel Service UPS and Bank of New York Mellon BK . Click to get this free report The Bank of New York Mellon Corporation (BK): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Lockheed Martin Corporation (LMT): Free Stock Analysis Report United Parcel Service, Inc. (UPS): Free Stock Analysis Report To read this article on Zacks.com click here. Consequently, strong order growth has been a primary growth driver for this company. |
33144.0 | 2018-12-27 00:00:00 UTC | Abbott (ABT) Outpaces Stock Market Gains: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-outpaces-stock-market-gains%3A-what-you-should-know-2018-12-27 | nan | nan | In the latest trading session, Abbott (ABT) closed at $70.63, marking a +1.45% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.86%. Meanwhile, the Dow gained 1.14%, and the Nasdaq, a tech-heavy index, added 0.38%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 4.41% over the past month. This has was narrower than the Medical sector's loss of 7.15% and the S&P 500's loss of 7.55% in that time.
Wall Street will be looking for positivity from ABT as it approaches its next earnings report date. This is expected to be January 23, 2019. The company is expected to report EPS of $0.81, up 9.46% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $7.79 billion, up 2.62% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $2.89 per share and revenue of $30.60 billion. These totals would mark changes of +15.6% and +11.74%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for ABT. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.03% higher. ABT is currently sporting a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that ABT has a Forward P/E ratio of 24.12 right now. For comparison, its industry has an average Forward P/E of 22.33, which means ABT is trading at a premium to the group.
We can also see that ABT currently has a PEG ratio of 2.06. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. ABT's industry had an average PEG ratio of 2.07 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 107, putting it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the latest trading session, Abbott (ABT) closed at $70.63, marking a +1.45% move from the previous day. Wall Street will be looking for positivity from ABT as it approaches its next earnings report date. Investors might also notice recent changes to analyst estimates for ABT. | In the latest trading session, Abbott (ABT) closed at $70.63, marking a +1.45% move from the previous day. Wall Street will be looking for positivity from ABT as it approaches its next earnings report date. Investors might also notice recent changes to analyst estimates for ABT. | In the latest trading session, Abbott (ABT) closed at $70.63, marking a +1.45% move from the previous day. Wall Street will be looking for positivity from ABT as it approaches its next earnings report date. Investors might also notice recent changes to analyst estimates for ABT. | In the latest trading session, Abbott (ABT) closed at $70.63, marking a +1.45% move from the previous day. Wall Street will be looking for positivity from ABT as it approaches its next earnings report date. Investors might also notice recent changes to analyst estimates for ABT. |
33145.0 | 2018-12-24 00:00:00 UTC | Why Abbott (ABT) Could Beat Earnings Estimates Again | ABT | https://www.nasdaq.com/articles/why-abbott-abt-could-beat-earnings-estimates-again-2018-12-24 | nan | nan | Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Abbott (ABT), which belongs to the Zacks Medical - Products industry.
This maker of infant formula, medical devices and drugs has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 2.08%.
For the last reported quarter, Abbott came out with earnings of $0.75 per share versus the Zacks Consensus Estimate of $0.74 per share, representing a surprise of 1.35%. For the previous quarter, the company was expected to post earnings of $0.71 per share and it actually produced earnings of $0.73 per share, delivering a surprise of 2.82%.
Price and EPS Surprise
For Abbott, estimates have been trending higher, thanks in part to this earnings surprise history. And when you look at the stock's positive Zacks Earnings ESP (Expected Surprise Prediction), it's a great indicator of a future earnings beat, especially when combined with its solid Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time . In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Abbott has an Earnings ESP of +0.25% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #3 (Hold), it shows that another beat is possibly around the corner. The company's next earnings report is expected to be released on January 23, 2019.
Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.
Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It is worth considering Abbott (ABT), which belongs to the Zacks Medical - Products industry. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. This maker of infant formula, medical devices and drugs has an established record of topping earnings estimates, especially when looking at the previous two reports. | It is worth considering Abbott (ABT), which belongs to the Zacks Medical - Products industry. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. And when you look at the stock's positive Zacks Earnings ESP (Expected Surprise Prediction), it's a great indicator of a future earnings beat, especially when combined with its solid Zacks Rank. | It is worth considering Abbott (ABT), which belongs to the Zacks Medical - Products industry. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. For the last reported quarter, Abbott came out with earnings of $0.75 per share versus the Zacks Consensus Estimate of $0.74 per share, representing a surprise of 1.35%. | It is worth considering Abbott (ABT), which belongs to the Zacks Medical - Products industry. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. And when you look at the stock's positive Zacks Earnings ESP (Expected Surprise Prediction), it's a great indicator of a future earnings beat, especially when combined with its solid Zacks Rank. |
33146.0 | 2018-12-20 00:00:00 UTC | Notable ETF Inflow Detected - XLV, ABBV, ABT, CVS | ABT | https://www.nasdaq.com/articles/notable-etf-inflow-detected-xlv-abbv-abt-cvs-2018-12-20 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $520.3 million dollar inflow -- that's a 2.9% increase week over week in outstanding units (from 209,920,000 to 216,020,000). Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 1.4%, and CVS Health Corporation (Symbol: CVS) is lower by about 1.2%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $84.75. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 1.4%, and CVS Health Corporation (Symbol: CVS) is lower by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $520.3 million dollar inflow -- that's a 2.9% increase week over week in outstanding units (from 209,920,000 to 216,020,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 1.4%, and CVS Health Corporation (Symbol: CVS) is lower by about 1.2%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $84.75. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 1.4%, and CVS Health Corporation (Symbol: CVS) is lower by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $520.3 million dollar inflow -- that's a 2.9% increase week over week in outstanding units (from 209,920,000 to 216,020,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $84.75. | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 1.4%, and CVS Health Corporation (Symbol: CVS) is lower by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $520.3 million dollar inflow -- that's a 2.9% increase week over week in outstanding units (from 209,920,000 to 216,020,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $84.75. |
33147.0 | 2018-12-18 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABT | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-2018-12-18 | nan | nan | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention - and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets.
But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.
In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.
The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential:
Another consideration with dividend growth stocks is just how much the dividend is growing . We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another.
These five stocks are part of our full Dividend Aristocrats List . The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com .
Get the latest Zacks research report on MMM - FREE
Get the latest Zacks research report on TDS - FREE
Dividend Growth Stocks: 25 Aristocrats »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing . Get the latest Zacks research report on MMM - FREE Get the latest Zacks research report on TDS - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Get the latest Zacks research report on MMM - FREE Get the latest Zacks research report on TDS - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing . | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. Get the latest Zacks research report on MMM - FREE Get the latest Zacks research report on TDS - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33148.0 | 2018-12-14 00:00:00 UTC | Daily Dividend Report: NLY, ABT, PFE, T, EQR | ABT | https://www.nasdaq.com/articles/daily-dividend-report-nly-abt-pfe-t-eqr-2018-12-14 | nan | nan | The Board of Directors of Annaly Capital Management declared the fourth quarter 2018 common stock cash dividend of $0.30 per common share. This dividend is payable January 31, 2019, to common shareholders of record on December 31, 2018. The ex-dividend date is December 28, 2018.
The board of directors of Abbott today increased the company's quarterly common dividend to 32 cents per share, marking a 14 percent increase. This marks the 380th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Feb. 15, 2019, to shareholders of record at the close of business on Jan. 15, 2019. Abbott has increased its dividend payout for 47 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.
The board of directors of Pfizer today declared a 36-cent first-quarter 2019 dividend on the company's common stock, payable March 1, 2019, to shareholders of record at the close of business on February 1, 2019. Pfizer increased the dividend by approximately 6 percent, to 36 cents from 34 cents per share. The first-quarter 2019 cash dividend will be the 321st consecutive quarterly dividend paid by Pfize
The board of directors of AT&T has approved a 2.0% increase in the company's quarterly dividend. AT&T's quarterly dividend will increase from $0.50 to $0.51 per share. The annual dividend will increase from $2.00 to $2.04 per share. "Our healthy cash flows and strong outlook for 2019 give us the confidence to raise our dividend for the 35th consecutive year. The dividend is an important way we provide value to our shareholders, and I'm proud that we are able to continue our history of annual increases," said Randall Stephenson, chairman and CEO, AT&T Inc. The dividend is payable on Feb. 1, 2019, to stockholders of record at the close of business on Jan. 10, 2019.
Equity Residential today announced that its Board of Trustees declared quarterly dividends on the Company's common and preferred shares. A regular common share dividend for the fourth quarter of $0.54 per share will be paid on January 11, 2019 to shareholders of record on January 2, 2019.
VIDEO: Daily Dividend Report: NLY, ABT, PFE, T, EQR
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | VIDEO: Daily Dividend Report: NLY, ABT, PFE, T, EQR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The board of directors of Pfizer today declared a 36-cent first-quarter 2019 dividend on the company's common stock, payable March 1, 2019, to shareholders of record at the close of business on February 1, 2019. The dividend is an important way we provide value to our shareholders, and I'm proud that we are able to continue our history of annual increases," said Randall Stephenson, chairman and CEO, AT&T Inc. | VIDEO: Daily Dividend Report: NLY, ABT, PFE, T, EQR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The Board of Directors of Annaly Capital Management declared the fourth quarter 2018 common stock cash dividend of $0.30 per common share. The board of directors of Abbott today increased the company's quarterly common dividend to 32 cents per share, marking a 14 percent increase. | VIDEO: Daily Dividend Report: NLY, ABT, PFE, T, EQR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The board of directors of Abbott today increased the company's quarterly common dividend to 32 cents per share, marking a 14 percent increase. Abbott has increased its dividend payout for 47 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years. | VIDEO: Daily Dividend Report: NLY, ABT, PFE, T, EQR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The board of directors of Abbott today increased the company's quarterly common dividend to 32 cents per share, marking a 14 percent increase. The board of directors of Pfizer today declared a 36-cent first-quarter 2019 dividend on the company's common stock, payable March 1, 2019, to shareholders of record at the close of business on February 1, 2019. |
33149.0 | 2018-12-14 00:00:00 UTC | 5 Biggest Medtech Stocks -- Are They Buys? | ABT | https://www.nasdaq.com/articles/5-biggest-medtech-stocks-are-they-buys-2018-12-14 | nan | nan | Medical technology, or medtech, is poised to generate nearly $600 billion in sales by 2024, according to projections made by market research company EvaluateMedTech. And that means higher revenue is likely on the way for the biggest medtech companies.
Currently, the five largest companies in terms of global medtech sales are Medtronic (NYSE: MDT) , Johnson & Johnson (NYSE: JNJ) , Abbott Laboratories (NYSE: ABT) , Siemens Healthineers (NASDAQOTH: SMMNY) , and Koninklijke Philips (NYSE: PHG) . But are any of these big medtech stocks smart picks to buy now?
1. Medtronic
Medtronic's global medtech sales totaled $30 billion last year. That was enough for the company to capture 7.4% of the total market, according to EvaluateMedTech.
Wall Street projects that Medtronic's growth over the next five years will top its performance over the last five years as well as handily beat the industry average. This growth should be fueled by Medtronic's product pipeline, which CEO Omar Ishrak says is "stronger than at any time in our company's history." Acquisitions should help as well, including Medtronic's buyout, announced in September , of Israeli surgical robot maker Mazor Robotics (NASDAQ: MZOR) .
2. Johnson & Johnson
Johnson & Johnson isn't just a medtech company. It also operates major consumer healthcare and pharmaceuticals businesses. But J&J's medtech sales totaled $26.6 billion last year, ranking the company No. 2 in the world.
J&J's earnings growth could slow a little over the next few years as the positive year-over-year comparisons from major acquisitions subside. It's also important to note that the pharmaceuticals segment is the main source of the company's growth, but sales are slipping for top-selling drug Remicade as it faces biosimilar competition. Still, J&J's medical device segment could experience growth as it moves beyond divestitures of some of its businesses.
3. Abbott Laboratories
Abbott Laboratories leaped into the third spot on EvaluateMedTech's rankings thanks to its acquisition of St. Jude Medical . Abbott's medtech sales totaled $16 billion last year, giving the company a market share of around 4%.
CEO Miles White noted in Abbott's Q3 conference call that three areas are driving the company's medtech growth: electrophysiology, structural heart, and diabetes care. The fastest growth is being achieved in diabetes care, led by continuous glucose monitoring (CGM) system FreeStyle Libre. Wall Street expects healthy growth for Abbott over the next few years thanks in large part to the company's new products.
4. Siemens Healthineers
Siemens Healthineers is the healthcare strategic unit of big conglomerate Siemens AG . However, its stock trades separately from its parent company. Siemens Healthineers stands as the fourth-largest medtech company in the world, with sales last year of $15.5 billion.
EvaluateMedTech projects that Siemens Healthineers' medtech revenue will increase by a modest 4% compound annual growth rate (CAGR) through 2024. While that growth should be enough for the company to hold on to its No. 4 ranking, Siemens Healthineers' market share is expected to slip from 3.8% last year to 3.4%.
5. Koninklijke Philips
Dutch consumer electronics and medical devices giant Koninklijke Philips landed in fifth place on EvaluateMedTech's list of the top medtech companies. Philips' 2017 medtech revenue totaled $13.6 billion.
The stock took a beating in November 2018 after Philips reported disappointing Q3 results. But the company's long-term prospects appear to be solid. However, EvaluateMedTech thinks that Philips will lose its top-five ranking despite growing medtech sales by a CAGR of 4.7% through 2024. That's because Becton Dickinson 's acquisition of C.R. Bard will allow the company to leapfrog Philips to take the No. 5 position.
Are they buys?
None of these five medtech stocks are bad picks. All of them should generate decent total returns over the long run. But I do think that one of these stocks stands out as the top pick. That stock is Abbott Labs.
Abbott should be able to grow earnings by a double-digit percentage over the next few years. The company ranks first or second globally in nearly every arena in which it competes. And Abbott has increased its dividend in every quarter since 1924.
It's not surprising that EvaluateMedTech thinks that Abbott will increase itsglobal marketshare to 4.5% over the next few years, the largest increase of any of the current top five companies. If you're looking to profit from growth in the medtech space, I think Abbott Labs is the best of the biggest medtech stocks.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of Johnson & Johnson and Medtronic and has the following options: short January 2019 $140 calls on Johnson & Johnson. The Motley Fool recommends Becton Dickinson and Mazor Robotics. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Currently, the five largest companies in terms of global medtech sales are Medtronic (NYSE: MDT) , Johnson & Johnson (NYSE: JNJ) , Abbott Laboratories (NYSE: ABT) , Siemens Healthineers (NASDAQOTH: SMMNY) , and Koninklijke Philips (NYSE: PHG) . It's also important to note that the pharmaceuticals segment is the main source of the company's growth, but sales are slipping for top-selling drug Remicade as it faces biosimilar competition. CEO Miles White noted in Abbott's Q3 conference call that three areas are driving the company's medtech growth: electrophysiology, structural heart, and diabetes care. | Currently, the five largest companies in terms of global medtech sales are Medtronic (NYSE: MDT) , Johnson & Johnson (NYSE: JNJ) , Abbott Laboratories (NYSE: ABT) , Siemens Healthineers (NASDAQOTH: SMMNY) , and Koninklijke Philips (NYSE: PHG) . Medtronic Medtronic's global medtech sales totaled $30 billion last year. Abbott's medtech sales totaled $16 billion last year, giving the company a market share of around 4%. | Currently, the five largest companies in terms of global medtech sales are Medtronic (NYSE: MDT) , Johnson & Johnson (NYSE: JNJ) , Abbott Laboratories (NYSE: ABT) , Siemens Healthineers (NASDAQOTH: SMMNY) , and Koninklijke Philips (NYSE: PHG) . Abbott's medtech sales totaled $16 billion last year, giving the company a market share of around 4%. If you're looking to profit from growth in the medtech space, I think Abbott Labs is the best of the biggest medtech stocks. | Currently, the five largest companies in terms of global medtech sales are Medtronic (NYSE: MDT) , Johnson & Johnson (NYSE: JNJ) , Abbott Laboratories (NYSE: ABT) , Siemens Healthineers (NASDAQOTH: SMMNY) , and Koninklijke Philips (NYSE: PHG) . Medtronic Medtronic's global medtech sales totaled $30 billion last year. That stock is Abbott Labs. |
33150.0 | 2018-12-14 00:00:00 UTC | Health Care Sector Update for 12/14/2018: JNJ, KANG, AXON, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-12142018-jnj-kang-axon-pfe-abt-mrk-amgn-2018-12-14 | nan | nan | Top Health Care Stocks:
JNJ: -9.38%
PFE: -2.02%
ABT: -1.51%
MRK: -2.19%
AMGN: -2.47%
Health care stocks were sinking in early Friday afternoon trading, including a 2.8% decline for the NYSE Health Care Index. Also, shares of health care companies in the S&P 500 were down 3% as a group, while the Nasdaq Biotechnology index was down 1.3% recently.
Stocks moving on news include:
(-) Johnson & Johnson ( JNJ ) was down 9% after Reuters reported that the company didn't disclose to regulators or the public that the its talc and finished powders tested positive for small amounts of asbestos from at least 1971 to the early 2000s.
In other sector news:
(+) iKang Healthcare Group ( KANG ) was up 11% after it announced a third amendment on its merger agreement with IK Healthcare Investment.
(-) Axovant Sciences Ltd ( AXON ) was 4% lower after it commenced an underwritten public offering of its common shares.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also, shares of health care companies in the S&P 500 were down 3% as a group, while the Nasdaq Biotechnology index was down 1.3% recently. Stocks moving on news include: (-) Johnson & Johnson ( JNJ ) was down 9% after Reuters reported that the company didn't disclose to regulators or the public that the its talc and finished powders tested positive for small amounts of asbestos from at least 1971 to the early 2000s. (-) Axovant Sciences Ltd ( AXON ) was 4% lower after it commenced an underwritten public offering of its common shares. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Stocks moving on news include: (-) Johnson & Johnson ( JNJ ) was down 9% after Reuters reported that the company didn't disclose to regulators or the public that the its talc and finished powders tested positive for small amounts of asbestos from at least 1971 to the early 2000s. | Health care stocks were sinking in early Friday afternoon trading, including a 2.8% decline for the NYSE Health Care Index. Stocks moving on news include: (-) Johnson & Johnson ( JNJ ) was down 9% after Reuters reported that the company didn't disclose to regulators or the public that the its talc and finished powders tested positive for small amounts of asbestos from at least 1971 to the early 2000s. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care Stocks: Health care stocks were sinking in early Friday afternoon trading, including a 2.8% decline for the NYSE Health Care Index. Also, shares of health care companies in the S&P 500 were down 3% as a group, while the Nasdaq Biotechnology index was down 1.3% recently. |
33151.0 | 2018-12-12 00:00:00 UTC | Notable ETF Outflow Detected - XLV, ABBV, ABT, CVS | ABT | https://www.nasdaq.com/articles/notable-etf-outflow-detected-xlv-abbv-abt-cvs-2018-12-12 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $122.7 million dollar outflow -- that's a 0.6% decrease week over week (from 211,265,324 to 209,920,000). Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and CVS Health Corporation (Symbol: CVS) is higher by about 1.5%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $92.82. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and CVS Health Corporation (Symbol: CVS) is higher by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $122.7 million dollar outflow -- that's a 0.6% decrease week over week (from 211,265,324 to 209,920,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and CVS Health Corporation (Symbol: CVS) is higher by about 1.5%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $92.82. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and CVS Health Corporation (Symbol: CVS) is higher by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $122.7 million dollar outflow -- that's a 0.6% decrease week over week (from 211,265,324 to 209,920,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $92.82. | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and CVS Health Corporation (Symbol: CVS) is higher by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $122.7 million dollar outflow -- that's a 0.6% decrease week over week (from 211,265,324 to 209,920,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $92.82. |
33152.0 | 2018-12-12 00:00:00 UTC | Abbott (ABT) Outpaces Stock Market Gains: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-outpaces-stock-market-gains%3A-what-you-should-know-2018-12-12 | nan | nan | Abbott (ABT) closed at $72.53 in the latest trading session, marking a +0.96% move from the prior day. This change outpaced the S&P 500's 0.54% gain on the day. Meanwhile, the Dow gained 0.64%, and the Nasdaq, a tech-heavy index, added 0.95%.
Coming into today, shares of the maker of infant formula, medical devices and drugs had gained 3.38% in the past month. In that same time, the Medical sector lost 2.71%, while the S&P 500 lost 4.97%.
Wall Street will be looking for positivity from ABT as it approaches its next earnings report date. This is expected to be January 23, 2019. The company is expected to report EPS of $0.81, up 9.46% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $7.79 billion, up 2.64% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $2.89 per share and revenue of $30.61 billion. These totals would mark changes of +15.6% and +11.74%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for ABT. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. ABT is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that ABT has a Forward P/E ratio of 24.9 right now. Its industry sports an average Forward P/E of 24.74, so we one might conclude that ABT is trading at a premium comparatively.
It is also worth noting that ABT currently has a PEG ratio of 2.13. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Products stocks are, on average, holding a PEG ratio of 2.14 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 148, putting it in the bottom 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed at $72.53 in the latest trading session, marking a +0.96% move from the prior day. Wall Street will be looking for positivity from ABT as it approaches its next earnings report date. Investors should also note any recent changes to analyst estimates for ABT. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) closed at $72.53 in the latest trading session, marking a +0.96% move from the prior day. Wall Street will be looking for positivity from ABT as it approaches its next earnings report date. | Abbott (ABT) closed at $72.53 in the latest trading session, marking a +0.96% move from the prior day. Wall Street will be looking for positivity from ABT as it approaches its next earnings report date. Investors should also note any recent changes to analyst estimates for ABT. | Abbott (ABT) closed at $72.53 in the latest trading session, marking a +0.96% move from the prior day. Wall Street will be looking for positivity from ABT as it approaches its next earnings report date. Investors should also note any recent changes to analyst estimates for ABT. |
33153.0 | 2018-12-08 00:00:00 UTC | Dividend aristocrat Abbott to extend its streak | ABT | https://www.nasdaq.com/articles/dividend-aristocrat-abbott-extend-its-streak-2018-12-08 | nan | nan | What's Happening
Abbott Labs ( ABT ) is a true dividend aristocrat with a lengthy 45-year streak of dividend increases. The stock currently has a dividend yield of 1.57% and the stock has gained 22% on the year.
Technical Analysis
ABT was recently trading at $69.77 down $5.15 from its 12-month high and $15.44 above its 12-month low. InvestorsObserver's Stock Score Report gives ABT an 89 long-term technical score and an 80 short-term technical score. The stock has recent support above $68 and recent resistance below $74. Of the 20 analysts who cover the stock 16 rate it Strong Buy, 2 rate it Buy, 2 rate it Hold, 0 rate it Sell, and 0 rate it Strong Sell, ABT gets a score of 78 from InvestorsObserver's Stock Score Report.
Analyst's Thoughts
Abbott has one of the longest streaks of dividend increases at 45 years, and it will look to extend that streak this week when it announces its next dividend. The stock has a low payout ratio of 39% so it can easily afford to extend its streak. Last year the company boosted its dividend by 5.6%, and despite the low payout ratio and current yield of just 1.5% I would not look for a big increase this year. Abbott has never been known for big increases, and this year's will likely take the dividend from $0.28 to $0.295 per share for a 5.3% increase. The stock will trade ex-dividend mid-January.
Stock Only Trade
If you're looking to establish a long stock position in ABT consider buying the stock under $70. Sell if it falls below $64.75 or take profits if it gets to $80.50.
Bullish Trade
If you want a bullish hedged trade on the stock, consider a 2/15/19 55/60 bull-put credit spread for a $0.35 credit. That's a potential 7.5% return (39% annualized*) and the stock would have to fall 14.5% to cause a problem.
Bearish Trade
If you want to take a bearish stance on the stock at this time, consider an 2/15/19 77.5/80 bear-call credit spread for a $0.25 credit. That's a potential 11.1% return (58% annualized*) and the stock would have to rise 11.4% to cause a problem.
Covered Call Trade
If you like the stock but wish to lower your cost basis on a new position, you may want to consider a 2/15/19 $70 covered call. Buy ABT shares (typically 100 shares, scale as appropriate), while selling the 2/15/19 $70 call for a debit of $66.77, per share. The trade has a target assigned return of 4.8%, and a target annualized return of 25.2% (for comparison purposes only).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Originally published on InvestorsObserver.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Technical Analysis ABT was recently trading at $69.77 down $5.15 from its 12-month high and $15.44 above its 12-month low. What's Happening Abbott Labs ( ABT ) is a true dividend aristocrat with a lengthy 45-year streak of dividend increases. InvestorsObserver's Stock Score Report gives ABT an 89 long-term technical score and an 80 short-term technical score. | InvestorsObserver's Stock Score Report gives ABT an 89 long-term technical score and an 80 short-term technical score. Of the 20 analysts who cover the stock 16 rate it Strong Buy, 2 rate it Buy, 2 rate it Hold, 0 rate it Sell, and 0 rate it Strong Sell, ABT gets a score of 78 from InvestorsObserver's Stock Score Report. What's Happening Abbott Labs ( ABT ) is a true dividend aristocrat with a lengthy 45-year streak of dividend increases. | Of the 20 analysts who cover the stock 16 rate it Strong Buy, 2 rate it Buy, 2 rate it Hold, 0 rate it Sell, and 0 rate it Strong Sell, ABT gets a score of 78 from InvestorsObserver's Stock Score Report. Stock Only Trade If you're looking to establish a long stock position in ABT consider buying the stock under $70. What's Happening Abbott Labs ( ABT ) is a true dividend aristocrat with a lengthy 45-year streak of dividend increases. | Technical Analysis ABT was recently trading at $69.77 down $5.15 from its 12-month high and $15.44 above its 12-month low. Stock Only Trade If you're looking to establish a long stock position in ABT consider buying the stock under $70. Buy ABT shares (typically 100 shares, scale as appropriate), while selling the 2/15/19 $70 call for a debit of $66.77, per share. |
33154.0 | 2018-12-03 00:00:00 UTC | AbbVie Stock Could Become a New Happy Pill for Investors | ABT | https://www.nasdaq.com/articles/abbvie-stock-could-become-new-happy-pill-investors-2018-12-03 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
While AbbVie (NYSE: ABBV ) has shown strong profit growth over the last year, ABBV stock has sold off recently over worries about Humira patent expirations in some parts of the world.
Although the concerns may be overblown, losing any patent protection on the widely prescribed drug breeds the type of uncertainty that often leads to stock declines. What gives investors confidence in the shares, though, is a promising drug pipeline should keep AbbVie stock on a growth trajectory even as Humira fades as a significant revenue contributor.
To be sure, AbbVie stock has struggled this year. ABBV peaked at $125.86 a share back in January. By April, it had fallen below $90 per share, and it has found itself stuck in a range since. Like many stocks, the October correction pushed it down further, taking the shares as low as $77.50 a piece.
Competition Aggravates Patent Expirations
Since its split from Abbott Laboratories (NYSE: ABT ) in 2013, AbbVie has built its fortunes on Humira, a treatment for a range of conditions, including rheumatoid arthritis, psoriatic arthritis and Crohn's disease. With its patent beginning to expire in some key markets, Humira is facing increased competition. ABBV stock has sold off as investors wonder where the company will go next.
10 High-Yield Monthly Dividend Stocks
I believe Wall Street may have overreacted. Data analysts at Evaluate Pharma rate AbbVie's pipeline as second-best in the industry for value creation. The company has also gained approval for drugs that treat conditions such as cancer, hepatitis C, and endometriosis. At the same time, AbbVie has managed to slow the loss of its patent on Humira. In the U.S., the patent will remain in place until at least 2022, which should give ABBV stock enough runway to transition into new revenue sources.
Compelling Financials
Despite the stock's struggles, analysts forecast 42% profit growth for this year. Over the next five years, they predict average annual increases of almost 17%.
The current price-to-earnings (PE) ratio stands at about 11.3, which seems remarkable on many levels. ABBV stock has maintained an average PE of about 26.8 over the last five years. Rarely do stocks posting double-digit profit growth fall into single-digit multiples.
Perhaps investors have begun to see its future potential. November has seen the stock turn around, and it again trades at about the $90 per share level. True, AbbVie stock remains range-bound, however these financials indicate it can eventually break out of its range.
Wall Street may need to see better sales numbers from newer drugs before they bid AbbVie shares higher. While they wait, ABBV's dividend will reward them for their patience. As a result of its previous association with Abbott, ABBV stock is considered a "dividend aristocrat" on the coattails of the former parent's 46 consecutive years of dividend increases.
10 Goldman Sachs Top Stock Picks for 2019
Approval of a dividend increase for February brought the annual payout to $4.28 per share. That give the stock a yield of about 4.75%. Among the dividend aristocrats, only AT&T (NYSE: T ) pays a higher cash return. Given company growth prospects and the expectations for increases that come with its aristocrat status, income investors will struggle to find better alternatives than AbbVie stock.
Bottom Line on AbbVie Stock
As Humira begins a slow fade from driving AbbVie revenue, new drugs should keep ABBV stock on a growth trajectory. Without a doubt, losing Humira poses risks for the company. However, despite this uncertainty, analysts still expect AbbVie to maintain its double-digit profit growth. Equally notable is that the decline in the stock price has pushed the PE ratio close to the single digits.
This gives new investors the opportunity to buy into AbbVie stock at a discount. It also serves income investors who can earn a dividend of about 4.75% with annual increases for years to come. Between the cash payouts and the potential for stock price appreciation, both growth and income investors should enjoy a profitable future in ABBV stock.
As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You canfollow Will on Twitterat @HealyWriting.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
10 Value Stocks to Buy for December
10 Boring Stocks to Buy for Red-Hot Returns
10 Stocks to Buy for a Rate Hike Slowdown
Compare Brokers
The post AbbVie Stock Could Become a New Happy Pill for Investors appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Competition Aggravates Patent Expirations Since its split from Abbott Laboratories (NYSE: ABT ) in 2013, AbbVie has built its fortunes on Humira, a treatment for a range of conditions, including rheumatoid arthritis, psoriatic arthritis and Crohn's disease. Although the concerns may be overblown, losing any patent protection on the widely prescribed drug breeds the type of uncertainty that often leads to stock declines. What gives investors confidence in the shares, though, is a promising drug pipeline should keep AbbVie stock on a growth trajectory even as Humira fades as a significant revenue contributor. | Competition Aggravates Patent Expirations Since its split from Abbott Laboratories (NYSE: ABT ) in 2013, AbbVie has built its fortunes on Humira, a treatment for a range of conditions, including rheumatoid arthritis, psoriatic arthritis and Crohn's disease. InvestorPlace - Stock Market News, Stock Advice & Trading Tips While AbbVie (NYSE: ABBV ) has shown strong profit growth over the last year, ABBV stock has sold off recently over worries about Humira patent expirations in some parts of the world. Bottom Line on AbbVie Stock As Humira begins a slow fade from driving AbbVie revenue, new drugs should keep ABBV stock on a growth trajectory. | Competition Aggravates Patent Expirations Since its split from Abbott Laboratories (NYSE: ABT ) in 2013, AbbVie has built its fortunes on Humira, a treatment for a range of conditions, including rheumatoid arthritis, psoriatic arthritis and Crohn's disease. InvestorPlace - Stock Market News, Stock Advice & Trading Tips While AbbVie (NYSE: ABBV ) has shown strong profit growth over the last year, ABBV stock has sold off recently over worries about Humira patent expirations in some parts of the world. Bottom Line on AbbVie Stock As Humira begins a slow fade from driving AbbVie revenue, new drugs should keep ABBV stock on a growth trajectory. | Competition Aggravates Patent Expirations Since its split from Abbott Laboratories (NYSE: ABT ) in 2013, AbbVie has built its fortunes on Humira, a treatment for a range of conditions, including rheumatoid arthritis, psoriatic arthritis and Crohn's disease. InvestorPlace - Stock Market News, Stock Advice & Trading Tips While AbbVie (NYSE: ABBV ) has shown strong profit growth over the last year, ABBV stock has sold off recently over worries about Humira patent expirations in some parts of the world. ABBV stock has sold off as investors wonder where the company will go next. |
33155.0 | 2018-11-30 00:00:00 UTC | 3 Beaten-Down Biotech Stocks to Buy Before the End of 2018 | ABT | https://www.nasdaq.com/articles/3-beaten-down-biotech-stocks-buy-end-2018-2018-11-30 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Biotech stocks, like the rest of the broader market, have been under heavy pressure in late 2018. The iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ), which includes several of the largest biotechnology stocks, and the SPDR S&P Biotech ETF (NYSEARCA: XBI ), which also includes the sectors sector's mid- and small-cap companies, have been in a free-fall since October, declining over 15% each.
Although many of these biotech stocks, including AbbVie (NYSE: ABBV ), Celgene (NASDAQ: CELG ) and Mylan (NASDAQ: MYL ), are much cheaper than they were at the start of September, investors should not expect the choppiness in individual share prices to be over yet.
Furthermore, the daily volatility of all three of these stocks is high, giving each a broad trading range. As such, investors should expect to see wide daily price swings in these names during the final weeks of 2018.
Most biotech stocks have been darlings of Wall Street until recently, but as we approach the end of the year, many analysts and investors are doubtful as to what is next for these stocks. Going into 2019, I believe investors will have to be more selective regarding which biotech stocks they choose to invest in, as some are likely to do better than others.
10 Value Stocks to Buy for December
With that said, here's why you should consider these three biotechnology stocks to buy for success in 2019.
AbbVie (ABBV)
Source: Shutterstock
Of the three biotech stocks in this article, I am most bullish on ABBV stock.
AbbVie's earnings release on Nov. 2 showed robust top-line growth, a strong pipeline of existing and new drugs and increased guidance for its full year 2018 earnings. Humira , the world's bestselling drug, which has U.S. patent protection through 2023, benefited from rising global sales of almost 10%. Imbruvica , its other flagship product in the lymphoma/leukemia segment, exhibited double-digit growth and exceeded revenue expectations, too.
AbbVie investors welcomed an increase in the company's quarterly cash dividend from 96 cents to $1.07 per share. Since its spin-off from Abbott Laboratories (NYSE: ABT ) - another dividend king - in 2013, ABV has increased dividends every year.
Despite competitive pressures from other healthcare and biotech companies, Abbvie has several potential cancer drugs in the pipeline that would keep the company ahead of the competition by providing a projected earnings growth of 15% per annum in the next few years.
During the rest of the year and in early 2019, I expect ABBV stock to trade between $80 - $95. Furthermore, AbbVie's healthy dividend yield of 5% is likely to provide strong support for the ABBV stock price in the weeks and months ahead.
Celgene (CELG)
Source: Shutterstock
For a year, investors in CELG stock have been let down with the price performance of their shares. Year-to-date, Celgene is down over 30%. The downtrend and negative momentum surrounding the stock have become quite extreme.
In addition to the overall weakness in biotech stocks that has affected investor sentiment, Wall Street has been worried about whether Celgene will be able to continue to increase revenues when its vital blockbuster drug Revlimid , which generates over 60% of the revenues, comes off patent in the U.S. in 2027. Yet analysts want to see if the new management led by CEO Mark Alles will succeed in decreasing the over-concentration risk on Revlimid and if there will be new earnings blockbusters.
I am of the firm opinion that smart money will come back to Celgene as its management grows the company both organically and inorganically through acquisitions, partnerships as well as commercialization as a result of in-house research and development (R&D).
When it reported earnings on Oct. 25, Celgene beat estimates and raised its full-year guidance. With a broad and robust pipeline , CELG stock is at the forefront of biotechnology companies developing profitable drugs that enable the company to grow revenues and increase cash flow with both current and potential drugs.
7 ETFs for the Inevitable Boom in Self-Driving Cars
During the first quarter of 2019, I expect the CELG stock price to form a base between $62.5 - $72.5, after which a new sustained leg up can take hold. Long-term investors may regard any dip in price an opportunity to get long Celgene stock.
Mylan (MYL)
Source: Shutterstock
Mylan, one of the most important global generic pharmaceuticals companies, has also had a difficult 2018 like the other biotech stocks on this list.
Year-to-date, MYL shares are down almost 20%. Developing a generic version of GlaxoSmithKline's (NYSE: GSK ) blockbuster drug Advair has been at the center of Mylan's recent R&D efforts. In October, Mylan management said that the FDA approval is imminent.
Wall Street expects Generic Advair to contribute to MYL's revenue and earnings significantly. In addition to the generic drug development, Mylan management has also been concentrating on improving the company's margins by cost-cutting measures.
Despite the company developing a robust pipeline of generic drugs for Restasis , Revefenacin and Copaxone , MYL stock investors realize that the company operates in a challenging and complex generic environment with a slow uptake of the generic Copaxone , and issues with getting generic Advai r and generic Restasis to market persisting.
In the next few months, I expect the MYL stock price to form a base between $27.5 - $37.5 after which a new sustained leg up can take hold. As such, patient investors who wait to get into MYL stock later in the year are likely to have good returns in 2019.
The Bottom Line on These Three Biotechnology Stocks
Source: Shutterstock
All three biotech stocks, ABBV, CELG and MYL stock, have strong fundamental growth prospects in the long-run, despite having come off significantly from their recent highs. Therefore, investors may start thinking about which shares they would like to see in their portfolio at these lower prices.
If I had to rank them, I would start the buying with ABBV stock, followed by MYL stock and finally CELG stock. November has not been a good time for entry into any of these stocks, but December may be a different story for these Biotechnology stocks as investors may decide to step in from the sidelines.
10 Stocks to Buy for a Rate Hike Slowdown
Ultimately, investors should always base their decisions on individual risk/return profiles and remember that most biotech stocks are not likely to have double-digit returns in 2019 while valuations and expectations become more rational.
As of this writing, Tezcan Gecgil did not hold a position in any of the aforementioned securities.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
10 Best Stocks Under $10
10 High-Yield Monthly Dividend Stocks
15 Artificial Intelligence Stocks Leading the New Wave
Compare Brokers
The post 3 Beaten-Down Biotech Stocks to Buy Before the End of 2018 appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Since its spin-off from Abbott Laboratories (NYSE: ABT ) - another dividend king - in 2013, ABV has increased dividends every year. Furthermore, AbbVie's healthy dividend yield of 5% is likely to provide strong support for the ABBV stock price in the weeks and months ahead. I am of the firm opinion that smart money will come back to Celgene as its management grows the company both organically and inorganically through acquisitions, partnerships as well as commercialization as a result of in-house research and development (R&D). | Since its spin-off from Abbott Laboratories (NYSE: ABT ) - another dividend king - in 2013, ABV has increased dividends every year. Although many of these biotech stocks, including AbbVie (NYSE: ABBV ), Celgene (NASDAQ: CELG ) and Mylan (NASDAQ: MYL ), are much cheaper than they were at the start of September, investors should not expect the choppiness in individual share prices to be over yet. Despite the company developing a robust pipeline of generic drugs for Restasis , Revefenacin and Copaxone , MYL stock investors realize that the company operates in a challenging and complex generic environment with a slow uptake of the generic Copaxone , and issues with getting generic Advai r and generic Restasis to market persisting. | Since its spin-off from Abbott Laboratories (NYSE: ABT ) - another dividend king - in 2013, ABV has increased dividends every year. The Bottom Line on These Three Biotechnology Stocks Source: Shutterstock All three biotech stocks, ABBV, CELG and MYL stock, have strong fundamental growth prospects in the long-run, despite having come off significantly from their recent highs. If I had to rank them, I would start the buying with ABBV stock, followed by MYL stock and finally CELG stock. | Since its spin-off from Abbott Laboratories (NYSE: ABT ) - another dividend king - in 2013, ABV has increased dividends every year. Although many of these biotech stocks, including AbbVie (NYSE: ABBV ), Celgene (NASDAQ: CELG ) and Mylan (NASDAQ: MYL ), are much cheaper than they were at the start of September, investors should not expect the choppiness in individual share prices to be over yet. Furthermore, AbbVie's healthy dividend yield of 5% is likely to provide strong support for the ABBV stock price in the weeks and months ahead. |
33156.0 | 2018-11-26 00:00:00 UTC | Notable ETF Inflow Detected - SPYG, ABT, BKNG, AMGN | ABT | https://www.nasdaq.com/articles/notable-etf-inflow-detected-spyg-abt-bkng-amgn-2018-11-26 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $112.8 million dollar inflow -- that's a 3.6% increase week over week in outstanding units (from 92,650,108 to 96,000,108). Among the largest underlying components of SPYG, in trading today Abbott Laboratories (Symbol: ABT) is up about 1.2%, Booking Holdings Inc (Symbol: BKNG) is up about 1.8%, and Amgen Inc (Symbol: AMGN) is higher by about 0.6%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average:
Looking at the chart above, SPYG's low point in its 52 week range is $31.69 per share, with $38.55 as the 52 week high point - that compares with a last trade of $34.14. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SPYG, in trading today Abbott Laboratories (Symbol: ABT) is up about 1.2%, Booking Holdings Inc (Symbol: BKNG) is up about 1.8%, and Amgen Inc (Symbol: AMGN) is higher by about 0.6%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $31.69 per share, with $38.55 as the 52 week high point - that compares with a last trade of $34.14. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of SPYG, in trading today Abbott Laboratories (Symbol: ABT) is up about 1.2%, Booking Holdings Inc (Symbol: BKNG) is up about 1.8%, and Amgen Inc (Symbol: AMGN) is higher by about 0.6%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $31.69 per share, with $38.55 as the 52 week high point - that compares with a last trade of $34.14. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SPYG, in trading today Abbott Laboratories (Symbol: ABT) is up about 1.2%, Booking Holdings Inc (Symbol: BKNG) is up about 1.8%, and Amgen Inc (Symbol: AMGN) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $112.8 million dollar inflow -- that's a 3.6% increase week over week in outstanding units (from 92,650,108 to 96,000,108). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $31.69 per share, with $38.55 as the 52 week high point - that compares with a last trade of $34.14. | Among the largest underlying components of SPYG, in trading today Abbott Laboratories (Symbol: ABT) is up about 1.2%, Booking Holdings Inc (Symbol: BKNG) is up about 1.8%, and Amgen Inc (Symbol: AMGN) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $112.8 million dollar inflow -- that's a 3.6% increase week over week in outstanding units (from 92,650,108 to 96,000,108). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $31.69 per share, with $38.55 as the 52 week high point - that compares with a last trade of $34.14. |
33157.0 | 2018-11-21 00:00:00 UTC | ABT January 2019 Options Begin Trading | ABT | https://www.nasdaq.com/articles/abt-january-2019-options-begin-trading-2018-11-21 | nan | nan | Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the January 2019 expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABT options chain for the new January 2019 contracts and identified one put and one call contract of particular interest.
The put contract at the $68.00 strike price has a current bid of $1.44. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $68.00, but will also collect the premium, putting the cost basis of the shares at $66.56 (before broker commissions). To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $68.44/share today.
Because the $68.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 55%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 2.12% return on the cash commitment, or 17.57% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for Abbott Laboratories, and highlighting in green where the $68.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $69.00 strike price has a current bid of $1.53. If an investor was to purchase shares of ABT stock at the current price level of $68.44/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $69.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 3.05% if the stock gets called away at the January 2019 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $69.00 strike highlighted in red:
Considering the fact that the $69.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 53%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 2.24% boost of extra return to the investor, or 18.54% annualized, which we refer to as the YieldBoost .
The implied volatility in the put contract example is 25%, while the implied volatility in the call contract example is 29%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $68.44) to be 20%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of Stocks Analysts Like »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $69.00 strike highlighted in red: Considering the fact that the $69.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the January 2019 expiration. | Below is a chart showing ABT's trailing twelve month trading history, with the $69.00 strike highlighted in red: Considering the fact that the $69.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the January 2019 expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABT options chain for the new January 2019 contracts and identified one put and one call contract of particular interest. | Below is a chart showing ABT's trailing twelve month trading history, with the $69.00 strike highlighted in red: Considering the fact that the $69.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the January 2019 expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABT options chain for the new January 2019 contracts and identified one put and one call contract of particular interest. | At Stock Options Channel , our YieldBoost formula has looked up and down the ABT options chain for the new January 2019 contracts and identified one put and one call contract of particular interest. Below is a chart showing ABT's trailing twelve month trading history, with the $69.00 strike highlighted in red: Considering the fact that the $69.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the January 2019 expiration. |
33158.0 | 2018-11-21 00:00:00 UTC | Health Care Sector Update for 11/21/2018: SYN, CYAD, JNJ, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-11212018-syn-cyad-jnj-pfe-abt-mrk-amgn-2018-11-21 | nan | nan | Top Health Care Stocks:
JNJ: -0.27%
PFE: -0.14%
ABT: Flat
MRK: +0.48%
AMGN: +0.54%
Health care stocks were narrowly mixed pre-market Wednesday.
Early movers include:
(+) Synthetic Biologics ( SYN ), which was surging more than 18% as the company said it successfully completed an end-of-phase 2 meeting with the US Food and Drug Administration on its ribaxamase for the prevention of Clostridium difficile infection.
In other sector news:
(-) The US Court of Appeals for the Federal Circuit denied Johnson & Johnson's ( JNJ ) request to block low-cost versions of Zytinga from entering the US market while the pharmaceutical firm appeals a trial judge's ruling that invalidated a patent on the blockbuster colorectal cancer drug, Bloomberg News reported. Johnson & Johnson stock was slightly lower in recent trading.
(=) Celyad SA ( CYAD ) was unchanged as it reported cash, cash equivalents, and short-term investments of EUR55.9 million ($63.73 million) as part of a Q3 business update.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: Flat Health care stocks were narrowly mixed pre-market Wednesday. Early movers include: (+) Synthetic Biologics ( SYN ), which was surging more than 18% as the company said it successfully completed an end-of-phase 2 meeting with the US Food and Drug Administration on its ribaxamase for the prevention of Clostridium difficile infection. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT: Flat Top Health Care Stocks: | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT: Flat In other sector news: (-) The US Court of Appeals for the Federal Circuit denied Johnson & Johnson's ( JNJ ) request to block low-cost versions of Zytinga from entering the US market while the pharmaceutical firm appeals a trial judge's ruling that invalidated a patent on the blockbuster colorectal cancer drug, Bloomberg News reported. | ABT: Flat Top Health Care Stocks: Health care stocks were narrowly mixed pre-market Wednesday. |
33159.0 | 2018-11-21 00:00:00 UTC | Abbott (ABT) Stock Sinks As Market Gains: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-stock-sinks-as-market-gains%3A-what-you-should-know-2018-11-21 | nan | nan | Abbott (ABT) closed the most recent trading day at $68.53, moving -0.77% from the previous trading session. This change lagged the S&P 500's 0.3% gain on the day. Elsewhere, the Dow 0%, while the tech-heavy Nasdaq added 0.92%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had gained 0.71% over the past month. This has outpaced the Medical sector's loss of 2.51% and the S&P 500's loss of 4.37% in that time.
ABT will be looking to display strength as it nears its next earnings release, which is expected to be January 23, 2019. On that day, ABT is projected to report earnings of $0.81 per share, which would represent year-over-year growth of 9.46%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.79 billion, up 2.64% from the year-ago period.
ABT's full-year Zacks Consensus Estimates are calling for earnings of $2.88 per share and revenue of $30.61 billion. These results would represent year-over-year changes of +15.2% and +11.74%, respectively.
Investors should also note any recent changes to analyst estimates for ABT. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% higher. ABT is currently a Zacks Rank #3 (Hold).
In terms of valuation, ABT is currently trading at a Forward P/E ratio of 23.96. This valuation marks a discount compared to its industry's average Forward P/E of 24.53.
Also, we should mention that ABT has a PEG ratio of 2.05. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Products stocks are, on average, holding a PEG ratio of 2.24 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 93, putting it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed the most recent trading day at $68.53, moving -0.77% from the previous trading session. ABT will be looking to display strength as it nears its next earnings release, which is expected to be January 23, 2019. On that day, ABT is projected to report earnings of $0.81 per share, which would represent year-over-year growth of 9.46%. | Abbott (ABT) closed the most recent trading day at $68.53, moving -0.77% from the previous trading session. ABT will be looking to display strength as it nears its next earnings release, which is expected to be January 23, 2019. On that day, ABT is projected to report earnings of $0.81 per share, which would represent year-over-year growth of 9.46%. | ABT's full-year Zacks Consensus Estimates are calling for earnings of $2.88 per share and revenue of $30.61 billion. Abbott (ABT) closed the most recent trading day at $68.53, moving -0.77% from the previous trading session. ABT will be looking to display strength as it nears its next earnings release, which is expected to be January 23, 2019. | Abbott (ABT) closed the most recent trading day at $68.53, moving -0.77% from the previous trading session. On that day, ABT is projected to report earnings of $0.81 per share, which would represent year-over-year growth of 9.46%. ABT is currently a Zacks Rank #3 (Hold). |
33160.0 | 2018-11-19 00:00:00 UTC | Health Care Sector Update for 11/19/2018: SNOA, GSK, PFE, MRK, ABT, AMGN, JNJ | ABT | https://www.nasdaq.com/articles/health-care-sector-update-11192018-snoa-gsk-pfe-mrk-abt-amgn-jnj-2018-11-19 | nan | nan | Top Health Care Stocks:
JNJ: Flat
PFE: +o.23%
ABT: Flat
MRK: -0.1%
AMGN: Flat
Health care stocks were showing little movement in Pre-bell trading Monday.
Early movers include:
(-) Sonoma Pharmaceuticals ( SNOA ), which was tumbling more than 22% after it priced a best efforts public offering of units, consisting of one share of common stock and one half of one warrant, at $1 per unit, a 9% discount to the stock's closing price on Friday.
In other sector news:
(+) GlaxoSmithKline ( GSK ) was slightly up after it filed a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration seeking an additional indication for the use of Nucala as an add-on treatment for severe eosinophilic asthma in pediatric patients aged six to 11 years.
(=) Pfizer ( PFE ) and Merck KGaA said the companies' phase 3 trial of avelumab alone or in combination with chemotherapy failed to meet its primary endpoints of overall survival and progression-free survival in certain types of ovarian cancer. Pfizer was unchanged after the news.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care Stocks: JNJ: Flat PFE: +o.23% ABT: Flat AMGN: Flat Health care stocks were showing little movement in Pre-bell trading Monday. Early movers include: (-) Sonoma Pharmaceuticals ( SNOA ), which was tumbling more than 22% after it priced a best efforts public offering of units, consisting of one share of common stock and one half of one warrant, at $1 per unit, a 9% discount to the stock's closing price on Friday. | Top Health Care Stocks: JNJ: Flat PFE: +o.23% ABT: Flat AMGN: Flat Health care stocks were showing little movement in Pre-bell trading Monday. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care Stocks: JNJ: Flat PFE: +o.23% ABT: Flat Early movers include: (-) Sonoma Pharmaceuticals ( SNOA ), which was tumbling more than 22% after it priced a best efforts public offering of units, consisting of one share of common stock and one half of one warrant, at $1 per unit, a 9% discount to the stock's closing price on Friday. In other sector news: (+) GlaxoSmithKline ( GSK ) was slightly up after it filed a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration seeking an additional indication for the use of Nucala as an add-on treatment for severe eosinophilic asthma in pediatric patients aged six to 11 years. | Top Health Care Stocks: JNJ: Flat PFE: +o.23% ABT: Flat AMGN: Flat Health care stocks were showing little movement in Pre-bell trading Monday. Early movers include: (-) Sonoma Pharmaceuticals ( SNOA ), which was tumbling more than 22% after it priced a best efforts public offering of units, consisting of one share of common stock and one half of one warrant, at $1 per unit, a 9% discount to the stock's closing price on Friday. |
33161.0 | 2018-11-18 00:00:00 UTC | Better Buy: Abbott Laboratories vs. Johnson & Johnson | ABT | https://www.nasdaq.com/articles/better-buy-abbott-laboratories-vs-johnson-johnson-2018-11-18 | nan | nan | When you think about blue chip stocks in healthcare, which stocks come to mind? For many, Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) would be at the top of the list. The two companies are large, established players in the healthcare sector with famous brands and solid financials.
But some blue chip stocks are more worthy of placing your chips on than others. So far this year, Abbott Labs has delivered greater returns for investors. Which of these two big healthcare stocks is the better pick for the future? Here's how Abbott Labs and Johnson & Johnson compare.
The case for Abbott Laboratories
Abbott Labs has been one of the hottest medical-device stocks of 2018 . The company's successful stock performance has been driven largely by growth from acquisitions and new products.
In particular, two key acquisitions have boosted Abbott's sales. The company's buyout of St. Jude Medical closed in January 2017. This deal strengthened Abbott's cardiovascular product lineup. Abbott acquired Alere in the fourth quarter of 2017. The transaction bolstered Abbott's diagnostics business, giving the company the leading point-of-care testing portfolio in the world.
Several new products have been vital to Abbott's improving fortunes. The company's sensor-based continuous glucose monitoring (CGM) system, FreeStyle Libre, has been an especially big hit. The system eliminates the need for diabetes patients to stick their fingers routinely to obtain blood for glucose testing. Another important new product for Abbott is its Confirm Rx insertable cardiac monitor (ICM), which is the first smartphone-compatible ICM to help physicians remotely identify cardiac arrhythmias.
But these acquisitions and new products really just point to the best argument for the stock: Abbott's focus on creating value for shareholders. Dealmaking and innovation are the fruits of this continual focus. And it has made Abbott No. 1 or No. 2 in nearly every market where it competes.
For numbers-oriented investors, Abbott Labs has plenty to offer. The company is on track to increase revenue by nearly 12% this year to around $31 billion. It has a cash stockpile, including cash, cash equivalents, and short-term investments, of more than $7.5 billion.
And Abbott has paid a dividend for 379 consecutive quarters. The company has increased its dividend for 46 years in a row, making Abbott Labs a member of the elite group of stocks known as Dividend Aristocrats . Abbott's dividend currently yields 1.54%.
The case for Johnson & Johnson
There are some similarities between the investing theses for Johnson & Johnson and Abbott Labs. For example, acquisitions have been important for J&J just as they have been for Abbott.
Johnson & Johnson's 2017 acquisition of Swiss drugmaker Actelion Pharmaceuticals brought pulmonary hypertension drugs Opsumit, Tracleer, and Uptravi into J&J's lineup. The company also picked up a new business last year from none other than Abbott Labs. The acquisition of Abbott Medical Optics has boosted J&J's eye-care products revenue.
While J&J is the largest healthcare company in the world, it's also a dominant player in multiple markets within the healthcare sector. The company's consumer healthcare products, medical devices, and pharmaceuticals each generate annual sales measured in the tens of billions of dollars.
J&J's pharmaceuticals segment typically provides the highest revenue growth, with cancer drugs Darzalex, Imbruvica, and Zytiga leading the way. The company's consumer business delivered a surprising sales jump in the third quarter thanks to higher U.S. demand for over-the-counter medications and beauty and baby care products.
Few companies are in the same league as J&J financially. The company will likely rake in close to $81 billion in revenue this year and more than $16 billion in profits. Johnson & Johnson sat on $19.4 billion in cash, cash equivalents, and marketable securities at the end of September 2018.
J&J has long been known for paying a solid dividend. The company has increased its dividend for 56 consecutive years. Its dividend currently yields 2.47%.
Better buy
I think that Abbott Labs is likely to deliver a higher total return over the next few years than Johnson & Johnson will. The problem for J&J is that it faces declining sales for top-selling drug Remicade in the wake of biosimilar competition. Sales are also slipping for other key drugs, including diabetes drug Invokana and anticoagulant Xarelto.
But while my view is that Abbott is the better buy right now, I like both of these stocks. Both Abbott Labs and Johnson & Johnson didn't achieve success decade after decade for 130 years or more by resting on their laurels. These companies should continue to create value for shareholders for a long time to come.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of Johnson & Johnson and has the following options: short January 2019 $140 calls on Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For many, Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) would be at the top of the list. The company's consumer healthcare products, medical devices, and pharmaceuticals each generate annual sales measured in the tens of billions of dollars. J&J's pharmaceuticals segment typically provides the highest revenue growth, with cancer drugs Darzalex, Imbruvica, and Zytiga leading the way. | For many, Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) would be at the top of the list. Sales are also slipping for other key drugs, including diabetes drug Invokana and anticoagulant Xarelto. Both Abbott Labs and Johnson & Johnson didn't achieve success decade after decade for 130 years or more by resting on their laurels. | For many, Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) would be at the top of the list. The case for Abbott Laboratories Abbott Labs has been one of the hottest medical-device stocks of 2018 . The company has increased its dividend for 46 years in a row, making Abbott Labs a member of the elite group of stocks known as Dividend Aristocrats . | For many, Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) would be at the top of the list. Johnson & Johnson's 2017 acquisition of Swiss drugmaker Actelion Pharmaceuticals brought pulmonary hypertension drugs Opsumit, Tracleer, and Uptravi into J&J's lineup. The company also picked up a new business last year from none other than Abbott Labs. |
33162.0 | 2018-11-16 00:00:00 UTC | Abbott (ABT) Up 3.8% Since Last Earnings Report: Can It Continue? | ABT | https://www.nasdaq.com/articles/abbott-abt-up-3.8-since-last-earnings-report%3A-can-it-continue-2018-11-16 | nan | nan | It has been about a month since the last earnings report for Abbott (ABT). Shares have added about 3.8% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Abbott due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Abbott Beats on Q3 Earnings, Narrows '18 EPS View
Abbott reported third-quarter 2018 adjusted earnings from continuing operations of 75 cents per share, a penny ahead of the Zacks Consensus Estimate. The bottom line improved 13.6% year over year and remained at the upper end of the company's guided range of 73-75 cents. Reported earnings from continuing operation in the quarter came in at 31 cents per share, a 3.1% drop year over year.
Third-quarter worldwide sales came in at $7.66 billion, up 12.1% year over year on a reported basis. The top line remained slightly below the Zacks Consensus Estimate of $7.67 billion.
On an organic basis (adjusting for the impact of foreign exchange as well as certain acquisitions and divestments) sales increased 7.8% year over year in the reported quarter.
Quarter in Detail
Abbott operates through four segments, namely Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics.
EPD sales dropped 0.9% on a reported basis (improved 5.9% on an organic basis) to $1.16 billion. This included a 6.8% adverse impact of from currency fluctuations. Sales in the key emerging markets declined 2.1% year over year on an 8.9% adverse impact of foreign exchange. Organically, sales improved 6.8% driven by double-digit growth in India and China.
The Medical Devices business sales increased 8.4% on a reported basis to $2.82 billion. On an organic basis, sales grew 9.8%.
Cardiovascular and Neuromodulation sales reportedly (up 4.8% on an organic basis) rose 3.6% on double-digit growth in Electrophysiology and Structural Heart. In Electrophysiology, growth was led by strong performance in cardiac mapping and ablation catheters as well as strong growth of Abbott's Confirm Rx Insertable Cardiac Monitor (ICM). Within Structural Heart, growth was driven by several product areas across Abbott's broad portfolio, including AMPLATZERPFO Occluder and MitraClip.
Diabetes Care sales improved 37.4% (up 39.8% organically), buoyed consistent consumer uptake of FreeStyle Libre, the revolutionary continuous glucose monitoring system of Abbott.
Nutrition sales were up 4% year over year on a reported basis (up 6.1% on an organic basis) to $1.84 billion. Pediatric Nutrition sales increased 8.5% on an organic basis. Adult Nutrition sales were up 3.2% organically.
Diagnostics sales soared 42.6% year over year on a reported basis (up 7.5% on a comparable operational basis) to $1.82 billion. Core Laboratory Diagnostics and Point of Care Diagnostics sales grew 8.1% and 4%, respectively, on an organic basis. Molecular Diagnostics sales were up 6.1% banking on strong growth in the infectious disease testing business. Rapid Diagnostics recorded sales of $481 million, driven by solid contributions from cardiometabolic testing.
Full-Year Guidance
Abbott has narrowed its 2018 adjusted earnings per share guidance. Adjusting for certain net specified items for the full year, adjusted earnings from continuing operations are now expected in the band of $2.87-$2.89 as compared to the earlier-projected range of $2.85-$2.91. The Zacks Consensus Estimate of $2.88 remains within this projected range.
The company has also provided fourth-quarter 2018 adjusted earnings per share outlook. It expects to report adjusted earnings from continuing operations in the range of 80-82 cents. The consensus mark of 81 cents falls within the predicted range.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
VGM Scores
Currently, Abbott has a strong Growth Score of A, though it is lagging a bit on the Momentum Score front with a B. Charting a somewhat similar path, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Abbott has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It has been about a month since the last earnings report for Abbott (ABT). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. It has been about a month since the last earnings report for Abbott (ABT). Abbott Beats on Q3 Earnings, Narrows '18 EPS View Abbott reported third-quarter 2018 adjusted earnings from continuing operations of 75 cents per share, a penny ahead of the Zacks Consensus Estimate. | It has been about a month since the last earnings report for Abbott (ABT). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Beats on Q3 Earnings, Narrows '18 EPS View Abbott reported third-quarter 2018 adjusted earnings from continuing operations of 75 cents per share, a penny ahead of the Zacks Consensus Estimate. | It has been about a month since the last earnings report for Abbott (ABT). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Beats on Q3 Earnings, Narrows '18 EPS View Abbott reported third-quarter 2018 adjusted earnings from continuing operations of 75 cents per share, a penny ahead of the Zacks Consensus Estimate. |
33163.0 | 2018-11-15 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABT | https://www.nasdaq.com/articles/5-dividend-growth-stocks-upside-analyst-targets-2018-11-15 | nan | nan | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention - and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets.
But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.
In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.
The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential:
Another consideration with dividend growth stocks is just how much the dividend is growing . We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another.
These five stocks are part of our full Dividend Aristocrats List . The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com .
Get the latest Zacks research report on TROW - FREE
Get the latest Zacks research report on ABT - FREE
Dividend Growth Stocks: 25 Aristocrats »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Get the latest Zacks research report on TROW - FREE Get the latest Zacks research report on ABT - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing . | Get the latest Zacks research report on TROW - FREE Get the latest Zacks research report on ABT - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. | Get the latest Zacks research report on TROW - FREE Get the latest Zacks research report on ABT - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. | Get the latest Zacks research report on TROW - FREE Get the latest Zacks research report on ABT - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. |
33164.0 | 2018-11-14 00:00:00 UTC | Abbott (ABT) Stock Moves -0.12%: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-stock-moves-0.12%3A-what-you-should-know-2018-11-14 | nan | nan | Abbott (ABT) closed at $69.41 in the latest trading session, marking a -0.12% move from the prior day. This change was narrower than the S&P 500's daily loss of 0.76%. At the same time, the Dow lost 0.82%, and the tech-heavy Nasdaq lost 0.9%.
Coming into today, shares of the maker of infant formula, medical devices and drugs had lost 2.06% in the past month. In that same time, the Medical sector lost 0.16%, while the S&P 500 lost 1.41%.
ABT will be looking to display strength as it nears its next earnings release, which is expected to be January 23, 2019. On that day, ABT is projected to report earnings of $0.81 per share, which would represent year-over-year growth of 9.46%. Meanwhile, our latest consensus estimate is calling for revenue of $7.79 billion, up 2.64% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $2.88 per share and revenue of $30.61 billion. These totals would mark changes of +15.2% and +11.74%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for ABT. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.04% higher. ABT is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, ABT is holding a Forward P/E ratio of 24.11. This valuation marks a discount compared to its industry's average Forward P/E of 25.7.
Meanwhile, ABT's PEG ratio is currently 2.07. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Products was holding an average PEG ratio of 2.29 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 92, putting it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed at $69.41 in the latest trading session, marking a -0.12% move from the prior day. ABT will be looking to display strength as it nears its next earnings release, which is expected to be January 23, 2019. On that day, ABT is projected to report earnings of $0.81 per share, which would represent year-over-year growth of 9.46%. | Abbott (ABT) closed at $69.41 in the latest trading session, marking a -0.12% move from the prior day. ABT will be looking to display strength as it nears its next earnings release, which is expected to be January 23, 2019. On that day, ABT is projected to report earnings of $0.81 per share, which would represent year-over-year growth of 9.46%. | Abbott (ABT) closed at $69.41 in the latest trading session, marking a -0.12% move from the prior day. ABT will be looking to display strength as it nears its next earnings release, which is expected to be January 23, 2019. On that day, ABT is projected to report earnings of $0.81 per share, which would represent year-over-year growth of 9.46%. | Abbott (ABT) closed at $69.41 in the latest trading session, marking a -0.12% move from the prior day. ABT will be looking to display strength as it nears its next earnings release, which is expected to be January 23, 2019. On that day, ABT is projected to report earnings of $0.81 per share, which would represent year-over-year growth of 9.46%. |
33165.0 | 2018-11-12 00:00:00 UTC | Surmodics' (SRDX) Q4 Earnings and Revenues Beat Estimates | ABT | https://www.nasdaq.com/articles/surmodics-srdx-q4-earnings-and-revenues-beat-estimates-2018-11-12 | nan | nan | Surmodics, Inc.SRDX reported adjusted earnings of 5 cents per share in fourth-quarter fiscal 2018, comparing favorably with the Zacks Consensus Estimate of a loss of a penny. Earnings however plummeted 72.2% on a year-over-year basis.
Revenues in the quarter increased 14.9% to $23 million, which beat the Zacks Consensus Estimate by 2.2%.
Over the past year, the Zacks Rank #3 (Hold) stock has skyrocketed 119.5% compared with the industry 's 4% rise. The current level is also higher than the S&P 500 index's increase of 7.5%.
FY18 at a Glance
Adjusted earnings per share on a full-year basis were 49 cents, also down 3.9% from fiscal 2017.
Fiscal 2018 revenues totaled $81.3 million, up 11.2% from fiscal 2017.
On a full-year basis, Medical Device revenues (74.4% of net revenues) grossed $60.5 million, up 12.1% from fiscal 2017. Surmodics IVD segment (25.6% of net revenues) raked in $20.8 million, up 8.9% from a year ago.
Surmodics, Inc. Price, Consensus and EPS Surprise
Surmodics, Inc. Price, Consensus and EPS Surprise | Surmodics, Inc. Quote
Q4 Details
Notably, Product sales in the quarter were $10.7 million, up 21.3% year over year. Per management, the uptick can be attributed to a substantial increase in balloon catheter unit volume as a result of recent customer product launches.
Royalty and license fee revenues totaled $10.3 million, up 11.9% from the year-ago quarter.
Research, development and other revenues were $2 million, up 0.1% year over year.
Segmental Analysis
Surmodics reports revenues under two segments - Medical Device and In Vitro Diagnostics (IVD).
Medical Device
In the reported quarter, sales rose 15.4% to $17 million. Per management, this includes $2.2 million from Surmodics' SurVeil agreement with Abbott Laboratories ABT .
However, the Medical Device business unit reported $2.1 million of operating loss in the fourth quarter.
IVD
In the quarter under review, sales increased 13.4% to $6.1 million. Per management, the segment saw strong growth in antigen and DNA slide sales in the quarter.
Operating income in the segment was $2.4 million in the reported quarter, marginally down from the year-ago quarter's level.
Operating Details
Surmodics registered Product costs of $4.1 million in the quarter, up 23.3% year over year.
The company had Research and development costs of $9.8 million, up 23.4%.
Selling, general and administrative expenditures were almost $12.6 million, up 29.6%.
Total operating costs and expenses in the quarter were $6.5 million, up 22.6%.
Total operating costs and expenses in the reported quarter were $25.5 million, up 29.7%.
Guidance
Surmodics expects fiscal 2019 revenues between $92 million and $97 million. The Zacks Consensus Estimate is pegged at $92.9 million, within the guided range.
Surmodics expects a loss of 7 cents per share to earnings of 23 cents per share for fiscal 2019. The Zacks Consensus Estimate for earnings per share is pinned at 3 cents, within the projected range.
Management expects Medical Device unit to contribute significantly to double-digit revenue growth in fiscal 2019.
Wrapping Up
Surmodics exited the fiscal 2018 on a solid note, with earnings and revenues topping estimates. The company continues to gain from its core Medical Device and IVD units. In fact, management expects notable contributions from them in fiscal 2019. Management also remains optimistic about agreement with MedTech behemoth Abbott for commercialization of its SurVeil drug-coated balloon. Surmodics also expects to complete the TRANSCEND clinical study enrollment by fiscal 2019.
On the flip side, significant year-over-year decline in Surmodics' earnings per share is worrisome. Surging operating expenses and operating losses in the Medical Device unit are likely to keep margins under pressure. The company's drug-coated balloons also face stiff competition in niche space.
Earnings of MedTech Majors at a Glance
Some better-ranked stocks from the broader Medical space that delivered robust results this earnings season are Intuitive Surgical ISRG and Stryker Corporation SYK . Notably, each of the stocks carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Intuitive Surgical reported third-quarter 2018 adjusted earnings per share of $2.83, which exceeded the Zacks Consensus Estimate of $2.65. Revenues totaled $920.9 million, which outpaced the consensus mark of $918.6 million.
Stryker posted third-quarter 2018 adjusted earnings per share of $1.69, which beat the Zacks Consensus Estimate by a penny. Operating margin was 17.8%, up 30 bps.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
Stryker Corporation (SYK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Per management, this includes $2.2 million from Surmodics' SurVeil agreement with Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. Surmodics, Inc.SRDX reported adjusted earnings of 5 cents per share in fourth-quarter fiscal 2018, comparing favorably with the Zacks Consensus Estimate of a loss of a penny. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. Per management, this includes $2.2 million from Surmodics' SurVeil agreement with Abbott Laboratories ABT . Surmodics, Inc. Price, Consensus and EPS Surprise Surmodics, Inc. Price, Consensus and EPS Surprise | Surmodics, Inc. Quote Q4 Details Notably, Product sales in the quarter were $10.7 million, up 21.3% year over year. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. Per management, this includes $2.2 million from Surmodics' SurVeil agreement with Abbott Laboratories ABT . Surmodics, Inc. Price, Consensus and EPS Surprise Surmodics, Inc. Price, Consensus and EPS Surprise | Surmodics, Inc. Quote Q4 Details Notably, Product sales in the quarter were $10.7 million, up 21.3% year over year. | Per management, this includes $2.2 million from Surmodics' SurVeil agreement with Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues in the quarter increased 14.9% to $23 million, which beat the Zacks Consensus Estimate by 2.2%. |
33166.0 | 2018-11-08 00:00:00 UTC | Abbott (ABT) Gains As Market Dips: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-gains-as-market-dips%3A-what-you-should-know-2018-11-08 | nan | nan | Abbott (ABT) closed the most recent trading day at $72.96, moving +0.63% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.25%. Elsewhere, the Dow gained 0.04%, while the tech-heavy Nasdaq lost 0.53%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had gained 5.19% over the past month. This has outpaced the Medical sector's loss of 1.06% and the S&P 500's loss of 2.35% in that time.
Wall Street will be looking for positivity from ABT as it approaches its next earnings report date. This is expected to be January 23, 2019. The company is expected to report EPS of $0.81, up 9.46% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $7.79 billion, up 2.64% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $2.88 per share and revenue of $30.61 billion. These totals would mark changes of +15.2% and +11.74%, respectively, from last year.
Any recent changes to analyst estimates for ABT should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.07% higher. ABT is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, ABT is currently trading at a Forward P/E ratio of 25.15. This valuation marks a discount compared to its industry's average Forward P/E of 25.86.
It is also worth noting that ABT currently has a PEG ratio of 2.16. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Products was holding an average PEG ratio of 2.4 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 101, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABT in the coming trading sessions, be sure to utilize Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed the most recent trading day at $72.96, moving +0.63% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its next earnings report date. Any recent changes to analyst estimates for ABT should also be noted by investors. | Abbott (ABT) closed the most recent trading day at $72.96, moving +0.63% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its next earnings report date. Any recent changes to analyst estimates for ABT should also be noted by investors. | Abbott (ABT) closed the most recent trading day at $72.96, moving +0.63% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its next earnings report date. Any recent changes to analyst estimates for ABT should also be noted by investors. | Abbott (ABT) closed the most recent trading day at $72.96, moving +0.63% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its next earnings report date. Any recent changes to analyst estimates for ABT should also be noted by investors. |
33167.0 | 2018-11-02 00:00:00 UTC | Abbott (ABT) Q3 Earnings Top Estimates | ABT | https://www.nasdaq.com/articles/abbott-abt-q3-earnings-top-estimates-2018-11-02 | nan | nan | Abbott (ABT) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.74 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 1.35%. A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would post earnings of $0.74 per share when it actually produced earnings of $0.75, delivering a surprise of 1.35%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $7.66 billion for the quarter ended December 2018, missing the Zacks Consensus Estimate by 0.12%. This compares to year-ago revenues of $7.59 billion. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Abbott shares have added about 22.9% since the beginning of the year versus the S&P 500's gain of 2.5%.
What's Next for Abbott?
While Abbott has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Abbott was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.66 on $7.66 billion in revenues for the coming quarter and $3.19 on $32.05 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.74 per share. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. | Abbott (ABT) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.74 per share. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $7.66 billion for the quarter ended December 2018, missing the Zacks Consensus Estimate by 0.12%. | Abbott (ABT) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.74 per share. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $7.66 billion for the quarter ended December 2018, missing the Zacks Consensus Estimate by 0.12%. | Abbott (ABT) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.74 per share. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. |
33168.0 | 2018-10-31 00:00:00 UTC | XLV, MDT, ABT, LLY: ETF Inflow Alert | ABT | https://www.nasdaq.com/articles/xlv-mdt-abt-lly-etf-inflow-alert-2018-10-31 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $146.2 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 202,165,324 to 203,815,324). Among the largest underlying components of XLV, in trading today Medtronic PLC (Symbol: MDT) is up about 1%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and Lilly (Eli) & Co (Symbol: LLY) is higher by about 1.6%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $89.33. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Medtronic PLC (Symbol: MDT) is up about 1%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and Lilly (Eli) & Co (Symbol: LLY) is higher by about 1.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $146.2 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 202,165,324 to 203,815,324). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Medtronic PLC (Symbol: MDT) is up about 1%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and Lilly (Eli) & Co (Symbol: LLY) is higher by about 1.6%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $89.33. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of XLV, in trading today Medtronic PLC (Symbol: MDT) is up about 1%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and Lilly (Eli) & Co (Symbol: LLY) is higher by about 1.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $146.2 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 202,165,324 to 203,815,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $89.33. | Among the largest underlying components of XLV, in trading today Medtronic PLC (Symbol: MDT) is up about 1%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and Lilly (Eli) & Co (Symbol: LLY) is higher by about 1.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $146.2 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 202,165,324 to 203,815,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $89.33. |
33169.0 | 2018-10-26 00:00:00 UTC | Health Care Sector Update for 10/26/2018: SGYP, RARE, JNJ, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-10262018-sgyp-rare-jnj-pfe-abt-mrk-amgn-2018-10-26 | nan | nan | Top Health Care Stocks:
JNJ: -0.48%
PFE: -0.71%
ABT: Flat
MRK: -0.51%
AMGN: -1.66%
Health care stocks were mixed in pre-bell trading Friday.
Stocks moving on news include:
(-) Synergy Pharmaceuticals ( SGYP ), which was slumping more than 67% after the company said its strategic review process has resulted in offers significantly below the market value and it does not believe it will get any offers much higher than what it has already seen. As a result, it believes it won't make a deal to be bought any time soon but it said it remains committed to the continued evaluation of all opportunities to enhance shareholder value, and there is no set timetable for completing this process.
(-) Ultragenyx Pharmaceutical ( RARE ) was declining by 14% after it said the phase 3 study of UX007 in patients with glucose transporter type-1 deficiency syndrome (Glut1 DS) did not achieve its primary endpoint, nor did it meet its key secondary endpoints.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: Flat Stocks moving on news include: (-) Synergy Pharmaceuticals ( SGYP ), which was slumping more than 67% after the company said its strategic review process has resulted in offers significantly below the market value and it does not believe it will get any offers much higher than what it has already seen. As a result, it believes it won't make a deal to be bought any time soon but it said it remains committed to the continued evaluation of all opportunities to enhance shareholder value, and there is no set timetable for completing this process. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT: Flat Top Health Care Stocks: | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT: Flat Stocks moving on news include: (-) Synergy Pharmaceuticals ( SGYP ), which was slumping more than 67% after the company said its strategic review process has resulted in offers significantly below the market value and it does not believe it will get any offers much higher than what it has already seen. | ABT: Flat Top Health Care Stocks: Health care stocks were mixed in pre-bell trading Friday. |
33170.0 | 2018-10-25 00:00:00 UTC | Abbott (ABT) Gains But Lags Market: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-gains-but-lags-market%3A-what-you-should-know-2018-10-25 | nan | nan | Abbott (ABT) closed at $67.68 in the latest trading session, marking a +1.11% move from the prior day. The stock lagged the S&P 500's daily gain of 1.86%. Meanwhile, the Dow gained 1.63%, and the Nasdaq, a tech-heavy index, added 2.95%.
Coming into today, shares of the maker of infant formula, medical devices and drugs had lost 8.1% in the past month. In that same time, the Medical sector lost 10.01%, while the S&P 500 lost 8.85%.
Investors will be hoping for strength from ABT as it approaches its next earnings release, which is expected to be January 23, 2019. On that day, ABT is projected to report earnings of $0.81 per share, which would represent year-over-year growth of 9.46%. Our most recent consensus estimate is calling for quarterly revenue of $7.79 billion, up 2.64% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $2.88 per share and revenue of $30.61 billion, which would represent changes of +15.2% and +11.74%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for ABT. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.03% higher. ABT currently has a Zacks Rank of #3 (Hold).
Digging into valuation, ABT currently has a Forward P/E ratio of 23.22. This valuation marks a discount compared to its industry's average Forward P/E of 25.
It is also worth noting that ABT currently has a PEG ratio of 1.99. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Products industry currently had an average PEG ratio of 2.27 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 151, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed at $67.68 in the latest trading session, marking a +1.11% move from the prior day. Investors will be hoping for strength from ABT as it approaches its next earnings release, which is expected to be January 23, 2019. On that day, ABT is projected to report earnings of $0.81 per share, which would represent year-over-year growth of 9.46%. | Abbott (ABT) closed at $67.68 in the latest trading session, marking a +1.11% move from the prior day. Investors will be hoping for strength from ABT as it approaches its next earnings release, which is expected to be January 23, 2019. On that day, ABT is projected to report earnings of $0.81 per share, which would represent year-over-year growth of 9.46%. | Abbott (ABT) closed at $67.68 in the latest trading session, marking a +1.11% move from the prior day. Investors will be hoping for strength from ABT as it approaches its next earnings release, which is expected to be January 23, 2019. On that day, ABT is projected to report earnings of $0.81 per share, which would represent year-over-year growth of 9.46%. | On that day, ABT is projected to report earnings of $0.81 per share, which would represent year-over-year growth of 9.46%. Abbott (ABT) closed at $67.68 in the latest trading session, marking a +1.11% move from the prior day. Investors will be hoping for strength from ABT as it approaches its next earnings release, which is expected to be January 23, 2019. |
33171.0 | 2018-10-22 00:00:00 UTC | Noteworthy ETF Inflows: IHI, MDT, ABT, TMO | ABT | https://www.nasdaq.com/articles/noteworthy-etf-inflows-ihi-mdt-abt-tmo-2018-10-22 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $197.5 million dollar inflow -- that's a 7.8% increase week over week in outstanding units (from 12,250,000 to 13,200,000). Among the largest underlying components of IHI, in trading today Medtronic PLC (Symbol: MDT) is off about 0.9%, Abbott Laboratories (Symbol: ABT) is down about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 1.7%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average:
Looking at the chart above, IHI's low point in its 52 week range is $170.272 per share, with $228.902 as the 52 week high point - that compares with a last trade of $206.05. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Medtronic PLC (Symbol: MDT) is off about 0.9%, Abbott Laboratories (Symbol: ABT) is down about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 1.7%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $170.272 per share, with $228.902 as the 52 week high point - that compares with a last trade of $206.05. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IHI, in trading today Medtronic PLC (Symbol: MDT) is off about 0.9%, Abbott Laboratories (Symbol: ABT) is down about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 1.7%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $170.272 per share, with $228.902 as the 52 week high point - that compares with a last trade of $206.05. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Medtronic PLC (Symbol: MDT) is off about 0.9%, Abbott Laboratories (Symbol: ABT) is down about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $197.5 million dollar inflow -- that's a 7.8% increase week over week in outstanding units (from 12,250,000 to 13,200,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $170.272 per share, with $228.902 as the 52 week high point - that compares with a last trade of $206.05. | Among the largest underlying components of IHI, in trading today Medtronic PLC (Symbol: MDT) is off about 0.9%, Abbott Laboratories (Symbol: ABT) is down about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $197.5 million dollar inflow -- that's a 7.8% increase week over week in outstanding units (from 12,250,000 to 13,200,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $170.272 per share, with $228.902 as the 52 week high point - that compares with a last trade of $206.05. |
33172.0 | 2018-10-19 00:00:00 UTC | Analysts Expect IEHS Will Reach $32 | ABT | https://www.nasdaq.com/articles/analysts-expect-iehs-will-reach-32-2018-10-19 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved U.S. Healthcare Staples ETF (Symbol: IEHS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $31.60 per unit.
With IEHS trading at a recent price near $28.71 per unit, that means that analysts see 10.07% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IEHS's underlying holdings with notable upside to their analyst target prices are Bruker Corp (Symbol: BRKR), PRA Health Sciences Inc (Symbol: PRAH), and Abbott Laboratories (Symbol: ABT). Although BRKR has traded at a recent price of $31.44/share, the average analyst target is 11.32% higher at $35.00/share. Similarly, PRAH has 11.05% upside from the recent share price of $102.26 if the average analyst target price of $113.56/share is reached, and analysts on average are expecting ABT to reach a target price of $75.56/share, which is 10.89% above the recent price of $68.14. Below is a twelve month price history chart comparing the stock performance of BRKR, PRAH, and ABT:
Combined, BRKR, PRAH, and ABT represent 5.27% of the iShares Evolved U.S. Healthcare Staples ETF. Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a twelve month price history chart comparing the stock performance of BRKR, PRAH, and ABT: Combined, BRKR, PRAH, and ABT represent 5.27% of the iShares Evolved U.S. Healthcare Staples ETF. Three of IEHS's underlying holdings with notable upside to their analyst target prices are Bruker Corp (Symbol: BRKR), PRA Health Sciences Inc (Symbol: PRAH), and Abbott Laboratories (Symbol: ABT). Similarly, PRAH has 11.05% upside from the recent share price of $102.26 if the average analyst target price of $113.56/share is reached, and analysts on average are expecting ABT to reach a target price of $75.56/share, which is 10.89% above the recent price of $68.14. | Similarly, PRAH has 11.05% upside from the recent share price of $102.26 if the average analyst target price of $113.56/share is reached, and analysts on average are expecting ABT to reach a target price of $75.56/share, which is 10.89% above the recent price of $68.14. Below is a twelve month price history chart comparing the stock performance of BRKR, PRAH, and ABT: Combined, BRKR, PRAH, and ABT represent 5.27% of the iShares Evolved U.S. Healthcare Staples ETF. Three of IEHS's underlying holdings with notable upside to their analyst target prices are Bruker Corp (Symbol: BRKR), PRA Health Sciences Inc (Symbol: PRAH), and Abbott Laboratories (Symbol: ABT). | Similarly, PRAH has 11.05% upside from the recent share price of $102.26 if the average analyst target price of $113.56/share is reached, and analysts on average are expecting ABT to reach a target price of $75.56/share, which is 10.89% above the recent price of $68.14. Three of IEHS's underlying holdings with notable upside to their analyst target prices are Bruker Corp (Symbol: BRKR), PRA Health Sciences Inc (Symbol: PRAH), and Abbott Laboratories (Symbol: ABT). Below is a twelve month price history chart comparing the stock performance of BRKR, PRAH, and ABT: Combined, BRKR, PRAH, and ABT represent 5.27% of the iShares Evolved U.S. Healthcare Staples ETF. | Below is a twelve month price history chart comparing the stock performance of BRKR, PRAH, and ABT: Combined, BRKR, PRAH, and ABT represent 5.27% of the iShares Evolved U.S. Healthcare Staples ETF. Three of IEHS's underlying holdings with notable upside to their analyst target prices are Bruker Corp (Symbol: BRKR), PRA Health Sciences Inc (Symbol: PRAH), and Abbott Laboratories (Symbol: ABT). Similarly, PRAH has 11.05% upside from the recent share price of $102.26 if the average analyst target price of $113.56/share is reached, and analysts on average are expecting ABT to reach a target price of $75.56/share, which is 10.89% above the recent price of $68.14. |
33173.0 | 2018-10-18 00:00:00 UTC | DexCom Launches CLARITY Mobile App, Strengthens CGM Profile | ABT | https://www.nasdaq.com/articles/dexcom-launches-clarity-mobile-app-strengthens-cgm-profile-2018-10-18 | nan | nan | DexCom, Inc.DXCM recently launched its mobile application, CLARITY. Notably, Notably, this smart app is a cloud-based diabetes management software that simplifies CGM (Continuous Glucose Monitoring) data reporting and facilitates confidential sharing of data between physicians and their patients. In fact, patients can now view the same on their phones.
Clearly, this latest development is likely to fortify DexCom's foothold in the CGM space.
About DexCom's CGM Profile
Based in California, this medical device company is known for designing, developing and commercializing CGM systems.
Currently, DexCom's FDA-cleared CGM system - the DexCom G4 Platinum - is driving its top line significantly. Its inbuilt features like the G4 Platinum make the DexCom G4 Platinum the most innovative CGM system in the market. Last year, DexCom announced the FDA approval of the Dexcom G5 mobile app for Android devices.
Diabetes Care Adopts Cloud-Based Services
Smart apps have made self-management and continuous monitoring of diabetes affordable through the use of cloud-based applications. These applications can show real-time data on patients' blood glucose levels on these apps.
For instance, consumer fitness brand Fitbit FIT entered the space by a $6-million investment in Sano.
Moreover, MedTech giant Medtronic MDT collaborated with IBM to develop Sugar.IQ - a cognitive mobile personal assistant app. This application intends to provide real-time actionable glucose insights and predictions for patients with diabetes.
Also, MedTech behemoth Abbott ABT is dedicated to developing innovative products that make glucose testing easier and more accurate. Abbott's products like Freestyle Libre, Freestyle Navigator II, Freestyle Lite, FreestyleInsulinx can be used by patients for personal glucose monitoring.
Market Prospects
In the United States, about 1.4 million new cases of diabetes are diagnosed every year.
Going by an article of Allied Market Research, the global CGM systems market is expected to see a CAGR of 22.9% between 2018 and 2024.
It also predicts that, theglobal marketfor artificial intelligence in diabetes management is expected to witness a CAGR of 50.7% between 2017 and 2023. Thus, DexCom's latest move has been a well-timed one.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Fitbit, Inc. (FIT): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
DexCom, Inc. (DXCM): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also, MedTech behemoth Abbott ABT is dedicated to developing innovative products that make glucose testing easier and more accurate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Fitbit, Inc. (FIT): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, MedTech giant Medtronic MDT collaborated with IBM to develop Sugar.IQ - a cognitive mobile personal assistant app. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Fitbit, Inc. (FIT): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Also, MedTech behemoth Abbott ABT is dedicated to developing innovative products that make glucose testing easier and more accurate. Notably, Notably, this smart app is a cloud-based diabetes management software that simplifies CGM (Continuous Glucose Monitoring) data reporting and facilitates confidential sharing of data between physicians and their patients. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Fitbit, Inc. (FIT): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Also, MedTech behemoth Abbott ABT is dedicated to developing innovative products that make glucose testing easier and more accurate. Notably, Notably, this smart app is a cloud-based diabetes management software that simplifies CGM (Continuous Glucose Monitoring) data reporting and facilitates confidential sharing of data between physicians and their patients. | Also, MedTech behemoth Abbott ABT is dedicated to developing innovative products that make glucose testing easier and more accurate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Fitbit, Inc. (FIT): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Clearly, this latest development is likely to fortify DexCom's foothold in the CGM space. |
33174.0 | 2018-10-18 00:00:00 UTC | Mid-Morning Market Update: Markets Open Lower; Philip Morris Profit Beats Estimates | ABT | https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-philip-morris-profit-beats-estimates-2018-10 | nan | nan | Following the market opening Thursday, the Dow traded down 0.48 percent to 25,582.53 while the NASDAQ declined 0.76 percent to 7,584.60. The S&P also fell, dropping 0.48 percent to 2,795.79.
Leading and Lagging Sectors
Thursday morning, the consumer staples shares rose by 0.38 percent. Meanwhile, top gainers in the sector included Philip Morris International Inc. (NYSE: PM ) up 5 percent, and Natural Grocers by Vitamin Cottage Inc (NYSE: NGVC ) up 4 percent.
In trading on Thursday, communication services shares fell 1.34 percent.
Top Headline
Philip Morris International Inc. (NYSE: ABT ) reported upbeat earnings for its third quarter.
Philip Morris posted quarterly earnings of $1.44 per share on revenue of $7.5 billion. However, analysts were expecting earnings of $1.28 per share on sales of $7.17 billion. Philip Morris reaffirmed its FY18 earnings guidance of $4.97 to $5.02 per share.
Equities Trading UP
Endocyte, Inc. (NASDAQ: ECYT ) shares shot up 51 percent to $23.435 after the company agreed to be acquired by Novartis AG (NYSE: NVS ) for $24 per share.
Shares of Proteostasis Therapeutics, Inc. (NASDAQ: PTI ) got a boost, shooting up 330 percent to $8.13 following positive preliminary results from its proprietary doublet in cystic fibrosis patients. PTI-801 and PTI-808 achieved statistical significance on all endpoints.
Yulong Eco-Materials Limited (NASDAQ: YECO ) shares were also up, gaining 38 percent to $14.0500 after climbing 571.05 percent on Wednesday.
Equities Trading DOWN
Insteel Industries, Inc. (NASDAQ: IIIN ) shares dropped 13 percent to $29.335 after the company reported downbeat Q4 results.
Shares of Texas Capital Bancshares, Inc. (NASDAQ: TCBI ) were down 11 percent to $68.80 after reporting a third-quarter earnings miss.
Textron Inc. (NYSE: TXT ) was down, falling around 8 percent to $59.78 after the company reported downbeat earnings for its third quarter and narrowed its FY18 adjusted earnings guidance.
Commodities
In commodity news, oil traded down 1.43 percent to $68.75 while gold traded up 0.11 percent to $1,228.70.
Silver traded down 0.23 percent Thursday to $14.63, while copper fell 1.39 to $2.7395.
Eurozone
European shares were mixed today. The eurozone's STOXX 600 rose 0.12 percent, the Spanish Ibex Index fell 0.59 percent, while Italy's FTSE MIB Index slipped 0.63 percent. Meanwhile the German DAX dropped 0.03 percent, and the French CAC 40 rose 0.42 percent while U.K. shares rose 0.03 percent.
Economics
Initial jobless claims slipped 5,000 to 210,000 in the latest week. However, economists were expecting a reading of 214,000.
The Philadelphia Fed manufacturing index dropped to 22.2 for October, versus a reading of 22.9 in September. Economists projected a reading of 19.7.
The index of leading economic indicators rose 0.5 percent for September.
The Energy Information Administration's weekly report on natural gas stocks in underground storage is schedule for release at 10:30 a.m. ET.
US Federal Reserve Bank Vice Chairman Randal K. Quarles will speak in New York, NY at 12:15 p.m. ET.
Data on money supply for the recent week will be released at 4:30 p.m. ET.
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Profit with More New & Research . Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Headline Philip Morris International Inc. (NYSE: ABT ) reported upbeat earnings for its third quarter. Shares of Proteostasis Therapeutics, Inc. (NASDAQ: PTI ) got a boost, shooting up 330 percent to $8.13 following positive preliminary results from its proprietary doublet in cystic fibrosis patients. Equities Trading DOWN Insteel Industries, Inc. (NASDAQ: IIIN ) shares dropped 13 percent to $29.335 after the company reported downbeat Q4 results. | Top Headline Philip Morris International Inc. (NYSE: ABT ) reported upbeat earnings for its third quarter. Meanwhile, top gainers in the sector included Philip Morris International Inc. (NYSE: PM ) up 5 percent, and Natural Grocers by Vitamin Cottage Inc (NYSE: NGVC ) up 4 percent. Equities Trading DOWN Insteel Industries, Inc. (NASDAQ: IIIN ) shares dropped 13 percent to $29.335 after the company reported downbeat Q4 results. | Top Headline Philip Morris International Inc. (NYSE: ABT ) reported upbeat earnings for its third quarter. Yulong Eco-Materials Limited (NASDAQ: YECO ) shares were also up, gaining 38 percent to $14.0500 after climbing 571.05 percent on Wednesday. The eurozone's STOXX 600 rose 0.12 percent, the Spanish Ibex Index fell 0.59 percent, while Italy's FTSE MIB Index slipped 0.63 percent. | Top Headline Philip Morris International Inc. (NYSE: ABT ) reported upbeat earnings for its third quarter. Equities Trading DOWN Insteel Industries, Inc. (NASDAQ: IIIN ) shares dropped 13 percent to $29.335 after the company reported downbeat Q4 results. Textron Inc. (NYSE: TXT ) was down, falling around 8 percent to $59.78 after the company reported downbeat earnings for its third quarter and narrowed its FY18 adjusted earnings guidance. |
33175.0 | 2018-10-17 00:00:00 UTC | Mid-Day Market Update: Crude Oil Down 2.7%; vTv Therapeutics Shares Spike Higher | ABT | https://www.nasdaq.com/articles/mid-day-market-update-crude-oil-down-27-vtv-therapeutics-shares-spike-higher-2018-10-17 | nan | nan | Midway through trading Wednesday, the Dow traded down 0.77 percent to 25,598.98 while the NASDAQ declined 0.51 percent to 7,606.85. The S&P also fell, dropping 0.57 percent to 2,793.91.
Leading and Lagging Sectors
On Wednesday, the communication services shares rose by 0.05 percent. Meanwhile, top gainers in the sector included QuinStreet, Inc. (NASDAQ: QNST ) up 8 percent, and Netflix, Inc. (NASDAQ: NFLX ) up 6 percent.
In trading on Wednesday, consumer discretionary shares fell 1.16 percent.
Top Headline
Abbott Laboratories (NYSE: ABT ) reported in-line earnings for its third quarter.
Abbott posted quarterly earnings of $0.75 per share on revenue of $7.66 billion. However, analysts were expecting earnings of $0.75 per share on sales of $7.65 billion. Abbott narrowed its FY18 adjusted earnings guidance from $2.85-$2.91 per share to $2.87-$2.89 per share.
Equities Trading UP
vTv Therapeutics Inc (NASDAQ: VTVT ) shares shot up 41 percent to $4.021. The company is engaged in the research and development of treatments for Alzheimer's disease and diabetes. This week, it announced the delivery of an oral presentation at the Clinical Trials on Alzheimer's Disease in Barcelona, Spain later this month. The oral presentation intends to detail the results from the Phase 3 study of azeliragon in patients with mild Alzheimer's. Additionally, a subgroup analysis from the STEADFAST trial will be presented, to discuss the missing link between diabetes and dementia.
Shares of Vicor Corporation (NASDAQ: VICR ) got a boost, shooting up 19 percent to $45.64 following Q3 earnings. The company reported a strong increase in both EPS and sales from last year.
Yulong Eco-Materials Limited (NASDAQ: YECO ) shares were also up, gaining 163 percent to $4.00 after the company earlier announced it is in the process of a sale and spin off of its China businesses in order to focus on its newly-acquired Millennium Sapphire business.
Equities Trading DOWN
Revolution Lighting Technologies, Inc. (NASDAQ: RVLT ) shares dropped 36 percent to $1.64 after the company cut FY18 and Q3 guidance estimates and said it does not believe it is in the best interest of shareholders to continue as a publicly traded company, proposed to take company private.
Shares of Rexahn Pharmaceuticals, Inc. (NYSE: RNN ) were down 29 percent to $1.18 after the company earlier reported a $7.5 million registered direct offering.
Smart Sand, Inc. (NASDAQ: SND ) was down, falling around 19 percent to $3.09. Jefferies downgraded Smart Sand from Hold to Underperform.
Commodities
In commodity news, oil traded down 2.7 percent to $69.98 while gold traded down 0.09 percent to $1,229.90.
Silver traded down 0.18 percent Wednesday to $14.675, while copper fell 0.49 to $2.766.
Eurozone
European shares were lower today. The eurozone's STOXX 600 dropped 0.62 percent, the Spanish Ibex Index fell 0.98 percent, while Italy's FTSE MIB Index slipped 1.42 percent. Meanwhile the German DAX dropped 0.76 percent, and the French CAC 40 fell 0.86 percent while U.K. shares fell 0.36 percent.
Economics
U.S. housing starts dropped 5.3 percent to an annual rate of 1.201 million in September. However, economists expected a 1.22 million pace.
Domestic crude supplies climbed 6.49 million barrels for the week ended October 12, the Energy Information Administration reported. However, analysts expected a gain of 1.07 million barrels. Gasoline stockpiles slipped 2.02 million barrels, while distillate stockpiles fell 827,000 barrels last week.
The Federal Open Market Committee will issue minutes of its latest meeting at 2:00 p.m. ET.
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Get insight into trading platforms. Compare the best online stock brokerages.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Headline Abbott Laboratories (NYSE: ABT ) reported in-line earnings for its third quarter. This week, it announced the delivery of an oral presentation at the Clinical Trials on Alzheimer's Disease in Barcelona, Spain later this month. Shares of Rexahn Pharmaceuticals, Inc. (NYSE: RNN ) were down 29 percent to $1.18 after the company earlier reported a $7.5 million registered direct offering. | Top Headline Abbott Laboratories (NYSE: ABT ) reported in-line earnings for its third quarter. Meanwhile the German DAX dropped 0.76 percent, and the French CAC 40 fell 0.86 percent while U.K. shares fell 0.36 percent. Gasoline stockpiles slipped 2.02 million barrels, while distillate stockpiles fell 827,000 barrels last week. | Top Headline Abbott Laboratories (NYSE: ABT ) reported in-line earnings for its third quarter. Equities Trading DOWN Revolution Lighting Technologies, Inc. (NASDAQ: RVLT ) shares dropped 36 percent to $1.64 after the company cut FY18 and Q3 guidance estimates and said it does not believe it is in the best interest of shareholders to continue as a publicly traded company, proposed to take company private. The eurozone's STOXX 600 dropped 0.62 percent, the Spanish Ibex Index fell 0.98 percent, while Italy's FTSE MIB Index slipped 1.42 percent. | Top Headline Abbott Laboratories (NYSE: ABT ) reported in-line earnings for its third quarter. The S&P also fell, dropping 0.57 percent to 2,793.91. This week, it announced the delivery of an oral presentation at the Clinical Trials on Alzheimer's Disease in Barcelona, Spain later this month. |
33176.0 | 2018-10-17 00:00:00 UTC | Earnings & Economic Data Deluge | ABT | https://www.nasdaq.com/articles/earnings-economic-data-deluge-2018-10-17 | nan | nan | As investors welcome mostly positive Q3 earnings results so far early on in the new reporting season, we also get new information on the housing market this morning, from a couple different sources: Housing Starts/Building Permits and new Mortgage Applications. All these figures reflect some strain within the all-important residential real estate sector.
Starting with Housing Starts , we saw September results fall 50 basis points lower than expected to -5.3%, or a tally of 1.201 million seasonally adjusted annualized units. This is lower by approximately 7000 from the consensus estimate. Revisions to the month of August were also lower, from 1.28 million originally reported to 1.268 million this morning - or down to +7.1% from the initial 9.2%.
Building Permits were down slightly in September from August's 1.25 million to 1.241 million. Looking at both this number, which are a forward indicator toward future Starts, and the actual Starts from last month, we may assume there are some negative affects from hurricane season, particularly Hurricane Florence on the Carolina coast. These month-over-month drops, if explained solely by the storms, are more than enough for us to continue out longer-term narrative of an overall strong housing market.
However, Mortgage Applications dropped again last week, this time by 7.1%. Banks have been seeing weakness in new mortgage loans (despite strong Q3 earnings results thus far from most of the big Wall Street banks) of late, and every step down the ladder further exacerbates this. With interest rates at the Fed continuing to rise gradually, we are seeing costs for new mortgages rising, now to an average of 5.1%, another 50 basis points higher than the previous read. This is the highest we've seen mortgage rates since February of 2011.
Speaking of interest rates, minutes from the last Federal Open Market Committee meeting , where participants agreed to raise interest rates another 25 basis points to a range of 2.00-2.25% last month, will be released at 2pm ET today. Analysts will be parsing language used in the report to determine future interest rate moves by the Fed, although it's already baked in the cake - mostly - that December will bring yet another quarter-point hike.
Switching to earnings, United Continental UAL missed estimates on the bottom line while beating slightly on the top: $3.06 per share versus $3.09 expected (and $3.23 per share in the year-ago quarter) was offset by an even $11.0 billion in sales for the quarter topping the $10.9 billion estimated and the $9.88 billion the airline major brought in for Q3 2017. Yet upward guidance has prodded the stock forward, up 5.5% in today's pre-market. For more on UAL's earnings, click here.
Abbott Labs ABT posted a slight beat on both top and bottom lines in its Q3 earnings report this morning, with 75 cents per share a penny above expectations, with a slight beat on revenues to $7.66 billion in the quarter, and well above last year's Q3 top line of $6.83 billion. But with markets trading mixed in today's early session, we see Abbott shares down slightly following the report. The company's stock is still up about 24% year to date. For more on ABT's earnings, click here.
And, lest we think we've already heard from all the big banks this earnings season, U.S. Bancorp USB comes out with its own positive earnings and revenue surprises ahead of the opening bell today. Earnings per share of $1.06 topped expectations by 2 cents, while revenues brought $5.7 billion in the quarter, ahead of the $5.6 billion in the Zacks consensus. Shares are trading even ahead of the bell. For more USB's earnings, click here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
United Continental Holdings, Inc. (UAL): Free Stock Analysis Report
U.S. Bancorp (USB): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ABT posted a slight beat on both top and bottom lines in its Q3 earnings report this morning, with 75 cents per share a penny above expectations, with a slight beat on revenues to $7.66 billion in the quarter, and well above last year's Q3 top line of $6.83 billion. For more on ABT's earnings, click here. Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. | Abbott Labs ABT posted a slight beat on both top and bottom lines in its Q3 earnings report this morning, with 75 cents per share a penny above expectations, with a slight beat on revenues to $7.66 billion in the quarter, and well above last year's Q3 top line of $6.83 billion. Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. For more on ABT's earnings, click here. | Abbott Labs ABT posted a slight beat on both top and bottom lines in its Q3 earnings report this morning, with 75 cents per share a penny above expectations, with a slight beat on revenues to $7.66 billion in the quarter, and well above last year's Q3 top line of $6.83 billion. Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. For more on ABT's earnings, click here. | Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT posted a slight beat on both top and bottom lines in its Q3 earnings report this morning, with 75 cents per share a penny above expectations, with a slight beat on revenues to $7.66 billion in the quarter, and well above last year's Q3 top line of $6.83 billion. For more on ABT's earnings, click here. |
33177.0 | 2018-10-17 00:00:00 UTC | Mid-Morning Market Update: Markets Open Lower; Abbott Laboratories Posts In-Line Q3 Earnings | ABT | https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-abbott-laboratories-posts-line-q3-earnings | nan | nan | Following the market opening Wednesday, the Dow traded down 0.87 percent to 25,574.66 while the NASDAQ declined 0.57 percent to 7,602.03. The S&P also fell, dropping 0.57 percent to 2,793.96.
Leading and Lagging Sectors
Wednesday morning, the communication services shares slipped by just 0.1 percent. Meanwhile, top gainers in the sector included QuinStreet, Inc. (NASDAQ: QNST ) up 8 percent, and Netflix, Inc. (NASDAQ: NFLX ) up 6 percent.
In trading on Wednesday, consumer discretionary shares fell 1.2 percent.
Top Headline
Abbott Laboratories (NYSE: ABT ) reported in-line earnings for its third quarter.
Abbott posted quarterly earnings of $0.75 per share on revenue of $7.66 billion. However, analysts were expecting earnings of $0.75 per share on sales of $7.65 billion. Abbott narrowed its FY18 adjusted earnings guidance from $2.85-$2.91 per share to $2.87-$2.89 per share.
Equities Trading UP
vTv Therapeutics Inc (NASDAQ: VTVT ) shares shot up 35 percent to $3.83. The company is engaged in the research and development of treatments for Alzheimer's disease and diabetes. This week, it announced the delivery of an oral presentation at the Clinical Trials on Alzheimer's Disease in Barcelona, Spain later this month. The oral presentation intends to detail the results from the Phase 3 study of azeliragon in patients with mild Alzheimer's. Additionally, a subgroup analysis from the STEADFAST trial will be presented, to discuss the missing link between diabetes and dementia.
Shares of Vicor Corporation (NASDAQ: VICR ) got a boost, shooting up 15 percent to $43.85 following Q3 earnings. The company reported a strong increase in both EPS and sales from last year.
Oragenics, Inc. (NYSE: OGEN ) shares were also up, gaining 9 percent to $1.238 after the company received clearance from The Belgian Health Authority to enroll patients into its Phase 2 clinical trial of AG013 for oral mucositis.
Equities Trading DOWN
Revolution Lighting Technologies, Inc. (NASDAQ: RVLT ) shares dropped 37 percent to $1.6201 after the company lowered its Q3 and FY18 guidance.
Shares of Blink Charging Co. (NASDAQ: BLNK ) were down 23 percent to $2.75 after rising 62.56 percent on Tuesday.
Smart Sand, Inc. (NASDAQ: SND ) was down, falling around 20 percent to $3.06. Jefferies downgraded Smart Sand from Hold to Underperform.
Commodities
In commodity news, oil traded down 0.86 percent to $71.30 while gold traded down 0.10 percent to $1,229.80.
Silver traded down 0.01 percent Wednesday to $14.70, while copper rose 0.22 to $2.7855.
Eurozone
European shares were lower today. The eurozone's STOXX 600 dropped 0.24 percent, the Spanish Ibex Index fell 0.63 percent, while Italy's FTSE MIB Index slipped 0.65 percent. Meanwhile the German DAX dropped 0.55 percent, and the French CAC 40 fell 0.29 percent while U.K. shares rose 0.19 percent.
Economics
U.S. housing starts dropped 5.3 percent to an annual rate of 1.201 million in September. However, economists expected a 1.22 million pace.
The Energy Information Administration's weekly report on petroleum inventories in the U.S. is schedule for release at 10:30 a.m. ET.
US Federal Reserve Bank Governor Lael Brainard is set to speak in Boston, MA at 12:10 p.m. ET.
The Federal Open Market Committee will issue minutes of its latest meeting at 2:00 p.m. ET.
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Get insight into trading platforms. Compare the best online stock brokerages.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Headline Abbott Laboratories (NYSE: ABT ) reported in-line earnings for its third quarter. This week, it announced the delivery of an oral presentation at the Clinical Trials on Alzheimer's Disease in Barcelona, Spain later this month. Oragenics, Inc. (NYSE: OGEN ) shares were also up, gaining 9 percent to $1.238 after the company received clearance from The Belgian Health Authority to enroll patients into its Phase 2 clinical trial of AG013 for oral mucositis. | Top Headline Abbott Laboratories (NYSE: ABT ) reported in-line earnings for its third quarter. This week, it announced the delivery of an oral presentation at the Clinical Trials on Alzheimer's Disease in Barcelona, Spain later this month. Meanwhile the German DAX dropped 0.55 percent, and the French CAC 40 fell 0.29 percent while U.K. shares rose 0.19 percent. | Top Headline Abbott Laboratories (NYSE: ABT ) reported in-line earnings for its third quarter. Following the market opening Wednesday, the Dow traded down 0.87 percent to 25,574.66 while the NASDAQ declined 0.57 percent to 7,602.03. The eurozone's STOXX 600 dropped 0.24 percent, the Spanish Ibex Index fell 0.63 percent, while Italy's FTSE MIB Index slipped 0.65 percent. | Top Headline Abbott Laboratories (NYSE: ABT ) reported in-line earnings for its third quarter. Following the market opening Wednesday, the Dow traded down 0.87 percent to 25,574.66 while the NASDAQ declined 0.57 percent to 7,602.03. However, analysts were expecting earnings of $0.75 per share on sales of $7.65 billion. |
33178.0 | 2018-10-17 00:00:00 UTC | Health Care Sector Update for 10/17/2018: VTVT, OGEN, FMS, JNJ, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-10172018-vtvt-ogen-fms-jnj-pfe-abt-mrk-amgn-2018-10-17 | nan | nan | Top Health Care Stocks:
JNJ: Flat
PFE: -0.10%
ABT: -1.82%
MRK: -0.14%
AMGN: Flat
Early Wednesday trading saw mixed trading in health care stocks.
Stocks moving on news include:
(+) vTv Therapeutics ( VTVT ), up by 47% after it said it will detail the results from the phase 3 STEADFAST study of azeliragon in patients with mild Alzheimer's disease on Oct. 26 at the Alzheimer's Disease (CTAD) Conference in Barcelona, Spain.
(+) Oragenics ( OGEN ) was 24% higher after it received clearance from the Belgian Health Authority to enroll patients residing in Belgium into its phase 2 clinical trial of AG013, a live biotherapeutic product for the potential prevention and treatment of oral mucositis.
(-) Fresenius Medical Care ( FMS ) was down 18% as the dialysis equipment provider reported Q3 adjusted income of EUR310 million ($363.4 million), down from EUR314 million in the same period a year ago.
(-) Abbott ( ABT ) was declining over 2% as it reported Q3 adjusted earnings of $0.75 per diluted share, up from $0.66 in the same period a year ago. That was in line with the estimate of $0.75 from analysts polled by Capital IQ.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (-) Abbott ( ABT ) was declining over 2% as it reported Q3 adjusted earnings of $0.75 per diluted share, up from $0.66 in the same period a year ago. Stocks moving on news include: (+) vTv Therapeutics ( VTVT ), up by 47% after it said it will detail the results from the phase 3 STEADFAST study of azeliragon in patients with mild Alzheimer's disease on Oct. 26 at the Alzheimer's Disease (CTAD) Conference in Barcelona, Spain. (+) Oragenics ( OGEN ) was 24% higher after it received clearance from the Belgian Health Authority to enroll patients residing in Belgium into its phase 2 clinical trial of AG013, a live biotherapeutic product for the potential prevention and treatment of oral mucositis. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (-) Abbott ( ABT ) was declining over 2% as it reported Q3 adjusted earnings of $0.75 per diluted share, up from $0.66 in the same period a year ago. (-) Fresenius Medical Care ( FMS ) was down 18% as the dialysis equipment provider reported Q3 adjusted income of EUR310 million ($363.4 million), down from EUR314 million in the same period a year ago. | (-) Abbott ( ABT ) was declining over 2% as it reported Q3 adjusted earnings of $0.75 per diluted share, up from $0.66 in the same period a year ago. Stocks moving on news include: (+) vTv Therapeutics ( VTVT ), up by 47% after it said it will detail the results from the phase 3 STEADFAST study of azeliragon in patients with mild Alzheimer's disease on Oct. 26 at the Alzheimer's Disease (CTAD) Conference in Barcelona, Spain. (-) Fresenius Medical Care ( FMS ) was down 18% as the dialysis equipment provider reported Q3 adjusted income of EUR310 million ($363.4 million), down from EUR314 million in the same period a year ago. | (-) Abbott ( ABT ) was declining over 2% as it reported Q3 adjusted earnings of $0.75 per diluted share, up from $0.66 in the same period a year ago. Top Health Care Stocks: JNJ: Flat AMGN: Flat Early Wednesday trading saw mixed trading in health care stocks. |
33179.0 | 2018-10-17 00:00:00 UTC | Abbott (ABT) Q3 Earnings Top Estimates | ABT | https://www.nasdaq.com/articles/abbott-abt-q3-earnings-top-estimates-2018-10-17 | nan | nan | Abbott (ABT) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.66 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 1.35%. A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would post earnings of $0.71 per share when it actually produced earnings of $0.73, delivering a surprise of 2.82%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $7.66 billion for the quarter ended September 2018, missing the Zacks Consensus Estimate by 0.12%. This compares to year-ago revenues of $6.83 billion. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Abbott shares have added about 24.3% since the beginning of the year versus the S&P 500's gain of 5.1%.
What's Next for Abbott?
While Abbott has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Abbott was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.81 on $7.94 billion in revenues for the coming quarter and $2.88 on $30.75 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the top 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.74 per share. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. | Abbott (ABT) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.74 per share. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $7.66 billion for the quarter ended September 2018, missing the Zacks Consensus Estimate by 0.12%. | Abbott (ABT) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.74 per share. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $7.66 billion for the quarter ended September 2018, missing the Zacks Consensus Estimate by 0.12%. | Abbott (ABT) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.74 per share. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. While Abbott has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? |
33180.0 | 2018-10-17 00:00:00 UTC | Earnings Reaction History: Abbott Laboratories, 54.5% Follow-Through Indicator, 2.3% Sensitive | ABT | https://www.nasdaq.com/articles/earnings-reaction-history-abbott-laboratories-545-follow-through-indicator-23-sensitive | nan | nan | Expected Earnings Release: 10/17/2018, Premarket
Avg. Extended-Hours Dollar Volume: $2,799,494
Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in ABT indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close.
Last 12 Qtrs Positive Only Price Reactions
Percent of time added to extended-hours gains: 57.1%
Average next regular session additional gain: 1.2%
Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.2%.
Last 12 Qtrs Negative Only Price Reactions
Percent of time added to extended-hours losses: 50%
Average next regular session additional loss: 2.7%
Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 50.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close.
Data provided by the MT Pro service at MTNewswires.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 57.1% Average next regular session additional gain: 1.2% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.2%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 50% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 50.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $2,799,494 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 57.1% Average next regular session additional gain: 1.2% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.2%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 50% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 50.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $2,799,494 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 57.1% Average next regular session additional gain: 1.2% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.2%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 50% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 50.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $2,799,494 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Extended-Hours Dollar Volume: $2,799,494 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 57.1% Average next regular session additional gain: 1.2% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.2%. Historical earnings event related premarket and after-hours trading activity in ABT indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close. |
33181.0 | 2018-10-17 00:00:00 UTC | 5 Top Stock Trades for Thursday | ABT | https://www.nasdaq.com/articles/5-top-stock-trades-thursday-2018-10-17 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
For the most part, the stock market hung onto most of its gains following Tuesday's monstrous move. As we get into earnings seasons though, investors will have to fight against both market-wide volatility and giant moves in individual stocks.
10 Marijuana Stocks for the Canadian 'Pot Rush'
With that in mind, here are our top stock trades for Thursday.
Netflix
The initial surge in Netflix (NASDAQ: NFLX ) stock in after-hours trading was impressive thanks to earnings . However, Wednesday's inability to hold onto those big gains was discouraging.
The move sort leaves Netflix floating around a bit aimlessly. On the one hand, it's above several major moving averages, but I would have much preferred it over this $380 to $385 level. A strong close would have done a lot for the market bulls' confidence too. Over this mark would allow a gap fill up toward $400 and pave the way to retesting its prior highs.
I'd be cautious on NFLX, especially if it takes out Wednesday's lows and falls below the 50-day. Over the 100-day moving average and perhaps Netflix can make a run at Tuesday's highs.
S&P 500 ETF
After looking like it was going to give back a bunch of Tuesday's gains, the SPDR S&P 500 ETF (NYSEARCA: SPY ) rallied back to flat Wednesday afternoon. Initially the ETF pulled back right off the 100-day moving average, a textbook move in this type of market. However, the $277.50 prior breakout level held as support.
So long as the SPY is above this mark and the 200-day moving average, then I am staying cautiously optimistic. A break below these marks and the recent lows are likely back on the table. If SPY can clear the 100-day, the 50-day is up next.
15 Tech Stocks With Hidden Potential
For short-term traders who bought over the last few days, booking some profits into the current range and up toward $282.50 might not be a bad idea. It's a different story for long-term investors who bought on the recent dip.
Lam Research
Lam Research (NASDAQ: LRCX ) is a big "tell" for others in the semiconductor space. The company beat on estimates and had a good quarter, but the reaction hasn't been that great.
The stock is barely positive on the day despite sporting after-hour gains of more than 10%. Like NFLX, Lam Research is sort of a mixed bag. On the one hand, it's above key downtrend resistance and the 20-day moving average. But it has a downtrending 50-day and failed at the $155 level.
I wouldn't want to stay long a LRCX trade should it break below $145. Over that and see how it handles the $155 level again and the 50-day.
Abbott Labs
Abbott Labs (NYSE: ABT ) also beat on revenue expectations and reported in-line earnings results , but is down slightly on the day. What gives?
Anyway, the results were decent and the stock is still trading really, really well. Above uptrend support (blue line) and the 50-day moving average and investors can stay long the stock. On a break below, I'd love a shot at buying ABT at $63.
7 Stocks Warren Buffett Can't Stop Buying
Over the 20-day and ABT can retest its highs.
Caesars Entertainment
Shares of Caesars Entertainment (NYSE: CZR ) spiked in morning trade as merger reports surfaced . According to reports, there's an offer for $13 per share on the table for CZR.
Over the 50-day and 20-day moving averages is encouraging, but man, has this been a tough run. It's been a hard year for CZR, as well as for Wynn Resorts (NASDAQ: WYNN ), MGM Resorts (NYSE: MGM ) and Las Vegas Sands (NYSE: LVS ).
For CZR, the move thrust shares right up to downtrend resistance. Over this mark and I would feel better about being long. Currently, just below it makes me want to take profits if I'm a short-term long or take a pass for the time being.
Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell . As of this writing, Bret Kenwell held no positions in any stocks mentioned.
More From InvestorPlace
30 Marijuana Stocks to Buy as the Future Turns Green
9 Marijuana Stocks to Play the Pot Craze
5 Marijuana Stocks to Watch
3 Pot Stocks that Stand Out in the Crowd
Compare Brokers
The post 5 Top Stock Trades for Thursday appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | 7 Stocks Warren Buffett Can't Stop Buying Over the 20-day and ABT can retest its highs. Abbott Labs Abbott Labs (NYSE: ABT ) also beat on revenue expectations and reported in-line earnings results , but is down slightly on the day. On a break below, I'd love a shot at buying ABT at $63. | Abbott Labs Abbott Labs (NYSE: ABT ) also beat on revenue expectations and reported in-line earnings results , but is down slightly on the day. On a break below, I'd love a shot at buying ABT at $63. 7 Stocks Warren Buffett Can't Stop Buying Over the 20-day and ABT can retest its highs. | Abbott Labs Abbott Labs (NYSE: ABT ) also beat on revenue expectations and reported in-line earnings results , but is down slightly on the day. On a break below, I'd love a shot at buying ABT at $63. 7 Stocks Warren Buffett Can't Stop Buying Over the 20-day and ABT can retest its highs. | Abbott Labs Abbott Labs (NYSE: ABT ) also beat on revenue expectations and reported in-line earnings results , but is down slightly on the day. On a break below, I'd love a shot at buying ABT at $63. 7 Stocks Warren Buffett Can't Stop Buying Over the 20-day and ABT can retest its highs. |
33182.0 | 2018-10-17 00:00:00 UTC | Abbott (ABT) Q3 Earnings Top Estimates, Guidance Narrowed | ABT | https://www.nasdaq.com/articles/abbott-abt-q3-earnings-top-estimates-guidance-narrowed-2018-10-17 | nan | nan | Abbott LaboratoriesABT reported third-quarter 2018 adjusted earnings from continuing operations of 75 cents per share, a penny ahead of the Zacks Consensus Estimate. The bottom line improved 13.6% year over year and remained at the upper end of the company's guided range of 73-75 cents. Reported earnings from continuing operation in the quarter came in at 31 cents per share, a 3.1% drop year over year.
Third-quarter worldwide sales came in at $7.66 billion, up 12.1% year over year on a reported basis. The top line remained slightly below the Zacks Consensus Estimate of $7.67 billion.
On an organic basis (adjusting for the impact of foreign exchange as well as certain acquisitions and divestments) sales increased 7.8% year over year in the reported quarter.
Quarter in Detail
Abbott operates through four segments, namely Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics.
Abbott Laboratories Price, Consensus and EPS Surprise
Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote
EPD sales dropped 0.9% on a reported basis (improved 5.9% on an organic basis) to $1.16 billion. This included a 6.8% adverse impact of from currency fluctuations. Sales in the key emerging markets declined 2.1% year over year on an 8.9% adverse impact of foreign exchange. Organically, sales improved 6.8% driven by double-digit growth in India and China.
The Medical Devices business sales increased 8.4% on a reported basis to $2.82 billion. On an organic basis, sales grew 9.8%.
Cardiovascular and Neuromodulation sales reportedly (up 4.8% on an organic basis) rose 3.6% on double-digit growth in Electrophysiology and Structural Heart. In Electrophysiology, growth was led by strong performance in cardiac mapping and ablation catheters as well as strong growth of Abbott's Confirm Rx Insertable Cardiac Monitor (ICM). Within Structural Heart, growth was driven by several product areas across Abbott's broad portfolio, including AMPLATZERPFO Occluder and MitraClip.
Diabetes Care sales improved 37.4% (up 39.8% organically), buoyed consistent consumer uptake of FreeStyle Libre, the revolutionary continuous glucose monitoring system of Abbott.
Nutrition sales were up 4% year over year on a reported basis (up 6.1% on an organic basis) to $1.84 billion. Pediatric Nutrition sales increased 8.5% on an organic basis. Adult Nutrition sales were up 3.2% organically.
Diagnostics sales soared 42.6% year over year on a reported basis (up 7.5% on a comparable operational basis) to $1.82 billion. Core Laboratory Diagnostics and Point of Care Diagnostics sales grew 8.1% and 4%, respectively, on an organic basis. Molecular Diagnostics sales were up 6.1% banking on strong growth in the infectious disease testing business. Rapid Diagnostics recorded sales of $481 million, driven by solid contributions from cardiometabolic testing.
Full-Year Guidance
Abbott has narrowed its 2018 adjusted earnings per share guidance. Adjusting for certain net specified items for the full year, adjusted earnings from continuing operations are now expected in the band of $2.87-$2.89 as compared to the earlier-projected range of $2.85-$2.91. The Zacks Consensus Estimate of $2.88 remains within this projected range.
The company has also provided fourth-quarter 2018 adjusted earnings per share outlook. It expects to report adjusted earnings from continuing operations in the range of 80-82 cents. The consensus mark of 81 cents falls within the predicted range.
Our Take
Abbott exited the third quarter on a mixed note with earnings ahead of the Zacks Consensus Estimate and revenues missing the mark. Increasing currency headwinds to some extent dented the company's strong international performance.
Overall, we are optimistic about Abbott's strong and consistent EPD and Medical Devices performance organically. Particularly, Abbott has been riding high on a healthy growth within its Diabetes Care business. The company has been hogging the limelight for developments in the flagship, sensor-based continuous glucose monitoring (CGM) system - FreeStyle Libre System. Also, solid contributions from the company's other two businesses encourage us.
The company continues to benefit from a strong integration synergy of St. Jude Medical, which offers it an industry-leading pipeline across cardiovascular, neuromodulation, diabetes and vision care. We are also impressed by Abbott's Alere integration. Synergies from this consolidation in the form of revenues from Rapid Diagnostics have been driving the company's growth.
Meanwhile, the company's emerging market performance has been extremely promising on several strategic developments.
Zacks Rank & Key Picks
Abbott currently carries a Zacks Rank #3 (Hold).
A few other top-ranked stocks in the broader medical space are Inogen, Inc. INGN , Baxter International Inc. BAX , and Edwards Lifesciences Corporation EW .
Inogen is expected to release third-quarter fiscal 2018 results on Nov 6. The Zacks Consensus Estimate for the quarter's adjusted EPS is pegged at 52 cents and for revenues stands at $91.1 million. The stock flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Baxter is expected to release third-quarter 2018 results on Oct 31. The Zacks Consensus Estimate for the period's adjusted EPS is 74 cents and for revenues, $2.79 billion. The stock carries a Zacks Rank #2.
Edwards Lifesciences is slated to release third-quarter 2018 results on Oct 23. The Zacks Consensus Estimate for adjusted EPS for the to-be-reported quarter is $1.02 and for the top line, $925 million. The stock carries a Zacks Rank #2.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Inogen, Inc (INGN): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Baxter International Inc. (BAX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT reported third-quarter 2018 adjusted earnings from continuing operations of 75 cents per share, a penny ahead of the Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report To read this article on Zacks.com click here. Diabetes Care sales improved 37.4% (up 39.8% organically), buoyed consistent consumer uptake of FreeStyle Libre, the revolutionary continuous glucose monitoring system of Abbott. | Abbott LaboratoriesABT reported third-quarter 2018 adjusted earnings from continuing operations of 75 cents per share, a penny ahead of the Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote EPD sales dropped 0.9% on a reported basis (improved 5.9% on an organic basis) to $1.16 billion. | Abbott LaboratoriesABT reported third-quarter 2018 adjusted earnings from continuing operations of 75 cents per share, a penny ahead of the Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote EPD sales dropped 0.9% on a reported basis (improved 5.9% on an organic basis) to $1.16 billion. | Abbott LaboratoriesABT reported third-quarter 2018 adjusted earnings from continuing operations of 75 cents per share, a penny ahead of the Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report To read this article on Zacks.com click here. Third-quarter worldwide sales came in at $7.66 billion, up 12.1% year over year on a reported basis. |
33183.0 | 2018-10-17 00:00:00 UTC | Bank Stocks Earnings Scorecard, Fed Minutes, & Trade Talks on "Hiatus" | ABT | https://www.nasdaq.com/articles/bank-stocks-earnings-scorecard-fed-minutes-trade-talks-hiatus-2018-10-17 | nan | nan | On today's episode of Free Lunch, Ryan McQueeney discusses the upcoming Fed minutes and Wilbur Ross' comments about U.S.-China trade talks. He also recaps earnings reports from United, Abbot Labs, and U.S. Bancorp. Later, he takes at a look at the earnings scorecard for bank stocks and explains why investors are worried about revenue growth.
Want more video content from Zacks? Subscribe to Zacks Investment News now!
Free Lunch is presented by Zacks Investment Research. It is streamed live, four times per week, and features breaking news and analysis from Zacks strategists. Free Lunch is available on YouTube, Facebook Live, Twitter, Ustream, and more.
U.S. stocks were down in morning trading Wednesday as investors cautiously waited for the latest Fed meeting minutes to be released later in the day. Wall Street has already baked in another rate hike in December, but today's Fed minutes could reveal how far ahead the central bank is looking for additional hikes, and that is what investors will be looking for in the notes.
Elsewhere, Commerce Secretary Wilbur Ross on CNBC this morning said trade talks between the U.S. and China were "on hiatus." This is not necessarily a surprise to those who have been following the negotiations closely, but Ross' confirmation that no progress has been made recently is certainly not great news.
These headwinds helped outweigh decent earnings results from the likes of United UAL , Abbot Labs ABT , and U.S Bancorp USB early this morning, although major indexes did muster a rally into the lunch hour.
United actually missed earnings estimates, but strong revenue and guidance helped move the airline stock higher. Abbot Labs recorded revenue growth of 12% from the prior year and beat expectations on the top and bottom lines. U.S. Bancorp, one of the last major banks to report, also topped estimates for both earnings and revenue.
Ryan covers each of these major headlines and earnings reports on the first half of today's show. Later, he uses USB's earnings report to pivot to a conversation on the Q3 results of the bank industry now that most major companies have filed.
Bank stocks have had a rough year, and although this earnings season once again proved that the business is going its profits, investors are more concerned with stagnating revenue growth and less-frequent top-line outperformance.
With this in mind, Ryan explores the earnings scoreboard for major banks and highlights a few key charts that investors should check out now!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
United Continental Holdings, Inc. (UAL): Free Stock Analysis Report
U.S. Bancorp (USB): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | These headwinds helped outweigh decent earnings results from the likes of United UAL , Abbot Labs ABT , and U.S Bancorp USB early this morning, although major indexes did muster a rally into the lunch hour. Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. On today's episode of Free Lunch, Ryan McQueeney discusses the upcoming Fed minutes and Wilbur Ross' comments about U.S.-China trade talks. | These headwinds helped outweigh decent earnings results from the likes of United UAL , Abbot Labs ABT , and U.S Bancorp USB early this morning, although major indexes did muster a rally into the lunch hour. Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. These headwinds helped outweigh decent earnings results from the likes of United UAL , Abbot Labs ABT , and U.S Bancorp USB early this morning, although major indexes did muster a rally into the lunch hour. Bank stocks have had a rough year, and although this earnings season once again proved that the business is going its profits, investors are more concerned with stagnating revenue growth and less-frequent top-line outperformance. | These headwinds helped outweigh decent earnings results from the likes of United UAL , Abbot Labs ABT , and U.S Bancorp USB early this morning, although major indexes did muster a rally into the lunch hour. Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Subscribe to Zacks Investment News now! |
33184.0 | 2018-10-17 00:00:00 UTC | Abbott Laboratories (ABT) Q3 2018 Earnings Conference Call Transcript | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-q3-2018-earnings-conference-call-transcript-2018-10-17 | nan | nan | Abbott Laboratories (NYSE: ABT)
Q3 2018 Earnings Conference Call
Oct. 17, 2018, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning and thank you for standing by. Welcome to Abbott's Third Quarter 2018 Earnings Conference Call. All participants will be able to listen only until the question-and-answer portion of this call. During the question-and-answer session, you will be able to ask your questions by pressing "*1" on your touchtone phone. Should you become disconnected throughout this conference call, please redial the number provided to you and reference the Abbott earnings call.
This call is being recorded by Abbott. With the exception of any participants' questions asked during the question and answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's express written permission. I would now like to introduce Mr. Scott Leinenweber, Vice President, Investor Relations, Licensing, and Acquisitions
Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions
Good morning and thank you for joining us. With me today are Miles White, Chairman of the Board and Chief Executive Officer, and Brian Yoor, Executive Vice President, Finance and Chief Financial Officer. Miles will provide opening remarks and Brian will discuss our performance and outlook in more detail. Following their comments, Miles, Brian, and I will take your questions.
Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2018. Abbott cautions that these forward-looking statements are subject to risk and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological, and other factors that may affect Abbott's operations are discussed in Item 1A, Risk Factors, to our annual report on Securities and Exchange Commission Form 10-K for the year ended December 31st, 2017. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments except as required by law. Please note the third quarter financial results and guidance provided on the call today for sales, EPS, and line items of the P&L will be for continuing operations only.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
On today's conference call, as in the past, non-GAAP financial measures will be used to help investors understand Abbott's ongoing business performance. These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at Abbott.com. Unless otherwise noted, our commentary on sales growth refers to organic sales growth, which adjusts the 2017 basis of comparison to exclude the impact of exchange and historical results for Abbott's medical optics and St. Jude's vascular closure businesses, which were divested during the first quarter of 2017, as well as current and prior-year sales for Alere, which was acquired on October 3rd, 2017. With that, I will now turn the call over to Miles.
Miles D. White -- Chairman and Chief Executive Officer
Okay. Thanks, Scott, and good morning. Today we reported results of another strong quarter, with ongoing earnings per share of $0.75 along with sales growth of approximately 8% on an organic basis, reflecting well-balanced growth across all four of our businesses. I'm particularly pleased with the continued productivity of our new product pipeline and would like to highlight a couple of areas where our products are creating and fundamentally shaping markets.
I'll start with structural heart, where we're the world or global leader in minimally invasive treatments for mitral regurgitation or a leaky heart valve. We've recently made several significant advancements in this area. In July in the U.S., we initiated a pivotal trial for Tendyne, our device that's designed to replace damaged mitral heart valves without the need for open heart surgery.
We also received U.S. FDA approval for our third-generation version of MitraClip, our market-leading device for the repair of mitral heart valve. And in September, we announced the results of our landmark COAPT trial, which demonstrated that MitraClip improved survival and clinical outcomes for patients with functional mitral regurgitation, the most prevalent form of this condition. We expect to submit this study data to the U.S. FDA in the coming weeks to support consideration of an expanded indication for MitraClip.
These advancements will further enhance and strengthen our leadership position in this large and highly under-penetrated disease area and will bring new therapies to patients where effective treatment options are currently limited.
Diabetes care is another area where our technologies are making a big impact, specifically FreeStyle Libre, a revolutionary glucose monitoring system that eliminates the need for routine finger sticks. In the U.S., we received FDA approval for a 14-day sensor with a shorter one-hour warmup, making Libre the longest lasting wearable glucose sensor available. And in Europe, we obtained CE mark for our FreeStyle Libre 2 system, our newest-generation 14-day system with optional real-time alarms. In a relatively short period of time, FreeStyle Libre now has more than 1 million users across the globe, a testament to the mass-market appeal of this product, which is fundamentally changing the way people with diabetes manage their disease.
I'll now summarize our third quarter results in more detail before turning the call over to Brian. I'll start with diagnostics, where sales grew 7.5% in the quarter. Alinity, our family of highly differentiated instruments, is achieving accelerated growth and strong competitive win rates in Europe, where more than 50% of Alinity instrument placements thus far are coming from share capture. The global rollout of Alinity positions this business for consistent above-market growth for years to come, as we capture share and bring the full suite of systems to additional geographies, including the U.S. In rapid diagnostics, third quarter sales were driven by cardiometabolic testing. We just completed the first-year anniversary of our acquiring this business and we're pleased with the progress we've made to position ourselves for growth and margin expansion going forward.
In established pharmaceuticals, or EPD, sales were led by double-digit growth in several geographies, including Russia and China. As expected, sales growth in the quarter was impacted by a difficult comparison versus the prior year when we saw channel restocking across the market in India following implementation of a new tax system in that country. Our unique branded generics business, focused specifically on key emerging markets, continues to execute its strategy and grow faster than the market in several of our priority countries, including India and China.
In nutrition, sales increased 6% in the quarter, led by strong performance in our international business. In pediatric nutrition, global growth was well-balanced across infant and toddler nutrition, as well as above-market growth in the U.S. and double-digit growth broadly across our international markets. And in adult nutrition, growth was led by our market-leading Ensure and Glucerna brands, most notably internationally, where we achieved 7% growth overall in adult nutrition.
Lastly, I'll cover our results from medical devices, where sales grew 10% in the quarter, led by double-digit growth in electrophysiology, structural heart, and diabetes care.
In electrophysiology, growth of 20% was led by double-digit growth across our heart mapping and ablation portfolio, as well as Confirm, the world's first and only smartphone-compatible, insertable cardiac monitor.
In structural heart, we achieved strong growth across several areas of our portfolio, including more than 20% growth of MitraClip and double-digit growth of AMPLATZER PFO, our minimally invasive device that plugs life-threatening holes in the heart.
And in diabetes care, sales grew 40% in the quarter, led by FreeStyle Libre, which achieved sales of over $300 million in the quarter, an increase of more than 100% versus the prior year.
So, in summary, this was another very good quarter, with all four businesses contributing to strong growth overall. Our pipeline continues to be highly productive, including significant recent advancements in structural heart and diabetes care that are creating and shaping markets. And lastly, we're forecasting EPS and organic sales growth at the upper end of the ranges we set at the beginning of the year.
I'll now turn the call over to Brian to discuss our results and outlook for the year in more detail. Brian?
Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer
Thanks, Miles. As Scott mentioned earlier, please note that all references to sales growth rates, unless otherwise noted, are on an organic basis, which is consistent with our previous guidance.
Turning to our results, sales for the third quarter increased 7.8% on an organic basis. Rapid diagnostics, which was acquired late last year and is therefore not included in our organic sales growth results, achieved sales of $481 million.
Exchange had an unfavorable year-over-year impact of 2.7% on third quarter sales. During the quarter, we saw the U.S. dollar strengthen versus several currencies, resulting in a larger unfavorable impact on our results this quarter compared to the expectations had exchange rates held steady since the time of our earnings call in July.
Regarding other aspects of the P&L, the adjusted gross margin ratio was 59.5% of sales, adjusted R&D investment was 7.3% of sales, and adjusted SG&A expense was 29.7% of sales.
Turning to our outlook for the full-year 2018, we forecast organic sales growth of approximately 7%, at the top end of the guidance range we provided at the beginning of the year. At current rates, we expect exchange would now have a slightly negative impact on full-year reported sales. In addition, we continue to expect rapid diagnostics to contribute sales of a little more than $2 billion.
We forecast an adjusted gross margin ratio of around 59.5% of sales, which includes underlying gross margin improvement across our businesses. We forecast adjusted R&D investment of a little less than 7.5% of sales and adjusted SG&A expense of around 30.5% of sales.
Turning to our outlook for the fourth quarter of 2018, we forecast an adjusted EPS of $0.80 to $0.82. We forecast organic sales growth of mid- to high single digits and, at current rates, would expect exchange to have a negative impact of a little more than 3% on reported sales. In addition, we expect rapid diagnostics to contribute sales of around $500 million in the fourth quarter, which as I previously mentioned is not included in our organic growth rate this year.
Before we open the call for questions, I'll now provide an overview of our fourth quarter organic sales growth outlook by business. For established pharmaceuticals, we forecast mid-single-digit sales growth, which reflects a difficult comparison in our non-core other business segment relative to the fourth quarter of last year, when sales increased strong double digits. In nutrition, we forecast low to mid-single-digit sales growth. In diagnostics, we forecast mid- to high single-digit sales growth. And in medical devices, we forecast high single-digit sales growth, which reflects double-digit growth in several areas of this business.
With that, we will now open the call for questions. Operator, we will now open the call.
Miles D. White -- Chairman and Chief Executive Officer
Is the operator there?
Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions
Operator? Operator, are you there?
Questions and Answers:
Operator
Please press "*1" on your touchtone telephone. If your question has been answered or you wish to remove yourself from the queue, please press "#". We kindly ask that if you are using a speakerphone to please pick up the handset before asking your question. And, again, that's "*1" to ask a question.
Our first question comes from David Lewis from Morgan Stanley.
Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions
We cannot hear the question, operator.
Operator
Please check that your line is not on mute.
David Lewis -- Morgan Stanley -- Analyst
Can you hear me now?
Miles D. White -- Chairman and Chief Executive Officer
Yes.
David Lewis -- Morgan Stanley -- Analyst
Okay. Thank you. So, Miles, two questions for you. Obviously, a lot of business momentum here in 2018 and meaningful drivers ahead, like Libre 2 and MitraClip. So, as you think about sort of sustainability, is sort of 6% to 7% range sustainable over the intermediate term and how are you feeling about Abbott's ability to deliver double-digit or low-teen earnings given the currency environment and all of these various opportunities to grow?
Miles D. White -- Chairman and Chief Executive Officer
Okay. Thanks, David. Let me take the first part of that. The answer is sort of definitively and absolutely yes on the sustainability of earnings -- or rather sales top-line and I'll get to earnings in a minute. In that 6% to 7% range, I say yes. And frankly, I'm even looking at 7% and better. But if you look at the underlying momentum of each of these businesses today and the underlying growth of each of these businesses, there's actually some places I think it could get better. There's places we're obviously trying to improve. I wouldn't forecast it yet but I still see plenty of growth, plenty of opportunity, frankly, with the new product pipeline for years to come.
And you're seeing the evidence of that right now in the performance of all the businesses. The diagnostics business growth rate has clearly turned up. That is clearly the impact of Alinity taking hold. It's having great success in Europe. Libre is doing super well. And on top of that, we haven't really put a lot of promotional emphasis behind it. So, I see a strong future for both of those. The new product cadence coming out of medical devices is really good and, frankly, we expect another approval imminently here in the U.S.
So, I think in terms of sustainability at top line, I feel very good about that. I feel very good about the underlying growth of the company, the sustainability of it, etc. The little elephant in the room is clearly exchange and I think that's true for practically every multinational out there. I think all of us -- all investors, all companies doing business in international markets -- are experiencing the upturn in exchange now. And frankly a bit of uncertainty about how long it lasts. Because every time we enter a new year, we kind of think we've got a notion of what exchange and currency and so forth is going to do and it never lasts the entire year. We always see it change once or twice during the year. And some of that's just driven by news. Some of it's driven by trade talk and other things. But I think for all of us, it's a little hard to forecast.
So, we see that in the third quarter. We've seen a tick-up in currency impact. We're clearly moving into a headwind here. We'll see that in the fourth quarter. And I think that's going to continue into next year. The question is how far into next year and how heavy is that headwind. And in our case, we look at the overall business and say, look, the underlying growth rates, the underlying strength of the business is really strong. And we've been able historically to absorb exchange, mitigate exchange, deal with exchange, etc., and be a very reliable performer for our investors. And that's always our goal. We always start the year with a double-digit earnings goal every year and it's the rare year when we don't achieve that, hit it or exceed it. And this is no different.
I think, right now, we're a few months ahead of next year and a lot always happens in the first quarter. So, we don't have any way to reliably tie down what we think currency is going to do. I don't think anybody does obviously. I know that it will be a headwind starting out and what happens from there, who knows. But we go into the year looking at double digits and with underlying growth like we have in all of our businesses, I'd say that looks pretty solid.
David Lewis -- Morgan Stanley -- Analyst
Okay, Miles, very clear. And the second, just a follow-up for you, is just can you help us put the Robert Ford announcement into perspective and sort of share your thoughts on what it means for you over the intermediate term?
Miles D. White -- Chairman and Chief Executive Officer
Well, what it means for me over the intermediate term is I get a lot more help, which I'm happy about. Look, it's obviously a succession step. And one of the things that I think any good leader has got to do with his company is make sure that there's always good, strong succession building, growing, etc. in the company. And that applies to me too. So, I think for the continuity of the performance of this company, the continuity of its strategies, the continuity of its sustainable growth rates and so forth going forward, that's important.
Robert Ford has been at this company his entire career. I've known him 22 years and paid a lot of attention to his career, as you might imagine, and he's been an excellent operator. He's handled our entire St. Jude integration, done a terrific job with medical devices, and consequently, I want all those medical device businesses continuing to report directly to him, even as he takes on more responsibility. And I'd say, with time, this will develop pretty nicely and I think it's a very good, strong move for the company.
David Lewis -- Morgan Stanley -- Analyst
Okay. Thanks so much.
Operator
Thank you. Our next question comes from Robbie Marcus from J.P. Morgan. Your line is open.
Robbie Marcus -- J.P. Morgan -- Analyst
Great. Thanks for taking the question and congratulations on the great quarter. Miles, I wanted to ask you about COAPT. A lot of us were at the TCT conference in San Diego last month and saw the great data there, to a room of standing ovation, which we don't see in medical devices that often. So, us on the street, we can think about big numbers with such a large patient opportunity. Maybe tell us how you're thinking about MitraClip over the next few years and how you think the street should be thinking about it.
Miles D. White -- Chairman and Chief Executive Officer
Well, I'll tell you what. Obviously, the performance of MitraClip in that study was a real homerun. And it's not often that studies are so definitively positive and so good in terms of their impact for patients. So, we're obviously very happy about that and very proud of that. Our objective will be to move through the regulatory processes as rapidly as can be done and make it available for that use as rapidly as we can. I think the medical community sees tremendous medical benefit in that. And when you can make that kind of a difference, it's obviously a big, important, good thing.
And how rapidly we go through that regulatory process, hard to predict. We have not got a lot of -- well, we don't have any particular impact for next year in our roadmap for next year at this point, for any impact from that product. So, anything that happens is upside. And obviously, beyond that, I think it's got a pretty sizable opportunity. And it's not a broad, mass-market product but the number of patients that will benefit from the product is significant. And so I think it will clearly make a difference in the overall performance of the company's medical device business, the company, etc. It's not one that's going to get lost in rounding error, I can tell you that. Scott, do you want to add anything to that?
Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions
No, that's fair. We'll submit it, as Miles mentioned in his prepared remarks, to the FDA in the coming weeks and after that, it's in their hands and we'll let that process play out.
Robbie Marcus -- J.P. Morgan -- Analyst
Okay, great. And maybe a follow-up on Libra. This is a product that's been wildly successful. You're now over $100 million run rate in the U.S., over $1 billion globally, and you really have one major competitor here that's -- let's call it at the upper end of the technology scale. And Abbott, I view as the low-cost, easy to access, very easy to use product in continuous glucose monitoring. So, as we think about the evolution of Libre over the next few years, how do you think about Libre staying at the lower end of the cost and ease-of-use curve versus moving up and trying to compete with your main competitor there? Thanks.
Miles D. White -- Chairman and Chief Executive Officer
Well, I'll tell you, interestingly enough, I don't actually look at it the way you just described. I think Libre is a pretty different product. It's got tremendous capability but given that value point that we have it priced at, it is accessible to patients all over the world. And when we first launched in Europe, we launched without any government reimbursement and, for the first time, glucose monitoring was patient-pay and it had wildly great acceptance just on that basis, which actually encouraged governments to reimburse the product. So, I think with healthcare today, a lot of things that come to market are very expensive, whether they're pharmaceuticals or devices. And in this particular case, it was important that this have a medical and an economic value proposition that made it accessible to all patients or as many as possible.
And there's tens of millions of diabetes patients out there. Obviously, there's Type 1s and insulin-dependent patients and there's Type 2s trying not to be. And so the product has a much broader appeal across a much broader patient base. And in our case, we have a much lower cost and far greater automated manufacturing capability to not only allow that cost but to allow for mass production. And that's the path we've taken. And we've gone at this from an access standpoint that's far more retail and direct-to-consumer oriented. It's made a big difference.
So, I'd say, at this point, we're making healthy profits on this product. We have no intention of changing the value proposition at all. I mean, your question sort of suggests that we would raise price in order to be competitive. I'd say you ought to be asking the other side what they're going to do to make themselves a value proposition because this product is an incredibly good value proposition which is why it's got such high demand. And to be honest, we don't even measure ourselves relative to any competition, including finger stick, at this point. We know how many potential patients there are out there and it's our intent to capture the vast majority or possible maximum of them that we possibly can in just a few years.
So, I look at Libre right now and a lot of people call it a wild success. I kind of think we're just getting started. And we're investing heavily in capacity to allow even more rapid expansion. And people will say, "Well, how do you model that?" And I think I'm not sure we can model it. It's that good. So, I'd tell you, you probably need to think about this a little differently, in terms of value proposition and the kind of access that affords.
And I think the future of healthcare kind of demands that from us, from all companies. There are certain products, obviously. They're small volume, they're niche medical treatments, and so forth, that are costly to develop, costly to make and provide and so forth. But there's others that have much broader impact and much broader appeal. And part of the future of healthcare and the necessity for companies like ours is making those things as broadly accessible as possible. And we still obviously have to earn our return and I can assure you we're making a nice, healthy return on Libre.
Robbie Marcus -- J.P. Morgan -- Analyst
That's very helpful. Thanks for taking the question.
Operator
Thank you. Our next question comes from Bob Hopkins from Bank of America. Your line is open.
Bob Hopkins -- Bank of America Merrill Lynch -- Analyst
Thank you and good morning. Can you hear me OK?
Miles D. White -- Chairman and Chief Executive Officer
Just fine.
Bob Hopkins -- Bank of America Merrill Lynch -- Analyst
Great. So, two quick questions. First, a product question and then an earnings growth question. On the product side, obviously the context here is that Abbott's a company delivering absolutely top-of-class revenue growth, but one thing in the quarter that I wanted to ask about was neuromodulation. That was a little slower, like the last quarter, and I'm just curious. Has your outlook for that business changed at all? Or is this just still temporary hiring issues and when do you think you can return to more like double-digit growth in that division?
Miles D. White -- Chairman and Chief Executive Officer
Okay. Thanks. I think it's more of the same from last quarter and I do think this is temporary. I think it's going to take us a couple of quarters to work through let's call it the commercial execution issue we have. And you don't fix that overnight but we will fix it and fix it in the near-term. And I do think that this is a business that should return to double-digit growth. So, I even look at that as something that gets better for us. It was obviously very strong last year. It hit a stall point during this year. But I do think that upside is there and it's strictly in our hands at this point. So, yeah, I'm pretty optimistic about it. Do you go to bed happy about it? No. Can you fix it? Yes. And we are.
Bob Hopkins -- Bank of America Merrill Lynch -- Analyst
Okay. Two other quick little things. What was the imminent U.S. product approval you guys were highlighting in your prepared remarks? And then I also want to just follow up really quickly on David's question on earnings growth. I realize you start every year at 10%. The street is modeling roughly 12% earnings growth for really the next couple of years. Given all the puts and takes, is that a reasonable place to start or could currency make that a little challenging? Thank you.
Miles D. White -- Chairman and Chief Executive Officer
Okay. First question is really easy. I was referencing HeartMate 3 and a new claim.
Second question, good question. I know the street is where it is. The street, generally, in its consensus, hasn't tried to factor in or tried to model exchange. And we're all looking at the same exchange trends right now, even the street. So, I'd say, look, if I privately polled the 20 analysts or so on the sell side that cover Abbott, or any company, for that matter, you'd probably all say, "Well, this is my current estimate based on underlying growth but I'm not sure how exchange is going to impact it. And, secondly, I'm not sure how much everybody's going to try to absorb in their P&L and how much they're going to pass through in their estimates and so forth." I think we're all kind of in that boat together right now.
Do I think that 10% to 12% range right now is reasonable? We start every year at double digits and whatever -- I think, as I said earlier, the underlying growth of these businesses is there. There's puts and takes, there's ins and outs. There's not just products ins and outs, there's tax rate. Everybody did experience tax reform, is going to experience some adjustments in tax rates this year. There's puts and takes. We obviously made a change in some of our debt costs with Euro debt. That's a positive for us. So, there's a bunch of pluses and minuses we've got to sort out. The one that's hard to forecast in some way is exchange. And yet, you know we're on the dot, to the penny or penny above or better, every single quarter. So, we tend to like a lot of precision in our forecasting and the hardest thing to forecast here is exchange.
So, do I think that could be a bit of a mitigator here? It might be. But we're all going to know a lot more about that in a few months when it's time to set our guidance for next year. Historically, as you know, we have always tried to offset in some fashion or mitigate as much exchange as possible so that we can reliably deliver what our investors expect. I mean, look, there's a lot of moving parts in the world and we're always trying to synthesize all those moving parts and give you, the investor, reliability to the penny every quarter. And so far, I think for the last 15-20 years, we've been pretty damn good at that. Going into next year, our goals will be no different.
And right now, I think that even analysts and their estimates that inform that 12% consensus that you referenced as being out there now is subject to change by analysts factoring in exchange or any number of other things. But in our case, we're always trying to mitigate that. I don't know where it'll come out but I think somewhere in that range is probably right. We'll be starting at 10% and we'll see what happens after that. I would tell you this: if exchange mitigates and we suddenly see a weak dollar, we're not going to have a problem making you happy.
Bob Hopkins -- Bank of America Merrill Lynch -- Analyst
Fair enough. Thanks for the answer.
Operator
Thank you. Our next question comes from Vijay Kumar from Evercore. Your line is open.
Vijay Kumar -- EvercoreISI -- Analyst
Hey, guys. Thanks for taking my question. Congrats on the nice quarter here. So, Miles, maybe the first one on the sustainability question. If I'm looking at '19, you have MitraClip FMR indication, which is incremental. Libre continues its trends. You have HeartMate 3, which is incremental. Portico U.S. launch, which is incremental. A stable fee outlook. In neuromod, your comps get easy. Alinity, it should be ramping in the U.S. It really feels like all the strength we've seen in '18, this should continue into '19. So, maybe can you just talk about some drivers for how we should be thinking about the pluses and the minuses?
Miles D. White -- Chairman and Chief Executive Officer
Well, Vijay, you forgot to mention Alere. You forgot to mention COAPT. You forgot to mention some improvements in EPD. It's interesting. I've never in my career here seen such breadth across the company in new products, new product launches, market conditions, etc. Even nutrition right now is doing considerably better than it has in the last couple of years. I wouldn't forecast better for nutrition but I like what it's doing right now. And EPD, it's in high growth, or at least moderate to high-growth, markets with great tailwinds. It, of course, has a currency headwind like everything else. But all of these things are performing really well. And even the ones that you can see and forecast and track pretty well, like Libre or Alinity, etc., they're actually accelerating. And that just gets better.
So, I think the sustainability of the growth and the diversity of it is a huge plus. It's not like we're reliant on a single product or a single country. We're not highly indexed in China and we're not over-dependent on a single product. There's just great diversity of growth opportunity across the board. And I'm really proud of the company from a productivity and pipeline standpoint. And that goes for St. Jude as well. As I've said a number of times, St. Jude, in the course of our acquisition negotiations with them, continued to talk to us the veracity of their pipeline and how good it was. And to be honest, they were right. And that's proven.
So, I'm pretty bullish on just the diversity of opportunity here. And while we can try to point to one or two of them, I think Libre and Alinity stick out, but incremental matters. And incremental in any business here, whether it's HeartMate 3 or neuro or even EPD or Alere or anything else, Portico, all of these things contribute to the growth of the company and that's how we like it. We like every bit of this company performing well.
Vijay Kumar -- EvercoreISI -- Analyst
That's helpful. And maybe one for Brian. Brian, when you look at the guidance for Q4 and implications for '19, the gross margins at 59.5%, that would imply an actual ratio to Q4. Any particular reason why GM sequentially should step up? How much did FX cost you guys in the EPS? Because a lot of questions on why guidance was not raised for the year. And it looks like at least $0.05 hit in the back half here. And is that sort of a similar number we should be thinking about, just given where FX is, when you think about for '19? Thank you.
Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer
All right, Vijay. Let me start with the gross margin. Our underlying gross margin improvement has been strong. It's ticking up nearly half a point year-over-year and that's largely the effect of our synergies that are going on, both with respect to Alere and its integration and also continued synergies with St. Jude. And every year, we put an emphasis on improving our underlying gross margin of all of our businesses so that we have the healthy reinvestment back into the business. FX really is not -- it mixes, it moves around a bit here and there. It changes every day. But it's not really having too much of an impact. So, we're seeing, call it close to 40 bps of gross margin improvement. That's all underlying for the year.
Your observation on FX as far as earnings is pretty spot-on. If you recall, we came out at the beginning of the year when we thought that FX would actually be a tailwind of about $0.05. It's probably now closer to that, $0.03 to $0.04 down on a full-year basis. So, we're powering through that. We're powering through that with all of the underlying performance that Miles has talked about with respect to all the businesses. So, when you look underlying, it's outstanding. Very strong performance that carries momentum into 2019.
Miles D. White -- Chairman and Chief Executive Officer
I would just add one comment to that. Blame it on the CEO comment. I don't get overly worked up about raising in the fourth quarter. We've been ahead all year. We're performing strong. Like you, I'm looking at next year and the continuity and sustainability of it all. Whatever the fourth quarter is, it will be, and we're not going to miss. I think that's incredibly unlikely. We are all observing that exchange is a bigger headwind. But when you get to giving guidance for the fourth quarter or raising, I think generally one is tweaking. And at this point in the year, I think tweaking for one quarter is kind of "eh." I'm looking at next year. And so I wouldn't read too much into that, other than, look, the obvious. We all know exchange is getting headier. But beyond that, I think the story here is the underlying growth and that is pretty strong and pretty sustainable. So, don't read too much into it.
Vijay Kumar -- EvercoreISI -- Analyst
Thanks, guys.
Operator
Thank you. Our next question comes from Raj Denhoy from Jefferies. Your line is open.
Raj Denhoy -- Jefferies -- Analyst
Hi, good morning. I wonder if I could maybe ask about one of the areas in medical devices that continues to be a little slower and that's vascular. So, a couple questions there. One, is there anything you can give us in terms of how the initial launch of the XIENCE Sierra stent is doing? And second to that, also the PHP, your percutaneous pump, that trial is still halted. So, any updates in terms of when that might get restarted?
Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions
Hi, Raj. This is Scott. Good morning. Yeah, I would just say with respect to the vascular business, I think the big news item earlier this year was the U.S. approval of our XIENCE Sierra stent. That's off to a very good start. We knew going into that that physician feedback on it was very positive through our experience in Europe there. So, we've added Sierra to a number of our contracts here in the U.S. We've actually recaptured several share points in the U.S. during the quarter. We also launched the product in Japan recently and it's performing there very well.
So, the business has some momentum behind the Sierra stent. It's a very good product. There's a little bit of masking of that growth with respect to some of the non-commercial royalty revenue that we get but that's noise. The commercial side of the business is really performing quite well with respect to that launch.
With respect to PHP, that's a program we're still committed to. Very much so. We have not provided any updates on the timeline of late. I would expect we will in the future at some point.
Raj Denhoy -- Jefferies -- Analyst
Okay. Fair. Maybe just, for my second question, just kind of a broader one on kind of the tone and outlook for the business broadly. Obviously, it depends a lot on the portfolio various companies have but is there anything you can offer in terms of how procedure volumes and pricing broadly are tracking in the industry right now?
Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions
Yeah. No change really. I mean, procedures and demand volume from that side of things are fairly constant to the way they've been running and trending for the last several quarters. Pricing in some of the segments, such as CRM and vascular, is a modest headwind. But demand is strong and offsetting most of that. Those are really the only two areas of the medical device business where we think about price. The others are very healthy.
Raj Denhoy -- Jefferies -- Analyst
Great. Thank you.
Operator
Thank you. Our next question comes from Glenn Navarro from RBC Capital Markets. Your line is open.
Glenn Navarro -- RBC Capital Markets -- Analyst
Good morning, guys. Two quick questions. First, Miles, on Alere, you'll do $2 billion in revenues this year. I think that's hitting expectations. But Alere is going to be folded into organic growth in 2019 so can you help us think about Alere growth in 2019 and beyond? That's the first question. And then quickly, on Libre 2, can you give us an update on the U.S. approval timing? Thanks.
Miles D. White -- Chairman and Chief Executive Officer
Yeah. Let me address Alere first. So, our first year, you're spot-on on all your observations. Our first year was obviously stabilize, integrate it, organize, put management in place, etc. All done, all done well, and so on. And we benefited in this last year from probably one of the stronger flu seasons in a long time so the infectious disease business in Alere, the infectious disease testing business, did well in that context. Going forward, obviously, we now need to turn to driving growth. And I can't give you a forecast or a prediction on that for '19 yet or even '20 beyond that. But that's where the attention turns.
I think we're mostly through all the disruption and/or transition, synergies, etc., all that activity. In fact, I've got an update on that after this meeting later today. And at this point, our entire emphasis turns to what kind of sustainable growth rate we can now generate and trend out of that business. So, I don't have a specific answer for you yet, Glenn, but I think that's one of our growth drivers of the future and that's kind of next steps with it. And I'm sorry. What was the second half of your question?
Glenn Navarro -- RBC Capital Markets -- Analyst
Timing Libre 2 in the U.S.
Miles D. White -- Chairman and Chief Executive Officer
I might have to ask Scott for some help on that because I'm not sure we can give you timing on that.
Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions
Yeah, that's right, Miles. We haven't provided timing yet on Libre 2 in the U.S. Obviously, we will bring an alarm version to the U.S. at some point in time. The current version is obviously doing quite well as well. So, that's just another opportunity in the pipeline but we have not provided specifics on timeline yet.
Miles D. White -- Chairman and Chief Executive Officer
I would tell you this. It should take a lot less time than it seems to. The U.S. lags Europe and the rest of the world on some of these approvals in a way that I find hard to explain but it is what it is.
Glenn Navarro -- RBC Capital Markets -- Analyst
Okay. Thanks, guys.
Operator
Thank you. Our next question comes from Larry Biegelsen from Wells Fargo. Your line is open.
Larry Biegelsen -- Wells Fargo Securities -- Analyst
Good morning. Thanks for taking the questions, guys. One on capital allocation, one on nutrition. Miles, you've been paying down debt. You've been quiet on the M&A front in 2018. Do you expect that to change in 2019? And I just had one question on nutrition.
Miles D. White -- Chairman and Chief Executive Officer
Okay. Let me deal with that one first. Well, first of all, I think the organization has done a terrific job on cash generation and debt pay down. And I give Brian Yoor and the management team total credit for that because what we've done for cash management, debt management, debt pay down, and stuff has been led by him and terrific job. And to be honest, when we took all the borrowing down in order to do the St. Jude and Alere acquisitions, our debt to EBITDA ratio was, I think, like 4.3, something like that. And we made commitments to the rating agencies that we would get that down pretty fast and we're down to, I think, 2. So we've obviously paid off a lot of debt very fast and we're happy with the rate of that. And it gives us a lot of flexibility from a capital allocation or strategic flexibility standpoint.
But will we continue to pay down debt? We will. But I think we also -- we have other capital needs. For example, we want to target our dividend in a certain range as a percent of our EPS and we are completely able to do that and meet those targets and those goals for dividend payouts. Some of our capital attention has been paid to growth. And we are investing in Alinity and we're investing in Libre. We're making a large investment in capacity expansion for Libre that I think you'll see drive even more growth out of Libre than you can see now and fulfill kind of the larger mass-market ramp-up we see for that product. We're putting a fair bit of investment into the expansion of Alinity. So, when we can invest our capital in growth, not only near-term but long-term with high return, that's a good use for our capital and we're obviously doing that.
We haven't, to be fair, seen a lot on the M&A front that interests us. And as I indicated in the past, we always keep our ear to the ground. We're always doing our homework on what possibilities may or may not be out there and what might interest us, what might fit our portfolio, but right now, we haven't seen anything that draws our attention that way. So, we don't have anything on our radar screen from the standpoint of M&A that we think is beneficial to us. We've got so much more opportunity in the company organically and out of our pipelines and the expansion of all the things we talked about earlier that that's really where our focus is. And fortunately for us, it can be, it ought to be. So, we just haven't seen anything to draw our cash for capital investment from the standpoint of M&A. I mean, there might be little things here and there but nothing that I would say is particularly needle-moving on a big scale here in any near-term way.
And then, finally, I suppose the fifth, last opportunity that I haven't mentioned -- it's not last in priority but -- is share buyback. And right now, we haven't been. What you're seeing in our EPS growth and so forth is pure growth and not enhanced at all by share buybacks. And to be honest, as we've all seen during the year, that hasn't been a high return investment for a lot of companies and we've had better uses for our capital that do have high returns for us. And so consequently, it doesn't rule it out. It doesn't rule out that we could do it but we'll only do it if it's got a good return for us and our investor, etc. And right now, our best investment is us. So, we're directing our cash that way. I think our cash flow is strong enough that we've got a lot of good choices. We will continue to pay down debt. But we're at the point where we've got strategic flexibility. It's just a question of where we use it. And I think that's all good.
Larry Biegelsen -- Wells Fargo Securities -- Analyst
Very clear. And just last for me, Miles, on nutrition. A year ago, that was the slowest growing business. That's clearly turned around. The international pediatric nutrition business is doing really well. Any color on what's going on in China? And lastly on that, the adult nutrition business in the U.S. has been a little weak recently. Is that still private label competition? What's the outlook there? Thanks for taking the questions.
Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer
Okay. Yeah, I'll take the last one first, Larry. This is Brian. With respect to the U.S., what you're seeing is the impact of a wind-down of a non-core product line for us. You'll see that here in Q3. Otherwise, the U.S. business would be growing. You'll see it in Q4 as well. It's non-core to us and we just decided to wind it down. That's the only thing going on in the U.S.
With respect to China, the transition has gone smoothly. The food safety law transition has gone smoothly. I think behavior has been rational in the market. The market growth rates in China have been strong and we're always trying there to grow share. But our greater China business has done quite well this year and we expect the market there in China to remain strong and stable going forward on the pediatric side of the business.
Miles D. White -- Chairman and Chief Executive Officer
Yeah, I would only add that the whole nutrition business obviously is doing a lot better this year than it did last year. And where it is right now, there's various countries or various segments of business where we want to do better. There's ups and downs. But overall, if you take it as a whole, a lot happier where it is today than where it was a year ago.
Larry Biegelsen -- Wells Fargo Securities -- Analyst
Great. Thank you.
Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions
Operator, we'll take one more question.
Operator
Thank you. Our final question comes from Chris Pasquale from Guggenheim. Your line is open.
Christopher Pasquale -- Guggenheim Securities -- Analyst
Thanks for sneaking me in. I wanted to follow up on the FX commentary and try to make sure we're all on the same page as we think about next year. Brian, if rates were to stay where they are right now, what would the earnings impact from currency be in 2019?
Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer
It's going to be somewhere probably between 3% and 4% of our earnings. And we've seen that before and as Miles said, we always work to mitigate as much of that as possible and the great news is that we have a lot of underlying growth in the businesses and sales growth that we're going to power through as much of that as possible.
Miles D. White -- Chairman and Chief Executive Officer
I would add to that, Chris, it's always kind of a judgment trade-off. If you could predict currency for the whole year or beyond, it would be one thing, but we can't. And so we take a lot of different actions to mitigate the volatility of it or the impact of it. We've got a very sophisticated and, frankly, complex rolling hedging program on the currencies that we can hedge. So, we take out a lot of the unpredictability with that. Obviously, over the long-term, we're not currency traders and we're not trying to be but we're trying to be able to make our earnings and our sales more predictable, more stable, more reliable, in terms of what our investors want to see, and, frankly, the impact on us so we can plan and manage.
That said, gosh, today's currency rates, if sustained, it would be a heavy headwind. Do I think all of that somehow passes through to the investor? I do not. Do I think that the current currency rates will be the same three months from now or the same six months from now? I do not. If you ask me do I think they'll be up or down, I have no idea. All I know is, as I told you earlier, we look at the right balance of what is right for us to try to mitigate or hedge or whatever we're going to do to perform to the investment identity that our investors expect of us and where are we in a prudent range of how we manage that balance and how we deal with exchange and so forth in the performance for our investors. And we always start with a double-digit target of growth so a lot of moving parts. And we'll see.
Right now, I think that's kind of the only elephant in the room for us. And everything else looks positive and strong or is in our hands to manage and the one that's not entirely in our hands to manage is what currency hands us. But then we do have a lot of things to do to try to minimize its impact on the overall performance of the company for our investors.
Christopher Pasquale -- Guggenheim Securities -- Analyst
Thanks for that. And, Brian, just to make sure that I'm hearing you correctly, you're saying about $0.10 headwind for next year, give or take?
Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer
It's a range. Currency moves every day. If you look at 3% to 4%, about that.
Christopher Pasquale -- Guggenheim Securities -- Analyst
Okay. And then, Miles, just one last one on Alinity in the U.S. What's the latest on the timing there and when you think you'll have a broad enough menu in place to really make a big push domestically with that product?
Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions
Hi, Chris. This is Scott. I would just say, as you know, that the clinical chemistry and amino assay instruments is the core business there. The instruments are approved and we are building our test menu at a pretty ratable kind of rate quarter-to-quarter, so to speak, and making progress on that front. It'll still take a few more quarters until we get what we consider a critical mass there. So, you're probably looking back half of 2019 where we feel like we're really going to have the menu and the systems we need to go out and get business.
Christopher Pasquale -- Guggenheim Securities -- Analyst
Great. Thanks.
Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions
Okay. Well, thank you, operator, and thank you for all of your questions. This now concludes Abbott's conference call. A webcast replay of this call will be available after 11:00 a.m. Central Time today on Abbott's Investor Relations website at abbottinvestor.com. Thank you for joining us today.
Operator
Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program and you may all disconnect. Everyone have a wonderful day.
Duration:52 minutes
Call participants:
Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions
Miles D. White -- Chairman and Chief Executive Officer
Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer
David Lewis -- Morgan Stanley -- Analyst
Robbie Marcus -- J.P. Morgan -- Analyst
Bob Hopkins -- Bank of America Merrill Lynch -- Analyst
Vijay Kumar -- EvercoreISI -- Analyst
Raj Denhoy -- Jefferies -- Analyst
Glenn Navarro -- RBC Capital Markets -- Analyst
Larry Biegelsen -- Wells Fargo Securities -- Analyst
Christopher Pasquale -- Guggenheim Securities -- Analyst
More ABT analysis
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Motley Fool Transcription has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (NYSE: ABT) Q3 2018 Earnings Conference Call Oct. 17, 2018, 9:00 a.m. Duration:52 minutes Call participants: Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer David Lewis -- Morgan Stanley -- Analyst Robbie Marcus -- J.P. Morgan -- Analyst Bob Hopkins -- Bank of America Merrill Lynch -- Analyst Vijay Kumar -- EvercoreISI -- Analyst Raj Denhoy -- Jefferies -- Analyst Glenn Navarro -- RBC Capital Markets -- Analyst Larry Biegelsen -- Wells Fargo Securities -- Analyst Christopher Pasquale -- Guggenheim Securities -- Analyst More ABT analysis This article is a transcript of this conference call produced for The Motley Fool. And in September, we announced the results of our landmark COAPT trial, which demonstrated that MitraClip improved survival and clinical outcomes for patients with functional mitral regurgitation, the most prevalent form of this condition. | Duration:52 minutes Call participants: Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer David Lewis -- Morgan Stanley -- Analyst Robbie Marcus -- J.P. Morgan -- Analyst Bob Hopkins -- Bank of America Merrill Lynch -- Analyst Vijay Kumar -- EvercoreISI -- Analyst Raj Denhoy -- Jefferies -- Analyst Glenn Navarro -- RBC Capital Markets -- Analyst Larry Biegelsen -- Wells Fargo Securities -- Analyst Christopher Pasquale -- Guggenheim Securities -- Analyst More ABT analysis This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q3 2018 Earnings Conference Call Oct. 17, 2018, 9:00 a.m. I would now like to introduce Mr. Scott Leinenweber, Vice President, Investor Relations, Licensing, and Acquisitions Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions Good morning and thank you for joining us. | Duration:52 minutes Call participants: Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer David Lewis -- Morgan Stanley -- Analyst Robbie Marcus -- J.P. Morgan -- Analyst Bob Hopkins -- Bank of America Merrill Lynch -- Analyst Vijay Kumar -- EvercoreISI -- Analyst Raj Denhoy -- Jefferies -- Analyst Glenn Navarro -- RBC Capital Markets -- Analyst Larry Biegelsen -- Wells Fargo Securities -- Analyst Christopher Pasquale -- Guggenheim Securities -- Analyst More ABT analysis This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q3 2018 Earnings Conference Call Oct. 17, 2018, 9:00 a.m. Unless otherwise noted, our commentary on sales growth refers to organic sales growth, which adjusts the 2017 basis of comparison to exclude the impact of exchange and historical results for Abbott's medical optics and St. Jude's vascular closure businesses, which were divested during the first quarter of 2017, as well as current and prior-year sales for Alere, which was acquired on October 3rd, 2017. | Duration:52 minutes Call participants: Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer David Lewis -- Morgan Stanley -- Analyst Robbie Marcus -- J.P. Morgan -- Analyst Bob Hopkins -- Bank of America Merrill Lynch -- Analyst Vijay Kumar -- EvercoreISI -- Analyst Raj Denhoy -- Jefferies -- Analyst Glenn Navarro -- RBC Capital Markets -- Analyst Larry Biegelsen -- Wells Fargo Securities -- Analyst Christopher Pasquale -- Guggenheim Securities -- Analyst More ABT analysis This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q3 2018 Earnings Conference Call Oct. 17, 2018, 9:00 a.m. Please note the third quarter financial results and guidance provided on the call today for sales, EPS, and line items of the P&L will be for continuing operations only. |
33185.0 | 2018-10-16 00:00:00 UTC | Can Abbott's (ABT) Steady Overall Growth Aid Q3 Earnings? | ABT | https://www.nasdaq.com/articles/can-abbotts-abt-steady-overall-growth-aid-q3-earnings-2018-10-16 | nan | nan | Abbott LaboratoriesABT is slated to report third-quarter 2018 results before the market opens on Oct 17. Last reported quarter, the company's earnings per share exceeded the Zacks Consensus Estimate by 2.8%. Moreover, Abbott delivered positive surprises in the trailing four quarters, the average beat being 1.86%.
Let's see how things are shaping up for this announcement.
Factors at Play
Over the past few quarters, Abbott has been riding high on a healthy growth curve within its Diabetes Care business. The company has been hogging the limelight for developments in the flagship, sensor-based continuous glucose monitoring (CGM) system - FreeStyle Libre System. Per a recent data, the number of Libre users now has crossed 650,000 across the globe, representing an unprecedented level of patient adoption in the industry. This has firmly boosted the company's top-line numbers in the recent quarters (growth of over 30% for the last three consecutive quarters).
This momentum should continue through the third quarter too, producing impressive results in the period. The company expects to see significant growth contributions from a line of recently launched products across the portfolio. The Zacks Consensus Estimate of $481 million for Diabetes Care revenues indicates an increase of 28.9% from the year-ago quarter's level.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
In sync with the prior quarter, Abbott is anticipated to gain from a strong performance by the Established Pharmaceuticals Division (EPD) business, which has been recording operational sales growth over the last few quarters. According to Abbott, its EPD business is growing at a faster pace than the market rate across several of its priority countries including India and China. Management expects mid-to-high single-digit sales growth during the third quarter 2018, considering the company's year-ago quarter's results, which were impacted by the implementation of the new tax system in India. The Zacks Consensus Estimate of $1.23 billion for EPD revenues shows a 4.6% rise from the year-earlier period's number.
We are also upbeat about the consistently sturdy Diagnostics business, courtesy of solid contributions from all sub-segments, namely Core Laboratories Diagnostics, Molecular Diagnostics and Point of Care. Moreover, synergies drawn from the Alere buyout in the form of revenues from Rapid Diagnostics have been benefiting the company.
This apart, we are impressed by the accelerated pace of the company's Alinity launch in Europe, driven by strong competitive win rates and even stronger retention rates. This business is growing more rapidly than its market rate. Per Abbott, it is well-positioned for sustainable growth for years to come based on the company's rollout of the full suite of Alinity systems across additional geographies including the United States.
Additionally, management estimates Rapid Diagnostics to contribute more than $2 billion in 2018. The Zacks Consensus Estimate for Core Laboratory Diagnostic revenues of $1.83 billion depicts a 42.7% improvement from the registered figure in the comparable quarter last year.
We encouragingly note that Nutrition is Abbott's most speedily-growing business owing to aging population, increasing rate of chronic diseases and the rise of the middle class in the emerging markets. Furthermore, Abbott's pediatric nutrition business continues to be robust in the United States. Thus, the Zacks Consensus Estimate of $1.82 billion for Nutrition revenues translates into a 2.9% rise from the year-ago quarter's figure.
Overall, third-quarter total revenues are projected at $7.67 billion, up 12.3% from the prior-year period's tally.
What the Model Suggests
Per the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has good chances of beating estimates if it also has a positive Earnings ESP . You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Abbott has a Zacks Rank #3, which increases the predictive power of ESP and an Earnings ESP of +0.49%. This combination suggests that the company is likely to beat on earnings this reporting season. The Zacks Consensus Estimate for bottom line of 74 cents reflects 12.1% growth year over year.
Other Stocks Worth a Look
Here are a few other medical stocks worth considering from the same space as these too comprise the right combination of elements to beat on earnings this time around.
Henry Schein, Inc. HSIC has an Earnings ESP of +0.33% and is a Zacks #2 Ranked player. You can see the complete list of today's Zacks #1 Rank stocks here .
DaVita Inc. DVA has an Earnings ESP of +2.41% and a Zacks Rank #2.
Masimo Corporation MASI has an Earnings ESP of +0.98% and a Zacks Rank of 2.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Masimo Corporation (MASI): Free Stock Analysis Report
DaVita Inc. (DVA): Free Stock Analysis Report
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT is slated to report third-quarter 2018 results before the market opens on Oct 17. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report DaVita Inc. (DVA): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Per Abbott, it is well-positioned for sustainable growth for years to come based on the company's rollout of the full suite of Alinity systems across additional geographies including the United States. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report DaVita Inc. (DVA): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is slated to report third-quarter 2018 results before the market opens on Oct 17. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote In sync with the prior quarter, Abbott is anticipated to gain from a strong performance by the Established Pharmaceuticals Division (EPD) business, which has been recording operational sales growth over the last few quarters. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report DaVita Inc. (DVA): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is slated to report third-quarter 2018 results before the market opens on Oct 17. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote In sync with the prior quarter, Abbott is anticipated to gain from a strong performance by the Established Pharmaceuticals Division (EPD) business, which has been recording operational sales growth over the last few quarters. | Abbott LaboratoriesABT is slated to report third-quarter 2018 results before the market opens on Oct 17. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report DaVita Inc. (DVA): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Additionally, management estimates Rapid Diagnostics to contribute more than $2 billion in 2018. |
33186.0 | 2018-10-16 00:00:00 UTC | 5 Earnings Charts in the Spotlight | ABT | https://www.nasdaq.com/articles/5-earnings-charts-spotlight-2018-10-16 | nan | nan | Third quarter earnings season really picks up this week with about 200 companies reporting. Many of them will be large cap companies, with some being Dow Industrial components.
Many are large multinational companies who face exposure to trade disputes and tariffs. Additionally, some are feeling the pinch from the tight US labor market and rising commodity costs.
If you want to know what's happening in the global economy right now, tune into the earnings reports of these 5 companies this week.
5 Stocks to Watch for Earnings This Week
1. Abbott Labs ABT hasn't missed in 5 years. Shares had been trading in a narrow range for several years but they finally broke out in 2017 and have continued to soar. Shares are up 20% year-to-date. Are the drug stocks finally "back"?
2. United Rentals URI has missed just once in the last 5 years. The largest equipment rental company in North America is a good barometer of the economy. Shares have pulled back off 2018 highs on rate jitters. Will this earnings report turn it around?
3. Winnebago WGO has beat 3 out of the last 4 quarters but demand for RVs has been strong thanks to the Baby Boomers and Millennial interest in hitting the open road. Shares are trading at just 8x now, however, as investors are worried about rising commodity cost and the super tight Northern Indian labor market. Tune in if you want to know what is happening with labor costs.
4. Pool Corporation POOL missed last quarter but shares are still up 12.8% year-to-date. Pools and pool supplies are discretionary items. Business has been strong in this hot economy. But can the red-hot growth continue or is consumer spending slowing?
5. Snap-On SNA , the diagnostic repair tool maker for the auto industry,hasn't missed in 5 years but shares are still stuck. They looked like they were finally breaking out, but the recent sell off has brought them back down to earth. Shares are now down 3.4% year-to-date. Will it see tariff or trade impacts?
[In full disclosure, the author of this article owns shares of URI in her personal portfolio.]
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
United Rentals, Inc. (URI): Free Stock Analysis Report
Winnebago Industries, Inc. (WGO): Free Stock Analysis Report
Pool Corporation (POOL): Free Stock Analysis Report
Snap-On Incorporated (SNA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ABT hasn't missed in 5 years. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report Winnebago Industries, Inc. (WGO): Free Stock Analysis Report Pool Corporation (POOL): Free Stock Analysis Report Snap-On Incorporated (SNA): Free Stock Analysis Report To read this article on Zacks.com click here. Winnebago WGO has beat 3 out of the last 4 quarters but demand for RVs has been strong thanks to the Baby Boomers and Millennial interest in hitting the open road. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report Winnebago Industries, Inc. (WGO): Free Stock Analysis Report Pool Corporation (POOL): Free Stock Analysis Report Snap-On Incorporated (SNA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT hasn't missed in 5 years. Additionally, some are feeling the pinch from the tight US labor market and rising commodity costs. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report Winnebago Industries, Inc. (WGO): Free Stock Analysis Report Pool Corporation (POOL): Free Stock Analysis Report Snap-On Incorporated (SNA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT hasn't missed in 5 years. Shares are trading at just 8x now, however, as investors are worried about rising commodity cost and the super tight Northern Indian labor market. | Abbott Labs ABT hasn't missed in 5 years. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report Winnebago Industries, Inc. (WGO): Free Stock Analysis Report Pool Corporation (POOL): Free Stock Analysis Report Snap-On Incorporated (SNA): Free Stock Analysis Report To read this article on Zacks.com click here. If you want to know what's happening in the global economy right now, tune into the earnings reports of these 5 companies this week. |
33187.0 | 2018-10-16 00:00:00 UTC | Pre-Market Earnings Report for October 17, 2018 : ABT, USB, ASML, MTB, NTRS, MTG, UNF, UBSH, BMI, WGO | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-october-17-2018-abt-usb-asml-mtb-ntrs-mtg-unf-ubsh-bmi-wgo-2018 | nan | nan | The following companies are expected to report earnings prior to market open on 10/17/2018. Visit our Earnings Calendar for a full list of expected earnings releases.
Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2018. The medical products company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.74. This value represents a 12.12% increase compared to the same quarter last year. In the past year ABT has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 2.82%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABT is 23.85 vs. an industry ratio of -21.00, implying that they will have a higher earnings growth than their competitors in the same industry.
U.S. Bancorp ( USB ) is reporting for the quarter ending September 30, 2018. The bank company's consensus earnings per share forecast from the 10 analysts that follow the stock is $1.04. This value represents a 18.18% increase compared to the same quarter last year. In the past year USB has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2018 Price to Earnings ratio for USB is 12.38 vs. an industry ratio of 11.50, implying that they will have a higher earnings growth than their competitors in the same industry.
ASML Holding N.V. ( ASML ) is reporting for the quarter ending September 30, 2018. The capital goods company's consensus earnings per share forecast from the 2 analysts that follow the stock is $1.90. This value represents a 25.00% increase compared to the same quarter last year. In the past year ASML has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 13.99%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ASML is 24.84 vs. an industry ratio of 12.40, implying that they will have a higher earnings growth than their competitors in the same industry.
M&T Bank Corporation ( MTB ) is reporting for the quarter ending September 30, 2018. The bank company's consensus earnings per share forecast from the 8 analysts that follow the stock is $3.35. This value represents a 49.55% increase compared to the same quarter last year. MTB missed the consensus earnings per share in the 3rd calendar quarter of 2017 by -6.67%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for MTB is 12.37 vs. an industry ratio of 11.50, implying that they will have a higher earnings growth than their competitors in the same industry.
Northern Trust Corporation ( NTRS ) is reporting for the quarter ending September 30, 2018. The bank company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.62. This value represents a 35.00% increase compared to the same quarter last year. In the past year NTRS has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 5.52%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for NTRS is 14.65 vs. an industry ratio of 11.50, implying that they will have a higher earnings growth than their competitors in the same industry.
MGIC Investment Corporation ( MTG ) is reporting for the quarter ending September 30, 2018. The insurance company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.36. This value represents a 12.50% increase compared to the same quarter last year. In the past year MTG has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 36.11%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for MTG is 7.61 vs. an industry ratio of 13.40.
Unifirst Corporation ( UNF ) is reporting for the quarter ending August 31, 2018. The uniform company's consensus earnings per share forecast from the 5 analysts that follow the stock is $1.64. This value represents a 13.89% increase compared to the same quarter last year. In the past year UNF has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 1.28%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for UNF is 25.65 vs. an industry ratio of 22.30, implying that they will have a higher earnings growth than their competitors in the same industry.
Union Bankshares Corporation ( UBSH ) is reporting for the quarter ending September 30, 2018. The banks (southeast) company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.66. This value represents a 34.69% increase compared to the same quarter last year. In the past year UBSH has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2018 Price to Earnings ratio for UBSH is 13.06 vs. an industry ratio of 17.90.
Badger Meter, Inc. ( BMI ) is reporting for the quarter ending September 30, 2018. The industrial company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.41. This value represents a 51.85% increase compared to the same quarter last year. Zacks Investment Research reports that the 2018 Price to Earnings ratio for BMI is 33.27 vs. an industry ratio of 20.70, implying that they will have a higher earnings growth than their competitors in the same industry.
Winnebago Industries, Inc. ( WGO ) is reporting for the quarter ending August 31, 2018. The building company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.86. This value represents a 8.51% decrease compared to the same quarter last year. WGO missed the consensus earnings per share in the 1st calendar quarter of 2018 by -4.62%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for WGO is 10.33 vs. an industry ratio of 15.30.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2018. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABT is 23.85 vs. an industry ratio of -21.00, implying that they will have a higher earnings growth than their competitors in the same industry. | Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABT is 23.85 vs. an industry ratio of -21.00, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2018. In the past year ABT has beat the expectations every quarter. | Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABT is 23.85 vs. an industry ratio of -21.00, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2018. In the past year ABT has beat the expectations every quarter. | Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2018. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABT is 23.85 vs. an industry ratio of -21.00, implying that they will have a higher earnings growth than their competitors in the same industry. |
33188.0 | 2018-10-15 00:00:00 UTC | Health Care Sector Update for 10/15/2018: SNGX, TNDM, JNJ, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-10152018-sngx-tndm-jnj-pfe-abt-mrk-amgn-2018-10-15 | nan | nan | Top Health Care Stocks:
JNJ: Flat
PFE: -0.25%
ABT: +0.30%
MRK: -0.43%
AMGN: Flat
Health care stocks were mixed in pre-market trading Monday.
Moving stocks on news include:
(+) Soligenix ( SNGX ), which was up 2%. The company said it received a positive recommendation from the independent Data Monitoring Committee (DMC) to continue enrolling into the company's phase 3 "Fluorescent Light Activated Synthetic Hypericin" (FLASH) study for SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL).
(+) Tandem Diabetes Care ( TNDM ) was up by 4.48% after it announced that it received a Heath Canada medical device license for the t:slim X2 insulin pump.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AMGN: Flat Health care stocks were mixed in pre-market trading Monday. The company said it received a positive recommendation from the independent Data Monitoring Committee (DMC) to continue enrolling into the company's phase 3 "Fluorescent Light Activated Synthetic Hypericin" (FLASH) study for SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL). (+) Tandem Diabetes Care ( TNDM ) was up by 4.48% after it announced that it received a Heath Canada medical device license for the t:slim X2 insulin pump. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AMGN: Flat Health care stocks were mixed in pre-market trading Monday. | Top Health Care Stocks: JNJ: Flat AMGN: Flat Health care stocks were mixed in pre-market trading Monday. The company said it received a positive recommendation from the independent Data Monitoring Committee (DMC) to continue enrolling into the company's phase 3 "Fluorescent Light Activated Synthetic Hypericin" (FLASH) study for SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL). | Top Health Care Stocks: JNJ: Flat AMGN: Flat Health care stocks were mixed in pre-market trading Monday. Moving stocks on news include: (+) Soligenix ( SNGX ), which was up 2%. |
33189.0 | 2018-10-15 00:00:00 UTC | Why Abbott Laboratories (ABT) Might Surprise This Earnings Season | ABT | https://www.nasdaq.com/articles/why-abbott-laboratories-abt-might-surprise-this-earnings-season-2018-10-15 | nan | nan | Investors are always looking for stocks that are poised to beat at earnings season and Abbott LaboratoriesABT may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Abbott Laboratories is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings - with the most up-to-date information possible - is a pretty good indicator of some favorable trends underneath the surface for ABT in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at 75 cents per share for ABT, compared to a broader Zacks Consensus Estimate of 74 cents per share. This suggests that analysts have very recently bumped up their estimates for ABT, giving the stock a Zacks Earnings ESP of +0.49% heading into earnings season.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here ).
Given that ABT has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Clearly, recent earnings estimate revisions suggest that good things are ahead for Abbott Laboratories, and that a beat might be in the cards for the upcoming report.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | After all, analysts raising estimates right before earnings - with the most up-to-date information possible - is a pretty good indicator of some favorable trends underneath the surface for ABT in this report. Given that ABT has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always looking for stocks that are poised to beat at earnings season and Abbott LaboratoriesABT may be one such company. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Investors are always looking for stocks that are poised to beat at earnings season and Abbott LaboratoriesABT may be one such company. After all, analysts raising estimates right before earnings - with the most up-to-date information possible - is a pretty good indicator of some favorable trends underneath the surface for ABT in this report. | This suggests that analysts have very recently bumped up their estimates for ABT, giving the stock a Zacks Earnings ESP of +0.49% heading into earnings season. Given that ABT has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always looking for stocks that are poised to beat at earnings season and Abbott LaboratoriesABT may be one such company. | Given that ABT has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always looking for stocks that are poised to beat at earnings season and Abbott LaboratoriesABT may be one such company. After all, analysts raising estimates right before earnings - with the most up-to-date information possible - is a pretty good indicator of some favorable trends underneath the surface for ABT in this report. |
33190.0 | 2018-10-12 00:00:00 UTC | Abbott (ABT) Gains But Lags Market: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-gains-but-lags-market%3A-what-you-should-know-2018-10-12 | nan | nan | Abbott (ABT) closed the most recent trading day at $69.33, moving +1.39% from the previous trading session. The stock lagged the S&P 500's daily gain of 1.42%. Elsewhere, the Dow gained 1.15%, while the tech-heavy Nasdaq added 2.29%.
Coming into today, shares of the maker of infant formula, medical devices and drugs had lost 0.18% in the past month. In that same time, the Medical sector lost 5.63%, while the S&P 500 lost 5.36%.
Investors will be hoping for strength from ABT as it approaches its next earnings release, which is expected to be October 17, 2018. The company is expected to report EPS of $0.74, up 12.12% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $7.67 billion, up 12.25% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $2.88 per share and revenue of $30.78 billion, which would represent changes of +15.2% and +12.36%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for ABT. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.03% lower. ABT is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, ABT is holding a Forward P/E ratio of 23.72. This represents a discount compared to its industry's average Forward P/E of 25.22.
It is also worth noting that ABT currently has a PEG ratio of 1.91. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Products industry currently had an average PEG ratio of 2.32 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 107, putting it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors will be hoping for strength from ABT as it approaches its next earnings release, which is expected to be October 17, 2018. Abbott (ABT) closed the most recent trading day at $69.33, moving +1.39% from the previous trading session. Investors should also note any recent changes to analyst estimates for ABT. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) closed the most recent trading day at $69.33, moving +1.39% from the previous trading session. Investors will be hoping for strength from ABT as it approaches its next earnings release, which is expected to be October 17, 2018. | Abbott (ABT) closed the most recent trading day at $69.33, moving +1.39% from the previous trading session. Investors will be hoping for strength from ABT as it approaches its next earnings release, which is expected to be October 17, 2018. Investors should also note any recent changes to analyst estimates for ABT. | Abbott (ABT) closed the most recent trading day at $69.33, moving +1.39% from the previous trading session. Investors will be hoping for strength from ABT as it approaches its next earnings release, which is expected to be October 17, 2018. Investors should also note any recent changes to analyst estimates for ABT. |
33191.0 | 2018-10-11 00:00:00 UTC | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for October 12, 2018 | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-ex-dividend-date-scheduled-october-12-2018-2018-10-11 | nan | nan | Abbott Laboratories ( ABT ) will begin trading ex-dividend on October 12, 2018. A cash dividend payment of $0.28 per share is scheduled to be paid on November 15, 2018. Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 4th quarter that ABT has paid the same dividend. At the current stock price of $68.92, the dividend yield is 1.63%.
The previous trading day's last sale of ABT was $68.92, representing a -7.05% decrease from the 52 week high of $74.15 and a 28.56% increase over the 52 week low of $53.61.
ABT is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Pfizer, Inc. ( PFE ). ABT's current earnings per share, an indicator of a company's profitability, is $.5. Zacks Investment Research reports ABT's forecasted earnings growth in 2018 as 15.33%, compared to an industry average of 5.4%.
For more information on the declaration, record and payment dates, visit the ABT Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ABT through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABT as a top-10 holding:
iShares U.S. Healthcare ETF ( IYH )
Fidelity MSCI Health Care Index ETF ( FHLC )
iShares Global Healthcare ETF ( IXJ )
NuShares Enhanced Yield US Aggregate Bond ETF ( NULV )
First Trust BuyWrite Income ETF ( FTHI ).
The top-performing ETF of this group is IYH with an increase of 10.3% over the last 100 days. It also has the highest percent weighting of ABT at 3.17%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABT's forecasted earnings growth in 2018 as 15.33%, compared to an industry average of 5.4%. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. | The following ETF(s) have ABT as a top-10 holding: iShares U.S. Healthcare ETF ( IYH ) Fidelity MSCI Health Care Index ETF ( FHLC ) iShares Global Healthcare ETF ( IXJ ) NuShares Enhanced Yield US Aggregate Bond ETF ( NULV ) First Trust BuyWrite Income ETF ( FTHI ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories ( ABT ) will begin trading ex-dividend on October 12, 2018. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Healthcare ETF ( IYH ) Fidelity MSCI Health Care Index ETF ( FHLC ) iShares Global Healthcare ETF ( IXJ ) NuShares Enhanced Yield US Aggregate Bond ETF ( NULV ) First Trust BuyWrite Income ETF ( FTHI ). | ABT's current earnings per share, an indicator of a company's profitability, is $.5. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Healthcare ETF ( IYH ) Fidelity MSCI Health Care Index ETF ( FHLC ) iShares Global Healthcare ETF ( IXJ ) NuShares Enhanced Yield US Aggregate Bond ETF ( NULV ) First Trust BuyWrite Income ETF ( FTHI ). Abbott Laboratories ( ABT ) will begin trading ex-dividend on October 12, 2018. |
33192.0 | 2018-10-10 00:00:00 UTC | Abbott (ABT) Q3 Earnings Preview: How Are Events Shaping Up? | ABT | https://www.nasdaq.com/articles/abbott-abt-q3-earnings-preview%3A-how-are-events-shaping-up-2018-10-10 | nan | nan | Wall Street expects a year-over-year increase in earnings on higher revenues when Abbott (ABT) reports results for the quarter ended September 2018. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on October 17, 2018, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on theearnings callwill mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus Estimate
This maker of infant formula, medical devices and drugs is expected to post quarterly earnings of $0.74 per share in its upcoming report, which represents a year-over-year change of +12.1%.
Revenues are expected to be $7.67 billion, up 12.3% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0.15% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time , and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Abbott?
For Abbott, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +0.27%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination indicates that Abbott will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Abbott would post earnings of $0.71 per share when it actually produced earnings of $0.73, delivering a surprise of +2.82%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Abbott appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Wall Street expects a year-over-year increase in earnings on higher revenues when Abbott (ABT) reports results for the quarter ended September 2018. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. | Wall Street expects a year-over-year increase in earnings on higher revenues when Abbott (ABT) reports results for the quarter ended September 2018. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. | Wall Street expects a year-over-year increase in earnings on higher revenues when Abbott (ABT) reports results for the quarter ended September 2018. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. | Wall Street expects a year-over-year increase in earnings on higher revenues when Abbott (ABT) reports results for the quarter ended September 2018. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. |
33193.0 | 2018-10-10 00:00:00 UTC | Ex-Dividend Reminder: Publix Super Markets, Becton, Dickinson and Abbott Laboratories | ABT | https://www.nasdaq.com/articles/ex-dividend-reminder-publix-super-markets-becton-dickinson-and-abbott-laboratories-2018-10 | nan | nan | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/18, Publix Super Markets Inc (Symbol: PUSH), Becton, Dickinson & Co (Symbol: BDXA), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Publix Super Markets Inc will pay its quarterly dividend of $0.26 on 11/1/18, Becton, Dickinson & Co will pay its quarterly dividend of $0.7656 on 11/1/18, and Abbott Laboratories will pay its quarterly dividend of $0.28 on 11/15/18. As a percentage of PUSH's recent stock price of $40.00, this dividend works out to approximately 0.65%, so look for shares of Publix Super Markets Inc to trade 0.65% lower - all else being equal - when PUSH shares open for trading on 10/12/18. Similarly, investors should look for BDXA to open 1.22% lower in price and for ABT to open 0.40% lower, all else being equal.
Below are dividend history charts for PUSH, BDXA, and ABT, showing historical dividends prior to the most recent ones declared.
Publix Super Markets Inc (Symbol: PUSH) :
Becton, Dickinson & Co (Symbol: BDXA) :
Abbott Laboratories (Symbol: ABT) :
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 2.60% for Publix Super Markets Inc, 4.86% for Becton, Dickinson & Co, and 1.58% for Abbott Laboratories.
In Wednesday trading, Publix Super Markets Inc shares are currently trading flat, Becton, Dickinson & Co shares are down about 0.4%, and Abbott Laboratories shares are down about 0.7% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/18, Publix Super Markets Inc (Symbol: PUSH), Becton, Dickinson & Co (Symbol: BDXA), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Similarly, investors should look for BDXA to open 1.22% lower in price and for ABT to open 0.40% lower, all else being equal. Below are dividend history charts for PUSH, BDXA, and ABT, showing historical dividends prior to the most recent ones declared. | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/18, Publix Super Markets Inc (Symbol: PUSH), Becton, Dickinson & Co (Symbol: BDXA), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Publix Super Markets Inc (Symbol: PUSH) : Becton, Dickinson & Co (Symbol: BDXA) : Abbott Laboratories (Symbol: ABT) : In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for BDXA to open 1.22% lower in price and for ABT to open 0.40% lower, all else being equal. | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/18, Publix Super Markets Inc (Symbol: PUSH), Becton, Dickinson & Co (Symbol: BDXA), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Publix Super Markets Inc (Symbol: PUSH) : Becton, Dickinson & Co (Symbol: BDXA) : Abbott Laboratories (Symbol: ABT) : In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for BDXA to open 1.22% lower in price and for ABT to open 0.40% lower, all else being equal. | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/18, Publix Super Markets Inc (Symbol: PUSH), Becton, Dickinson & Co (Symbol: BDXA), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Similarly, investors should look for BDXA to open 1.22% lower in price and for ABT to open 0.40% lower, all else being equal. Below are dividend history charts for PUSH, BDXA, and ABT, showing historical dividends prior to the most recent ones declared. |
33194.0 | 2018-10-10 00:00:00 UTC | Health Care Sector Update for 10/10/2018: IGC, AKRX, JNJ, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-10102018-igc-akrx-jnj-pfe-abt-mrk-amgn-2018-10-10 | nan | nan | Top Health Care Stocks:
JNJ: +0.28%
PFE: +0.29%
ABT: -0.21%
MRK: +0.01%
AMGN: Flat
Health care stocks were mixed pre-bell Wednesday.
Early movers include:
(+) India Globalization Capital ( IGC ) was trading more than 17% higher after the company said it filed a provisional method and composition patent application in the US for a cannabidiol-infused drink for the treatment of fatigue and energy restoration.
(+) Akorn ( AKRX ) shares were 8.9% higher as the company said the US Food and Drug Administration has approved its abbreviated new drug application for Bimatoprost ophthalmic solution for the treatment of hypotrichosis of the eyelashes.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AMGN: Flat Health care stocks were mixed pre-bell Wednesday. Early movers include: (+) India Globalization Capital ( IGC ) was trading more than 17% higher after the company said it filed a provisional method and composition patent application in the US for a cannabidiol-infused drink for the treatment of fatigue and energy restoration. (+) Akorn ( AKRX ) shares were 8.9% higher as the company said the US Food and Drug Administration has approved its abbreviated new drug application for Bimatoprost ophthalmic solution for the treatment of hypotrichosis of the eyelashes. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Top Health Care Stocks: | AMGN: Flat Health care stocks were mixed pre-bell Wednesday. Early movers include: (+) India Globalization Capital ( IGC ) was trading more than 17% higher after the company said it filed a provisional method and composition patent application in the US for a cannabidiol-infused drink for the treatment of fatigue and energy restoration. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care Stocks: AMGN: Flat Health care stocks were mixed pre-bell Wednesday. Early movers include: (+) India Globalization Capital ( IGC ) was trading more than 17% higher after the company said it filed a provisional method and composition patent application in the US for a cannabidiol-infused drink for the treatment of fatigue and energy restoration. |
33195.0 | 2018-10-08 00:00:00 UTC | Top Stock Reports for Apple, Microsoft & Pfizer | ABT | https://www.nasdaq.com/articles/top-stock-reports-apple-microsoft-pfizer-2018-10-08 | nan | nan | Monday, October 8, 2018
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Microsoft (MSFT) and Pfizer (PFE). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Buy-ranked Apple 's shares have gained +32.6% year to date and have outperformed the broader market with the S&P 500 gaining +7.9% over the same period. The company is expected to benefit from an expanded portfolio with the launch of new iPhones. The Zacks analyst thinks higher average selling price (ASP) and a loyal customer base are key catalysts. Moreover, robust demand for wearables is expected to drive results.
As customers increase the usage of Apple Music and Apple Pay, Services revenues are expected to increase manifold. Further, the acquisition of Akonia Holographics, a manufacturer of lenses for AR glasses, strengthens the belief that Apple can foray into the wearable AR glasses space. Moreover, the company is testing self-driving vehicles and has 66 autonomous vehicles approved for testing in California.
Meanwhile, estimates have been going up ahead of the company's fiscal Q4 earnings release. The company has positive record of earnings surprises in recent quarters.
(You can read the full research report on Apple here >>> ).
Shares of Buy-ranked Microsoft have outperformed the Zacks Technology sector on a year-to-date basis (up +31.1% versus +7.5%). Microsoft has a dominant position in the desktop PC market, with its operating systems being used in the majority of PCs worldwide.
The Zacks analyst thinks the company is benefiting from growing user base of its different applications like Office 365 commercial, Dynamics, Outlook mobile and Teams. Moreover, Azure's expanding customer base is a key catalyst. Microsoft's gaming segment is performing well, primarily driven by a combination of Xbox Live, Game Pass subscriptions and Mixer, which are driving user engagement. Further, acquisitions like PlayFab and GitHub expand Microsoft's total addressable market (TAM) and penetration.
Additionally, the company's expanding partner base is a key catalyst. However, projections of a moderating growth rate in commercial cloud gross margin, and OEM Pro and Windows commercial businesses is a headwind.
(You can read the full research report on Microsoft here >>> ).
Buy-ranked Pfizer 's shares have outperformed its peer group year-to-date (the stock is up +23.9% over this period vs. a +7% increase for the Zacks Large-Cap Pharmaceuticals industry). Pfizer is facing top-line headwinds in the form of genericization of key drugs, supply challenges in the legacy Hospira portfolio, pricing pressure and rising competition.
Nevertheless, the Zacks analyst thinks new products like Ibrance, contribution from acquisitions, cost-cutting efforts, a lower tax rate and share buybacks should help the company achieve its guidance. Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals through 2022, including around 15 products that have blockbuster potential.
Pfizer's growing immuno-oncology portfolio has strong potential. Bavencio is being considered a key long-term growth driver for Pfizer. In oncology, Pfizer has three potential medicines under FDA's priority review. Though, estimates have gone down slightly ahead of its Q3 earnings release, Pfizer has a positive record of earnings surprises in recent quarters.
(You can read the full research report on Pfizer here >>> ).
Other noteworthy reports we are featuring today include Abbott (ABT), Caterpillar (CAT) and ConocoPhillips (COP).
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Robust Portfolio, Services Strength to Benefit Apple (AAPL)
Azure Adoption, Office 365 Strength Aids Microsoft (MSFT)
Pfizer (PFE) Boasts Solid Pipeline of Potential Blockbusters
Featured Reports
Caterpillar (CAT) Rides on Favorable Markets, High Costs Ail
Per the Zacks analyst, improved end-user demand across most end markets will drive Caterpillar's top-line. However, material cost inflation and higher transportation costs will dent near-term margins.
ConocoPhillips (COP) Gains from Oil-Rich Eagle Ford Acreage
The Zacks analyst believes that huge acreage holdings in the prospective Eagle Ford Shale play will drive ConocoPhillips' oil production.
Marsh & McLennan (MMC) Rides on Accretive Acquisitions
The Zacks analyst views favorably numerous acquisitions that have enabled the company to enter new geographies, businesses and expand the product portfolio, thereby leading to top line growth.
Restructuring Plans Aid Molina Healthcare (MOH), Costs Hurt
Per the Zacks analyst, Molina Healthcare's restructuring initiatives should improve its efficiency and restore profitability.
Restructuring Plans Aid CIT Group (CIT), Asset Quality a Woe
Per the Zacks analyst, CIT Group's initiatives to restructure businesses continue to improve operating efficiency, while deteriorating asset quality is a major near-term concern.
Enterprise Technology to Drive Ubiquiti's (UBNT) Revenues
Per the Zacks analyst, impressive performance of Ubiquiti's Enterprise Technology business should drive the company's revenues in the upcoming quarters.
Acquisitions Bode Well for RPM International (RPM), Costs High
Per the Zacks analyst, acquisition and cost saving initiatives are the major growth drivers of RPM International.
New Upgrades
Markel (MKL) Continues to Gain from Increasing Premiums
Per the Zacks analyst, Markel will continue to see improvement in premiums, primarily driven by strong performance across Insurance and Reinsurance segments.
Network Expansion & Customer Additions Boost T-Mobile (TMUS)
Per the Zacks analyst, T-Mobile's collaboration with Ericsson to boost the deployment of a nationwide 5G network and expand customer base will continue to drive its service revenues and profitability.
Norfolk Southern (NSC) Rides on Volume Growth & Cost Cuts
The Zacks analyst likes the company's impressive volume expansion, driving growth in turn. Additionally, its cost-reduction efforts to boost the bottom line are encouraging.
New Downgrades
Oil & Natural Gas Prices To Hit Hawaiian Electric (HE)
Per the Zacks analyst, fluctuations in the oil price in theglobal marketcoupled with rise in price of natural gas may affect Hawaiian Electric's ability to generate power.
High Production Costs & Flat Gold Reserves Ail Newmont (NEM)
The Zacks analyst is worried about Newmont's rising production costs due to higher per unit costs and increased spending on advanced projects. Lack of growth in gold reserves is another concern.
EPD in Russia Worries Abbott (ABT), Soft Vascular Sales Ail
The Zacks analyst worries about Abbott's dull Established Pharmaceuticals (EPD) sales in Russia due to a distribution channel dynamics disruption. Falling revenues in core Vascular is another concern.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE): Free Stock Analysis Report
Microsoft Corporation (MSFT): Free Stock Analysis Report
ConocoPhillips (COP): Free Stock Analysis Report
Caterpillar Inc. (CAT): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Apple Inc. (AAPL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other noteworthy reports we are featuring today include Abbott (ABT), Caterpillar (CAT) and ConocoPhillips (COP). EPD in Russia Worries Abbott (ABT), Soft Vascular Sales Ail The Zacks analyst worries about Abbott's dull Established Pharmaceuticals (EPD) sales in Russia due to a distribution channel dynamics disruption. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report ConocoPhillips (COP): Free Stock Analysis Report Caterpillar Inc. (CAT): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report ConocoPhillips (COP): Free Stock Analysis Report Caterpillar Inc. (CAT): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report To read this article on Zacks.com click here. Other noteworthy reports we are featuring today include Abbott (ABT), Caterpillar (CAT) and ConocoPhillips (COP). EPD in Russia Worries Abbott (ABT), Soft Vascular Sales Ail The Zacks analyst worries about Abbott's dull Established Pharmaceuticals (EPD) sales in Russia due to a distribution channel dynamics disruption. | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report ConocoPhillips (COP): Free Stock Analysis Report Caterpillar Inc. (CAT): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report To read this article on Zacks.com click here. Other noteworthy reports we are featuring today include Abbott (ABT), Caterpillar (CAT) and ConocoPhillips (COP). EPD in Russia Worries Abbott (ABT), Soft Vascular Sales Ail The Zacks analyst worries about Abbott's dull Established Pharmaceuticals (EPD) sales in Russia due to a distribution channel dynamics disruption. | Other noteworthy reports we are featuring today include Abbott (ABT), Caterpillar (CAT) and ConocoPhillips (COP). EPD in Russia Worries Abbott (ABT), Soft Vascular Sales Ail The Zacks analyst worries about Abbott's dull Established Pharmaceuticals (EPD) sales in Russia due to a distribution channel dynamics disruption. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report ConocoPhillips (COP): Free Stock Analysis Report Caterpillar Inc. (CAT): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report To read this article on Zacks.com click here. |
33196.0 | 2018-10-05 00:00:00 UTC | Health Care Sector Update for 10/05/2018: JNJ, PFE, ABT, MRK, AMGN, HSGX, KMPH | ABT | https://www.nasdaq.com/articles/health-care-sector-update-10052018-jnj-pfe-abt-mrk-amgn-hsgx-kmph-2018-10-05 | nan | nan | Top Health Care Stocks:
JNJ: +0.23%
PFE: -0.40%
ABT: Flat
MRK: Flat
AMGN: +0.09%
Health care stocks were mostly lower early Friday.
Among the stocks moving on recent news:
(-) Histogenics ( HSGX ) was trading more than 40% lower after unveiling a plan to to sell shares and accompanying warrants through an underwritten public offering to raise funds to complete its NeoCart biologics license application and commercialization following approval by the US Food and Drug Administration.
(-) KemPharm ( KMPH ) was down more than 36% after saying it intends to sell shares in an underwritten public offering to raise funds for new drug application submission for KP415, to initiate a pivotal trial for KP484 and for general corporate purposes.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: Flat MRK: Flat Health care stocks were mostly lower early Friday. Among the stocks moving on recent news: (-) Histogenics ( HSGX ) was trading more than 40% lower after unveiling a plan to to sell shares and accompanying warrants through an underwritten public offering to raise funds to complete its NeoCart biologics license application and commercialization following approval by the US Food and Drug Administration. | ABT: Flat MRK: Flat Among the stocks moving on recent news: (-) Histogenics ( HSGX ) was trading more than 40% lower after unveiling a plan to to sell shares and accompanying warrants through an underwritten public offering to raise funds to complete its NeoCart biologics license application and commercialization following approval by the US Food and Drug Administration. (-) KemPharm ( KMPH ) was down more than 36% after saying it intends to sell shares in an underwritten public offering to raise funds for new drug application submission for KP415, to initiate a pivotal trial for KP484 and for general corporate purposes. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT: Flat MRK: Flat Among the stocks moving on recent news: (-) Histogenics ( HSGX ) was trading more than 40% lower after unveiling a plan to to sell shares and accompanying warrants through an underwritten public offering to raise funds to complete its NeoCart biologics license application and commercialization following approval by the US Food and Drug Administration. | ABT: Flat MRK: Flat Top Health Care Stocks: Health care stocks were mostly lower early Friday. |
33197.0 | 2018-10-04 00:00:00 UTC | Will Walgreens (WBA) Q4 Earnings Gain From Overall Strength? | ABT | https://www.nasdaq.com/articles/will-walgreens-wba-q4-earnings-gain-from-overall-strength-2018-10-04 | nan | nan | Walgreens Boots Alliance, Inc.WBA is slated to release fourth-quarter and fiscal 2018 results on Oct 11, before the market opens.
Last reported quarter, the company delivered a positive earnings surprise of 4.08%. Walgreens Boots has outperformed the Zacks Consensus Estimate in all the preceding four quarters, the average positive earnings surprise being 5.97%.
Let's take a look at how things are shaping up prior to this announcement.
Key Catalysts
Over the recent past, Walgreens Boots' Retail Pharmacy USA division witnessed comparable prescription growth and benefited from a strong retail prescription market. Notably, revenues from this division accounted for more than 75% of total third-quarter fiscal 2018 revenues.
Within this segment, Walgreens Boots has been making a good progress on account of an increasing prescription volume. Last reported quarter, total pharmacy sales were up 19.3%, primarily due to higher prescription volume from the acquired Rite Aid stores and central specialty.
Several planned developments, early benefits of new pharmacy contracts as well as volume expansion owing to previously-announced pharmacy partnerships have been driving growth in this space. At the same time, the company has been gaining from its strategic partnership with FedEx regarding its existing stores. Moreover, the retail pharmacy market has been seeing a rising expenditure on prescription drugs and growing demand for specialty drugs.
However, on second-quarter fiscalearnings call Walgreens Boots noted that this was the last quarter before the lapse of the promotional optimization program.
The Zacks Consensus Estimate for fourth-quarter total revenues at the Retail Pharmacy USA division is pegged at $25.30 billion.
Meanwhile, tough market conditions, particularly in retail, have been leading to sluggishness in Retail Pharmacy International division. Last reported quarter, adjusted operating income was down 9.3% majorly due to phasing of certain SG&A expenditures. The remaining decline reflects lower gross profit, largely offset by cost-containment measures.
Walgreens Boots Alliance, Inc. Price and EPS Surprise
Walgreens Boots Alliance, Inc. Price and EPS Surprise | Walgreens Boots Alliance, Inc. Quote
However, the company has been taking steps like entering into tie-ups and controlling costs to boost segments. The Zacks Consensus Estimate remains at $3.02 billion for revenues from the Retail Pharmacy International division .
Strong growth in certain emerging markets is expected to consistently drive the company's Pharmaceutical Wholesale division. The Zacks Consensus Estimate for the division's fourth-quarter revenue is $5.79 billion.
The Zacks Consensus Estimate for total revenues of $33.64 billion depicts an 11.7% rise on a year-over-year basis.
On the flip side, Walgreens Boots' gross margin figure has been declining over a while. However, the company is working to gain efficiency and provide high quality, cost-effective pharmacy services in order to reduce pharmacy costs.
Overall, Walgreens Boots' fiscal 2018 earnings outlook looks quite promising with the company expecting to register EPS in the band of $5.90-$6.05. The Zacks Consensus Estimate for earnings of $5.98 per share remains within this guided range.
Here is what our quantitative model predicts:
Walgreens Boots has the right combination of two main ingredients - a positive Earnings ESP and a Zacks Rank #3 (Hold) or higher - needed for increasing the odds of an earnings beat.
Earnings ESP : Walgreens Boots has an Earnings ESP of +1.02%, indicating a likely earnings surprise. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank : Walgreens Boots carries a Zacks Rank of 3, which increases the predictive power of ESP.
The Zacks Consensus Estimate for earnings of $1.44 represents a 9.9% improvement on a year-over-year basis.
Other Stocks Worth a Look
Here are a few other medical stocks worth considering as these too have the perfect combination of elements to come up with an earnings beat this to-be-reported quarter.
Abbott Laboratories ABT has an Earnings ESP of +0.27% and is a Zacks #3 Ranked player. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Inogen, Inc. INGN has an Earnings ESP of +0.64% and a Zacks Rank #2 (Buy).
Masimo Corporation MASI has an Earnings ESP of +0.98% and a Zacks Rank of 2.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Masimo Corporation (MASI): Free Stock Analysis Report
Inogen, Inc (INGN): Free Stock Analysis Report
Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT has an Earnings ESP of +0.27% and is a Zacks #3 Ranked player. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. Walgreens Boots has outperformed the Zacks Consensus Estimate in all the preceding four quarters, the average positive earnings surprise being 5.97%. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT has an Earnings ESP of +0.27% and is a Zacks #3 Ranked player. Key Catalysts Over the recent past, Walgreens Boots' Retail Pharmacy USA division witnessed comparable prescription growth and benefited from a strong retail prescription market. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT has an Earnings ESP of +0.27% and is a Zacks #3 Ranked player. Walgreens Boots Alliance, Inc. Price and EPS Surprise Walgreens Boots Alliance, Inc. Price and EPS Surprise | Walgreens Boots Alliance, Inc. Quote However, the company has been taking steps like entering into tie-ups and controlling costs to boost segments. | Abbott Laboratories ABT has an Earnings ESP of +0.27% and is a Zacks #3 Ranked player. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Consensus Estimate remains at $3.02 billion for revenues from the Retail Pharmacy International division . |
33198.0 | 2018-10-04 00:00:00 UTC | US Diabetes Market Gaining Momentum: 3 Stocks in Focus | ABT | https://www.nasdaq.com/articles/us-diabetes-market-gaining-momentum-3-stocks-focus-2018-10-04 | nan | nan | Diabetes is one of the most challenging health conditions in the United States. About 1.4 million new cases of diabetes are diagnosed every year in the country, thanks to rise in the geriatric population, urbanization and poor lifestyle practices.
Per Allied Market Research, the global diabetes therapeutics market is estimated to reach a worth of $186,842 million by 2023, at a CAGR of 16%.
Thus, companies involved in the development of medical devices for diabetes are most likely to draw investors' attention.
Artificial Intelligence - A Mega Trend in Diabetes Care
Digitization has made big data technologies more relevant in healthcare, the diabetes care space being no exception.
Smart apps have made self-management and monitoring of diabetes affordable. These applications can show real-time data on patients' blood glucose levels on these apps. Consumer fitness brand Fitbit FIT also entered the sapce by a $6-million investment in Sano.
Additionally, MedTech giant Medtronic MDT collaborated with IBM to develop Sugar.IQ, a cognitive mobile personal assistant app that aims to provide real-time actionable glucose insights and predictions for patients with diabetes.
Per Research and Market, theglobal marketfor artificial intelligence in diabetes management is expected to see a CAGR of 50.7% between 2017 and 2023.
Treatment Procedures
Continuous Glucose Monitoring (CGM)
Blood glucose monitoring is a way of testing the concentration of glucose in the blood.
Self-monitoring by patients is the easiest and the most widely adopted method of glucose monitoring across the world. This has encouraged companies in the MedTech industry to focus on the development of glucose monitoring devices.
Going by an article of Research and Markets, the blood glucose monitoring devices market is expected to see a CAGR of 8% between 2018 and 2024.
Insulin
Patients diagnosed with Type I diabetes frequently require insulin injections. The procedure involves use of needles, syringes, insulin pens or insulin pumps. Medtronic's MiniMed Insulin Pump therapy deserves a special mention here.
Meanwhile, drugs like Metformin and Sulfonylureas are used to treat Type II diabetes.
Research by Market Watch suggests that the global human insulin drugs and devices market will cross a value of $45.36 billion by 2022, at a CAGR of 8%.
Set against this backdrop, let's take a look at a few companies which are raking in billions by providing quality diabetes care.
Stocks to Watch
We have zeroed in on three stocks, each with a Zacks Rank #3 (Hold). We believe each of these companies can tap into the promising prospects of the diabetes device market. These stocks have also outperformed their respective industries in the past year. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Our first pick is Abbott LaboratoriesABT . The Illinois-based MedTech giant is dedicated to developing innovative products that make glucose testing easier and more accurate.
The company's products like Freestyle Libre, Freestyle Navigator II, Freestyle Lite, Freestyle Insulinx can be used by patients for personal glucose monitoring. Abbott has also launched mobile applications like Librelink and Librelinkup. It is encouraging to note that earlier this year, the company announced the availability of FreeStyle LibreLink app in Europe for use on smartphones (both iPhone and Android).
The stock has rallied 31.1% compared with the industry 's 22% rise.
Next on our list is New Jersey-based Becton, Dickinson and CompanyBDX , also known as BD. The medical technology bigwig's products are designed to provide effective diabetes care.
BD's FlowSmart technology enables a new infusion set with a unique design to help reduce unplanned flow interruptions and keep patients' diabetes management on track. The company also offers a wide array of insulin syringes like BD 1-mL conventional insulin syringes, SafetyGlide 6mm insulin syringe, Safety-Lok insulin syringe. Moreover, BD's pen needles are compatible with leading diabetes medication pens in the United States. This range includes AutoShield Duo pen needle, Nano 4mm pen needle and Ultra-Fine pen needles.
The stock has gained 31.1% compared with the industry 's increase of 15.8%.
Investors may also keep an eye on DexCom, Inc.DXCM . The California-based medical device company is known for designing, developing and commercializing CGM systems.
The company's FDA-cleared CGM system - the DexCom G4 Platinum - is significantly boosting the top line. The inbuilt features of G4 Platinum make it the most innovative CGM system in the market. Last year, DexCom announced the FDA approval of the Dexcom G5 mobile app for Android devices.
In fact, the FDA recently granted a De Novo request for the DexCom G6 CGM System. In June, DexCom announced the receipt of CE Mark for its DexCom G6 System for people with diabetes ages two years and above. In August, DexCom acquired TypeZero Technologies, whose inControl diabetes management system is designed to provide personalized diabetes management solutions.
In fact, Tandem Diabetes TNDM plans to launch its new FDA-approved t:slim X2 Insulin Pump with DexCom's G6 CGM system.
The stock has rallied 162.8% compared with the industry 's 25.7% rise.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Fitbit, Inc. (FIT): Free Stock Analysis Report
Tandem Diabetes Care, Inc. (TNDM): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
DexCom, Inc. (DXCM): Free Stock Analysis Report
Becton, Dickinson and Company (BDX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Our first pick is Abbott LaboratoriesABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Fitbit, Inc. (FIT): Free Stock Analysis Report Tandem Diabetes Care, Inc. (TNDM): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. Additionally, MedTech giant Medtronic MDT collaborated with IBM to develop Sugar.IQ, a cognitive mobile personal assistant app that aims to provide real-time actionable glucose insights and predictions for patients with diabetes. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Fitbit, Inc. (FIT): Free Stock Analysis Report Tandem Diabetes Care, Inc. (TNDM): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. Our first pick is Abbott LaboratoriesABT . Treatment Procedures Continuous Glucose Monitoring (CGM) Blood glucose monitoring is a way of testing the concentration of glucose in the blood. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Fitbit, Inc. (FIT): Free Stock Analysis Report Tandem Diabetes Care, Inc. (TNDM): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. Our first pick is Abbott LaboratoriesABT . The company also offers a wide array of insulin syringes like BD 1-mL conventional insulin syringes, SafetyGlide 6mm insulin syringe, Safety-Lok insulin syringe. | Our first pick is Abbott LaboratoriesABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Fitbit, Inc. (FIT): Free Stock Analysis Report Tandem Diabetes Care, Inc. (TNDM): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. This has encouraged companies in the MedTech industry to focus on the development of glucose monitoring devices. |
33199.0 | 2018-10-03 00:00:00 UTC | Notable ETF Inflow Detected - SPYG, ABT, INTC, PFE | ABT | https://www.nasdaq.com/articles/notable-etf-inflow-detected-spyg-abt-intc-pfe-2018-10-03 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $55.5 million dollar inflow -- that's a 1.5% increase week over week in outstanding units (from 96,750,108 to 98,200,108). Among the largest underlying components of SPYG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.4%, Intel Corp (Symbol: INTC) is up about 1.9%, and Pfizer Inc (Symbol: PFE) is up by about 1.1%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average:
Looking at the chart above, SPYG's low point in its 52 week range is $7.7753 per share, with $38.55 as the 52 week high point - that compares with a last trade of $38.48. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SPYG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.4%, Intel Corp (Symbol: INTC) is up about 1.9%, and Pfizer Inc (Symbol: PFE) is up by about 1.1%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $7.7753 per share, with $38.55 as the 52 week high point - that compares with a last trade of $38.48. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of SPYG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.4%, Intel Corp (Symbol: INTC) is up about 1.9%, and Pfizer Inc (Symbol: PFE) is up by about 1.1%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $7.7753 per share, with $38.55 as the 52 week high point - that compares with a last trade of $38.48. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SPYG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.4%, Intel Corp (Symbol: INTC) is up about 1.9%, and Pfizer Inc (Symbol: PFE) is up by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $55.5 million dollar inflow -- that's a 1.5% increase week over week in outstanding units (from 96,750,108 to 98,200,108). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $7.7753 per share, with $38.55 as the 52 week high point - that compares with a last trade of $38.48. | Among the largest underlying components of SPYG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.4%, Intel Corp (Symbol: INTC) is up about 1.9%, and Pfizer Inc (Symbol: PFE) is up by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $55.5 million dollar inflow -- that's a 1.5% increase week over week in outstanding units (from 96,750,108 to 98,200,108). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $7.7753 per share, with $38.55 as the 52 week high point - that compares with a last trade of $38.48. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.